<SEC-DOCUMENT>0001401914-19-000081.txt : 20190814
<SEC-HEADER>0001401914-19-000081.hdr.sgml : 20190814
<ACCEPTANCE-DATETIME>20190814160624
ACCESSION NUMBER:		0001401914-19-000081
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		53
CONFORMED PERIOD OF REPORT:	20190630
FILED AS OF DATE:		20190814
DATE AS OF CHANGE:		20190814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Dare Bioscience, Inc.
		CENTRAL INDEX KEY:			0001401914
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				204139823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36395
		FILM NUMBER:		191026285

	BUSINESS ADDRESS:	
		STREET 1:		3655 NOBEL DRIVE
		STREET 2:		SUITE 260
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-926-7655

	MAIL ADDRESS:	
		STREET 1:		3655 NOBEL DRIVE
		STREET 2:		SUITE 260
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cerulean Pharma Inc.
		DATE OF NAME CHANGE:	20090714

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tempo Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070604
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>dare_10qx20190630.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7205C6A113F653E1A51637166C12C058"></a></div><div style="line-height:120%;padding-top:2px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:16pt;"><font style="font-family:Arial;font-size:16pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:Arial;font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">WASHINGTON, DC 20549</font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:16pt;"><font style="font-family:Arial;font-size:16pt;font-weight:bold;">FORM 10-Q</font></div><div style="line-height:120%;padding-top:2px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(Mark One)</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:2px;text-align:center;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">For the transition period from </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;to </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;"><img src="darebioinlinefullcolorrgb.jpg" alt="darebioinlinefullcolorrgb.jpg" style="height:106px;width:269px;"></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:0px;text-indent:24px;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:27%;"></td><td style="width:46%;"></td><td style="width:27%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:18pt;"><font style="font-family:Arial;font-size:18pt;font-weight:bold;">DAR&#201; BIOSCIENCE, INC.</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(Exact Name of Registrant as Specified in its Charter)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Delaware</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(State or Other Jurisdiction</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">of Incorporation)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Commission File No. 001-36395</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">20-4139823</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(IRS Employer</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Identification No.)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3655 Nobel Drive, Suite 260</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">San Diego, CA</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(Address of Principal Executive Offices)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(858) 926-7655</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(Registrant&#8217;s telephone number, including area code)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">92122</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(Zip Code)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(Former name, former address and former fiscal year, if changed since last report)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Securities registered pursuant to Section 12(b) of the Act:</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:37%;"></td><td style="width:25%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Title of each class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Trading Symbol(s)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Name of each exchange on which registered</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">DARE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nasdaq Capital Market</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">x</font><font style="font-family:Arial;font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">o</font></div><div style="line-height:120%;padding-top:5px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:9pt;">Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">x</font><font style="font-family:Arial;font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">o</font></div><div style="line-height:120%;padding-top:5px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:24%;"></td><td style="width:3%;"></td><td style="width:4%;"></td><td style="width:40%;"></td><td style="width:25%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Large Accelerated Filer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Accelerated filer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">o</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Non-accelerated filer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Smaller reporting company</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">x</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Emerging growth company</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-indent:24px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">x </font></div><div style="line-height:120%;padding-top:5px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">o</font><font style="font-family:Arial;font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">x </font></div><div style="line-height:120%;padding-top:5px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">As of </font><font style="font-family:Arial;font-size:9pt;">August&#160;13, 2019</font><font style="font-family:Arial;font-size:9pt;">, 16,683,411 shares of the Registrant&#8217;s Common Stock, par value $0.0001, were issued and outstanding.</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="s41B727C161955476B8036CD8FBB9938C"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">This Quarterly Report on Form 10-Q, in particular &#8220;Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations,&#8221; of Part I. Financial Information, and the information incorporated by reference herein contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this report, including statements regarding our strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;design,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;could,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;contemplate,&#8221; project,&#8221; &#8220;target,&#8221; &#8220;tend to,&#8221; or the negative version of these words and similar expressions.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including those factors described in Part II, Item 1A, &#8220;Risk Factors,&#8221; in this report, and elsewhere in this report. Given these uncertainties, you should not place undue reliance on any forward-looking statement. The following factors are among those that may cause such differences:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Inability to continue as a going concern;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Inability to raise additional capital, under favorable terms or at all;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Inability to successfully attract partners and enter into collaborations on acceptable terms;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Failure to select or capitalize on the most scientifically, clinically or commercially promising or profitable indications or therapeutic areas for our product candidates due to limited financial resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Inability to develop and commercialize our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Failure or delay in starting, conducting and completing clinical trials or obtaining United States Food and Drug Administration, or FDA, or foreign regulatory approval for our product candidates in a timely manner;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">A change in the FDA&#8217;s primary oversight responsibility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">A change in regulatory requirements for our product candidates, including the development pathway pursuant to Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or the FDA's 505(b)(2) pathway;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Unsuccessful clinical trial outcomes stemming from clinical trial designs, failure to enroll a sufficient number of patients, higher than anticipated patient dropout rates, failure to meet established clinical endpoints, undesirable side effects and other safety concerns;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Negative publicity concerning the safety and efficacy of our product candidates, or of product candidates being developed by others that share characteristics similar to our candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Inability to demonstrate sufficient efficacy of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Loss of our licensed rights to develop and commercialize a product candidate as a result of the termination of the underlying licensing agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Monetary obligations and other requirements in connection with our exclusive, in-license agreements covering the patents and related intellectual property related to our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Developments by our competitors that make our product candidates less competitive or obsolete;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Dependence on third parties to conduct clinical trials and to manufacture product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Dependence on third parties to supply clinical supplies and raw materials, drugs and other materials required to produce a finished product and to produce the quantities needed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Failure of our product candidates, if approved, to gain market acceptance or obtain adequate coverage for third party reimbursement;</font></div></td></tr></table><div><br></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">A reduction in demand for contraceptives caused by an elimination of current requirements that health insurance plans cover and reimburse certain FDA-cleared or approved contraceptive products without cost sharing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Lack of precedent to help assess whether health insurance plans will cover our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">The reimbursement environment relating to our product candidates at the time we obtain regulatory approval, if ever;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Difficulty in introducing branded products in a market made up of generic products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Inability to adequately protect or enforce our, or our licensor&#8217;s, intellectual property rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Lack of patent protection for the active ingredients in certain of our product candidates which could expose those product candidates to competition from other formulations using the same active ingredients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Higher risk of failure associated with product candidates in pre-clinical stages of development that may lead investors to assign them little to no value and make these assets difficult to fund;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Disputes or other developments concerning our intellectual property rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Actual and anticipated fluctuations in our quarterly or annual operating results;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Price and volume fluctuations in the stock market, and in our stock in particular, which could subject us to securities class-action litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Failure to maintain the listing of the Company&#8217;s common stock on the Nasdaq Capital Market or another nationally recognized exchange;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Litigation or public concern about the safety of our potential products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Strict government regulations on our business, including various fraud and abuse laws, including, without limitation, the U.S. federal Anti-Kickback Statute, the U.S. federal False Claims Act and the U.S. Foreign Corrupt Practices Act;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Regulations governing the production or marketing of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Loss of, or inability to attract, key personnel; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Increased costs as a result of operating as a public company, and substantial time devoted by our management to compliance initiatives and corporate governance practices.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">All forward-looking statements in this report are current only as of the date of this report. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any statement is made or to reflect the occurrence of unanticipated events, except as required by law.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="s008C96FA91E25F88A43BD2D1512B362F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:86%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Page</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;font-weight:bold;" href="#s9913E52B7243530A82F0A7AB940BF38E"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PART I. FINANCIAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA1172BBAF0025E6AA5BA16A246680FF2"><font style="font-family:Arial;font-size:10pt;">Consolidated Financial Statements (Unaudited)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s9913E52B7243530A82F0A7AB940BF38E">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sDFD3CE0BD25C53E7AE0939B4E71AE0B9"><font style="font-family:Arial;font-size:10pt;">Management's Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sDFD3CE0BD25C53E7AE0939B4E71AE0B9">20</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 3.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sED2B4CA2673A5A61BAD1FE06FDA1552F"><font style="font-family:Arial;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sED2B4CA2673A5A61BAD1FE06FDA1552F">30</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 4.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sF619928A7ECC5DECA9BB9032B29511B9"><font style="font-family:Arial;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sF619928A7ECC5DECA9BB9032B29511B9">30</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;font-weight:bold;" href="#s71543815C0365BD692987333D76E3840"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PART II. OTHER INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s6D61C87E208950DE9BA556E011233247"><font style="font-family:Arial;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s6D61C87E208950DE9BA556E011233247">31</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 1A.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA59D18DC745B51FFAB05085628F141F6"><font style="font-family:Arial;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA59D18DC745B51FFAB05085628F141F6">31</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s1018F5EB6E11569EA2FEC2B71BF1EDE5"><font style="font-family:Arial;font-size:10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s1018F5EB6E11569EA2FEC2B71BF1EDE5">32</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 3.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s6ED950516635523E8EDD555D990EE84E"><font style="font-family:Arial;font-size:10pt;">Defaults Upon Senior Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s6ED950516635523E8EDD555D990EE84E">32</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 4.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sD214E371D0075599A4DB4266E0D65C07"><font style="font-family:Arial;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sD214E371D0075599A4DB4266E0D65C07">32</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 5.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s386193EC3238521B918C9E8A90141702"><font style="font-family:Arial;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s386193EC3238521B918C9E8A90141702">32</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 6.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sD46874C0FADC5C898A064024A9537C41"><font style="font-family:Arial;font-size:10pt;">Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sD46874C0FADC5C898A064024A9537C41">32</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s7B1EE239891E52FA856764E3D547E258"><font style="font-family:Arial;font-size:10pt;">SIGNATURES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s7B1EE239891E52FA856764E3D547E258">34</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s9913E52B7243530A82F0A7AB940BF38E"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PART I.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">FINANCIAL INFORMATION</font></div></td></tr></table><div><a name="sA1172BBAF0025E6AA5BA16A246680FF2"></a></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 1. Consolidated Financial Statements (Unaudited)</font></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s0D7B11A375125E588F4BAD3FA19125CC"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dar&#233; Bioscience, Inc. and Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Consolidated Balance Sheets</font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">June&#160;30, <br>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, <br>2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Current assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,630,569</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,805,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">493,019</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31,037</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prepaid expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">437,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">403,097</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,561,546</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,240,023</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,396</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other non-current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">692,305</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">577,968</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,260,932</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,827,387</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Liabilities and stockholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Current liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">632,118</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">459,705</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,341,811</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">631,351</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,973,929</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,091,056</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">203,948</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,711</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,177,877</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,100,767</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Commitments and contingencies (Note 8)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Stockholders' equity</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Common stock, $0.0001 par value; 120,000,000 shares authorized; 16,683,411 and 11,422,161 shares issued and outstanding, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,668</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,143</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(97,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(96,728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">41,942,062</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">35,791,972</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(36,763,651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(28,969,767</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total stockholders' equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,083,055</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,726,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total liabilities and stockholders' equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,260,932</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,827,387</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">See accompanying notes to interim consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="s365B18A8186859F69A909EDE6EC9146B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dar&#233; Bioscience</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Inc</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">and</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Consolidated</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Statements</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">of</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Operations</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">and</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Comprehensive</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Loss</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unaudited</font><font style="font-family:inherit;font-size:10pt;">)</font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three months ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Operating expenses</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,307,379</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,157,174</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,584,559</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,460,363</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,512,572</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,217,622</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,205,963</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,304,275</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">License expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">162,500</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">250,000</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">275,000</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">350,000</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Impairment of goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,187,519</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,982,451</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,624,796</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,065,522</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,302,157</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,982,451</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,624,796</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,065,522</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11,302,157</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">30,001</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">42,626</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">61,232</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">54,370</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,952,450</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,582,170</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,004,290</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11,247,787</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deemed dividend from trigger of down round provision feature</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(789,594</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(789,594</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Net loss to common shareholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4,742,044</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,582,170</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,793,884</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11,247,787</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign currency translation adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,917</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(27,485</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(296</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(41,231</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4,749,961</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,609,655</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,794,180</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11,289,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Loss per common share - basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.29</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.57</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1.13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Weighted average number of common shares outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16,105,252</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,422,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13,776,643</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10,031,249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">See accompanying notes to interim consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s0F5B7573464957FE851DC96D889485E2"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dar&#233; Bioscience, Inc. and Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Consolidated Statements of Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:25%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Additional</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Accumulated<br>other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">paid-in</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">comprehensive</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Accumulated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">stockholders'</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Balance at March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">11,422,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,143</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">35,889,940</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(89,107</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(32,021,607</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3,780,369</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">111,351</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">111,351</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Issuance of common stock via public offering, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,261,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,151,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,151,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deemed dividend from trigger of down round provision</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">789,594</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(789,594</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,952,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,952,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign currency translation adjustments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,917</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,917</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Balance at June 30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">16,683,411</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,668</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">41,942,062</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(97,024</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(36,763,651</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5,083,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Six Months Ended June 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Additional</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Accumulated<br>other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">paid-in</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">comprehensive</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Accumulated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">stockholders'</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">11,422,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,143</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">35,791,972</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(96,728</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(28,969,767</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6,726,620</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">209,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">209,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Issuance of common stock via public offering, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,261,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">525</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,151,177</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,151,702</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deemed dividend from trigger of down round provision</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">789,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(789,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,004,290</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,004,290</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign currency translation adjustments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Balance at June 30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">16,683,411</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,668</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">41,942,062</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(97,024</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(36,763,651</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5,083,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">See accompanying notes to interim consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dar&#233; Bioscience, Inc. and Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Consolidated Statements of Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:24%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Additional</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Accumulated<br>other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">paid-in</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">comprehensive</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Accumulated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">stockholders'</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Balance at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">11,422,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">35,747,609</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(31,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(19,896,570</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">15,820,356</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Public offering costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2,160</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2,160</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,582,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,582,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign currency translation adjustments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(27,485</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(27,485</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">11,422,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">35,754,872</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(59,311</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(23,478,740</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12,217,963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Six Months Ended June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Additional</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Accumulated<br>other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">paid-in</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">comprehensive</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Accumulated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">stockholders'</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6,047,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">605</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">25,541,210</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(18,080</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(12,230,953</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">13,292,782</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Issuance of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">375,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,037,727</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,037,764</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net proceeds from issuance of common stock and warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,000,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,157,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,157,888</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11,247,787</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11,247,787</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign currency translation adjustments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(41,231</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(41,231</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">11,422,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">35,754,872</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(59,311</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(23,478,740</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12,217,963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">See accompanying notes to interim consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="sF9F74E057D025317BBBE29016D96F2E2"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dar&#233; Bioscience, Inc. and Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Consolidated Statements of Cash Flows</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(Unaudited)</font><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,004,290</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11,247,787</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Non-cash adjustments reconciling net loss to operating cash flows:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,315</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">288</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">209,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Non-cash lease expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10,549</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">452,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Impairment of goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,187,519</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(461,982</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">259,562</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prepaid expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(34,861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(35,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">193,495</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other non-current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">79,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">66,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">172,413</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,739</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">710,459</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">288,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(9,711</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(75</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(6,326,726</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4,807,544</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(8,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Acquisition of Pear Tree and Hydra asset</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(452,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(460,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net proceeds from issuance of common stock and warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,151,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10,195,653</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,151,702</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10,195,653</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effect of exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(41,231</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Net change in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,175,320</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,886,678</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,805,889</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,559,846</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cash and cash equivalents, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,630,569</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12,446,524</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Supplemental disclosure of non-cash operating and financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Operating right-of-use assets obtained in exchange for new operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">231,698</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deemed dividend from trigger of down round provision</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">789,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">See accompanying notes to interim consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="s320B83E0E33E55609C0D86206B540FED"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dar&#233; Bioscience, Inc. and Subsidiaries</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Unaudited)</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sF265C0FBDBC75CB2B02049042A30C7C1"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ORGANIZATION AND DESCRIPTION OF THE BUSINESS</font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dar&#233; Bioscience, Inc. is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women&#8217;s health. Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries operate in </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;">&#32;segment. In this report, the &#8220;Company&#8221; refers collectively to Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is driven by a mission to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. The Company's business strategy is to license or otherwise acquire the rights to differentiated product candidates in women's health, some of which have existing clinical proof-of-concept data, and to advance those candidates through clinical development and regulatory approval alone or in collaboration with strategic partners.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has assembled a portfolio of clinical-stage and pre-clinical-stage candidates addressing unmet needs in women&#8217;s health. The Company&#8217;s portfolio includes these six clinical-stage candidates:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-BV1, a novel solution-to-gel formulation containing clindamycin phosphate 2% to treat bacterial vaginosis, or BV; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ovaprene, a non-hormonal monthly contraceptive intravaginal ring; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder, or FSAD; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy, or VVA, in patients with hormone-receptor positive breast cancer; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and for fertility support as part of an </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:Arial;font-size:10pt;">&#32;fertilization, or IVF, treatment plan.</font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company's portfolio also includes several pre-clinical stage product candidates:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ORB-204 and ORB-214, 6-month and 12-month formulations of injectable etonogestrel for contraception;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-RH1, a novel approach to non-hormonal contraception for both men and women by targeting the CatSper ion channel; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-OAB1, an intravaginal ring containing oxybutynin for the treatment of overactive bladder. </font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s primary operations have consisted of, and are expected to continue to consist of, product research and development and advancing its portfolio of product candidates through clinical development and regulatory approval. We expect that the bulk of our development expenses over the next two years will support the advancement of our clinical-stage product candidates.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">To date, the Company has not obtained any regulatory approvals for any of its product candidates, commercialized any of its product candidates or generated any product revenue. The Company is subject to several risks common to clinical-stage biopharmaceutical companies, including dependence on key individuals, competition from other companies, the need to develop commercially viable products in a timely and cost-effective manner, and the need to obtain adequate additional capital to fund the development of product candidates. The Company is also subject to several risks common to other companies in the industry, including rapid technology change, regulatory </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">approval of products, uncertainty of market acceptance of products, competition from substitute products, competition from larger companies with recognized brands, greater capital resources and higher levels of dedicated staff, and compliance with government regulations, protection of proprietary technology, dependence on third parties, and product liability.</font></div><div><a name="s4E8C69597F555D99962FCB3D4317F3E2"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">GOING CONCERN</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, as of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company had an accumulated deficit of approximately </font><font style="font-family:Arial;font-size:10pt;">$36.8 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and had cash and cash equivalents of approximately </font><font style="font-family:Arial;font-size:10pt;">$5.6 million</font><font style="font-family:Arial;font-size:10pt;">. The Company also had negative cash flow from operations of approximately </font><font style="font-family:Arial;font-size:10pt;">$6.3 million</font><font style="font-family:Arial;font-size:10pt;">&#32;during the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#32;In March of 2019, the Company announced that it received a second Notice of Award for an additional </font><font style="font-family:Arial;font-size:10pt;">$982,851</font><font style="font-family:Arial;font-size:10pt;">&#32;of the anticipated </font><font style="font-family:Arial;font-size:10pt;">$1.9 million</font><font style="font-family:Arial;font-size:10pt;">&#32;from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or the NIH Grant, which is being applied to the clinical development efforts supporting Ovaprene. As of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company recorded a receivable in the amount of </font><font style="font-family:Arial;font-size:10pt;">$456,484</font><font style="font-family:Arial;font-size:10pt;">&#32;for expenses eligible for reimbursement under the NIH Grant that were incurred through </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">. See Note 9, "Grant Award," herein. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In April of 2019, the Company completed a sale of common stock raising net proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$5.2 million</font><font style="font-family:Arial;font-size:10pt;">. See Note 6, "Stockholders' Equity," herein. The Company needs to raise additional capital to continue to fund its operations and to successfully execute its current operating plan, including the development of its current product candidates. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has a history of losses from operations, expects negative cash flows from its operations will continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops its existing product candidates and seeks to acquire, license or develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is focused primarily on the development and commercialization of innovative products in women&#8217;s health. The Company will continue to incur significant research and development and other expenses related to these activities. If the clinical trials for any of the Company&#8217;s product candidates fail to produce successful results such that those product candidates do not advance in clinical development, then the Company&#8217;s business and prospects may suffer. Even if the product candidates advance in clinical development, they may fail to gain regulatory approval. Even if the product candidates are approved, they may fail to achieve market acceptance, and the Company may never become profitable. Even if the Company becomes profitable, it may not sustain profitability.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company believes that its current available cash resources will be sufficient to fund planned operations into the first quarter of 2020. For the foreseeable future, the Company's ability to continue its operations will depend on its ability to obtain additional capital.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is currently evaluating a variety of capital raising options, including financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements to cover its operating expenses, including the development of its product candidates and any future product candidates it may license or otherwise acquire. The amount and timing of the Company's capital needs have been and will continue to depend highly on many factors, including the product development programs the Company chooses to pursue and the pace and results of its clinical development efforts. If the Company raises capital through collaborations, strategic alliances or other similar types of arrangements, it may have to relinquish, on terms that are not favorable to the Company, rights to some of its technologies or product candidates it would otherwise seek to develop or commercialize. There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. Additionally, equity or debt financings may have a dilutive effect on the holdings of the Company's existing stockholders. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sFA2C1AF6698B5734AC15EC9088F10CC9"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s significant accounting policies are described in Note 1 to the interim consolidated financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, filed with the Securities and Exchange Commission, or SEC on April 1, 2019. Since the date of those consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies, except as described below.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#8217;s opinion, the accompanying interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying interim consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use, or ROU, lease assets, current portion of lease obligations, and long-term lease obligations on the Company's balance sheets.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. If the lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease and the related payments are only included in the lease liability when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. (See Note 7, Leased Properties.)</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 2: inputs other than level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents of </font><font style="font-family:Arial;font-size:10pt;">$5.6 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$6.8 million</font><font style="font-family:Arial;font-size:10pt;">&#32;are measured at fair value as of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, respectively, and are classified within Level 1 of the fair value hierarchy. Other receivables are financial assets with carrying values that approximate fair value due to the short-term nature of these assets. Accounts payable and accrued expenses and other liabilities are financial liabilities with carrying values that approximate fair value due to the short-term nature of these liabilities.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Standards</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2014, FASB issued Accounting Standards Update, or ASU, 2014-09, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Arial;font-size:10pt;">, which impacts the way in which some entities recognize revenue for certain types of transactions. The new standard became effective beginning in 2018 for public companies. Because the Company does not currently have any contracts with customers, the Company&#8217;s adoption of this accounting standard did not impact the Company&#8217;s interim consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2016, FASB issued ASU 2016-02, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Arial;font-size:10pt;">, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The new standard is effective for public companies for fiscal years beginning after December&#160;15, 2018, with early adoption permitted. ASU 2016-02 became effective for the Company on January 1, 2019 and was adopted using a modified retrospective approach and the effective date is as of the initial application. Consequently, financial information was not updated, and the disclosures required under ASU 2016-02 are not provided for dates and periods prior to January 1, 2019. ASU 2016-02 provides a number of optional practical expedients and accounting policy elections. The Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases. The Company recorded approximately </font><font style="font-family:Arial;font-size:10pt;">$232,000</font><font style="font-family:Arial;font-size:10pt;">&#32;right-of-use assets and </font><font style="font-family:Arial;font-size:10pt;">$241,000</font><font style="font-family:Arial;font-size:10pt;">&#32;lease liabilities related to its lease of office space as of the adoption date in the consolidated balance sheets. There are no changes to the statement of operations or cash flows as a result of the adoption.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2017, FASB issued ASU 2017-01, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</font><font style="font-family:Arial;font-size:10pt;">, which intended to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The standard became effective for the Company on January 1, 2018. The Company&#8217;s early adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Disclosure Update and Simplification,</font><font style="font-family:Arial;font-size:10pt;">&#32;amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements relating to the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of income is required to be filed. This final rule was effective November 5, 2018. In accordance with the new rule, the Company added a Consolidated Statement of Stockholders' Equity in this report and elected to present a reconciliation in a single statement that shows the changes in stockholders' equity for each interim period, as well as each comparable period.</font></div><div><a name="sAD1E7CDB8E575045881A0EB54462A688"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ACQUISITIONS</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Cerulean/Private Dar&#233; Stock Purchase Transaction</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In </font><font style="font-family:Arial;font-size:10pt;">July 2017</font><font style="font-family:Arial;font-size:10pt;">, the Company completed its business combination with Dar&#233; Bioscience Operations, Inc., a privately held Delaware corporation, or Private Dar&#233;, in which Private Dar&#233; stockholders sold their shares to the Company in exchange for newly issued shares of the Company&#8217;s common stock, and as a result, Private Dar&#233; became a wholly owned subsidiary of the Company and the Private Dar&#233; stockholders became majority stockholders of the Company. In connection with the closing of that transaction, the Company changed its name from &#8220;Cerulean Pharma Inc.&#8221; to &#8220;Dar&#233; Bioscience, Inc.&#8221; In this report, that transaction is referred to as the Cerulean/Private Dar&#233; stock purchase transaction and &#8220;Cerulean&#8221; refers to Cerulean Pharma Inc. before that transaction closed.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Cerulean/Private Dar&#233; stock purchase transaction was accounted for as a reverse merger under the acquisition method of accounting whereby Private Dar&#233; was considered to have acquired Cerulean for financial reporting purposes. Pursuant to business combination accounting, the Company applied the acquisition method, which requires the assets acquired and liabilities assumed be recorded at fair value with limited exceptions. The excess of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the purchase price over the assets acquired and liabilities assumed represents goodwill. The goodwill was primarily attributable to the cash and cash equivalents at closing of the transaction of approximately </font><font style="font-family:Arial;font-size:10pt;">$9.9 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and the impact of the unamortized fair value of stock options granted by Cerulean that were outstanding immediately before the transaction closed of approximately </font><font style="font-family:Arial;font-size:10pt;">$3.7 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company tests its goodwill for impairment at least annually as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31</font><font style="font-family:Arial;font-size:10pt;">&#32;and between annual tests if it becomes aware of an event or change in circumstance that would indicate the carrying value may be impaired. The Company tests goodwill for impairment at the entity level because it operates on the basis of a single reporting unit. A goodwill impairment is the amount by which a reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. When impaired, the carrying value of goodwill is written down to fair value. Any excess of the reporting unit goodwill carrying value over the fair value is recognized as impairment loss.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company assessed goodwill at March 31, 2018, determined there was an impairment and recognized an impairment charge of approximately </font><font style="font-family:Arial;font-size:10pt;">$5.2 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the interim consolidated statement of operations and comprehensive loss for the three months ended March 31, 2018. As of March 31, 2018, the goodwill carrying value on the Company&#8217;s consolidated balance sheet was written off in its entirety.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Pear Tree Merger</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On </font><font style="font-family:Arial;font-size:10pt;">April&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company entered into an Agreement and Plan of Merger, the Merger Agreement, with Pear Tree Pharmaceuticals, Inc., or Pear Tree, Dar&#233; Merger Sub, Inc., a wholly-owned subsidiary of the Company, or Merger Sub, and two individuals in their respective capacities as Pear Tree stockholders&#8217; representatives. The transactions contemplated by the Merger Agreement closed on </font><font style="font-family:Arial;font-size:10pt;">May&#160;16, 2018</font><font style="font-family:Arial;font-size:10pt;">, and as a result, Pear Tree became the Company&#8217;s wholly owned subsidiary. The Company acquired Pear Tree to secure the rights to develop DARE-VVA1, a proprietary vaginal formulation of tamoxifen, as a potential treatment for vulvar and vaginal atrophy.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company determined that the acquisition of Pear Tree should be accounted for as an asset acquisition instead of a business combination because substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, and therefore, the asset is not considered a business. Transaction costs of approximately </font><font style="font-family:Arial;font-size:10pt;">$452,000</font><font style="font-family:Arial;font-size:10pt;">&#32;associated with the merger were included in the Company&#8217;s research and development expense.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under the Merger Agreement, certain former and continuing Pear Tree service providers and former holders of Pear Tree&#8217;s capital stock, or the Holders, were eligible to receive a </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;">&#32;payment due on the one-year anniversary of the closing of the merger and are eligible to receive tiered royalties, subject to customary provisions permitting royalty reductions and offset, based on percentages of annual net sales of certain products subject to license agreements the Company assumed and a percentage of sublicense revenue. The Company must also make contingent payments to the Holders based on achieving certain clinical, regulatory and commercial milestones, which may be paid, in the Company&#8217;s sole discretion, in cash or shares of the Company&#8217;s common stock.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In accordance with the terms of the Merger Agreement, because the Negative Consideration Amount (as defined below) exceeded the Positive Consideration Amount (as defined below), at the time of the closing of the merger, the excess amount (approximately </font><font style="font-family:Arial;font-size:10pt;">$132,000</font><font style="font-family:Arial;font-size:10pt;">) offset the </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;">&#32;payment due on the </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;">-year anniversary of the closing of the merger and the balance will offset future payments otherwise due under the Merger Agreement to the Holders. Positive Consideration Amount means the sum of </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;">, and the cash and cash equivalents held by Pear Tree at closing, and Negative Consideration Amount means the sum of (i) certain Pear Tree indebtedness and transaction expenses, (ii) transaction expenses of the stockholders&#8217; representatives, and (iii) amounts payable under Pear Tree&#8217;s management incentive plan. </font></div><div><a name="sD205B600B8725DD8985DB67A37AAE4E7"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">STOCK-BASED COMPENSATION</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">The 2015 Employee, Director and Consultant Equity Incentive Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to the Cerulean/Private Dar&#233; stock purchase transaction, Private Dar&#233; maintained the 2015 Employee, Director and Consultant Equity Incentive Plan, or the 2015 Private Dar&#233; Plan. Upon closing of the Cerulean/Private Dar&#233; stock purchase transaction, the Company assumed the 2015 Private Dar&#233; Plan and each then outstanding award granted thereunder, which consisted of options and restricted stock. Based on the exchange ratio for the Cerulean/Private Dar&#233; stock purchase transaction and after giving effect to the reverse stock split effected in connection with the closing of that transaction, the outstanding options and restricted stock awards granted under the  2015 Private Dar&#233; Plan were replaced with options to purchase </font><font style="font-family:Arial;font-size:10pt;">10,149</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of the Company&#8217;s common stock with a correspondingly adjusted exercise price, all of which were outstanding as of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">223,295</font><font style="font-family:Arial;font-size:10pt;">&#32;restricted shares of the Company&#8217;s common stock. Those options are fully vested and expire in December 2025.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No further awards may be granted under the 2015 Private Dar&#233; Plan following the closing of the Cerulean/Private Dar&#233; stock purchase transaction.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">2014 Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s 2014 Employee Stock Purchase Plan, or the ESPP, became effective in April 2014, but no offering period has been initiated thereunder since January 2017 and there was </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;">&#32;stock-based compensation related to the ESPP for the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Amended and Restated 2014 Stock Incentive Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company maintains the Amended and Restated 2014 Plan, or the Amended 2014 Plan. There were </font><font style="font-family:Arial;font-size:10pt;">2,046,885</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of common stock authorized for issuance under the Amended 2014 Plan when it was approved by the Company's stockholders in July 2018. The number of authorized shares increases annually on the first day of each fiscal year until, and including, the fiscal year ending December 31, 2024 by the least of (i) </font><font style="font-family:Arial;font-size:10pt;">2,000,000</font><font style="font-family:Arial;font-size:10pt;">, (ii) </font><font style="font-family:Arial;font-size:10pt;">4%</font><font style="font-family:Arial;font-size:10pt;">&#32;of the number of outstanding shares of common stock on such date, or (iii) an amount determined by the Company&#8217;s board of directors. On January 1, 2019, the number of authorized shares increased by </font><font style="font-family:Arial;font-size:10pt;">456,886</font><font style="font-family:Arial;font-size:10pt;">&#32;to </font><font style="font-family:Arial;font-size:10pt;">2,503,771</font><font style="font-family:Arial;font-size:10pt;">, which increase represented </font><font style="font-family:Arial;font-size:10pt;">4%</font><font style="font-family:Arial;font-size:10pt;">&#32;of the number of outstanding shares of common stock on such date.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Summary of Stock Option Activity</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below summarizes stock option activity under the Amended 2014 Plan, and related information for the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">. The exercise price of all options granted during the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;was equal to the market value of the Company&#8217;s common stock on the date of the grant. As of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, unamortized stock-based compensation expense of </font><font style="font-family:Arial;font-size:10pt;">$1,348,159</font><font style="font-family:Arial;font-size:10pt;">&#32;will be amortized over a weighted average period of </font><font style="font-family:Arial;font-size:10pt;">2.9 years</font><font style="font-family:Arial;font-size:10pt;">. At </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">497,032</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of common stock were reserved for future issuance under the Amended 2014 Plan.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Outstanding at December 31, 2018 (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,635,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">698,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.79</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Canceled/forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(316,832</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24.55</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">59.48</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Outstanding at June 30, 2019 (unaudited) (1)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,016,888</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exercisable at June&#160;30, 2019 (unaudited)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">427,702</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">21.83</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:0px;padding-top:8px;text-indent:0px;"><font style="padding-top:8px;font-family:Arial;font-size:10pt;padding-right:48px;">(1)</font><font style="font-family:Arial;font-size:10pt;">Includes </font><font style="font-family:Arial;font-size:10pt;">10,149</font><font style="font-family:Arial;font-size:10pt;">&#32;shares subject to options granted under the 2015 Private Dar&#233; Plan assumed in connection with the Cerulean/Private Dar&#233; stock purchase transaction.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Compensation Expense</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total stock-based compensation expense related to stock options granted to employees and directors recognized in the consolidated statement of operations is as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br>June 30,</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Six Months Ended<br>June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26,996</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">51,699</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">84,355</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,423</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">157,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18,547</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">111,351</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,423</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">209,319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18,547</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;padding-bottom:24px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br>June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Six Months Ended<br>June 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected life in years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.0</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.09%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.58%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">123%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">121%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Forfeiture rate</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.0%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.0%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.0%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Weighted-average fair value of options granted</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$0.86</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$0.75</font></div></td></tr></table></div></div><div><a name="s1862E2F90F8C5D9CA1803F0447887702"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">STOCKHOLDERS&#8217; EQUITY</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">ATM Sales Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2018, the Company entered into a common stock sales agreement under which the Company may sell up to an aggregate of </font><font style="font-family:Arial;font-size:10pt;">$10 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in gross proceeds through the sale of shares of common stock from time to time in &#8220;at-the-market&#8221; equity offerings (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended). The Company will pay a commission of up to </font><font style="font-family:Arial;font-size:10pt;">3%</font><font style="font-family:Arial;font-size:10pt;">&#32;of the gross proceeds of any common stock sold under this agreement plus certain legal expenses. This agreement was amended in August 2018 to refer to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-227019) that was filed to replace the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-206396) that expired on August 28, 2018.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company sold </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;">&#32;shares under this agreement during either the three or six months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;or the three months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">. During the six months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company sold an aggregate of </font><font style="font-family:Arial;font-size:10pt;">375,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares common stock under this agreement for gross proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$1.1 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and incurred issuance costs of </font><font style="font-family:Arial;font-size:10pt;">$237,403</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">February 2018 Underwritten Public Offering</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2018, the Company closed an underwritten public offering of </font><font style="font-family:Arial;font-size:10pt;">5.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of its common stock and warrants to purchase up to </font><font style="font-family:Arial;font-size:10pt;">3.5 million</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of its common stock. Each share of common stock was sold with a warrant to purchase up to </font><font style="font-family:Arial;font-size:10pt;">0.70</font><font style="font-family:Arial;font-size:10pt;">&#32;of a share of the Company&#8217;s common stock. The Company granted the underwriter a </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;">-day over-allotment option to purchase up to an additional </font><font style="font-family:Arial;font-size:10pt;">750,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of common stock and/or warrants to purchase up to </font><font style="font-family:Arial;font-size:10pt;">525,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of common stock.&#160; The underwriter exercised the option with respect to warrants to purchase </font><font style="font-family:Arial;font-size:10pt;">220,500</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of common stock. The Company received gross proceeds of </font><font style="font-family:Arial;font-size:10pt;">$10.3 million</font><font style="font-family:Arial;font-size:10pt;">, including the proceeds from the sale of the warrants upon exercise of the underwriter&#8217;s over-allotment option, and net proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$9.4 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Warrants</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The warrants issued in the February 2018 underwritten offering initially had an exercise price of </font><font style="font-family:Arial;font-size:10pt;">$3.00</font><font style="font-family:Arial;font-size:10pt;">&#32;per share and</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:10pt;">are exercisable through February 2023.</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:10pt;">The warrants include a price-based anti-dilution provision, which provides that, subject to certain limited exceptions, the exercise price of the warrants will be reduced each time the Company issues or sells securities for a consideration per share less than a price equal to the exercise price of those warrants in effect immediately prior to such issuance or sale. In addition, subject to certain exceptions, if the Company issues, sells or enters into any agreement to issue or sell securities at a price which varies or may vary with the market price of the shares of the Company&#8217;s common stock, the warrant holders have the right to substitute such variable price for the exercise price of the warrant then in effect. These warrants are exercisable only for cash, unless a registration statement covering the shares issued upon exercise of the warrants is not effective, in which case the warrants may be exercised on a cashless basis. A registration statement covering the shares issued upon exercise of the warrants is currently effective. The Company estimated the fair value of the warrants as of February 15, 2018 to be approximately </font><font style="font-family:Arial;font-size:10pt;">$3.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;which has been recorded in equity as of the grant date. The Company early adopted ASU 2017-11 as of January 1, 2018 and recorded the fair value of the warrants as equity. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On April 11, 2019, in accordance with the anti-dilution provision of these warrants and as a result of the sale of shares in the public offering that closed on that date and which is discussed below, the exercise price of these warrants was automatically reduced to </font><font style="font-family:Arial;font-size:10pt;">$0.98</font><font style="font-family:Arial;font-size:10pt;">&#32;per share. For the three and six months ended June 30, 2019 the Company recorded </font><font style="font-family:Arial;font-size:10pt;">$0.8 million</font><font style="font-family:Arial;font-size:10pt;">&#32;to additional paid in capital as a result of the triggering of the anti-dilution provisions.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to the warrants issued in the February 2018 underwritten offering, as of June 30, 2019, there are outstanding warrants to purchase </font><font style="font-family:Arial;font-size:10pt;">30,333</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of the Company&#8217;s common stock, which are further described in the table below. </font></div><div style="line-height:120%;padding-top:8px;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No</font><font style="font-family:Arial;font-size:10pt;">&#32;warrants were exercised during the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">2018</font><font style="font-family:Arial;font-size:10pt;">. As of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company had the following warrants outstanding:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:34%;"></td><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:23%;"></td><td style="width:4%;"></td><td style="width:31%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Shares Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Outstanding Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Expiration Date</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,906</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120.40</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;1, 2021</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,737</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120.40</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;6, 2021</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17,190</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">60.50</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">January&#160;8, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,500</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">April&#160;4, 2026</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,720,500</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.98</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">February&#160;15, 2023</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,750,833</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">April 2019 Underwritten Public Offering</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On April 11, 2019, the Company closed an underwritten public offering of </font><font style="font-family:Arial;font-size:10pt;">4,575,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of its common stock at a public offering price of </font><font style="font-family:Arial;font-size:10pt;">$1.10</font><font style="font-family:Arial;font-size:10pt;">&#32;per share. The Company granted the underwriters a </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;">-day over-allotment option to purchase up to an additional </font><font style="font-family:Arial;font-size:10pt;">686,250</font><font style="font-family:Arial;font-size:10pt;">&#32;shares which was exercised in full on April 12, 2019. Including the over-allotment shares, the Company issued a total of </font><font style="font-family:Arial;font-size:10pt;">5,261,250</font><font style="font-family:Arial;font-size:10pt;">&#32;shares in the underwritten public offering, and received gross proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$5.8 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and net proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$5.2 million</font><font style="font-family:Arial;font-size:10pt;">&#32;after deducting underwriting discounts and offering expenses.</font></div><div><a name="s6BDA4062E86E5054A887234DD2BAFFE8"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">LEASED PROPERTIES</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effective January 1, 2019, the Company adopted ASC 842, which requires recognition of a right-of-use asset and lease liability for all leases at the commencement date based on the present value of lease payments over the lease term. Additional qualitative and quantitative disclosures regarding the Company's leasing arrangements are also required. The Company adopted ASC 842 prospectively and elected the package of transition practical expedients that does not require reassessment of: (1) whether any existing or expired contracts are or contain leases, (2) lease classification and (3) initial direct costs. In addition, the Company has elected other available practical expedients to not separate lease and nonlease components, which consist principally of common area maintenance charges, for all classes of underlying assets and to exclude leases with an initial term of 12 months or less.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company's lease for its corporate headquarters (</font><font style="font-family:Arial;font-size:10pt;">3,169</font><font style="font-family:Arial;font-size:10pt;">&#32;square feet of office space) commenced on July 1, 2018, has term of </font><font style="font-family:Arial;font-size:10pt;">37 months</font><font style="font-family:Arial;font-size:10pt;">, and terminates on July 31, 2021. The Company has the option to extend the term of the lease for </font><font style="font-family:Arial;font-size:10pt;">one year</font><font style="font-family:Arial;font-size:10pt;">&#32;at the Company's discretion. The gross monthly base rent is </font><font style="font-family:Arial;font-size:10pt;">$8,873</font><font style="font-family:Arial;font-size:10pt;">, which increases approximately </font><font style="font-family:Arial;font-size:10pt;">4%</font><font style="font-family:Arial;font-size:10pt;">&#32;per year, subject to certain future adjustments. The base rent was abated during the second month of the lease. The Company evaluates renewal options at lease inception and on an ongoing basis, and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The lease does not require material variable lease payments, a residual value guarantee or restrictive covenants. This is the Company&#8217;s only lease.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The lease does not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company used an incremental borrowing rate of </font><font style="font-family:Arial;font-size:10pt;">7%</font><font style="font-family:Arial;font-size:10pt;">&#32;as of January 1, 2019 for the operating lease that commenced prior to that date. The depreciable lives of operating lease assets and leasehold improvements are limited by the expected lease term.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company recorded a right of use asset of </font><font style="font-family:Arial;font-size:10pt;">$193,399</font><font style="font-family:Arial;font-size:10pt;">&#32;in other non-current assets, and </font><font style="font-family:Arial;font-size:10pt;">$87,859</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$116,089</font><font style="font-family:Arial;font-size:10pt;">, respectively, in current and non-current other liabilities on the consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, future minimum lease payments for the Company's corporate headquarters are:</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Years ending December 31:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Remainder of 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">55,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">112,943</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">67,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total future minimum lease payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">236,069</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Less: Difference between future minimum lease payments and discounted operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">42,669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total operating lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">193,400</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Operating lease costs were&#160;</font><font style="font-family:Arial;font-size:10pt;">$27,038</font><font style="font-family:Arial;font-size:10pt;">&#160;and </font><font style="font-family:Arial;font-size:10pt;">$54,076</font><font style="font-family:Arial;font-size:10pt;">&#32;for the three and six months ended&#160;</font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, respectively. Operating lease costs are included in general and administrative expenses in the condensed consolidated statement of operations. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash paid for amounts included in the measurement of operating lease liabilities were&#160;</font><font style="font-family:Arial;font-size:10pt;">$26,620</font><font style="font-family:Arial;font-size:10pt;">&#160;and </font><font style="font-family:Arial;font-size:10pt;">$53,240</font><font style="font-family:Arial;font-size:10pt;">&#32;for the three and six months ended&#160;</font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, respectively, and these amounts are included in operating activities in the condensed consolidated statements of cash flows. </font></div><div><a name="sA1917968807158998917A68E84EFA631"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">License and Research Agreements</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">ADVA-Tec License Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In March 2017, the Company entered into a license agreement, or the ADVA-Tec License Agreement, with ADVA-Tec, Inc., or ADVA-Tec, under which the Company was granted the exclusive right to develop and commercialize Ovaprene for human contraceptive use worldwide. ADVA-Tec and its affiliates own issued patents or patent applications covering Ovaprene and control proprietary trade secrets covering the manufacture of Ovaprene. As of the date of this report, this patent portfolio includes </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;">&#32;issued U.S. patents and </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;">&#32;pending U.S. patent application, and </font><font style="font-family:Arial;font-size:10pt;">59</font><font style="font-family:Arial;font-size:10pt;">&#32;granted patents and </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;">&#32;pending patent applications in other major markets, all of which are exclusively licensed to the Company for the human contraceptive use of Ovaprene as a human contraceptive device. Under the terms of the ADVA-Tec Agreement, the Company has a right of first refusal to license these patents and patent applications for additional indications.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of other terms of the ADVA-Tec License Agreement:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Research and Development.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">ADVA-Tec will conduct certain research and development work as necessary to allow the Company to seek a Premarket Approval, or PMA, from the United States Food and Drug Administration, or the FDA, and will supply the Company with its requirements of Ovaprene for clinical and commercial use on commercially reasonable terms. The Company must use commercially reasonable efforts to develop and commercialize Ovaprene, and must meet certain minimum spending amounts per year, such amounts totaling </font><font style="font-family:Arial;font-size:10pt;">$5.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate over the first </font><font style="font-family:Arial;font-size:10pt;">three years</font><font style="font-family:Arial;font-size:10pt;">, to cover such activities until a final PMA is filed, or until the first commercial sale of Ovaprene, whichever occurs first.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone Payments.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">The Company will pay ADVA-Tec: (1) up to </font><font style="font-family:Arial;font-size:10pt;">$14.6 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate based on the achievement of specified development and regulatory milestones; and (2) up to </font><font style="font-family:Arial;font-size:10pt;">$20 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate based on the achievement of certain worldwide net sales milestones. The development and regulatory milestones  include: the completion of a successful postcoital clinical study, which is required before the Company can commence a Phase 3 pivotal human clinical trial; approval by the FDA to commence such Phase 3 pivotal human clinical trial; successful completion of such Phase 3 pivotal human clinical trial; the FDA&#8217;s acceptance of a PMA filing for Ovaprene; the FDA&#8217;s approval of the PMA for Ovaprene; obtaining Conformit&#233; Europ&#233;enne Marking of Ovaprene in at least </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;">&#32;designated European countries; obtaining regulatory approval in at least three designated European countries; and obtaining regulatory approval in Japan. Because these milestone payments depend upon the successful progress of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the Company&#8217;s product development programs, the Company cannot estimate with certainty when these payments will occur, if ever.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For products currently in development, future potential milestone payments based on product development are approximately </font><font style="font-family:Arial;font-size:10pt;">$14.6 million</font><font style="font-family:Arial;font-size:10pt;">&#32;as of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">. Future potential milestone payments related to commercialization totaled </font><font style="font-family:Arial;font-size:10pt;">$20 million</font><font style="font-family:Arial;font-size:10pt;">&#32;at </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">. The Company is unable to estimate with certainty the timing on when these milestone payments will occur as these payments depend on the Company's product development programs.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Royalty Payments.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">After the commercial launch of Ovaprene, the Company will pay to ADVA-Tec royalties based on aggregate annual net sales of Ovaprene in specified regions, at a royalty rate that will vary between </font><font style="font-family:Arial;font-size:10pt;">1%</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">10%</font><font style="font-family:Arial;font-size:10pt;">&#32;and will increase based on various net sales thresholds. The Company is unable to estimate with certainty the timing on when these royalty payments will occur as these payments depend on the Company's product development programs.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Termination Rights.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">Unless earlier terminated, the license the Company received under the ADVA-Tec License Agreement continues on a country-by-country basis until the later of the life of the licensed patents or the Company's last commercial sale of Ovaprene. In addition to customary termination rights for both parties: (A) the Company may terminate the agreement with or without cause in whole or on a country-by-country basis upon </font><font style="font-family:Arial;font-size:10pt;">60</font><font style="font-family:Arial;font-size:10pt;">&#32;days prior written notice; and (B) ADVA-Tec may terminate the agreement if the Company develops or commercializes any non-hormonal ring-based vaginal contraceptive device competitive to Ovaprene or if the Company fails to: (1) in certain limited circumstances, commercialize Ovaprene in certain designated countries within three years of the first commercial sale of Ovaprene, (2) satisfy the annual spending obligation described above, (3) use commercially reasonable efforts to complete all necessary pre-clinical and clinical studies required to support and submit a PMA, (4) conduct clinical trials as set forth in the development plan that is agreed by the Company and ADVA-Tec, and as may be modified by a joint research committee, unless such failure is caused by events outside of the Company&#8217;s reasonable control, or (5) enroll a patient in the first non-significant risk medical device study or clinical trial as allowed by an institutional review board within </font><font style="font-family:Arial;font-size:10pt;">six months</font><font style="font-family:Arial;font-size:10pt;">&#32;of the production and release of Ovaprene, unless such failure is caused by events outside of its reasonable control.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">SST License and Collaboration Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2018, the Company entered into a license and collaboration agreement, or the SST License Agreement, with Strategic Science &amp;&#160;Technologies-D,&#160;LLC and Strategic Science &amp; Technologies, LLC, referred to collectively as SST. The SST License Agreement provides the Company with an exclusive, royalty-bearing, sublicensable license to develop and commercialize, in all countries and geographic territories of the world, for all indications for women related to female sexual dysfunction and/or female reproductive health, including treatment of female sexual arousal disorder, or the Field of Use, SST&#8217;s topical formulation of Sildenafil Cream, 3.6% as it exists as of the effective date of the SST License Agreement, or any other topically applied pharmaceutical product containing sildenafil or a salt thereof as a pharmaceutically active ingredient, alone or with other active ingredients, but specifically excluding any product containing ibuprofen or any salt derivative of ibuprofen, or the Licensed Products.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of other terms of the SST License Agreement:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Invention </font><font style="font-family:Arial;font-size:10pt;">Ownership</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">The Company retains rights to inventions made by its employees, SST retains rights to inventions made by its employees, and each party shall own a </font><font style="font-family:Arial;font-size:10pt;">50%</font><font style="font-family:Arial;font-size:10pt;">&#32;undivided interest in all joint inventions.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Joint </font><font style="font-family:Arial;font-size:10pt;">Development</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;Committee</font><font style="font-family:Arial;font-size:10pt;">. The parties will collaborate through a joint development committee that will determine the strategic objectives for, and generally oversee, the development efforts of both parties under the SST License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Development</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">The Company must use commercially reasonable efforts to develop the Licensed Products in the Field of Use in accordance with a development plan in the SST License Agreement, and to commercialize the Licensed Products in the Field of Use. The Company is responsible for all reasonable internal and external costs and expenses incurred by SST in its performance of the development activities it must perform under the SST License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Royalty </font><font style="font-family:Arial;font-size:10pt;">Payments.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">SST will be eligible to receive (1) tiered royalties based on percentages of annual net sales of Licensed Products in the single digits to the mid double digits, subject to customary royalty reductions and offsets, and (2) a percentage of sublicense revenue.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone Payments.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">SST will be eligible to receive payments (1) ranging from </font><font style="font-family:Arial;font-size:10pt;">$0.5 million</font><font style="font-family:Arial;font-size:10pt;">&#32;to </font><font style="font-family:Arial;font-size:10pt;">$18.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate on achieving certain clinical and regulatory milestones in the U.S. and worldwide, and (2) between </font><font style="font-family:Arial;font-size:10pt;">$10.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$100 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate upon achieving certain commercial sales milestones. If the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Company enters into strategic development or distribution partnerships related to the Licensed Products, additional milestone payments would be due to SST.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">License Term.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s license received under the SST License Agreement continues on a country-by-country basis until the later of </font><font style="font-family:Arial;font-size:10pt;">10 years</font><font style="font-family:Arial;font-size:10pt;">&#32;from the date of the first commercial sale of such Licensed Product or the expiration of the last valid claim of patent rights covering the Licensed Product in the Field of Use. Upon expiration (but not termination) of the SST License Agreement in a particular country, the Company will have a fully paid-up license under the licensed intellectual property to develop and commercialize the applicable Licensed Products in the applicable country on a non-exclusive basis.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Termination.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">In addition to customary termination rights for both parties: (1) prior to receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including New Drug Application Approval, or NDA Approval, the Company may terminate the SST License Agreement without cause upon </font><font style="font-family:Arial;font-size:10pt;">90</font><font style="font-family:Arial;font-size:10pt;">&#32;days prior written notice to SST; (2)&#160;following receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including NDA Approval, the Company may terminate the SST License Agreement without cause upon </font><font style="font-family:Arial;font-size:10pt;">180</font><font style="font-family:Arial;font-size:10pt;">&#160;days prior written notice; and (3) SST may terminate the SST License Agreement with respect to the applicable Licensed Product(s) in the applicable country(ies) upon </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;">&#160;days&#8217; notice to the Company if the Company fails to use commercially reasonable efforts to perform development activities in substantial accordance with the development plan and does not cure such failure within </font><font style="font-family:Arial;font-size:10pt;">60</font><font style="font-family:Arial;font-size:10pt;">&#160;days of receipt of SST&#8217;s notice thereof.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Orbis Development and Option Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In March 2018, the Company entered into an exclusive development and option agreement, or the Orbis Agreement, with Orbis Biosciences, or Orbis, for the development of long-acting injectable etonogestrel contraceptive with 6- and 12-month durations (ORB-204 and ORB-214, respectively). Under the Orbis Agreement, the  Company paid Orbis </font><font style="font-family:Arial;font-size:10pt;">$300,000</font><font style="font-family:Arial;font-size:10pt;">&#32;to conduct the first stage of development work, Stage 1, as follows: </font><font style="font-family:Arial;font-size:10pt;">$150,000</font><font style="font-family:Arial;font-size:10pt;">&#32;upon signing the Orbis Agreement, </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;">&#32;at the </font><font style="font-family:Arial;font-size:10pt;">50%</font><font style="font-family:Arial;font-size:10pt;">&#32;completion point, not later than 6 months following the date the Orbis Agreement was signed (which the Company paid in September 2018), and </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;">&#32;upon delivery by Orbis of the 6-month batch, not later than 11 months following the date the Orbis Agreement was signed (which the Company paid in January 2019). Upon Orbis successfully completing Stage 1 of the development program and achieving the predetermined target milestones for Stage 1, the Company will have </font><font style="font-family:Arial;font-size:10pt;">90</font><font style="font-family:Arial;font-size:10pt;">&#32;days to instruct Orbis whether to commence the second stage of development work, Stage 2. Should the Company execute its option to proceed to Stage 2, it will have to provide additional funding to Orbis for such activities. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pre-clinical studies for the 6- and 12-month formulations have been completed, including establishing pharmacokinetics and pharmacodynamics profiles. The collaboration with Orbis will continue to advance the program through formulation optimization with the goal of achieving sustained release over the target time period.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Orbis Agreement provides the Company with an option to enter into a license agreement for ORB-204 and ORB-214 should development efforts be successful.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Juniper Pharmaceuticals - License Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In April 2018,&#160;the Company entered into an Exclusive License Agreement, or the Juniper License Agreement, with Juniper Pharmaceuticals, Inc., or Juniper, under which Juniper granted the Company (a) an exclusive, royalty-bearing worldwide license under certain patent rights, either owned by or exclusively licensed to Juniper, to make, have made, use, have used, sell, have sold, import and have imported products and processes; and (b) a non-exclusive, royalty-bearing worldwide license to use certain technological information owned by Juniper to make, have made, use, have used, sell, have sold, import and have imported products and processes. The Company is entitled to sublicense the rights granted to it under the Juniper License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-indent:94px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of certain terms of the Juniper License Agreement:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Upfront Fee.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">The Company paid a </font><font style="font-family:Arial;font-size:10pt;">$250,000</font><font style="font-family:Arial;font-size:10pt;">&#32;non-creditable upfront license fee to Juniper in connection with the execution of the Juniper License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Annual Maintenance Fee</font><font style="font-family:Arial;font-size:10pt;">. The Company will pay an annual license maintenance fee to Juniper on each anniversary of the date of the Juniper License Agreement, the amount of which will be </font><font style="font-family:Arial;font-size:10pt;">$50,000</font><font style="font-family:Arial;font-size:10pt;">&#32;for the first two years and </font><font style="font-family:Arial;font-size:10pt;">$100,000</font><font style="font-family:Arial;font-size:10pt;">&#32;thereafter, and which will be creditable against royalties and other payments due to Juniper in the same calendar year but may not be carried forward to any other year.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone </font><font style="font-family:Arial;font-size:10pt;">Payments.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">The Company must make potential future development and sales milestone payments of (1) up to </font><font style="font-family:Arial;font-size:10pt;">$13.5 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate upon achieving certain clinical and regulatory milestones, and (2) </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">up to </font><font style="font-family:Arial;font-size:10pt;">$30.3 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate upon achieving certain commercial sales milestones for each product or process covered by the licenses granted under the Juniper License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Royalty Payments</font><font style="font-family:Arial;font-size:10pt;">. During the royalty term, the Company will pay Juniper mid-single-digit to low double-digit royalties based on worldwide net sales of products and processes covered by the licenses granted under the Juniper</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">License</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">Agreement. In lieu of such royalty payments, the Company will pay Juniper a low double-digit percentage of all sublicense income the Company receives for the sublicense of rights under the Juniper License Agreement to a third party. The royalty term, which is determined on a country-by-country basis and product-by-product basis (or process-by-process basis), begins with the first commercial sale of a product or process in a country and terminates on the latest of (1) the expiration date of the last valid claim within the licensed patent rights with respect to such product or process in such country, (2) </font><font style="font-family:Arial;font-size:10pt;">10 years</font><font style="font-family:Arial;font-size:10pt;">&#32;following the first commercial sale of such product or process in such country, and (3) when one or more generic products for such product or process are commercially available in such country, except that if there is no such generic product by the 10th year following the first commercial sale in such country, then the royalty term will terminate on the 10-year anniversary of the first commercial sale in such country.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Efforts</font><font style="font-family:Arial;font-size:10pt;">. The Company must use commercially reasonable efforts to develop and make at least one product or process available to the public, which efforts include achieving specific diligence requirements by specific dates specified in the Juniper License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">T</font><font style="font-family:Arial;font-size:10pt;">erm. Unless earlier terminated, the term of the Juniper License Agreement will continue on a country-by-country basis until the later of (1) the expiration date of the last valid claim within such country, or (2) 10 years from the date of first commercial sale of a product or process in such country. Upon expiration (but not early termination) of the Juniper License Agreement, the licenses granted thereunder will convert automatically to fully-paid irrevocable licenses. Juniper may terminate the Juniper License Agreement (1) upon </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;">&#32;days&#8217; notice for the Company&#8217;s uncured breach of any payment obligation under the Juniper License Agreement, (2) if the Company fails to maintain required insurance, (3) immediately upon the Company&#8217;s insolvency or the making of an assignment for the benefit of the Company&#8217;s creditors or if a bankruptcy petition is filed for or against the Company, which petition is not dismissed within </font><font style="font-family:Arial;font-size:10pt;">90 days</font><font style="font-family:Arial;font-size:10pt;">, or (4) upon </font><font style="font-family:Arial;font-size:10pt;">60</font><font style="font-family:Arial;font-size:10pt;">&#32;days&#8217; notice for any uncured material breach by the Company of any of its other obligations under the Juniper License Agreement. The Company may terminate the Juniper License Agreement on a country-by-country basis for any reason by giving </font><font style="font-family:Arial;font-size:10pt;">180</font><font style="font-family:Arial;font-size:10pt;">&#32;days&#8217; notice (or </font><font style="font-family:Arial;font-size:10pt;">90 days</font><font style="font-family:Arial;font-size:10pt;">&#8217; notice if such termination occurs prior to receipt of marketing approval in the United States). If Juniper terminates the Juniper License Agreement for the reason described in clause (4) above or if the Company terminates the Juniper License Agreement, Juniper will have full access including the right to use and reference all product data generated during the term of the Juniper License Agreement that is owned by the Company.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Pear Tree Acquisition</font></div><div style="line-height:120%;padding-top:8px;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company may be required to make certain royalty and milestone payments under the Merger Agreement (see Note 4).</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Hammock/MilanaPharm Assignment and License Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 5, 2018, the Company entered into (a) an Assignment Agreement with Hammock Pharmaceuticals, Inc., or the Assignment Agreement, and (b) a First Amendment to License Agreement with TriLogic Pharma, LLC and MilanaPharm LLC, or the License Amendment. Both agreements relate to the Exclusive License Agreement among Hammock, TriLogic and MilanaPharm dated as of January 9, 2017, or the MilanaPharm License Agreement. Under the Assignment Agreement and the MilanaPharm License Agreement, as amended by the License Amendment, the Company acquired an exclusive, worldwide license under certain intellectual property to, among other things, develop and commercialize products for the diagnosis, treatment and prevention of human diseases or conditions in or through any intravaginal or urological applications. The licensed intellectual property relates to the hydrogel drug delivery platform of TriLogic and MilanaPharm known as TRI-726. In DARE-BV1, this proprietary technology is formulated with clindamycin, an antibiotic used to treat certain bacterial infections, including BV, and has been engineered to produce a dual release pattern after vaginal application, providing maximum duration of exposure to clindamycin at the site of infection.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of other terms of the License Amendment:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">License Fees.</font><font style="font-family:Arial;font-size:10pt;">&#32;The Company paid </font><font style="font-family:Arial;font-size:10pt;">$25,000</font><font style="font-family:Arial;font-size:10pt;">&#32;to MilanaPharm in connection with the execution of the License Amendment and must pay </font><font style="font-family:Arial;font-size:10pt;">$200,000</font><font style="font-family:Arial;font-size:10pt;">&#32;to MilanaPharm (in the Company's discretion, either in cash or with shares of the Company's common stock) within 15 days of the first to occur of December 5, 2019 or the closing of an equity financing in which the Company raises aggregate proceeds of at least </font><font style="font-family:Arial;font-size:10pt;">$10.0 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone Payments.</font><font style="font-family:Arial;font-size:10pt;">&#32;The Company will pay to MilanaPharm (1) up to </font><font style="font-family:Arial;font-size:10pt;">$300,000</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate upon achievement of certain development milestones; and (2) up to </font><font style="font-family:Arial;font-size:10pt;">$1.75 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate upon achieving certain commercial sales milestones. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Foreign Sublicense Income.</font><font style="font-family:Arial;font-size:10pt;">&#32;The Company will pay MilanaPharm a low double-digit percentage of all income received by the Company or its affiliates in connection with any sublicense granted to a third party for use outside of the United States, subject to certain exclusions.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Royalty Payments.</font><font style="font-family:Arial;font-size:10pt;">&#32;During the royalty term, the Company will pay MilanaPharm high single-digit to low double-digit royalties based on annual worldwide net sales of licensed products and processes. The royalty term, which is determined on a country-by-country basis and licensed product-by-product basis (or process-by-process basis), begins with the first commercial sale of a licensed product or process in a country and terminates on the latest of (a) the expiration date of the last valid claim of the licensed patent rights that cover the method of use of such product or process in such country, or (b) 10 years following the first commercial sale of such product or process in such country. Royalty payments are subject to reduction in certain circumstances, including as a result of generic competition, patent prosecution expenses incurred by the Company, or payments to third parties for rights or know-how that are required for the Company to exercise the licenses granted to it under the MilanaPharm License Agreement or that are strategically important or could add value to a licensed product or process in a manner expected to materially generate or increase sales.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Efforts</font><font style="font-family:Arial;font-size:10pt;">. The Company must use commercially reasonable efforts and resources to (1) develop and commercialize at least one licensed product or process in the United States and at least one licensed product or process in at least one of Canada, the United Kingdom, France, Germany, Italy or Spain, and (2) continue to commercialize that product or process following the first commercial sale of a licensed product or process in the applicable jurisdiction.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Term</font><font style="font-family:Arial;font-size:10pt;">. Unless earlier terminated, the term of the MilanaPharm License Agreement will continue until (1) on a licensed product-by-product (or process-by-process basis) and country-by-country basis, the date of expiration of the royalty term with respect to such licensed product in such country, and (2) the expiration of all applicable royalty terms under the MilanaPharm License Agreement with respect to all licensed products and processes in all countries. Upon expiration of the term with respect to any licensed product or process in a country (but not upon earlier termination of the MilanaPharm License Agreement), the licenses granted to the Company under the MilanaPharm License Agreement will convert automatically to an exclusive, fully paid-up, royalty-free, perpetual, non-terminable and irrevocable right and license under the licensed intellectual property. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to customary termination rights for all parties, MilanaPharm may terminate the license granted to the Company solely with respect to a licensed product or process in a country if, after having launched such product or process in such country, (1) the Company, or its affiliates or sublicensees, discontinue the sale of such product or process in such country and MilanaPharm notifies the Company of such termination within 60 days of having first been notified by the Company of such discontinuation, or (2) the Company, or its affiliates or sublicensees, (A) discontinues all commercially reasonable marketing efforts to sell, and discontinues all sales of, such product or process in such country for nine months or more, (B) fails to resume such commercially reasonable marketing efforts within 120 days of having been notified of such failure by MilanaPharm, (C) fails to reasonably demonstrate a strategic justification for the discontinuation and failure to resume to MilanaPharm, and (D) MilanaPharm gives 90 days&#8217; notice to the Company.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of other terms of the Assignment Agreement with Hammock:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Assignment; Technology Transfer</font><font style="font-family:Arial;font-size:10pt;">. Hammock assigned and transferred to the Company all of its right, title and interest in and to the MilanaPharm License Agreement and agreed to cooperate to transfer to the Company all of the data, materials and the licensed technology in its possession pursuant to a technology transfer plan to be agreed upon by the parties, with a goal for the Company to independently practice the licensed intellectual property as soon as commercially practical in order to develop and commercialize the licensed products and processes. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Fees</font><font style="font-family:Arial;font-size:10pt;">. The Company paid </font><font style="font-family:Arial;font-size:10pt;">$250,000</font><font style="font-family:Arial;font-size:10pt;">&#32;to Hammock in connection with the execution of the Assignment Agreement and must pay </font><font style="font-family:Arial;font-size:10pt;">$250,000</font><font style="font-family:Arial;font-size:10pt;">&#32;to Hammock (in the Company's discretion either in cash or with shares of the Company's common stock) within 15 days of the first to occur of December 5, 2019 or the closing of an equity financing in which the Company raises aggregate proceeds of at least </font><font style="font-family:Arial;font-size:10pt;">$10.0 million</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone Payments</font><font style="font-family:Arial;font-size:10pt;">. The Company will pay Hammock up to </font><font style="font-family:Arial;font-size:10pt;">$1.1 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate upon achievement of certain clinical and regulatory development milestones.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Term</font><font style="font-family:Arial;font-size:10pt;">. The Assignment Agreement will terminate upon the later of (1) completion of the parties&#8217; technology transfer plan, and (2) payment to Hammock of the last of the payments described above, including the milestone payments.</font></div><div><a name="s6F85D529CE0D52E9B9A8C406761FFEA7"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">GRANT AWARD</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In April 2018, the Company received a Notice of Award for the first </font><font style="font-family:Arial;font-size:10pt;">$224,665</font><font style="font-family:Arial;font-size:10pt;">&#32;of the anticipated </font><font style="font-family:Arial;font-size:10pt;">$1.9 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, a division of the National Institutes of Health, or the NIH.&#160;The Company must incur and track expenses eligible for reimbursement under the award and submit a detailed accounting of such expenses to receive payment. The Company received all </font><font style="font-family:Arial;font-size:10pt;">$224,665</font><font style="font-family:Arial;font-size:10pt;">&#32;of the award payments under this Notice of Award. Such payments were applied to clinical development efforts supporting Ovaprene and were recognized in the statement of operations as a reduction to research and development activities as the related costs were incurred to meet those obligations over the period. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On March 11, 2019, the Company received a second Notice of Award for an additional </font><font style="font-family:Arial;font-size:10pt;">$982,851</font><font style="font-family:Arial;font-size:10pt;">&#32;of the anticipated </font><font style="font-family:Arial;font-size:10pt;">$1.9 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The second award followed the NIH's review of an interim data analysis and other results of the first phase of the research supporting Ovaprene. Award payments under this second notice of award (</font><font style="font-family:Arial;font-size:10pt;">$161,007</font><font style="font-family:Arial;font-size:10pt;">&#32;received through June 30, 2019) are being applied to clinical development efforts supporting Ovaprene. At June&#160;30, 2019, the Company recorded a receivable of </font><font style="font-family:Arial;font-size:10pt;">$456,484</font><font style="font-family:Arial;font-size:10pt;">&#32;for expenses incurred through such date that are eligible for reimbursement under this second notice of award.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The remaining portion of the award under the grant, </font><font style="font-family:Arial;font-size:10pt;">$730,722</font><font style="font-family:Arial;font-size:10pt;">, is contingent upon, among other matters, assessment that the results of the ongoing Ovaprene study satisfy specified requirements set out in the award notice, and the availability of funds.</font></div><div><a name="s611394C5CB945C42B9E667893071E656"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NET LOSS PER SHARE</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under outstanding options and warrants to purchase shares of the Company&#8217;s common stock. Common share equivalents are excluded from the diluted net loss per share calculation if their effect is anti-dilutive.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Potentially dilutive securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Three Months Ended<br>June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Six Months Ended<br>June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,190,360</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">547,571</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,190,360</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">547,571</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,750,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,751,002</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,750,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,751,002</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,941,193</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,298,573</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,941,193</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,298,573</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><a name="sDFD3CE0BD25C53E7AE0939B4E71AE0B9"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">The following discussion and analysis of financial condition and results of operations should be read in conjunction with our interim consolidated financial statements and notes thereto included in this Quarterly Report on Form 10-Q and our audited financial statements and notes thereto for the year ended December 31, 2018 included in our Annual Report on Form 10-K for the year ended December 31, 2018, or our 2018 10-K, filed with the Securities and Exchange Commission, or SEC, on April 1, 2019. Past operating results are not necessarily indicative of results that may occur in future periods.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;The following discussion includes forward-looking statements.&#160;See &#8220;CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS,&#8221; above. Forward-looking statements are not guarantees of future performance and our actual results may differ materially from those currently anticipated and from historical results depending upon a variety of factors, including, but not limited to, those discussed in Part I, Item 1A. Risk Factors in our 2018 10-K and in our subsequent filings with the SEC, including any discussed in Part II, Item 1A of this report under the heading &#8220;Risk Factors,&#8221; which are incorporated herein by reference.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In this report, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Dar&#233;&#8221; or the &#8220;Company&#8221; refer collectively to Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires. All information presented in this report is based on our fiscal year. Unless otherwise stated, references to particular years, quarters, months or periods refer to our fiscal years ending December 31 and the associated quarters, months and periods of those fiscal years.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dar&#233; Bioscience</font><font style="font-family:Arial;font-size:9pt;">&#174;</font><font style="font-family:Arial;font-size:10pt;">&#32;is a registered trademark of Dar&#233; Bioscience, Inc. Ovaprene</font><font style="font-family:Arial;font-size:9pt;">&#174;</font><font style="font-family:Arial;font-size:10pt;">&#32;is a registered trademark licensed to Dar&#233; Bioscience, Inc. All other trademarks, service marks or trade names appearing in this report are the property of their respective owners. Use or display by us of other parties&#8217; trademarks, service marks or trade names is not intended to and does not imply a relationship with, or endorsements or sponsorship of, us by the trademark, service mark or trade name owners.</font></div><div><a name="s82880118D30B58248FE2862E7F5069E1"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women&#8217;s health. We are driven by a mission to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. Our business strategy is to license or otherwise acquire the rights to differentiated product candidates in our areas of focus, some of which have existing clinical proof-of-concept data, and to take those candidates through advanced stages of clinical development. We and our wholly owned subsidiaries operate in one business segment.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Since July 2017, we have assembled a portfolio of clinical-stage and pre-clinical stage candidates addressing unmet needs in women's health. Our portfolio includes these six clinical-stage product candidates:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-BV1, a novel solution-to-gel formulation containing clindamycin phosphate 2% for bacterial vaginosis, or BV;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ovaprene&#174;, a non-hormonal monthly contraceptive intravaginal ring;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil for female sexual arousal disorder, or FSAD;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy, or HRT, following menopause;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy, or VVA, in patients with hormone-receptor positive breast cancer;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and for fertility support as part of an IVF treatment plan; and</font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our portfolio also includes these pre-clinical stage product candidates:</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:144px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-RH1, a novel approach to non-hormonal contraception for both men and women by targeting the CatSper ion channel;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ORB-204 and ORB-214, 6-month and 12-month formulations of injectable etonogestrel for contraception; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-OAB1, an intravaginal ring containing oxybutynin for the treatment of overactive bladder.</font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our primary operations have consisted of, and are expected to continue to consist of, product research and development and advancing our portfolio of product candidates through clinical development and regulatory approval. We expect that the bulk of our development expenses over the next two years will support the advancement of our clinical-stage product candidates.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">To date, we have not obtained any regulatory approvals for any of our product candidates, commercialized any of our product candidates or generated any revenue. We are subject to several risks common to clinical-stage biopharmaceutical companies, including dependence on key individuals, competition from other companies, the need to develop commercially viable products in a timely and cost-effective manner, and the need to obtain adequate additional capital to fund the development of product candidates. We are also subject to several risks common to other companies in the industry, including rapid technology change, regulatory approval of products, uncertainty of market acceptance of products, competition from substitute products and larger companies, compliance with government regulations, protection of proprietary technology, dependence on third parties, and product liability.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Clinical Stage Product Candidates</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following provides a brief overview of the clinical stage product candidates on which we are primarily focusing our development efforts at this time.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">DARE-BV1</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-BV1 is a novel solution-to-gel formulation containing clindamycin, an antibiotic used to treat certain bacterial infections, including BV. DARE-BV1 is designed to be administered in a convenient, single vaginal dose with a dual release pattern to prolong the duration of exposure to clindamycin at the site of infection and to potentially improve the rate of effectiveness compared to existing FDA-approved therapies. Current FDA-approved therapies for BV have clinical cure rates of less than 70 percent. In an investigator initiated proof-of-concept study that enrolled 30 women, DARE-BV1 demonstrated an 86 percent clinical cure rate in evaluable subjects (n=26) at the test-of-cure visit (Day 7-14) after one administration. We plan to utilize the FDA's 505(b)(2) pathway to obtain marketing approval of DARE-BV1 for BV in the U.S. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2019, the FDA granted DARE-BV1 Qualified Infectious Disease Product (QIDP) designation for the treatment of BV in women.  QIPD designation is available under Title VIII of the FDA Safety and Innovation Act, titled General Antibiotic Incentive Now (GAIN), which creates incentives for the development of antibacterial and antifungal drug products that treat serious or life-threatening infections. The primary incentive is a five-year exclusivity extension added to any exclusivity for which a QIDP qualifies upon FDA approval. Additionally, DARE BV-1's QIDP designation makes it eligible for Fast Track designation and Priority Review. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We expect to commence a Phase 3 clinical study of DARE-BV1 in approximately 250 women in the fourth quarter of 2019 and, if the study is successful, to be in a position to file a new drug application, or NDA, with the FDA in 2020. We anticipate that the cost of the Phase 3 clinical study, including manufacturing activities, and the NDA filing thereafter to be less than $10.0 million.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ovaprene</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ovaprene is an intravaginal ring that, if approved, would represent a new category of birth control. Ovaprene does not contain hormones and is designed to be worn conveniently over multiple weeks and to require no intervention at the time of intercourse. Ovaprene is a silicone-reinforced ring with a soft, absorbable scaffolding that encircles a fluid-permeable barrier. A polymer matrix in the center of the ring functions as a physical barrier to sperm. The silicone ring also releases ferrous gluconate to create a spermiostatic environment within the vagina. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ovaprene is a combination product and, following a request for designation process, the FDA designated Center for Devices and Radiological Health, or CDRH, as the lead agency FDA program center for premarket review and product regulation. CDRH has determined that a PMA will be required to market Ovaprene in the U.S. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2018, we announced initiation of a postcoital test, or PCT, clinical trial of Ovaprene and in July 2019 we announced that we completed recruitment. &#160;This ongoing clinical trial is designed to assess general safety, acceptability, and effectiveness in preventing progressively motile sperm, or PMS, from reaching the cervical canal following intercourse. The study will enroll approximately 50 couples, with the woman to be evaluated over the course of five menstrual cycles, with a target of having approximately 25 women complete a total of 21 visits. Each woman&#8217;s cervical mucus will be measured at several points during the study, including a baseline measurement at menstrual cycle 1 that excludes the use of any product. Subsequent cycles and visits will include the use of a diaphragm (menstrual cycle 2) and Ovaprene (menstrual cycles 3, 4 and 5). Topline data from the PCT clinical trial are expected to be available in the fourth quarter of 2019. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PCT clinical trials have been used as a surrogate marker for contraceptive effectiveness. Infertility research suggests that higher rates of pregnancy are associated with PMS per high power field, or HPF, of from greater than one to greater than 20 sperm, and less than 5 PMS per HPF is considered reflective of contraceptive effectiveness.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If the PCT clinical trial demonstrates that less than 5 PMS per HPF progressed into the cervical canal in most women and that Ovaprene can be safely worn over multiple weeks, we intend to prepare and file an Investigational Device Exemption, or IDE, with the FDA to commence a pivotal clinical trial to support marketing approvals of Ovaprene in the United States, Europe and other countries worldwide.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Sildenafil Cream, 3.6%</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sildenafil Cream, 3.6%, which incorporates sildenafil, the same active ingredient in the male erectile dysfunction drug Viagra&#174;, if approved, could be the first FDA-approved FSAD treatment option for women. FSAD is characterized primarily by a persistent or recurrent inability to attain or maintain sufficient physical sexual arousal, frequently resulting in distress or interpersonal difficulty. Sildenafil Cream, 3.6% is formulated to increase blood flow locally to the vulvar-vaginal tissue, leading to a potential improvement in genital arousal response. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We plan to leverage the existing data and established safety profile of sildenafil and the Viagra&#174; brand to utilize the FDA&#8217;s 505(b)(2) pathway to obtain marketing approval of Sildenafil Cream, 3.6% in the U.S. During the third quarter of 2018, we had a Type C meeting with the FDA regarding the design of our Phase 2b clinical trial for Sildenafil Cream, 3.6% and the overall development program for this product candidate. Based on the FDA guidance we received from that meeting, we commenced Phase 2b related activities during the fourth quarter of 2018 with the initiation of a non-interventional content validity study intended to support the validity of specific patient reported outcome, or PRO, measures. This study seeks to identify and document the genital arousal symptoms that will be assessed in our planned at-home Phase 2b trial, as well as our Phase 3 studies, and to demonstrate that these symptoms are the most important and relevant to our target population and are also acceptable endpoints for the FDA. We are in the final stages of completing this study. We believe that completing this study will be a significant de-risking event for our Sildenafil Cream, 3.6% program because it will position us to hold a Type C meeting with the FDA to review the study's findings and&#160;to obtain the FDA&#8217;s guidance on the endpoints for our Phase 2b and Phase 3 clinical trials, including whether the FDA agrees that the PRO instruments are content valid for the target population. Our plan is for the endpoints used in the Phase 2b trial to reflect the endpoints used in the Phase 3 trial. The timing of when we initiate the Phase 2b at-home trial will be influenced by  the FDA's guidance. We continue to explore additional clinical and non-clinical work that might be valuable or required to support the overall program and anticipated design of the Phase 2b trial. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-HRT1</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-HRT1 is an intravaginal ring, or IVR, containing bio-identical estradiol and bio-identical progesterone to treat the vasomotor symptoms (VMS) associated with menopause as part of a hormone replacement therapy regimen. There are currently no FDA-approved IVRs that deliver bio-identical progesterone in combination with bio-identical estradiol. The IVR technology used in DARE-HRT1 was developed by Dr. Robert Langer from the Massachusetts Institute of Technology and Dr. William Crowley from Massachusetts General Hospital and Harvard Medical School. We plan to utilize the FDA's 505(b)(2) pathway to obtain marketing approval of DARE-HRT1 in the U.S. We intend to initiate a Phase 1 clinical study for DARE-HRT1 during 2019 and to report topline results in 2020. DARE-HRT1 has the potential to be a first-in-class product. </font></div><div><a name="s6D76B02E0527586CB803B58485B4CB97"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Financial Overview</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We incurred a loss of approximately </font><font style="font-family:Arial;font-size:10pt;">$7.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">. As of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, we had (a) an accumulated deficit of approximately </font><font style="font-family:Arial;font-size:10pt;">$36.8 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and (b) cash and cash equivalents of approximately </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$5.6 million</font><font style="font-family:Arial;font-size:10pt;">. We also had negative cash flow from operations of approximately </font><font style="font-family:Arial;font-size:10pt;">$6.3 million</font><font style="font-family:Arial;font-size:10pt;">&#32;during the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">. As further discussed below, in an underwritten public offering we closed in April 2019, we received aggregate net proceeds of approximately $5.2 million. We will need to raise substantial additional capital to continue to fund our operations and to successfully execute our current operating plan, including the development of our current product candidates. The amount and timing of future funding will depend on many factors, including the pace and results of our clinical development efforts. If we do not raise capital as and when needed, we will not be able to continue development of our product candidates or we will be required to delay, scale back or eliminate some or all of our development programs or cease operations.</font></div><div><a name="s71B26BFD51095C59AC3E99852B93B49C"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Recent Events</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Underwritten Public Offering</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On April 11, 2019, we closed an underwritten public offering of 4,575,000 shares of our common stock at a public offering price of $1.10 per share. We granted the underwriters a 30-day over-allotment option to purchase up to an additional 686,250 shares, which was exercised in full on April 12, 2019. Including the over-allotment shares, we issued a total of 5,261,250 shares, and received gross proceeds of approximately $5.8 million and net proceeds of approximately $5.2 million after deducting underwriting discounts and offering expenses.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As a result of the sale of shares of our common stock in the offering described above, per the terms of the warrants we issued in February 2018, their exercise price was automatically reduced from $3.00 to $0.98 per share on April 11, 2019. For additional information, see Note 6 to our unaudited interim consolidated financial statements contained in this report.</font></div><div><a name="sB26A83CEDA7A58218DE38B102499DEFE"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Financial Operations Overview</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">To date we have not generated any revenue and do not expect to generate any revenue for the foreseeable future. In the future, we may generate revenue from product sales, license fees, milestone and research and development payments in connection with strategic partnerships, and royalties resulting from the sales of products developed under licenses of intellectual property.  Our ability to generate product revenue will depend on the successful clinical development of our product candidates, receiving regulatory approvals to market such products and the eventual successful commercialization of product candidates. If we fail to complete the development of products candidates in a timely manner, or to receive regulatory approval for such product candidates, our ability to generate future revenue and our results of operations would be materially adversely affected.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development expenses include research and development costs for our product candidates and transaction costs related to our acquisitions. We recognize all research and development expenses as they are incurred. Research and development expenses consist primarily of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:78px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">expenses incurred under agreements with consultants and clinical trial sites that conduct research and development activities on our behalf;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:78px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">laboratory and vendor expenses related to the execution of clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:78px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">contract manufacturing expenses, primarily for the production of clinical supplies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:78px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">transaction costs related to the acquisition of technologies and related intellectual property; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:78px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">internal costs that are associated with activities performed by our research and development organization and generally benefit multiple programs.</font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We expect research and development expenses to increase in the future as we invest in the development of our clinical-stage product candidates and as any other potential product candidates we may develop are advanced into and through clinical trials in the pursuit of regulatory approvals. Such activities will require a significant increase in investment in regulatory support, clinical supplies, inventory build-up related costs, and the payment of success-based milestones. In addition, we continue to evaluate opportunities to acquire or in-license other product candidates and technologies, which may result in higher research and development expenses due to, among other factors, license fee and/or milestone payments.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may not obtain regulatory approval for any product candidate on a timely and cost-effective basis or at all. The probability of success of our product candidates may be affected by numerous factors, including clinical results and data, competition, intellectual property rights, manufacturing capability and commercial viability. As a result, we cannot accurately determine the duration and completion costs of development projects or when and to what extent we will generate revenue from the commercialization of any of our product candidates.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expense</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">General and administrative expenses consist of personnel costs, facility expenses, expenses for outside professional services, including legal, audit and accounting services. Personnel costs consist of salaries, benefits and stock-based compensation. Facility expenses consist of rent and other related costs. </font></div><div><a name="sB9B876E8F55550A286E6FE6E48B79AC0"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Management&#8217;s discussion and analysis of financial condition and results of operations is based on our interim consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Preparing these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. On an ongoing basis, we evaluate these estimates and judgments. We base our estimates on historical experience and on various assumptions we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our unaudited consolidated interim financial statements, refer to Item 7 in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and Note 1 to our financial statements contained in our 2018 10-K and Note 3 to our unaudited interim consolidated financial statements contained in this report.</font></div><div><a name="s7D0EE3E9612B551DAACE2FCA08F08592"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of Three Months Ended </font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">2018</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#32;(Unaudited)</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes our results for the periods indicated, together with the changes in those items in dollars:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three months ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Dollar</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">General and administrative expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,307,379</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,157,174</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">150,205</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,512,572</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,217,622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">294,950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">License expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">162,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">250,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(87,500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,982,451</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,624,796</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">357,655</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,982,451</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,624,796</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(357,655</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">30,001</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">42,626</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(12,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,952,450</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,582,170</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(370,280</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deemed dividend from trigger of down round provision feature</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(789,594</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(789,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss to common shareholders</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4,742,044</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,582,170</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,159,874</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other comprehensive loss:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign currency translation adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,917</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(27,485</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19,568</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4,749,961</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,609,655</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,140,306</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We did not recognize any revenues for either of the three months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">General and administrative expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The increase of </font><font style="font-family:Arial;font-size:10pt;">$150,205</font><font style="font-family:Arial;font-size:10pt;">&#32;in general and administrative expenses&#160;for the three months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to the three months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;was primarily attributable to an increase in (i) personnel costs of approximately $102,422 reflecting the hiring of additional employees which resulted in higher salary, benefit and bonus expenses in the current period, and (ii) an increase in stock-based compensation expense of </font><font style="font-family:Arial;font-size:10pt;">$74,932</font><font style="font-family:Arial;font-size:10pt;">. Those increases were partially offset by a decrease of approximately $53,612 in expenses for outside professional services in the current period as compared to the same period of the prior year.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Research and development expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The increase of </font><font style="font-family:Arial;font-size:10pt;">$294,950</font><font style="font-family:Arial;font-size:10pt;">&#32;in research and development expenses for the three months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to the three months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;was primarily attributable to (i) an increase in costs related to development activities of approximately $518,051 for Ovaprene and Sildenafil Cream, 3.6%, and to a lesser extent, for DARE-BV1 and DARE-HRT1, offset by grant funding recorded as a reduction to research and development expense related to Ovaprene of approximately </font><font style="font-family:Arial;font-size:10pt;">$456,484</font><font style="font-family:Arial;font-size:10pt;">, (ii) an increase in personnel costs of approximately $233,382 reflecting the hiring of additional employees which resulted in higher salary, benefit and bonus expenses, and (iii) an increase in stock-based compensation expense of $26,996.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">License expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The license expenses of </font><font style="font-family:Arial;font-size:10pt;">$162,500</font><font style="font-family:Arial;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;related to (i) the accrual of $112,500 of deferred license fees in the aggregate due under the Assignment Agreement with Hammock Pharmaceuticals, Inc. and the First Amendment to License Agreement with TriLogic Pharma, LLC and MilanaPharm LLC, and (ii) the $50,000 annual license maintenance fee due under the Juniper License Agreement. During the quarter, we accrued (y) $62,500 of the $250,000 of license fees payable under the Assignment Agreement and (z) $50,000 of the $200,000 of license fees payable under the First Amendment to License Agreement. Both of these license fees are due in December 2019, and in our discretion, may be paid either in cash or with shares of our common stock.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The license expense of $250,000 for the three months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;was entirely related to the $250,000 non-creditable upfront license fee payment to Juniper in connection with the execution of the Juniper License Agreement.  </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For further discussion of these license fees, see Note 8 to our unaudited interim consolidated financial statements contained in this report.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Other income</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The decrease of </font><font style="font-family:Arial;font-size:10pt;">$12,625</font><font style="font-family:Arial;font-size:10pt;">&#32;in other income for the three months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to the three months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;was primarily due to interest earned on cash balances in the current period.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of Six Months Ended </font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">2018</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#32;(Unaudited)</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes our results for the periods indicated, together with the changes in those items in dollars:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Six months ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Dollar</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">General and administrative expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,584,559</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,460,363</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">124,196</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,205,963</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,304,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">901,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">License expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">275,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">350,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(75,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Impairment of goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,187,519</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(5,187,519</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,065,522</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,302,157</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4,236,635</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,065,522)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11,302,157)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4,236,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">61,232</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">54,370</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,862</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,004,290)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11,247,787)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,243,497</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deemed dividend from trigger of down round provision feature</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(789,594</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">789,594</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss to common shareholders</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,793,884</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11,247,787</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,453,903</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other comprehensive loss:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign currency translation adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(296)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(41,231)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">40,935</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,794,180</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11,289,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,494,838</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We did not recognize any revenues for either of the six months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">General and administrative expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The increase of </font><font style="font-family:Arial;font-size:10pt;">$124,196</font><font style="font-family:Arial;font-size:10pt;">&#32;in general and administrative expenses&#160;for the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;was primarily attributable to an increase in (i) personnel costs of approximately $344,028 reflecting the hiring of additional employees which resulted in higher salary, benefit and bonus expenses in the current period, and (ii) an increase in stock-based compensation expense of </font><font style="font-family:Arial;font-size:10pt;">$139,073</font><font style="font-family:Arial;font-size:10pt;">. Those increases were partially offset by a decrease of approximately $365,465 in expenses for outside professional services</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Research and development expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The increase of </font><font style="font-family:Arial;font-size:10pt;">$901,688</font><font style="font-family:Arial;font-size:10pt;">&#32;in research and development expenses for the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;was primarily attributable to (i) an increase in costs related to development activities of approximately $922,064 for Ovaprene and Sildenafil Cream, 3.6%, and to a lesser extent, for DARE-BV1 and DARE-HRT1, offset by grant funding recorded as a reduction to research and development expense related to Ovaprene of approximately $617,491, (ii) an increase in personnel costs of approximately $344,028 due to increased salary, benefit and bonus expenses due to staff additions, and (iii) an increase in stock-based compensation expense of </font><font style="font-family:Arial;font-size:10pt;">$51,699</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">License expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The license expenses of </font><font style="font-family:Arial;font-size:10pt;">$275,000</font><font style="font-family:Arial;font-size:10pt;">&#32;for the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;related to (i) the accrual of deferred license fees due under the Assignment Agreement with Hammock Pharmaceuticals, Inc. and the First Amendment to License Agreement with TriLogic Pharma, LLC and MilanaPharm LLC; and (ii) the $50,000 annual license maintenance fee due under the Juniper License Agreement. During the six months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, we accrued (y) $125,000 of the $250,000 of license fees payable under the Assignment Agreement and (z) $100,000 of the $200,000 of license fees payable under the First Amendment to License Agreement. Both of these license fees are due in December 2019, and in our discretion, may be paid either in cash or with shares of our common stock</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The license expenses of </font><font style="font-family:Arial;font-size:10pt;">$350,000</font><font style="font-family:Arial;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;was related to the $250,000 non-creditable upfront license fee payment to Juniper in connection with the execution of the Juniper License Agreement and to the $100,000 in license fees paid to SST. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For further discussion of these license fees, see Note 8 to our unaudited interim consolidated financial statements contained in this report.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill impairment expense</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We incurred an impairment loss of $5,187,519 for the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended June 30, 2018 due to our determination that the carrying amount of our goodwill exceeded its estimated fair value at June 30, 2018. For a discussion of our goodwill analysis, see Note 4 to our unaudited interim consolidated financial statements contained in this report.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Other income</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The increase of </font><font style="font-family:Arial;font-size:10pt;">$6,862</font><font style="font-family:Arial;font-size:10pt;">&#32;in other income for the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;was primarily due to interest earned on cash balances in the current period.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sEF26B93BDC4E5C13ADE51B8B3E89F118"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources and Financial Condition</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We prepared the accompanying consolidated financial statements on a going concern basis, which assumes that we will realize our assets and satisfy our liabilities in the normal course of business. In addition, we have a history of losses from operations, we expect negative cash flows from our operations to continue for the foreseeable future, and we expect that our net losses will continue for at least the next several years as we develop our existing product candidates and seek to acquire, license or develop additional product candidates.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, our accumulated deficit was approximately </font><font style="font-family:Arial;font-size:10pt;">$36.8 million</font><font style="font-family:Arial;font-size:10pt;">, our cash and cash equivalents were approximately </font><font style="font-family:Arial;font-size:10pt;">$5.6 million</font><font style="font-family:Arial;font-size:10pt;">, our working capital was approximately </font><font style="font-family:Arial;font-size:10pt;">$4.6 million</font><font style="font-family:Arial;font-size:10pt;">, and we had incurred a net loss from operations of </font><font style="font-family:Arial;font-size:10pt;">$7.1 million</font><font style="font-family:Arial;font-size:10pt;">. We had negative cash flow from operations of approximately </font><font style="font-family:Arial;font-size:10pt;">$6.3 million</font><font style="font-family:Arial;font-size:10pt;">&#32;during the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">. We received gross proceeds of approximately $5.8 million, and net proceeds of approximately $5.2 million after deducting underwriting discounts and offering expenses, from our underwritten public offering that closed in April 2019. Considering our current cash resources, we believe our existing resources will be sufficient to fund planned operations into the first quarter of 2020. For the foreseeable future, our ability to continue our operations will depend upon our ability to obtain additional capital.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">These circumstances raise substantial doubt about our ability to continue as a going concern. The accompanying interim consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and reclassification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of our ability to remain a going concern.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Plan of Operations and Future Funding Requirements</font></div><div style="line-height:120%;padding-top:13px;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our primary uses of capital are, and we expect will continue to be, staff-related expenses, the cost of clinical trials and regulatory activities related to our product candidates, costs associated with contract manufacturing services and third-party clinical research and development services, payments due under license agreements upon the successful achievement of milestones of our product candidates, legal expenses, other regulatory expenses and general overhead costs.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We expect our expenses to increase during the rest of 2019 as we continue the development of our product candidates, including as we (1) complete the Ovaprene PCT clinical trial, (2) prepare for the initiation of a Phase 3 clinical trial of DARE-BV1, (3) continue Phase 2b-related activities and prepare for the potential commencement of the at-home Phase 2b clinical study of Sildenafil Cream, 3.6%, (4) prepare for the initiation of a Phase 1 clinical study of DARE-HRT1, and (5) to a lesser extent, continue to advance our other product candidates.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">To date, we have not obtained any regulatory approvals for any of our product candidates, commercialized any of our product candidates or generated any product revenue, and we cannot anticipate if, and when we will generate any revenue. We have devoted significant resources to acquiring our portfolio of product candidates and to research and development activities for our product candidates. We must obtain regulatory approvals to sell any of our products in the future. We will need to generate sufficient safety and efficacy data on our product candidates for them to be attractive assets for potential strategic partners to license or for pharmaceutical companies to acquire, and for us to generate cash and other license fees related to such product candidates.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on our current operating plan estimates, we do not have sufficient cash to satisfy our working capital needs and other liquidity requirements over at least the next 12 months from the date of issuance of the accompanying interim consolidated financial statements. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We will need to raise substantial additional capital to continue to fund our operations and to successfully execute our current operating plan, including the development of our current product candidates. We are currently evaluating a variety of capital raising options, including financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements to cover our operating expenses, including the development of our product candidates and any future product candidates we may license or otherwise acquire. The amount and timing of our capital needs have been and will continue to depend highly on many factors, including the product development programs we choose to pursue and the pace and results of our clinical development efforts. If we raise capital through collaborations, strategic alliances or other similar types of arrangements, we may have to relinquish, on terms that are not favorable to us, rights to some of our technologies or product candidates we would otherwise seek to develop or commercialize. There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to us and our stockholders. In addition, equity or debt financings may have a dilutive effect on the holdings of our existing stockholders. If we cannot raise capital when needed, on favorable terms or at all, we will not be able to continue development of our product candidates, will need to reevaluate our planned operations and may need to delay, scale back or eliminate some or all of our development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If we become unable to continue as a going concern, we may have to liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and stockholders may lose all or part of their investment in our common stock. See &#8220;ITEM 1A. RISK FACTORS&#8212;Risks Related to Our Business&#8212;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">We will need to raise additional capital to continue our operations</font><font style="font-family:Arial;font-size:10pt;">,&#8221; in our 2018 10-K.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table shows a summary of our cash flows for the periods indicated:</font></div><div style="line-height:120%;padding-top:8px;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(6,326,726</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4,807,544</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(460,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,151,702</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10,195,653</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effect of exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(296</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(41,231</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:76px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net increase (decrease) in cash</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1,175,320</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,886,678</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Net cash used in operating activities</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash used in operating activities for the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;included the net loss of </font><font style="font-family:Arial;font-size:10pt;">$7,004,290</font><font style="font-family:Arial;font-size:10pt;">, decreased by non-cash stock-based compensation expense of </font><font style="font-family:Arial;font-size:10pt;">$209,319</font><font style="font-family:Arial;font-size:10pt;">. Major components reducing operating cash in this period were a </font><font style="font-family:Arial;font-size:10pt;">$461,982</font><font style="font-family:Arial;font-size:10pt;">&#32;increase in other receivables and a </font><font style="font-family:Arial;font-size:10pt;">$34,861</font><font style="font-family:Arial;font-size:10pt;">&#32;increase in prepaid expenses. Major components providing operating cash in this period were a </font><font style="font-family:Arial;font-size:10pt;">$710,459</font><font style="font-family:Arial;font-size:10pt;">&#32;increase in accrued expenses, a </font><font style="font-family:Arial;font-size:10pt;">$172,413</font><font style="font-family:Arial;font-size:10pt;">&#32;increase in accounts payable, and a </font><font style="font-family:Arial;font-size:10pt;">$79,063</font><font style="font-family:Arial;font-size:10pt;">&#32;increase in other non-current assets.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash used in operating activities for the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;included the net loss of $11,247,787, decreased by non-cash impairment of goodwill of $5,187,519, acquired in-process research and development expense of approximately $452,000 and non-cash stock-based compensation expense of $18,547. Major components providing operating cash in this period were a $288,846 increase of accounts payable, a $9,739 increase of accrued expenses, a $259,562 decrease in other receivables and a $193,495 decrease in other current assets.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Net cash used in investing activities</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No cash was provided by or used in investing activities for the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash used in investing activities for the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;consisted of approximately $452,000 of transaction costs associated with our acquisition of Pear Tree and approximately $8,200 related to the purchase of property and equipment.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Net cash provided by financing activities</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash provided by financing activities for the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;consisted of proceeds from the underwritten public offering completed in April 2019. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash provided by financing activities for the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;consisted of proceeds from the underwritten public offering completed in February 2018 and sales under the at-the-market offering agreement in January and February 2018.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">License and Royalty Agreements</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have to make various royalty and milestone payments under the product license and development agreements related to DARE-BV1, Ovaprene, and Sildenafil Cream, 3.6%, and under the other agreements related to our other clinical and preclinical candidates.&#160;For further discussion of these potential payments, see Note 8 to our unaudited interim consolidated financial statements contained in this report.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Other Contracts</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We enter into contracts in the normal course of business with various third parties for research studies, clinical trials, testing and other services. These contracts generally provide for termination upon notice, and we do not believe that our non-cancelable obligations under these agreements are material.</font></div><div><a name="s87BEAF57FF065079AE80D10963105C1E"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><a name="sED2B4CA2673A5A61BAD1FE06FDA1552F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 3. Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under SEC rules and regulations, as a smaller reporting company we are not required to provide the information required by this item.</font></div><div><a name="sF619928A7ECC5DECA9BB9032B29511B9"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 4. Controls and Procedures</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) were effective as of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;at the reasonable assurance level.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the fiscal quarter to which this report relates that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><a name="s71543815C0365BD692987333D76E3840"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PART II. OTHER INFORMATION</font></div><div><a name="s6D61C87E208950DE9BA556E011233247"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 1. Legal Proceedings</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">From time to time, we may become involved in various claims and legal proceedings. Regardless of outcome, litigation and other legal and administrative proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. There are no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which we are a party or of which any of our property is in the subject.</font></div><div><a name="sA59D18DC745B51FFAB05085628F141F6"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 1A. Risk Factors</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">An investment in shares of our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described in our 2018 10-K, in addition to other information in this report, before investing in our common stock. The occurrence of any of these risks could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. There have been no material changes from the risk factors disclosed in Part I, Item 1A. Risk Factors in our 2018 10-K other than as described below:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Risks Related to Our Securities</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">There is no assurance that we will continue to satisfy the listing requirements of the Nasdaq Capital Market.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our common stock is listed on the Nasdaq Capital Market. As previously reported, on June 21, 2019, we received a letter from the Listing Qualifications Department (the &#8220;Nasdaq Staff&#8221;) of the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) notifying us that, for the last 30 consecutive business days, the closing bid price for our common stock was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the &#8220;Minimum Bid Price Requirement&#8221;), and that we have until December 18, 2019 to regain compliance. We will regain compliance if the closing bid price of our common stock is at least $1.00 for a minimum of 10 consecutive business days at any time between June 21, 2019 and December 18, 2019, unless the Nasdaq Staff exercises its discretion to extend such 10-day period. From June 21, 2019 through August 13, 2019, the closing bid price of our common stock has been less than $1.00. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If we have not regained compliance by December 18, 2019, we may be eligible for an additional 180-day compliance period. To qualify for this additional compliance period, we would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, other than the Minimum Bid Price Requirement, including having stockholders&#8217; equity of at least $5 million. In addition, we would also be required to notify Nasdaq of our intent to cure the minimum bid price deficiency during the additional compliance period, which may include, if necessary, implementing a reverse stock split. Our stockholders' equity at June 30, 2019 was $5.1 million, and, as such, we expect that we will need to raise additional equity capital to be eligible for the additional compliance period. If our stockholders' equity is not at least $5.0 million at September 30, 2019 but increases to at least $5.0 million after September 30, 2019 and before December 18, 2019, we understand that the Nasdaq Staff has discretion whether to consider such increase for purposes of determining our eligibility for the additional compliance period. If we are not granted the additional compliance period for any reason, the Nasdaq Staff will provide written notice to us that our common stock will be subject to delisting. At that time, we may appeal the Nasdaq Staff&#8217;s delisting determination to a Nasdaq Hearing Panel.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font><font style="font-family:Arial;font-size:10pt;">There can be no assurance we will regain compliance with the Minimum Bid Price Requirement or continue to satisfy the other continued listing requirements of The Nasdaq Capital Market. The delisting of our common stock for whatever reason could, among other things, substantially impair our ability to raise additional capital; result in the loss of interest from institutional investors, the loss of confidence in our company by investors and employees, and in fewer financing, strategic and business development opportunities; and could result in potential breaches of agreements under which we made representations or covenants relating to our compliance with applicable listing requirements. Claims related to any such breaches, with or without merit, could result in costly litigation, significant liabilities and diversion of our management&#8217;s time and attention and could have a material adverse effect on our financial condition, business and results of operations. In addition, the delisting of our common stock for whatever reason may materially impair our stockholders&#8217; ability to buy and sell shares of our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><a name="s1018F5EB6E11569EA2FEC2B71BF1EDE5"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</font></div><div style="line-height:120%;padding-left:0px;padding-top:10px;text-align:justify;text-indent:96px;"><font style="padding-top:10px;text-align:justify;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;">None.</font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:96px;"><font style="text-align:justify;font-family:Arial;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:10pt;">None.</font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:96px;"><font style="text-align:justify;font-family:Arial;font-size:10pt;padding-right:48px;">(c)</font><font style="font-family:Arial;font-size:10pt;">None.</font></div><div><a name="s6ED950516635523E8EDD555D990EE84E"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 3. Defaults Upon Senior Securities</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">None.</font></div><div><a name="sD214E371D0075599A4DB4266E0D65C07"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 4. Mine Safety Disclosures</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Not applicable.</font></div><div><a name="s386193EC3238521B918C9E8A90141702"></a></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 5. Other Information</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a) None.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b) None.</font></div><div><a name="sD46874C0FADC5C898A064024A9537C41"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 6. Exhibits</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Incorporated by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Description of Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:0px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">File No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Filed Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit311_20190630.htm"><font style="font-family:Arial;font-size:10pt;">Certification of principal executive officer pursuant to Rule&#160;13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit312_20190630.htm"><font style="font-family:Arial;font-size:10pt;">Certification of principal financial officer pursuant to Rule&#160;13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">32.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit321_20190630.htm"><font style="font-family:Arial;font-size:10pt;">Certification of principal executive officer pursuant to 18&#160;U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">#</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">32.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit322_20190630.htm"><font style="font-family:Arial;font-size:10pt;">Certification of principal financial officer pursuant to 18&#160;U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">#</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XBRL Instance Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XBRL Taxonomy Extension Schema Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">X</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"># Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">not to be incorporated herein by reference into any filing of the registrant whether made before or after the date hereof, regardless of any general incorporation in such filing.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><a name="s7B1EE239891E52FA856764E3D547E258"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Signatures</font></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:46%;"></td><td style="width:7%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dar&#233; Bioscience, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date: August&#160;14, 2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Sabrina Martucci Johnson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sabrina Martucci Johnson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date: August&#160;14, 2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Lisa Walters-Hoffert</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lisa Walters-Hoffert</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">34</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311_20190630.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9E732146BCD65E7AB735C9EC2FD01810"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 31.1 </font></div><div style="line-height:120%;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CERTIFICATIONS</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I, Sabrina Martucci Johnson, certify that: </font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:Arial;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc.;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">d.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date:  </font><font style="font-family:Arial;font-size:10pt;">August&#160;14, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:39.20335429769392%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Sabrina Martucci Johnson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sabrina Martucci Johnson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(principal executive officer)</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312_20190630.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE97B44DE50F9522CA6C319F6B01EFCE9"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 31.2 </font></div><div style="line-height:120%;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CERTIFICATIONS </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I, Lisa Walters-Hoffert, certify that: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc.;</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">d.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date: </font><font style="font-family:Arial;font-size:10pt;">August&#160;14, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:39.20335429769392%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Lisa Walters-Hoffert</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lisa Walters-Hoffert</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(principal financial officer)</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321_20190630.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE58698FBCDD85345A81B9CA6AB70EFEE"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 32.1 </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In connection with the Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Sabrina Martucci Johnson, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to her knowledge on the date hereof: </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date: </font><font style="font-family:Arial;font-size:10pt;">August&#160;14, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:39.95726495726496%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Sabrina Martucci Johnson</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sabrina Martucci Johnson</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(principal executive officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit322_20190630.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1849BC45B68F582C873FFFDAC2E64E82"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 32.2 </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In connection with the Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Lisa Walters-Hoffert, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to her knowledge on the date hereof: </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date: </font><font style="font-family:Arial;font-size:10pt;">August&#160;14, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:39.95726495726496%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Lisa Walters-Hoffert</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lisa Walters-Hoffert</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(principal financial officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>dare-20190630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:93C392CEEAF65CDE9C66B4C9923E0D2F,x:d27555d3dcfb48d49181e19e66353811-->
<xbrli:xbrl xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:dare="http://darebioscience.com/20190630" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2018-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="dare-20190630.xsd" xlink:type="simple" />
	<xbrli:context id="FD2019Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q3Aug13">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Mar_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_HealthCareTrustFundAxis_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_NationalInstitutesOfHealthMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HealthCareTrustFundAxis">dare:EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:SecondPhaseOfResearchAndAvailabilityOfFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Apr">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q2Apr">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Jan1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2May15-May16_us-gaap_BusinessAcquisitionAxis_dare_PearTreePharmaceuticalsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:PearTreePharmaceuticalsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-15</xbrli:startDate>
			<xbrli:endDate>2018-05-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2May16_us-gaap_BusinessAcquisitionAxis_dare_PearTreePharmaceuticalsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:PearTreePharmaceuticalsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Jul19">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-07-19</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Jul18-Jul19">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-18</xbrli:startDate>
			<xbrli:endDate>2017-07-19</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2May15-May16_us-gaap_BusinessAcquisitionAxis_dare_PearTreePharmaceuticalsIncMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:PearTreePharmaceuticalsIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-15</xbrli:startDate>
			<xbrli:endDate>2018-05-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3Jul10-Jul10_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-10</xbrli:startDate>
			<xbrli:endDate>2018-07-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_dei_LegalEntityAxis_dare_PrivateDareMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:PrivateDareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Jan1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3Jul10_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-07-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Jan1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2YTD_us-gaap_PlanNameAxis_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_dei_LegalEntityAxis_dare_PrivateDareMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:PrivateDareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2YTD_us-gaap_PlanNameAxis_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q2Apr11_us-gaap_SubsidiarySaleOfStockAxis_dare_PublicStockOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PublicStockOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-04-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q2Apr11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-11</xbrli:startDate>
			<xbrli:endDate>2019-04-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb_us-gaap_SubsidiarySaleOfStockAxis_dare_PublicStockOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PublicStockOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb01-Feb28_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb01-Feb28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q2Apr11">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-11</xbrli:startDate>
			<xbrli:endDate>2019-04-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q2Apr11_us-gaap_SubsidiarySaleOfStockAxis_dare_PublicStockOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PublicStockOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-11</xbrli:startDate>
			<xbrli:endDate>2019-04-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb15_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201711Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201711Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q2Apr11_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-04-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan01-Jan31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3Jul1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-07-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3Jul1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-07-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_OrbisMember_us-gaap_TypeOfArrangementAxis_dare_DevelopmentAndOptionAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:OrbisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:DevelopmentAndOptionAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Dec5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_MilanaPharmMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-05</xbrli:startDate>
			<xbrli:endDate>2018-12-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2YTD_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dare_FutureMilestonePaymentsBasedOnCommercializationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:FutureMilestonePaymentsBasedOnCommercializationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb01-Feb28_srt_ProductOrServiceAxis_dare_OvapreneMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:OvapreneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Apr_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar01-Mar31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar01-Mar31_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar01-Mar31_srt_ProductOrServiceAxis_dare_OvapreneMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:OvapreneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb01-Feb28_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb01-Feb28_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb01-Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar01-Mar31_srt_RangeAxis_srt_MaximumMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Dec5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_HammockPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_dare_AssignmentAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:HammockPharmaceuticalsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-05</xbrli:startDate>
			<xbrli:endDate>2018-12-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar_us-gaap_RelatedPartyTransactionAxis_dare_UponSigningOfDevelopmentAndOptionAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_OrbisMember_us-gaap_TypeOfArrangementAxis_dare_DevelopmentAndOptionAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponSigningOfDevelopmentAndOptionAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:OrbisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:DevelopmentAndOptionAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar01-Mar31_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponReachingCertainWorldwideNetSalesMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Dec5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_MilanaPharmMember_us-gaap_TypeOfArrangementAxis_dare_AssignmentAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-05</xbrli:startDate>
			<xbrli:endDate>2018-12-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Dec5_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_dare_UponAchievingCertainCommercialMilestonesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_MilanaPharmMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-05</xbrli:startDate>
			<xbrli:endDate>2018-12-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb01-Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_us-gaap_TypeOfArrangementAxis_dare_LicenseAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb01-Feb28_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_dare_UponAchievingCertainCommercialMilestonesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_us-gaap_TypeOfArrangementAxis_dare_LicenseAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Apr_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_SalesMilestonesMember_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:SalesMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar01-Mar31_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Apr_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ClinicalAndRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2YTD_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:FutureMilestonePaymentsBasedOnProductDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_srt_ProductOrServiceAxis_dare_OvapreneMember_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:OvapreneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar_us-gaap_RelatedPartyTransactionAxis_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_OrbisMember_us-gaap_TypeOfArrangementAxis_dare_DevelopmentAndOptionAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:OrbisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:DevelopmentAndOptionAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar01-Mar31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Dec5_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_HammockPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_dare_AssignmentAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:HammockPharmaceuticalsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-05</xbrli:startDate>
			<xbrli:endDate>2018-12-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_HealthCareTrustFundAxis_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_NationalInstitutesOfHealthMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HealthCareTrustFundAxis">dare:EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:SecondPhaseOfResearchAndAvailabilityOfFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Mar11_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_HealthCareTrustFundAxis_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_NationalInstitutesOfHealthMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HealthCareTrustFundAxis">dare:EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:SecondPhaseOfResearchAndAvailabilityOfFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-11</xbrli:startDate>
			<xbrli:endDate>2019-03-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1_srt_ProductOrServiceAxis_us-gaap_GrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Mar11_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_HealthCareTrustFundAxis_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_NationalInstitutesOfHealthMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HealthCareTrustFundAxis">dare:EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:RemainingPortionOfResearchAndAvailabilityOfFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-11</xbrli:startDate>
			<xbrli:endDate>2019-03-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="country">
		<xbrli:measure>dare:country</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>dare:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="patent">
		<xbrli:measure>dare:patent</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="U_darePatent">
		<xbrli:measure>dare:Patent</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued contextRef="FD2018Q2YTD" decimals="0" id="Fact-C4B6C837AE2C5B668A2A6E3257F71311" unitRef="usd">9157888</dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued>
	<dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-3234FC40B0E958B6BE1D70D01DCD06CA" unitRef="usd">9157388</dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued>
	<dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-91BAEFF535DA51EEBD3073263A3F9071" unitRef="usd">500</dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued>
	<dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-F00F747D16D357DAA827F9BF52B7FA4E" unitRef="shares">5000000</dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares>
	<dare:AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease contextRef="D2017Q1Mar01-Mar31_srt_ProductOrServiceAxis_dare_OvapreneMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" id="Fact-137519BB89BE524E9E7D2778C93638CB">P6M</dare:AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease>
	<dare:AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries contextRef="D2017Q1Mar01-Mar31_srt_ProductOrServiceAxis_dare_OvapreneMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" id="Fact-3A8FF238B5405456869F92C4A6ACAC6B">P3Y</dare:AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries>
	<dare:BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="I2017Q3Jul19" decimals="-5" id="Fact-879107E09D765624A03D87CC71C8E63F" unitRef="usd">9900000</dare:BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
	<dare:BusinessCombinationReverseMergerStockPurchaseTransactionCost contextRef="D2018Q2May15-May16_us-gaap_BusinessAcquisitionAxis_dare_PearTreePharmaceuticalsIncMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-218C03B554AA5183ADB1B2395B64DB8D" unitRef="usd">452000</dare:BusinessCombinationReverseMergerStockPurchaseTransactionCost>
	<dare:BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions contextRef="D2017Q3Jul18-Jul19" decimals="-5" id="Fact-C45D073CC9205A0886FB294ADF93F199" unitRef="usd">3700000</dare:BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions>
	<dare:ClassOfWarrantOrRightsWarrantsExpirationDate contextRef="FD2019Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" id="Fact-F120758BE1F755C49187A0BE802120C0">2026-04-04</dare:ClassOfWarrantOrRightsWarrantsExpirationDate>
	<dare:ClassOfWarrantOrRightsWarrantsExpirationDate contextRef="FD2019Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" id="Fact-75DBB717F13F506680287DE7678B71CA">2021-12-01</dare:ClassOfWarrantOrRightsWarrantsExpirationDate>
	<dare:ClassOfWarrantOrRightsWarrantsExpirationDate contextRef="FD2019Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" id="Fact-BC7A623B00FF5AD5AD659D739128DA3A">2021-12-06</dare:ClassOfWarrantOrRightsWarrantsExpirationDate>
	<dare:ClassOfWarrantOrRightsWarrantsExpirationDate contextRef="FD2019Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" id="Fact-421DEBCF03E551E28F8EB11DF34B94DC">2023-02-15</dare:ClassOfWarrantOrRightsWarrantsExpirationDate>
	<dare:ClassOfWarrantOrRightsWarrantsExpirationDate contextRef="FD2019Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember" id="Fact-7A8AD75AE219589C94C11A7CF8838609">2020-01-08</dare:ClassOfWarrantOrRightsWarrantsExpirationDate>
	<dare:CommencementPeriodForStageTwoUponAchievementOfStageOne contextRef="D2018Q1Mar_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_OrbisMember_us-gaap_TypeOfArrangementAxis_dare_DevelopmentAndOptionAgreementMember" id="Fact-4F3B3B3DD1ED51158D58208E16C267EC">P90D</dare:CommencementPeriodForStageTwoUponAchievementOfStageOne>
	<dare:EstimatedFairValueOfWarrantsRecordedInEquity contextRef="I2018Q1Feb15_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201711Member" decimals="-5" id="Fact-5513964B0C6B781A4D237228C25CAD6C" unitRef="usd">3000000</dare:EstimatedFairValueOfWarrantsRecordedInEquity>
	<dare:GrossProceedsFromIssuanceOfCommonStock contextRef="D2018Q1Jan01-Jan31" decimals="INF" id="Fact-0A439094F04F5909B534F06484440A7F" unitRef="usd">10000000</dare:GrossProceedsFromIssuanceOfCommonStock>
	<dare:GrossProceedsFromIssuanceOfCommonStock contextRef="FD2018Q2YTD" decimals="-5" id="Fact-07335702FD906C8C5179722487CFB3BB" unitRef="usd">1100000</dare:GrossProceedsFromIssuanceOfCommonStock>
	<dare:GrossProceedsFromOfferingOfCommonStockAndWarrants contextRef="D2018Q1Feb01-Feb28_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="-5" id="Fact-CD7CF9AA9CE55EA0914902A380BFFD3A" unitRef="usd">10300000</dare:GrossProceedsFromOfferingOfCommonStockAndWarrants>
	<dare:GrossProceedsFromOfferingOfCommonStockAndWarrants contextRef="D2019Q2Apr11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="-5" id="Fact-5C674150F7C70B87B74C722C7ECA2D8B" unitRef="usd">5800000</dare:GrossProceedsFromOfferingOfCommonStockAndWarrants>
	<dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges contextRef="FD2018Q2YTD" decimals="0" id="Fact-89C2FFCBBCEA5A4990A47737205E452C" unitRef="usd">-66160</dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges>
	<dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges contextRef="FD2019Q2YTD" decimals="0" id="Fact-15AD3E8AA1045F44AFE3E9A32FFECC60" unitRef="usd">-79063</dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges>
	<dare:LicenseAgreementExpirationPeriod contextRef="D2018Q1Feb01-Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" id="Fact-5D034F1F2DB65F33A14B1B98EEFA72EA">P10Y</dare:LicenseAgreementExpirationPeriod>
	<dare:LicenseAgreementNoticePeriodOfTermination contextRef="D2018Q2Apr_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member" id="Fact-D201E285DE6650F9B135FE0AB64A88B0">P180D</dare:LicenseAgreementNoticePeriodOfTermination>
	<dare:LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation contextRef="D2018Q2Apr_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member" id="Fact-207282A95A24537EA81D59441196328A">P60D</dare:LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation>
	<dare:LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation contextRef="D2018Q2Apr_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member" id="Fact-7C7FDF36E5345242A4FD7458CB93A60A">P30D</dare:LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation>
	<dare:LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess contextRef="D2018Q2Apr_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member" id="Fact-C1F4A2C157525A2299BBBC9E49561E13">P10Y</dare:LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess>
	<dare:LicenseAgreementTerminationPeriodAfterReceiptOfApproval contextRef="D2018Q1Feb01-Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" id="Fact-20E0EB40232A5A96B8CF79050DAF9AF5">P180D</dare:LicenseAgreementTerminationPeriodAfterReceiptOfApproval>
	<dare:LicenseAgreementTerminationPeriodDueToPerformanceFailure contextRef="D2017Q1Mar01-Mar31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" id="Fact-F26BA8D5AAA353019E8301D888CB8C0C">P60D</dare:LicenseAgreementTerminationPeriodDueToPerformanceFailure>
	<dare:LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries contextRef="D2018Q1Feb01-Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" id="Fact-C9681FD3893D585C9182AABE26A1BB2D">P30D</dare:LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries>
	<dare:LicenseAgreementTerminationPeriodPriorToReceiptOfApproval contextRef="D2018Q1Feb01-Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" id="Fact-214879ACAEA159978519A6C2DD927F11">P90D</dare:LicenseAgreementTerminationPeriodPriorToReceiptOfApproval>
	<dare:LicenseAgreementTerminationPeriodPriorToReceiptOfApproval contextRef="D2018Q1_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsMember" id="Fact-0E4E24C60820508DA15E65331A98FE4D">P90D</dare:LicenseAgreementTerminationPeriodPriorToReceiptOfApproval>
	<dare:LicenseFee contextRef="D2018Q4Dec5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_HammockPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_dare_AssignmentAgreementMember" decimals="-3" id="Fact-5D6B16F5277D6C3765D25E80544E64C1" unitRef="usd">250000</dare:LicenseFee>
	<dare:LicenseFee contextRef="D2018Q4Dec5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_MilanaPharmMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="-3" id="Fact-A6156B4F693F2DE8363E5E7FCA97088C" unitRef="usd">25000</dare:LicenseFee>
	<dare:LicenseFee contextRef="FD2018Q2QTD" decimals="0" id="Fact-C13CF9749C1C53E994F4CE803C48377A" unitRef="usd">250000</dare:LicenseFee>
	<dare:LicenseFee contextRef="FD2018Q2YTD" decimals="0" id="Fact-611A9FDBA54FEB673BC05E958A311EF4" unitRef="usd">350000</dare:LicenseFee>
	<dare:LicenseFee contextRef="FD2019Q2QTD" decimals="0" id="Fact-23B4AAA802E55FFC9FC1EF9E0C755E01" unitRef="usd">162500</dare:LicenseFee>
	<dare:LicenseFee contextRef="FD2019Q2YTD" decimals="0" id="Fact-5835ACEE3887554B945333C4A6C3A245" unitRef="usd">275000</dare:LicenseFee>
	<dare:LicenseFeeToBePaidUponContingency contextRef="D2018Q4Dec5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_HammockPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_dare_AssignmentAgreementMember" decimals="-3" id="Fact-6B924787A3963EF3886B5E80B5ACEE49" unitRef="usd">250000</dare:LicenseFeeToBePaidUponContingency>
	<dare:LicenseFeeToBePaidUponContingency contextRef="D2018Q4Dec5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_MilanaPharmMember_us-gaap_TypeOfArrangementAxis_dare_AssignmentAgreementMember" decimals="-3" id="Fact-9600FBE8719E52F6680A5E8147938718" unitRef="usd">300000</dare:LicenseFeeToBePaidUponContingency>
	<dare:LicenseFeeToBePaidUponContingency contextRef="D2018Q4Dec5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_MilanaPharmMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="-3" id="Fact-26719324EC0BFD4A472B5E7F6916B8C1" unitRef="usd">200000</dare:LicenseFeeToBePaidUponContingency>
	<dare:MaximumPotentialMilestonePayments contextRef="D2018Q2Apr_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ClinicalAndRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member" decimals="-5" id="Fact-C06BC2D1FC69592095B09E73E83ABC9D" unitRef="usd">13500000</dare:MaximumPotentialMilestonePayments>
	<dare:MaximumPotentialMilestonePayments contextRef="D2018Q2Apr_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_SalesMilestonesMember_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member" decimals="-5" id="Fact-1362C4846B945602839F235911492A05" unitRef="usd">30300000</dare:MaximumPotentialMilestonePayments>
	<dare:MilestonePaymentsContingentAmount contextRef="D2018Q1Feb01-Feb28_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_dare_UponAchievingCertainCommercialMilestonesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_us-gaap_TypeOfArrangementAxis_dare_LicenseAndCollaborationAgreementMember" decimals="-6" id="Fact-1687EF8AC3C55C21BA1FFE3ED57D3D5D" unitRef="usd">100000000</dare:MilestonePaymentsContingentAmount>
	<dare:MilestonePaymentsContingentAmount contextRef="D2018Q1Feb01-Feb28_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" decimals="INF" id="Fact-3EDE961D11045B20B2ED566EA25A488C" unitRef="usd">18000000</dare:MilestonePaymentsContingentAmount>
	<dare:MilestonePaymentsContingentAmount contextRef="D2018Q1Feb01-Feb28_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" decimals="INF" id="Fact-BBF7621E3BD153388BFE81C76AAC81C5" unitRef="usd">500000.0</dare:MilestonePaymentsContingentAmount>
	<dare:MilestonePaymentsContingentAmount contextRef="D2018Q4Dec5_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_HammockPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_dare_AssignmentAgreementMember" decimals="-5" id="Fact-53A0C4967F6A4A7145E45E7D5365D7B6" unitRef="usd">1100000</dare:MilestonePaymentsContingentAmount>
	<dare:MilestonePaymentsContingentAmount contextRef="D2018Q4Dec5_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_dare_UponAchievingCertainCommercialMilestonesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_MilanaPharmMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="-4" id="Fact-46C7124D9054D6497A3A5E7DCF47C8B2" unitRef="usd">1750000</dare:MilestonePaymentsContingentAmount>
	<dare:NetProceedsFromIssuanceOfCommonStockAndWarrants contextRef="FD2018Q2YTD" decimals="0" id="Fact-097A4781DEAC54288B6E52A010FE08C4" unitRef="usd">10195653</dare:NetProceedsFromIssuanceOfCommonStockAndWarrants>
	<dare:NetProceedsFromIssuanceOfCommonStockAndWarrants contextRef="FD2019Q2YTD" decimals="0" id="Fact-C627C9123A7551D0B9283FC889FF747D" unitRef="usd">5151702</dare:NetProceedsFromIssuanceOfCommonStockAndWarrants>
	<dare:NonCashLeaseExpense contextRef="FD2018Q2YTD" decimals="0" id="Fact-B503F0371FB7D84CBF056D5C9680B539" unitRef="usd">0</dare:NonCashLeaseExpense>
	<dare:NonCashLeaseExpense contextRef="FD2019Q2YTD" decimals="0" id="Fact-81AA91E3C6ED5E9993EAC2E6F988B297" unitRef="usd">10549</dare:NonCashLeaseExpense>
	<dare:NoticePeriodForTerminationOfAgreementForBothParties contextRef="D2018Q1Feb01-Feb28_srt_ProductOrServiceAxis_dare_OvapreneMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" id="Fact-C808B460DDDB520D88529CD15B55D818">P60D</dare:NoticePeriodForTerminationOfAgreementForBothParties>
	<dare:NumberOfCommonStockWarrantsExercised contextRef="FD2018Q2YTD" decimals="INF" id="Fact-AC757DB74C5B5B95AB8ECBF466D54184" unitRef="shares">0</dare:NumberOfCommonStockWarrantsExercised>
	<dare:NumberOfCommonStockWarrantsExercised contextRef="FD2019Q2YTD" decimals="INF" id="Fact-0097EFB4432358149126BC1A3DD7B73B" unitRef="shares">0</dare:NumberOfCommonStockWarrantsExercised>
	<dare:NumberOfDesignatedCountries contextRef="D2017Q1Mar01-Mar31_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="INF" id="Fact-C7D8CD6262CA560AAA0F04FDA1BFFC9D" unitRef="country">3</dare:NumberOfDesignatedCountries>
	<dare:NumberOfPatentApplications contextRef="FI2019Q2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember" decimals="INF" id="Fact-50835DAFBA4058D59834F00BB6C8CEA5" unitRef="U_darePatent">4</dare:NumberOfPatentApplications>
	<dare:NumberOfPatentsGranted contextRef="FI2019Q2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember" decimals="INF" id="Fact-4D4C1BD2E9855947ABEA13F7B3632C51" unitRef="U_darePatent">59</dare:NumberOfPatentsGranted>
	<dare:NumberOfPatentsIssued contextRef="FI2019Q2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember" decimals="INF" id="Fact-ACCE1F7502705CB1A45AE7D5D53F0BF0" unitRef="patent">9</dare:NumberOfPatentsIssued>
	<dare:NumberOfPendingPatents contextRef="FI2019Q2_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember" decimals="INF" id="Fact-4396CC5966BA53599F96B021EEE2EBFC" unitRef="U_darePatent">1</dare:NumberOfPendingPatents>
	<dare:PercentageOfAggregateCommission contextRef="D2018Q1Jan01-Jan31" decimals="INF" id="Fact-4C8CC91D479B5A609173C84B3DA2CD48" unitRef="number">0.03</dare:PercentageOfAggregateCommission>
	<dare:PercentageOfIncreaseInAnnualBaseRent contextRef="D2018Q3Jul1" decimals="2" id="Fact-AC46531A123FDB4BD3E95E786BF760B8" unitRef="number">0.04</dare:PercentageOfIncreaseInAnnualBaseRent>
	<dare:PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement contextRef="D2018Q1Feb01-Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" decimals="INF" id="Fact-0162B7CA3C8B58BD8D57B5003991A69B" unitRef="number">0.50</dare:PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement>
	<dare:PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement contextRef="D2018Q1Feb01-Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_us-gaap_TypeOfArrangementAxis_dare_LicenseAndCollaborationAgreementMember" decimals="INF" id="Fact-7838E5B8539255DFACB2DCA0C27158D2" unitRef="number">0.5</dare:PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement>
	<dare:PercentageOfRoyaltyRate contextRef="D2017Q1Mar01-Mar31_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="2" id="Fact-974FCE8AEA185124BBE0E39B38663CD5" unitRef="number">0.10</dare:PercentageOfRoyaltyRate>
	<dare:PercentageOfRoyaltyRate contextRef="D2017Q1Mar01-Mar31_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="2" id="Fact-9D152553DF54585697EE1317DAEDA519" unitRef="number">0.01</dare:PercentageOfRoyaltyRate>
	<dare:PeriodOfDismissalOfBankruptcyPetition contextRef="D2018Q2Apr_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member" id="Fact-ED58CBA1D91051359AB76C7E94EB27EC">P90D</dare:PeriodOfDismissalOfBankruptcyPetition>
	<dare:PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne contextRef="D2018Q2Apr_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member" decimals="-3" id="Fact-0AC715633958577F988C9AB6088CB380" unitRef="usd">50000</dare:PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne>
	<dare:PotentialAnnualLicenseMaintenanceFeePaymentsThereafter contextRef="D2018Q2Apr_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member" decimals="-3" id="Fact-B32D5791D1675401834D0CF6B9149A63" unitRef="usd">100000</dare:PotentialAnnualLicenseMaintenanceFeePaymentsThereafter>
	<dare:PotentialCashPaymentsToAcquireBusiness contextRef="I2018Q2May16_us-gaap_BusinessAcquisitionAxis_dare_PearTreePharmaceuticalsIncMember" decimals="-3" id="Fact-C82573D8B8AB595A83A9F87CB8054D31" unitRef="usd">75000</dare:PotentialCashPaymentsToAcquireBusiness>
	<dare:ProceedsRaisedFromEquityFinancing contextRef="D2018Q4Dec5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_HammockPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_dare_AssignmentAgreementMember" decimals="-5" id="Fact-1CF5722D6E7822735CF75E7E4B17169A" unitRef="usd">10000000</dare:ProceedsRaisedFromEquityFinancing>
	<dare:ProceedsRaisedFromEquityFinancing contextRef="D2018Q4Dec5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_MilanaPharmMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="-5" id="Fact-59152F9F0FC3C61AD7625E7EFA12A773" unitRef="usd">10000000</dare:ProceedsRaisedFromEquityFinancing>
	<dare:ReimbursementOfGrantExpensesReceivable contextRef="FI2019Q2" decimals="0" id="Fact-CE61D4E6DCA77303A5F06D29B0180698" unitRef="usd">456484</dare:ReimbursementOfGrantExpensesReceivable>
	<dare:ResearchAndDevelopmentMilestonePayment contextRef="D2017Q1Mar01-Mar31_srt_RangeAxis_srt_MaximumMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="-5" id="Fact-307E23D2F3A05AC788DE93799F08A9FE" unitRef="usd">14600000</dare:ResearchAndDevelopmentMilestonePayment>
	<dare:ResearchAndDevelopmentMilestonePayment contextRef="D2017Q1Mar01-Mar31_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="-6" id="Fact-EA04586534D4589EA950E1B04F607A53" unitRef="usd">20000000</dare:ResearchAndDevelopmentMilestonePayment>
	<dare:ResearchAndDevelopmentMilestonePayment contextRef="D2018Q1Mar01-Mar31" decimals="-3" id="Fact-28BBE5780FF6562393DCD37EDF834EC9" unitRef="usd">75000</dare:ResearchAndDevelopmentMilestonePayment>
	<dare:ResearchAndDevelopmentMilestonePayment contextRef="D2018Q1Mar_us-gaap_RelatedPartyTransactionAxis_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_OrbisMember_us-gaap_TypeOfArrangementAxis_dare_DevelopmentAndOptionAgreementMember" decimals="-3" id="Fact-6F7B51B0525A56D392961387B334590C" unitRef="usd">75000</dare:ResearchAndDevelopmentMilestonePayment>
	<dare:ResearchAndDevelopmentMilestonePayment contextRef="D2018Q1Mar_us-gaap_RelatedPartyTransactionAxis_dare_UponSigningOfDevelopmentAndOptionAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_OrbisMember_us-gaap_TypeOfArrangementAxis_dare_DevelopmentAndOptionAgreementMember" decimals="-3" id="Fact-EF13EF05162452A5B600AFB6D4DD6035" unitRef="usd">150000</dare:ResearchAndDevelopmentMilestonePayment>
	<dare:ResearchAndDevelopmentMilestonePayment contextRef="D2018Q1Mar_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_OrbisMember_us-gaap_TypeOfArrangementAxis_dare_DevelopmentAndOptionAgreementMember" decimals="-3" id="Fact-7E5D98B796A35D679E3D30A9DF791D48" unitRef="usd">300000</dare:ResearchAndDevelopmentMilestonePayment>
	<dare:ResearchAndDevelopmentMilestonePayment contextRef="FD2019Q2YTD_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dare_FutureMilestonePaymentsBasedOnCommercializationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="-6" id="Fact-40E03BD38F284120BB4E721502675913" unitRef="usd">20000000</dare:ResearchAndDevelopmentMilestonePayment>
	<dare:ResearchAndDevelopmentMilestonePayment contextRef="FD2019Q2YTD_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="-5" id="Fact-EF26C8D883A7F3B16EA0721504D17C6A" unitRef="usd">14600000</dare:ResearchAndDevelopmentMilestonePayment>
	<dare:SecuredInvestmentRequiredForLicenseAgreement contextRef="I2018Q1Feb_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" decimals="-5" id="Fact-36DBB18132F25C53A36E04B0BB1E4B70" unitRef="usd">10000000</dare:SecuredInvestmentRequiredForLicenseAgreement>
	<dare:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate contextRef="FD2019Q2QTD" decimals="0" id="Fact-E413036E901A5BD5BF9A1A1CB1A620EE" unitRef="number">0</dare:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
	<dare:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate contextRef="FD2019Q2YTD" decimals="0" id="Fact-AA4097528FC35EBCAE94EDDE3FD3D6E5" unitRef="number">0</dare:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
	<dare:UnderwritersOptionToPurchaseAdditionalShares contextRef="D2018Q1Feb01-Feb28_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-ACCE46E640365F2C9C9744EF3214AE61" unitRef="shares">750000</dare:UnderwritersOptionToPurchaseAdditionalShares>
	<dare:UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod contextRef="D2018Q1Feb01-Feb28_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" id="Fact-CA1FB053E96352BEAADE87D1B6FA06CC">P30D</dare:UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod>
	<dare:UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod contextRef="D2019Q2Apr11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" id="Fact-70EFDD28198DC264C8D0722BBB5424CE">P30D</dare:UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod>
	<dare:UpfrontLicenseFeePaid contextRef="D2018Q1_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsMember" decimals="-3" id="Fact-34A8EA8F68265494BC10080E34A3CBC2" unitRef="usd">250000</dare:UpfrontLicenseFeePaid>
	<dare:WeightedAverageAmortizationPeriod contextRef="FD2019Q2YTD" id="Fact-5A53BDBC3755514893F27D7493D99025">P2Y10M24D</dare:WeightedAverageAmortizationPeriod>
	<dei:AmendmentFlag contextRef="FD2019Q2YTD" id="Fact-105E20AE2033551DB452A7AF4A06243F">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2019Q2YTD" id="Fact-5BB0B3326E075EA893718F283C7649CE">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2019Q2YTD" id="Fact-3784968452B25027AEE6D54528E511A5">Q2</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2019Q2YTD" id="Fact-3E75276DBBAF5BE69A77DD47F5F9E06F">2019</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2019Q2YTD" id="Fact-45C523F2FF4454288635A01A167FBE0C">2019-06-30</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2019Q2YTD" id="Fact-33C2AA69AD995AB68DB0640019E69E92">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2019Q2YTD" id="Fact-92E5BD4D1275512EBC08326772FA806A">0001401914</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2019Q3Aug13" decimals="INF" id="Fact-9FEB03613CCA57D0BAC93F694E474A59" unitRef="shares">16683411</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2019Q2YTD" id="Fact-302BF6B2A608F2C969955E908E5F6A46">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityEmergingGrowthCompany contextRef="FD2019Q2YTD" id="Fact-A41661CFD42F5FB1BFC631FADF3989F0">true</dei:EntityEmergingGrowthCompany>
	<dei:EntityExTransitionPeriod contextRef="FD2019Q2YTD" id="Fact-56CDC91A841253D6B48F57AA8BD96461">true</dei:EntityExTransitionPeriod>
	<dei:EntityFilerCategory contextRef="FD2019Q2YTD" id="Fact-80EAD1A3FDE0539A948C6013692B56C6">Non-accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2019Q2YTD" id="Fact-139C7A43F55F5CB7A3E230D637AB26F8">Dare Bioscience, Inc.</dei:EntityRegistrantName>
	<dei:EntityShellCompany contextRef="FD2019Q2YTD" id="Fact-A95A9ACFB605D40F2E4F5E8FF488A03F">false</dei:EntityShellCompany>
	<dei:EntitySmallBusiness contextRef="FD2019Q2YTD" id="Fact-1DE0972E099950AE92D140C390D82A00">true</dei:EntitySmallBusiness>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="0" id="Fact-AEB2C123656E51BF9651F03813998EB2" unitRef="usd">459705</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2019Q2" decimals="0" id="Fact-69F62382DC265894A85A11EF3DC252D6" unitRef="usd">632118</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="0" id="Fact-E6CE02F313265C0DB06C5B273C74C4A8" unitRef="usd">631351</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2019Q2" decimals="0" id="Fact-3162C2380EAC50C8B74C9D704334F0A3" unitRef="usd">1341811</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4" decimals="0" id="Fact-7BAB98BCFCC7554F866616C139031E8C" unitRef="usd">-96728</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2019Q2" decimals="0" id="Fact-42D9272337A5502484B4C07F931F7894" unitRef="usd">-97024</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2018Q4" decimals="0" id="Fact-D3A9C6C969895AF38EF0F321BB164C7E" unitRef="usd">35791972</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2019Q2" decimals="0" id="Fact-FC69D2BBAC185F5EB639B68725AA504F" unitRef="usd">41942062</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q2QTD" decimals="0" id="Fact-B21C1EDB5046143AAF285EAC8B5613C2" unitRef="usd">9423</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-B99FB86699AA3265D7C65EAC823D5928" unitRef="usd">9423</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q2YTD" decimals="0" id="Fact-E00BC7D4092358B38CD052F5F55CCD37" unitRef="usd">18547</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-107C37725C225D07A1CD83B4C20BAA14" unitRef="usd">18547</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q2QTD" decimals="0" id="Fact-3D353396FCBF52F1A8575EA5BB080039" unitRef="usd">111351</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-4170BDD0648176E939B35EA5B51773A5" unitRef="usd">111351</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q2YTD" decimals="0" id="Fact-2A0EC3AB24A1503FBF1771FDE8914849" unitRef="usd">209319</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-4D0979A3AB155F759C9D9DD6D5AEF93F" unitRef="usd">209319</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="FD2018Q2QTD" decimals="0" id="Fact-75A28440ADCF9C3DFC2B5EACD5E94490" unitRef="usd">2160</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-B8E788767014E678293C5EACCDA202E2" unitRef="usd">2160</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-049090367517502CB53D9B176986C442" unitRef="usd">9423</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="0" id="Fact-E19582259E805237877DC92D1EDB4E86" unitRef="usd">9423</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="0" id="Fact-2CC4507F6D3157188F8A227D8FE52F06" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-E7AC9881E18053078DFD822D17C15E3E" unitRef="usd">18547</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="0" id="Fact-AF96858533335128B6EDE05900D5C0A4" unitRef="usd">18547</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="0" id="Fact-EC1D581D1CC881E58D086D91C4713AFF" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q2YTD_us-gaap_PlanNameAxis_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" decimals="0" id="Fact-4B6BC9CA480557CD856D643F19645D65" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-4C14C2E5318453BD919924E268053762" unitRef="usd">111351</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="0" id="Fact-67692CB5D09050A2AAEE2368BDA17F0B" unitRef="usd">84355</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="0" id="Fact-7A6999EBCA9356879BE6700743BCA4EE" unitRef="usd">26996</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-8A0EA31CAC9B5CB7AB59442499593B79" unitRef="usd">209319</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="0" id="Fact-74E37780405D590B92DC5EB5729AF180" unitRef="usd">157620</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="0" id="Fact-550E548DC9E8599FAA86BEAFA50F92DB" unitRef="usd">51699</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q2YTD_us-gaap_PlanNameAxis_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" decimals="INF" id="Fact-32F28D0E148054368C53D430B206D9DD" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q2QTD" decimals="0" id="Fact-6B541E18B1C55D0BBDDF390F5D04DB6D" unitRef="shares">4298573</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-349947BD95345A98B99A6E5A49C6DD8D" unitRef="shares">547571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-6E6C339D3B115FE8BDF4DF6EAC5DB4F2" unitRef="shares">3751002</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q2YTD" decimals="0" id="Fact-99F08CC016605B2DA62A8D7ECD501E98" unitRef="shares">4298573</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-1C7211C86AE95BEFA613309B0239BF26" unitRef="shares">547571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-F4A7DD3F563659D9951449E82D6957BE" unitRef="shares">3751002</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q2QTD" decimals="0" id="Fact-6CE964F5CF715E77A0C72DA3E1E3952B" unitRef="shares">5941193</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-FE306688D543523D9D4C561C86AB5E8B" unitRef="shares">2190360</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-2452579CFEAB59F18CA853ABAF5FFDD2" unitRef="shares">3750833</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q2YTD" decimals="0" id="Fact-0FF812405E8053A08F0EC49C1005F5E3" unitRef="shares">5941193</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-138E5CB63EEC508AB3A9C301C6ED8B46" unitRef="shares">2190360</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-F1FCDCB800F851FC969A8BB06D72053B" unitRef="shares">3750833</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2018Q4" decimals="0" id="Fact-921F96E97CF05D8DA21BB3F16020F6EB" unitRef="usd">7827387</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2019Q2" decimals="0" id="Fact-8B7AC37D12EC5CDAAAFE0228361E9F42" unitRef="usd">7260932</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2018Q4" decimals="0" id="Fact-2DEDCD98F5105BAB8523FDD52448D06C" unitRef="usd">7240023</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2019Q2" decimals="0" id="Fact-272B6576F2CD5991B6FE8081002F778E" unitRef="usd">6561546</us-gaap:AssetsCurrent>
	<us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="D2018Q2May15-May16_us-gaap_BusinessAcquisitionAxis_dare_PearTreePharmaceuticalsIncMember" decimals="-3" id="Fact-6C1724DD3D355BFCBE068A90043A41B7" unitRef="usd">132000</us-gaap:BusinessCombinationConsiderationTransferred1>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="0" id="Fact-A59662E2A477528AA5F5E6A3480E0D81" unitRef="usd">6805889</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2019Q2" decimals="0" id="Fact-D0EE011479A95174AB262246ED570DD5" unitRef="usd">5630569</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2019Q2" decimals="-5" id="Fact-02850068B161548BB53C3EBBFBF41708" unitRef="usd">5600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-497E3C6DD89C51BDB7FACCB6A6EB9E4E" unitRef="usd">6800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-130E1C841E9C55A8BF5C29337D62331E" unitRef="usd">5600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2017Q4" decimals="0" id="Fact-51D0146AEB985802A8F8446AAEBA037D" unitRef="usd">7559846</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q2" decimals="0" id="Fact-CDD87AE6D36E512B94C0F56762BA083C" unitRef="usd">12446524</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q4" decimals="0" id="Fact-1E79F1DD33C0553DA4204407FA712949" unitRef="usd">6805889</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2019Q2" decimals="0" id="Fact-182A394BCD82550F8E98C3F63F524181" unitRef="usd">5630569</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2018Q2YTD" decimals="0" id="Fact-C4BDED0B18AB53A1915878805921237E" unitRef="usd">4886678</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2019Q2YTD" decimals="0" id="Fact-4E8066ADEE5D5F3D842D49C0BD0A30D8" unitRef="usd">-1175320</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2019Q2_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" decimals="2" id="Fact-5B168DF363BA51D899AEDA24EEB4E358" unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2019Q2_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" decimals="2" id="Fact-E2EF06B6A8D850959C246574C4FABFCB" unitRef="usdPerShare">120.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2019Q2_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" decimals="2" id="Fact-B72D27249CB159E0B17C608F3A73A73B" unitRef="usdPerShare">120.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2019Q2_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" decimals="2" id="Fact-707751F4A7815D7B91E9E834C09E7DFC" unitRef="usdPerShare">0.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2019Q2_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember" decimals="2" id="Fact-99198FA91AAA57008F900B232BC728F5" unitRef="usdPerShare">60.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2018Q1Feb_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="2" id="Fact-E46C193AE2D0B8A27D0B72286D407633" unitRef="usdPerShare">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2019Q2Apr11_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" decimals="2" id="Fact-E606F2DA230BDB89A771722921010DDF" unitRef="usdPerShare">0.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2019Q2" decimals="INF" id="Fact-504D2A2F99090E68E5FA723B4EF70834" unitRef="shares">30333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2018Q1Feb" decimals="INF" id="Fact-A049D2579750522FAC27EF8D41C3DBF5" unitRef="shares">3500000.0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2018Q1Feb_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-6242FE74026A54A191B9D5D8AF4265E5" unitRef="shares">525000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2019Q2" decimals="INF" id="Fact-D18E64405F185CECB7D2AAAF73336635" unitRef="shares">3750833</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2019Q2_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" decimals="INF" id="Fact-D2D1B36B1C5457D9926491ABD53ADCA4" unitRef="shares">6500</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2019Q2_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" decimals="INF" id="Fact-22AB91A169EA59A8953B03F3338EDBF9" unitRef="shares">2906</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2019Q2_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" decimals="INF" id="Fact-B264DF46D7CF553D9DDB330F60ACD93A" unitRef="shares">3737</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2019Q2_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" decimals="INF" id="Fact-10039A38FAB1589D88FA4C28303F23CE" unitRef="shares">3720500</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2019Q2_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember" decimals="INF" id="Fact-19E0F34A1EED575BAE756DA4373C4FFD" unitRef="shares">17190</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2018Q4" id="Fact-1BB8EF60355150478D27B50F13F502C0" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2019Q2" id="Fact-B9B4DF4D96C054908836A17ADB37B0A9" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-7B391574FA44517AA1DF30EB71B6ABEA" unitRef="shares">497032</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-7D7D97DECAEB5A4F89440205032EB9D0" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2019Q2" decimals="INF" id="Fact-4EEEAB0237815F7EBC5A41B88F291BF9" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-62118021E489517AAD0D8D8DEDA89637" unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2019Q2" decimals="INF" id="Fact-8A16DC8CE5115FFD81CF9520F5A9F61F" unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-8688D70A3924526E8E606D57F27261AF" unitRef="shares">11422161</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2019Q2" decimals="INF" id="Fact-BF7C743D97445B7B84A51E359489A9F3" unitRef="shares">16683411</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-038217132E3B5313850D1F04EB526BB1" unitRef="shares">11422161</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2019Q2" decimals="INF" id="Fact-69AFD8CE1BB451399DD65420C51FC174" unitRef="shares">16683411</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2019Q2_dei_LegalEntityAxis_dare_PrivateDareMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember" decimals="INF" id="Fact-1274B15C960B5EB8B6125C9E03122587" unitRef="shares">223295</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2018Q4" decimals="0" id="Fact-9C50AA69ED145C149746CBB5EC503D4A" unitRef="usd">1143</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2019Q2" decimals="0" id="Fact-EEE3BA9C104158AFB58DDE6CF6F1B3AC" unitRef="usd">1668</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q2QTD" decimals="0" id="Fact-B013AB05AC9855E19AE3D0893865328E" unitRef="usd">-3609655</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q2YTD" decimals="0" id="Fact-DE1F9AD39D4356908177C80D0659FA0F" unitRef="usd">-11289018</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2019Q2QTD" decimals="0" id="Fact-A6653C90991854F1A807B70386E3B36A" unitRef="usd">-4749961</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2019Q2YTD" decimals="0" id="Fact-71F03CBA74365B5E9555D9473B414671" unitRef="usd">-7794180</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ContractualObligation contextRef="FI2017Q1_srt_ProductOrServiceAxis_dare_OvapreneMember_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="INF" id="Fact-71D014D12D295F0F92772DAF7785CDA3" unitRef="usd">5000000</us-gaap:ContractualObligation>
	<us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent contextRef="FI2019Q2" decimals="0" id="Fact-C6892E0761B7521486C9FFA9144EFA70" unitRef="usd">1348159</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
	<us-gaap:Depreciation contextRef="FD2018Q2YTD" decimals="0" id="Fact-E2227F41F4BB53958E952DA4F26C974D" unitRef="usd">288</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2019Q2YTD" decimals="0" id="Fact-EF4645DD0E2750699D6C7D0FE542F4F1" unitRef="usd">2315</us-gaap:Depreciation>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q2QTD" decimals="2" id="Fact-774E822ECC4D52F6BE1C435841AF44BE" unitRef="usdPerShare">-0.32</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q2YTD" decimals="2" id="Fact-D3B0B5065CC45B52A2C208AD34477011" unitRef="usdPerShare">-1.13</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2019Q2QTD" decimals="2" id="Fact-8CD39F89CF335E4193BA32847A81DEE1" unitRef="usdPerShare">-0.29</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2019Q2YTD" decimals="2" id="Fact-3C4AA5F4F9A95EBD82540D254B545882" unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2018Q2YTD" decimals="0" id="Fact-942400885BE5508CA99E0C7F5C76D1D2" unitRef="usd">-41231</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2019Q2YTD" decimals="0" id="Fact-E730813F8DD55FF3AF5872CE3BEA77FA" unitRef="usd">-296</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q2QTD" decimals="0" id="Fact-AB02FDA05F665E778EAC290813B81799" unitRef="usd">1157174</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q2YTD" decimals="0" id="Fact-C342733EEB2E50C7B330C972C65F3B20" unitRef="usd">2460363</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2019Q2QTD" decimals="0" id="Fact-286F10EB9AEF51759F264FD5F4F5D995" unitRef="usd">1307379</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2019Q2YTD" decimals="0" id="Fact-9096C6FBDBFE56C7A10B10CF6287BC85" unitRef="usd">2584559</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2018Q1QTD" decimals="-5" id="Fact-9CE594A21F6D523AABEFFF1ACD22E383" unitRef="usd">5200000</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2018Q2QTD" decimals="0" id="Fact-EBE59D2BF588592180815DD481EB9EAF" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2018Q2YTD" decimals="0" id="Fact-5A335EA0AE795786B1985E958E7BFBD6" unitRef="usd">5187519</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2019Q2QTD" decimals="0" id="Fact-331E42F05ADF58F986051117D1D4EB85" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2019Q2YTD" decimals="0" id="Fact-351368050CBF5BF29166EAD394068FBC" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GrantsReceivable contextRef="FI2019Q2" decimals="0" id="Fact-B1A92CA84072B3E0A56572118A82BD1F" unitRef="usd">456484</us-gaap:GrantsReceivable>
	<us-gaap:GrantsReceivable contextRef="I2018Q2Apr" decimals="-5" id="Fact-1F43A89398EA507285CA36D44C042A0A" unitRef="usd">1900000</us-gaap:GrantsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2018Q2YTD" decimals="0" id="Fact-3BD93A7CAC945917B29A676BDC6BF939" unitRef="usd">9739</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2019Q2YTD" decimals="0" id="Fact-D2B31C0AA19E5B5091CDED50E7EFEB8A" unitRef="usd">172413</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2018Q2YTD" decimals="0" id="Fact-AF21A8E35BD558AE94BADE20C8878CCB" unitRef="usd">288846</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2019Q2YTD" decimals="0" id="Fact-2EC426CD09725014976E37670F26B67D" unitRef="usd">710459</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="FD2018Q2YTD" decimals="0" id="Fact-A91FD2B2A88F5A8FB1D1FDE175A17C2D" unitRef="usd">-193495</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="FD2019Q2YTD" decimals="0" id="Fact-72174C0D1AAB5FD0A580A6EDE525007C" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2018Q2YTD" decimals="0" id="Fact-87FE73B83A345C06AA1885867E0B9AA0" unitRef="usd">-75</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2019Q2YTD" decimals="0" id="Fact-A6BB85AA5D1257D4B3B6180A32B6BF9A" unitRef="usd">-9711</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="FD2018Q2YTD" decimals="0" id="Fact-7ED8B6B195EB5BA09990824BE64817AD" unitRef="usd">-259562</us-gaap:IncreaseDecreaseInOtherReceivables>
	<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="FD2019Q2YTD" decimals="0" id="Fact-EADED35CA147561AA8D013B5C80D4333" unitRef="usd">461982</us-gaap:IncreaseDecreaseInOtherReceivables>
	<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="FD2018Q2YTD" decimals="0" id="Fact-A77298F4A79157558FEBAAE18856B762" unitRef="usd">35838</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="FD2019Q2YTD" decimals="0" id="Fact-B3C11FAEF142593EBF82D76E776D216A" unitRef="usd">34861</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:LesseeOperatingLeaseDiscountRate contextRef="I2019Q1Jan1" decimals="INF" id="Fact-2FA54D53EE73EA510BF587D81D6792A0" unitRef="number">0.07</us-gaap:LesseeOperatingLeaseDiscountRate>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="FI2019Q2" decimals="0" id="Fact-5FB4AD9BE1FD5CD793C12E40F60C0C9A" unitRef="usd">236069</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="FI2019Q2" decimals="0" id="Fact-878263017E405EF9A19328CE9EE446AD" unitRef="usd">55531</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="FI2019Q2" decimals="0" id="Fact-184F75E87BCA5C0F8D2A791AA32784A1" unitRef="usd">67595</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="FI2019Q2" decimals="0" id="Fact-A691CB930BDB5139B29BA7762FC59787" unitRef="usd">112943</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
	<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="FI2019Q2" decimals="0" id="Fact-87127147A46F551E96C77FB320819EC7" unitRef="usd">42669</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
	<us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="I2018Q3Jul1" id="Fact-3BDECDDCF2FBF9F55E3D5E7B70EEFACB">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
	<us-gaap:LesseeOperatingLeaseTermOfContract contextRef="I2018Q3Jul1" id="Fact-098BF54CF8B32590A7B75E7C5A18E208">P37M</us-gaap:LesseeOperatingLeaseTermOfContract>
	<us-gaap:Liabilities contextRef="FI2018Q4" decimals="0" id="Fact-0132083DCE7357668BDC4E459806B6C7" unitRef="usd">1100767</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2019Q2" decimals="0" id="Fact-6ECC83C71474562D8F9DD2C6C5430DBE" unitRef="usd">2177877</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q4" decimals="0" id="Fact-E45998BEB8DD5AD8B1CE0CDFC4F13391" unitRef="usd">7827387</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2019Q2" decimals="0" id="Fact-ADEF856D4F475AFABC5EB344929EAD20" unitRef="usd">7260932</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q4" decimals="0" id="Fact-443E29EA601F5E278613393B36F9F048" unitRef="usd">1091056</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2019Q2" decimals="0" id="Fact-5DFB062D7E8651909D15320E9E3A67B0" unitRef="usd">1973929</us-gaap:LiabilitiesCurrent>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q2YTD" decimals="0" id="Fact-832EBC60040D5B15AF15600C47104756" unitRef="usd">10195653</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2019Q2YTD" decimals="0" id="Fact-B0FB4B98B04755ACB15EE1C030BB7D69" unitRef="usd">5151702</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2018Q2YTD" decimals="0" id="Fact-D40005E450BF6CC4A3F85EE9F35C030A" unitRef="usd">-460200</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2019Q2YTD" decimals="0" id="Fact-CFA7A08D91202DD97D515EE9F32D32AD" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q2YTD" decimals="0" id="Fact-F41B6519E5C5507583E0AE67B0B9B8C7" unitRef="usd">-4807544</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2019Q2YTD" decimals="0" id="Fact-390B928626295C0F913C07655AE42F4C" unitRef="usd">-6326726</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2019Q2YTD" decimals="-5" id="Fact-192861BC28F35BE48964EB5A5BCC2A70" unitRef="usd">-6300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q2QTD" decimals="0" id="Fact-15C9E0429EBA51E8AC90CAF13D689938" unitRef="usd">-3582170</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-D1D003E00B5572B6461A5EADDB0C3F8F" unitRef="usd">-3582170</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q2YTD" decimals="0" id="Fact-DFE9238A55C85748B3D8809019E69554" unitRef="usd">-11247787</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-7E1E72CDB55BE5F5C32A5EACFB92A90F" unitRef="usd">-11247787</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q2QTD" decimals="0" id="Fact-B18DA5E263055E049593093CB58E6E9B" unitRef="usd">-3952450</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-36444A611E98903BA73B5EA5CEFBA5DC" unitRef="usd">-3952450</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q2YTD" decimals="0" id="Fact-CCAD83891E9F50F18F7C31A01E61045B" unitRef="usd">-7004290</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-B58F87043FCB5AA7B1D73CE9316AF590" unitRef="usd">-7004290</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2018Q2QTD" decimals="0" id="Fact-419C7D0ADCDC2453BBD95E98D7536072" unitRef="usd">-3582170</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2018Q2YTD" decimals="0" id="Fact-26994F43EA2B010DE0F55E98D6FB1924" unitRef="usd">-11247787</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2019Q2QTD" decimals="0" id="Fact-B0B28FEDE9191227FC5D5E98D71F63DD" unitRef="usd">-4742044</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2019Q2YTD" decimals="0" id="Fact-0588E1A852ADDC32E3295E98D6DB5545" unitRef="usd">-7793884</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetRentableArea contextRef="I2018Q3Jul1" decimals="0" id="Fact-E7428EC34AAF9053C18D5E7A5B4A5431" unitRef="sqft">3169</us-gaap:NetRentableArea>
	<us-gaap:NumberOfOperatingSegments contextRef="FD2019Q2YTD" decimals="INF" id="Fact-658CA8AD8C75B17F63FE5E77BF83BC24" unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
	<us-gaap:OperatingExpenses contextRef="FD2018Q2QTD" decimals="0" id="Fact-418693EF9DE55F3FB14F10E1403DD33D" unitRef="usd">3624796</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q2YTD" decimals="0" id="Fact-2A8F0730E8615DEFB25070C974E48785" unitRef="usd">11302157</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2019Q2QTD" decimals="0" id="Fact-4D06AACD0CA758749EF9F83A4C71994E" unitRef="usd">3982451</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2019Q2YTD" decimals="0" id="Fact-8C23BA6325605876A378C67661B53603" unitRef="usd">7065522</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q2QTD" decimals="0" id="Fact-27F830D0166350B3A22E8EC2B3F13458" unitRef="usd">-3624796</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q2YTD" decimals="0" id="Fact-6508F00D0DE65842BED65CFB29A7DB78" unitRef="usd">-11302157</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2019Q2QTD" decimals="0" id="Fact-708E6505DA825D32B42B8378E35005FE" unitRef="usd">-3982451</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2019Q2YTD" decimals="0" id="Fact-7033B6D82C055FD6B5F831723C8033A8" unitRef="usd">-7065522</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeaseCost contextRef="FD2019Q2QTD" decimals="0" id="Fact-0D57FA2F9B9E5603A8B50ACFD91AD89B" unitRef="usd">27038</us-gaap:OperatingLeaseCost>
	<us-gaap:OperatingLeaseCost contextRef="FD2019Q2YTD" decimals="0" id="Fact-869165957B618AEFBC446D2C5DA1E2CF" unitRef="usd">54076</us-gaap:OperatingLeaseCost>
	<us-gaap:OperatingLeaseLiability contextRef="FI2019Q2" decimals="0" id="Fact-36CF42A83A46557CBCC0139D7A8F01B6" unitRef="usd">193400</us-gaap:OperatingLeaseLiability>
	<us-gaap:OperatingLeaseLiability contextRef="I2019Q1Jan1" decimals="-3" id="Fact-C920A7A5240B52D0B4A2DFBDFF9CD4FF" unitRef="usd">241000</us-gaap:OperatingLeaseLiability>
	<us-gaap:OperatingLeaseLiabilityCurrent contextRef="FI2019Q2" decimals="0" id="Fact-6BB1B6AE1E51CCABB19C5E791E23A6EC" unitRef="usd">87859</us-gaap:OperatingLeaseLiabilityCurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2019Q2" decimals="0" id="Fact-00AE843135ED63AB35345E796DCAEB43" unitRef="usd">116089</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeasePayments contextRef="FD2019Q2QTD" decimals="0" id="Fact-FB608A01C112553C9ED8AD7A51CE1A45" unitRef="usd">26620</us-gaap:OperatingLeasePayments>
	<us-gaap:OperatingLeasePayments contextRef="FD2019Q2YTD" decimals="0" id="Fact-1FE8F8B1E7B519BC43746D2C9B906042" unitRef="usd">53240</us-gaap:OperatingLeasePayments>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2019Q2" decimals="0" id="Fact-57B944818D4456B1A521D503652F6BC7" unitRef="usd">193399</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="I2019Q1Jan1" decimals="-3" id="Fact-E902C7DB8DB2541D9F814F37B1EC1F48" unitRef="usd">232000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="D2018Q3Jul1" decimals="0" id="Fact-A6656A0398D4AF7913C45E7AF30AE6F3" unitRef="usd">8873</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q4" decimals="0" id="Fact-CE7DBCEE5AFF5B6CB0661359AC4825D8" unitRef="usd">577968</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2019Q2" decimals="0" id="Fact-23B2BEE072CF564587E5365251BF1891" unitRef="usd">692305</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2018Q2QTD" decimals="0" id="Fact-1C64657224D65DEAA7AE02188D383ECB" unitRef="usd">-27485</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-48D5C22C2FB11E3859105EADE8C9696D" unitRef="usd">-27485</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2018Q2YTD" decimals="0" id="Fact-F14965B1A9FC5BAE88B7E4A263A52F6D" unitRef="usd">-41231</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-ABC507C38CBE51D99B09780BE026C22A" unitRef="usd">-41231</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2019Q2QTD" decimals="0" id="Fact-38A725D21D1859608B924A6EB81FF02E" unitRef="usd">-7917</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-E9D5227F2F88906B9F395EA5D898FD68" unitRef="usd">-7917</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2019Q2YTD" decimals="0" id="Fact-B434735E82DF51D5946304E50C78E71D" unitRef="usd">-296</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-3C6EF08C813A5E00AE9565797C3881B8" unitRef="usd">-296</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2018Q4" decimals="0" id="Fact-1903A1B39DCF5FF092569B1EF6584D0D" unitRef="usd">9711</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2019Q2" decimals="0" id="Fact-9AD0F3C9ECE3506582E9B1BB3BECE6C8" unitRef="usd">203948</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2018Q2QTD" decimals="0" id="Fact-5CCC6ED91871508C9B2E7DB23860845E" unitRef="usd">42626</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2018Q2YTD" decimals="0" id="Fact-14A910F7A61451F9B3D6DA1FE47E0552" unitRef="usd">54370</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2019Q2QTD" decimals="0" id="Fact-D0CE28355C305E8DB1447442A8ED765B" unitRef="usd">30001</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2019Q2YTD" decimals="0" id="Fact-350AEBEDFC265A8F87C0DF74B0CE142F" unitRef="usd">61232</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherReceivablesNetCurrent contextRef="FI2018Q4" decimals="0" id="Fact-ECF93C28BAAB547FA0B693662C3CFDBA" unitRef="usd">31037</us-gaap:OtherReceivablesNetCurrent>
	<us-gaap:OtherReceivablesNetCurrent contextRef="FI2019Q2" decimals="0" id="Fact-7066B9C768905244AD67B41FA4B7EAC9" unitRef="usd">493019</us-gaap:OtherReceivablesNetCurrent>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2018Q2YTD" decimals="0" id="Fact-47D684A78E535F7BF94472260081AB5E" unitRef="usd">237403</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="FD2018Q2YTD" decimals="0" id="Fact-F7A2B871278F641C852C5EE9F31D9C43" unitRef="usd">452000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="FD2019Q2YTD" decimals="0" id="Fact-82C68745CF390CA5AC8F5EE9F2CFBBE0" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2018Q2YTD" decimals="0" id="Fact-F6DA67A152C0860891C55EE9F37B2980" unitRef="usd">8200</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2019Q2YTD" decimals="0" id="Fact-4B24C67F0F525047FEB05EE9F36C0CF8" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-A31717FE60915E27A31F4C785494BAE7" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2019Q2" decimals="INF" id="Fact-C419F21A2D6851949659051A18E0DC60" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-D07007DCDA2056D1BB796531202A8B1C" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2019Q2" decimals="INF" id="Fact-E3495B31AED45769B8F390C5ABC875EA" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-129143B633005283ABB5534B360A806D" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2019Q2" decimals="INF" id="Fact-A7D5000045745B6ABE1D828E3E7509B7" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-548A28FF20635A24991AF41B03BAB4D8" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2019Q2" decimals="INF" id="Fact-CE46D20D62945C3792320A862281CB45" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2018Q4" decimals="0" id="Fact-864F064F034D5B32A8BC5BAAABC7755A" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2019Q2" decimals="0" id="Fact-D251256F53C459DAA10314C62044C7E7" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseCurrent contextRef="FI2018Q4" decimals="0" id="Fact-F65BE2EAF7565F588A0AB3D452EB02DE" unitRef="usd">403097</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:PrepaidExpenseCurrent contextRef="FI2019Q2" decimals="0" id="Fact-F490B0F6294A5D6CBBE9629F33D2B74C" unitRef="usd">437958</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2019Q2Apr" decimals="-5" id="Fact-22E113AB854A5AF29EDEBDA0A61BF350" unitRef="usd">5200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProfitLoss contextRef="FD2018Q2YTD" decimals="0" id="Fact-33653BBEEF455849B8AB3AA0DCD49B0E" unitRef="usd">-11247787</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2019Q2YTD" decimals="0" id="Fact-D977AB5582AD5009A6DC8976B11DB584" unitRef="usd">-7004290</us-gaap:ProfitLoss>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q4" decimals="0" id="Fact-3A7199F30D915F17ACD8983BA1CCF792" unitRef="usd">9396</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2019Q2" decimals="0" id="Fact-F82C24D445A95B93A9D5D6A4E01D05FF" unitRef="usd">7081</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred contextRef="FD2019Q2YTD" decimals="0" id="Fact-64053C722922566DB1E07FE50F2AEEF1" unitRef="usd">224665</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q2QTD" decimals="0" id="Fact-2B0F2F6DD39A5C2CBEF36DB42FF306BF" unitRef="usd">2217622</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q2YTD" decimals="0" id="Fact-670EFE6A7E8553A0A065C95FEFCACBAB" unitRef="usd">3304275</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q2QTD" decimals="0" id="Fact-69566E5FC66E511398BCF4356751C5D7" unitRef="usd">2512572</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q2YTD" decimals="0" id="Fact-C2AFF4ED5F0A501FB11F9B632F17BCA9" unitRef="usd">4205963</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2018Q2YTD" decimals="0" id="Fact-E60E7B18D26752018F8C5A311F219C64" unitRef="usd">452000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2019Q2YTD" decimals="0" id="Fact-D6682099E1645AAE8123B0AA505DA2AD" unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4" decimals="0" id="Fact-B4E9442CBF51510EA7F356552D824CAB" unitRef="usd">-28969767</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2019Q2" decimals="0" id="Fact-631582FAD5F35981A4A897832BDAB29A" unitRef="usd">-36763651</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2019Q2" decimals="-5" id="Fact-68B8A30EC7625A40811526EA980499AA" unitRef="usd">-36800000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q1_srt_ProductOrServiceAxis_us-gaap_GrantMember" decimals="0" id="Fact-3AC98C52C3165D068D5B8BC5A46737FE" unitRef="usd">224665</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2019Q1Mar11_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_HealthCareTrustFundAxis_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_NationalInstitutesOfHealthMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember" decimals="0" id="Fact-BB2283111DC42FDEE4635E826B596794" unitRef="usd">730722</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2019Q1Mar11_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_HealthCareTrustFundAxis_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_NationalInstitutesOfHealthMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember" decimals="0" id="Fact-54765A5F8CE89645B9635E82E20AE34B" unitRef="usd">982851</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2019Q1Mar_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_HealthCareTrustFundAxis_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_NationalInstitutesOfHealthMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember" decimals="0" id="Fact-F4CA34F1EAD355EE9848786DE227239B" unitRef="usd">982851</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_HealthCareTrustFundAxis_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_NationalInstitutesOfHealthMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember" decimals="0" id="Fact-04FE910768BB23C392C0721148002934" unitRef="usd">161007</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="FD2018Q2YTD" decimals="0" id="Fact-87D2BF43B8785FE922CF6D5D8E908E29" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
	<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="FD2019Q2YTD" decimals="0" id="Fact-652B2B886E4DB120A7B05EE9F34C005F" unitRef="usd">231698</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2018Q1Feb01-Feb28_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="-5" id="Fact-12E424E678B053598F8D8268498015CC" unitRef="usd">9400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2019Q2Apr11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="-5" id="Fact-96650BEC3CC5BB9B89EE722CD319747A" unitRef="usd">5200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2018Q1Feb_us-gaap_SubsidiarySaleOfStockAxis_dare_PublicStockOfferingMember" decimals="INF" id="Fact-6A902C427B8C53A98FC272BB02D60B20" unitRef="usdPerShare">0.70</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2019Q2Apr11_us-gaap_SubsidiarySaleOfStockAxis_dare_PublicStockOfferingMember" decimals="INF" id="Fact-028AC4D19D832973D3237231D7566761" unitRef="usdPerShare">1.10</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q2YTD" decimals="0" id="Fact-30BBD25146615893902AA4C98D52354A" unitRef="usd">18547</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2019Q2YTD" decimals="0" id="Fact-FDC832A545435BE882A611C6921D7E59" unitRef="usd">209319</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2019Q2QTD" decimals="0" id="Fact-38B946FB87225AFCA5AA5800B5359304" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2019Q2YTD" decimals="0" id="Fact-5A95F06875D5508D9B7DDD279F165C77" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2019Q2QTD" decimals="2" id="Fact-8FC57149E70D51339AC1CADEF1D17CAC" unitRef="number">1.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2019Q2YTD" decimals="2" id="Fact-D5F1BF38BFAC50CBB5B2B915489994A8" unitRef="number">1.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2019Q2QTD" decimals="4" id="Fact-1A790F0BC1295E4F92D6054CF2677E43" unitRef="number">0.0209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2019Q2YTD" decimals="4" id="Fact-8B9F497005595657AA5352F82574E0BF" unitRef="number">0.0258</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2018Q3Jul10_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-C8495292ACEE591380BF35E589AD5952" unitRef="shares">2046885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2019Q1Jan1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-4205B16429D759F6B2ECC76674B1EFCD" unitRef="shares">2503771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2019Q2" decimals="INF" id="Fact-C76F34BB98725922B0B83324D1FFF17D" unitRef="shares">427702</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2019Q2" decimals="2" id="Fact-DFDAF561C5135D5E814FEAAA537EA9C6" unitRef="usdPerShare">21.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2019Q2YTD" decimals="INF" id="Fact-596289B2B20B5B3FAD8284ED0CAEF788" unitRef="shares">70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2019Q2YTD" decimals="INF" id="Fact-E1BC1F8B1F9E5B68BB40BEB8D0B397E4" unitRef="shares">316832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2019Q2YTD" decimals="INF" id="Fact-68AFE41E31C955D9AACD1A977D24F737" unitRef="shares">698000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2019Q2QTD" decimals="2" id="Fact-4C70F81297245962B9CAB6AB10D1129D" unitRef="usdPerShare">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2019Q2YTD" decimals="2" id="Fact-8D5CF4ACAD2156EEBB6EE88544447F40" unitRef="usdPerShare">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q4" decimals="INF" id="Fact-24CD4F9D96535150AB6991663EC14D0E" unitRef="shares">1635790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q4_dei_LegalEntityAxis_dare_PrivateDareMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember" decimals="INF" id="Fact-718E1DCF3EA5586587F34FB4AD24960C" unitRef="shares">10149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2019Q2" decimals="INF" id="Fact-C18B35EF2F4B51DBA703BB0C01799905" unitRef="shares">2016888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember" decimals="INF" id="Fact-4AFA82BE0CB75D1898FFDD4DCA232D83" unitRef="shares">10149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="I2018Q3Jul10_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-EA4A5DE7A3425DD0ADA290EEBF286D23" unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q4" decimals="2" id="Fact-186D61CA98DE5B9B86E51E1411D5610F" unitRef="usdPerShare">11.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2019Q2" decimals="2" id="Fact-E0F02623D6575EBD9CF86ECE93732F15" unitRef="usdPerShare">5.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="D2018Q3Jul10-Jul10_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-CB04C8AD64945CA9B32CCCDEFDDB4F29" unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="D2019Q1Jan1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-340D0F6FB30E5FB693224616C468282C" unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2019Q2YTD" decimals="2" id="Fact-E11D8725A9835A0DB35087A89457251E" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2019Q2YTD" decimals="2" id="Fact-48138D27D5545A0C840AE27B60A2D25C" unitRef="usdPerShare">59.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2019Q2YTD" decimals="2" id="Fact-A931D8A7176D5CC7949FCD9D983AAB4E" unitRef="usdPerShare">24.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2019Q2YTD" decimals="2" id="Fact-1EBA0BD64B855EF5B883D4CD92EBFF3F" unitRef="usdPerShare">0.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2019Q2QTD" id="Fact-269E21D687E259F3A961B217B90B1CAF">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2019Q2YTD" id="Fact-A2C18601EA4C5E85960F4FFB1ECFF5BE">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease contextRef="D2019Q1Jan1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-767502D143B45F39B7643FF1C9E61276" unitRef="shares">456886</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease>
	<us-gaap:SharesOutstanding contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-9215C03B5F985FCE9014AEDD49A9ED4C" unitRef="shares">6047161</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A53CEE7BB6D8B5EE66F85EAC34CDD2B2" unitRef="shares">11422161</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-AF906D9E69905D54A8C6D8DFE0019D95" unitRef="shares">11422161</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-7A3C7960BD57521AA72BDF75E3FC9DBF" unitRef="shares">11422161</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-534FDF6E0C26E2DB3A415E9EF9C86094" unitRef="shares">11422161</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-B6BF6DFB8064973BF7EF5EA5E06C6C7E" unitRef="shares">16683411</us-gaap:SharesOutstanding>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2018Q1Feb01-Feb28" decimals="-5" id="Fact-6A61720F036256ACBCB77FED2049779F" unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2018Q1Feb01-Feb28_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-ADD5B4318E175888BF76F937EC85D454" unitRef="shares">220500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2019Q2Apr11" decimals="INF" id="Fact-6AC3A14577B4482372A0722F15EE621A" unitRef="shares">5261250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2019Q2Apr11_us-gaap_SubsidiarySaleOfStockAxis_dare_PublicStockOfferingMember" decimals="INF" id="Fact-EF3B7A77B7CDFF295C39722AA66228FA" unitRef="shares">4575000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2019Q2Apr11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-E6198DC0DCB9E83AD14D722C0053D5BE" unitRef="shares">686250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q2QTD" decimals="INF" id="Fact-B612804812B059F2A14E72232AA4A311" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q2YTD" decimals="INF" id="Fact-CBD722F75E435614981304B7114E5DA8" unitRef="shares">375000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-3EC34378A82C548FB2C3F50A28A1EAF1" unitRef="shares">375000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2019Q2QTD" decimals="INF" id="Fact-B9A6E65E0DCDAEA5CE6772219248D6BC" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-DAF6CBB4D625FAED3C765EA98A06CEFE" unitRef="shares">5261250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2019Q2YTD" decimals="INF" id="Fact-BA93DFF15FD0F69A98AE72232BC20E45" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-0863C0764300E43B421A5EAAA380ECB2" unitRef="shares">5261250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2019Q2YTD" decimals="INF" id="Fact-78D55587D4355118945C318EF54250EB" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q2YTD" decimals="0" id="Fact-936999EBE05E57989E1EF2434456B169" unitRef="usd">1037764</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-26519AEE06BF5456917FEE7DFE8914A7" unitRef="usd">1037727</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-E3A88619087E51B594598440F405AB7D" unitRef="usd">37</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q2QTD" decimals="0" id="Fact-5BA091A58A83DA9F65AE5EA92091D475" unitRef="usd">5151702</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-CAE843E3AC72BC8291175EA920727F71" unitRef="usd">5151177</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-7099297D3CD3E4FBF9405EA92081833E" unitRef="usd">525</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q2YTD" decimals="0" id="Fact-71A96854035AAA13E9A65EAAB4170AD6" unitRef="usd">5151702</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-19D157AC3CD8F1CC95F65EAAABBE88E0" unitRef="usd">5151177</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-574C43040509D9C371835EAAA6AE654A" unitRef="usd">525</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="0" id="Fact-468BE2BA3F0D5B1BA98F8658C3B0127C" unitRef="usd">13292782</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-5166A8B82454536DB7389AE7EB06F762" unitRef="usd">-18080</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-4DCECB2AA89D59D09CA0D609DDF61B4C" unitRef="usd">25541210</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-A0A06FF414A75DB091981734EE99CB99" unitRef="usd">605</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-655782374430514684DE0F970687C145" unitRef="usd">-12230953</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1" decimals="0" id="Fact-60CCD5823A334488602D5EAC524120E8" unitRef="usd">15820356</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-97288335489A14F143AA5EAC4792D7F0" unitRef="usd">-31826</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-28BE69735ABBBD80E4FA5EAC408D7D9D" unitRef="usd">35747609</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-E048941152B6BAD0C37A5EAC3A76BD70" unitRef="usd">1142</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-83727753A14ADAFFE8115EAC4CE9C818" unitRef="usd">-19896570</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2" decimals="0" id="Fact-68248A43BA32535F871F009CB0C97210" unitRef="usd">12217963</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-104A31F9A46591B7C7525EAE43340140" unitRef="usd">-59311</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-F6D2F0A7441A5A52BAEAB0D57D591CA9" unitRef="usd">35754872</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-9FE79DBF336F427F87A05EAE37592D09" unitRef="usd">1142</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-7D665565BA51738339CB5EAE4909F7B8" unitRef="usd">-23478740</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4" decimals="0" id="Fact-E229336187185D7EBA16AF18E32067F5" unitRef="usd">6726620</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-6C28D823E3045F7E86599AC4B787E1BE" unitRef="usd">-96728</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-EE8726E3E837570FBBA48CAB24B00554" unitRef="usd">35791972</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-9E3082DDF5995EED99148AB8AF0D0AAC" unitRef="usd">1143</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-8B33C6E97E205122A7E9A53B2EA749FE" unitRef="usd">-28969767</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1" decimals="0" id="Fact-2E0D707634E537260BB15E9F0E76F6D3" unitRef="usd">3780369</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-8769F8BD1497AB34D8735E9F07260B1B" unitRef="usd">-89107</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-857436F05B6852C643F05E9F03032239" unitRef="usd">35889940</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-D760D1A86BE5494428D75E9EFEBEFA30" unitRef="usd">1143</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-78FBD3B973365949F7635E9F0B2B115A" unitRef="usd">-32021607</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2" decimals="0" id="Fact-5CA551F7DD8D5DBAB4C7A46D5B58F2D3" unitRef="usd">5083055</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-268E072E405C54A095E10988A171EE81" unitRef="usd">-97024</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-E06D6B48775CCA3ADBE05EA5E874644C" unitRef="usd">41942062</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-AAF4D8EF03F87F1C65D55EA5E4151A9A" unitRef="usd">1668</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-A7084894D4C29C578FE65EA5F17AF0E7" unitRef="usd">-36763651</us-gaap:StockholdersEquity>
	<us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount contextRef="FD2018Q2QTD" decimals="0" id="Fact-6318FEBC855CC366DD185E9C6E236C3B" unitRef="usd">0</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
	<us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount contextRef="FD2018Q2YTD" decimals="0" id="Fact-FB56E16ABBD9D65A2A285E9C6DFB2FCD" unitRef="usd">0</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
	<us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount contextRef="FD2019Q2QTD" decimals="-5" id="Fact-F2AD4C5B3603518959BA7264DB06A0EB" unitRef="usd">800000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
	<us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount contextRef="FD2019Q2QTD" decimals="0" id="Fact-E8BCA463CB13FA3243715E9C6E4B53D9" unitRef="usd">789594</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
	<us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-C86E30E8966E2FD892695EDFBA546B97" unitRef="usd">-789594</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
	<us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-112FCA11E50A5012923F5EDFC4209FA4" unitRef="usd">789594</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
	<us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount contextRef="FD2019Q2YTD" decimals="-5" id="Fact-B56AFAA8643D217FB9FE72658D59250B" unitRef="usd">800000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
	<us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount contextRef="FD2019Q2YTD" decimals="0" id="Fact-7FA4FBF209FB05E08B1A5E9C6E9B98CB" unitRef="usd">789594</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
	<us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-9F2EFE2B4DBD0167C3BE5EE0748A077E" unitRef="usd">-789594</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
	<us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-8C555989404507DA5B675EE07C8AC57C" unitRef="usd">789594</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q2QTD" decimals="0" id="Fact-940EA29F0A165668BE9B84FAF2D48822" unitRef="shares">11422161</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q2YTD" decimals="0" id="Fact-A82F065EBAB55C718381C3712575A761" unitRef="shares">10031249</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2019Q2QTD" decimals="0" id="Fact-FA827FCA6AD75FD6B22D527904C31394" unitRef="shares">16105252</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2019Q2YTD" decimals="0" id="Fact-EDA82E3CB6285642AD5EECFEBC2E38C4" unitRef="shares">13776643</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<dare:GrantAwardTextBlock contextRef="FD2019Q2YTD" id="Fact-75653D47B7DB599BA74B8E255CD0C950">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;GRANT AWARD&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In April 2018, the Company received a Notice of Award for the first &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$224,665&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the anticipated &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, a division of the National Institutes of Health, or the NIH.&amp;#160;The Company must incur and track expenses eligible for reimbursement under the award and submit a detailed accounting of such expenses to receive payment. The Company received all &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$224,665&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the award payments under this Notice of Award. Such payments were applied to clinical development efforts supporting Ovaprene and were recognized in the statement of operations as a reduction to research and development activities as the related costs were incurred to meet those obligations over the period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On March 11, 2019, the Company received a second Notice of Award for an additional &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$982,851&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the anticipated &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The second award followed the NIH's review of an interim data analysis and other results of the first phase of the research supporting Ovaprene. Award payments under this second notice of award (&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$161,007&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; received through June 30, 2019) are being applied to clinical development efforts supporting Ovaprene. At June&amp;#160;30, 2019, the Company recorded a receivable of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$456,484&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for expenses incurred through such date that are eligible for reimbursement under this second notice of award.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The remaining portion of the award under the grant, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$730,722&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, is contingent upon, among other matters, assessment that the results of the ongoing Ovaprene study satisfy specified requirements set out in the award notice, and the availability of funds.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</dare:GrantAwardTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2019Q2YTD" id="Fact-17B09C7088765C4CBC6ED55EAADF0D4E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X.&amp;#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&amp;#8217;s opinion, the accompanying interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying interim consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:BusinessCombinationDisclosureTextBlock contextRef="FD2019Q2YTD" id="Fact-8E2FBF5C9E7D582183D3BA5D2FF6ED56">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;ACQUISITIONS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cerulean/Private Dar&amp;#233; Stock Purchase Transaction&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;July 2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company completed its business combination with Dar&amp;#233; Bioscience Operations, Inc., a privately held Delaware corporation, or Private Dar&amp;#233;, in which Private Dar&amp;#233; stockholders sold their shares to the Company in exchange for newly issued shares of the Company&amp;#8217;s common stock, and as a result, Private Dar&amp;#233; became a wholly owned subsidiary of the Company and the Private Dar&amp;#233; stockholders became majority stockholders of the Company. In connection with the closing of that transaction, the Company changed its name from &amp;#8220;Cerulean Pharma Inc.&amp;#8221; to &amp;#8220;Dar&amp;#233; Bioscience, Inc.&amp;#8221; In this report, that transaction is referred to as the Cerulean/Private Dar&amp;#233; stock purchase transaction and &amp;#8220;Cerulean&amp;#8221; refers to Cerulean Pharma Inc. before that transaction closed.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Cerulean/Private Dar&amp;#233; stock purchase transaction was accounted for as a reverse merger under the acquisition method of accounting whereby Private Dar&amp;#233; was considered to have acquired Cerulean for financial reporting purposes. Pursuant to business combination accounting, the Company applied the acquisition method, which requires the assets acquired and liabilities assumed be recorded at fair value with limited exceptions. The excess of the purchase price over the assets acquired and liabilities assumed represents goodwill. The goodwill was primarily attributable to the cash and cash equivalents at closing of the transaction of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$9.9 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and the impact of the unamortized fair value of stock options granted by Cerulean that were outstanding immediately before the transaction closed of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$3.7 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company tests its goodwill for impairment at least annually as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and between annual tests if it becomes aware of an event or change in circumstance that would indicate the carrying value may be impaired. The Company tests goodwill for impairment at the entity level because it operates on the basis of a single reporting unit. A goodwill impairment is the amount by which a reporting unit&amp;#8217;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. When impaired, the carrying value of goodwill is written down to fair value. Any excess of the reporting unit goodwill carrying value over the fair value is recognized as impairment loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company assessed goodwill at March 31, 2018, determined there was an impairment and recognized an impairment charge of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the interim consolidated statement of operations and comprehensive loss for the three months ended March 31, 2018. As of March 31, 2018, the goodwill carrying value on the Company&amp;#8217;s consolidated balance sheet was written off in its entirety.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Pear Tree Merger&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;April&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company entered into an Agreement and Plan of Merger, the Merger Agreement, with Pear Tree Pharmaceuticals, Inc., or Pear Tree, Dar&amp;#233; Merger Sub, Inc., a wholly-owned subsidiary of the Company, or Merger Sub, and two individuals in their respective capacities as Pear Tree stockholders&amp;#8217; representatives. The transactions contemplated by the Merger Agreement closed on &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;May&amp;#160;16, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, and as a result, Pear Tree became the Company&amp;#8217;s wholly owned subsidiary. The Company acquired Pear Tree to secure the rights to develop DARE-VVA1, a proprietary vaginal formulation of tamoxifen, as a potential treatment for vulvar and vaginal atrophy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company determined that the acquisition of Pear Tree should be accounted for as an asset acquisition instead of a business combination because substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, and therefore, the asset is not considered a business. Transaction costs of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$452,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; associated with the merger were included in the Company&amp;#8217;s research and development expense.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Under the Merger Agreement, certain former and continuing Pear Tree service providers and former holders of Pear Tree&amp;#8217;s capital stock, or the Holders, were eligible to receive a &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; payment due on the one-year anniversary of the closing of the merger and are eligible to receive tiered royalties, subject to customary provisions permitting royalty reductions and offset, based on percentages of annual net sales of certain products subject to license agreements the Company assumed and a percentage of sublicense revenue. The Company must also make contingent payments to the Holders based on achieving certain clinical, regulatory and commercial milestones, which may be paid, in the Company&amp;#8217;s sole discretion, in cash or shares of the Company&amp;#8217;s common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In accordance with the terms of the Merger Agreement, because the Negative Consideration Amount (as defined below) exceeded the Positive Consideration Amount (as defined below), at the time of the closing of the merger, the excess amount (approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$132,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;) offset the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; payment due on the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;-year anniversary of the closing of the merger and the balance will offset future payments otherwise due under the Merger Agreement to the Holders. Positive Consideration Amount means the sum of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, and the cash and cash equivalents held by Pear Tree at closing, and Negative Consideration Amount means the sum of (i) certain Pear Tree indebtedness and transaction expenses, (ii) transaction expenses of the stockholders&amp;#8217; representatives, and (iii) amounts payable under Pear Tree&amp;#8217;s management incentive plan.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
	<us-gaap:CommitmentsDisclosureTextBlock contextRef="FD2019Q2YTD" id="Fact-BE2CC18508995AC885E67D1812BEBAB7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;License and Research Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ADVA-Tec License Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In March 2017, the Company entered into a license agreement, or the ADVA-Tec License Agreement, with ADVA-Tec, Inc., or ADVA-Tec, under which the Company was granted the exclusive right to develop and commercialize Ovaprene for human contraceptive use worldwide. ADVA-Tec and its affiliates own issued patents or patent applications covering Ovaprene and control proprietary trade secrets covering the manufacture of Ovaprene. As of the date of this report, this patent portfolio includes &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; issued U.S. patents and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; pending U.S. patent application, and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;59&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; granted patents and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; pending patent applications in other major markets, all of which are exclusively licensed to the Company for the human contraceptive use of Ovaprene as a human contraceptive device. Under the terms of the ADVA-Tec Agreement, the Company has a right of first refusal to license these patents and patent applications for additional indications.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following is a summary of other terms of the ADVA-Tec License Agreement:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Research and Development.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;ADVA-Tec will conduct certain research and development work as necessary to allow the Company to seek a Premarket Approval, or PMA, from the United States Food and Drug Administration, or the FDA, and will supply the Company with its requirements of Ovaprene for clinical and commercial use on commercially reasonable terms. The Company must use commercially reasonable efforts to develop and commercialize Ovaprene, and must meet certain minimum spending amounts per year, such amounts totaling &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate over the first &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;three years&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, to cover such activities until a final PMA is filed, or until the first commercial sale of Ovaprene, whichever occurs first.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Milestone Payments.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company will pay ADVA-Tec: (1) up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$14.6 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate based on the achievement of specified development and regulatory milestones; and (2) up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$20 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate based on the achievement of certain worldwide net sales milestones. The development and regulatory milestones  include: the completion of a successful postcoital clinical study, which is required before the Company can commence a Phase 3 pivotal human clinical trial; approval by the FDA to commence such Phase 3 pivotal human clinical trial; successful completion of such Phase 3 pivotal human clinical trial; the FDA&amp;#8217;s acceptance of a PMA filing for Ovaprene; the FDA&amp;#8217;s approval of the PMA for Ovaprene; obtaining Conformit&amp;#233; Europ&amp;#233;enne Marking of Ovaprene in at least &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; designated European countries; obtaining regulatory approval in at least three designated European countries; and obtaining regulatory approval in Japan. Because these milestone payments depend upon the successful progress of the Company&amp;#8217;s product development programs, the Company cannot estimate with certainty when these payments will occur, if ever.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;For products currently in development, future potential milestone payments based on product development are approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$14.6 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. Future potential milestone payments related to commercialization totaled &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$20 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Company is unable to estimate with certainty the timing on when these milestone payments will occur as these payments depend on the Company's product development programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Royalty Payments.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;After the commercial launch of Ovaprene, the Company will pay to ADVA-Tec royalties based on aggregate annual net sales of Ovaprene in specified regions, at a royalty rate that will vary between &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and will increase based on various net sales thresholds. The Company is unable to estimate with certainty the timing on when these royalty payments will occur as these payments depend on the Company's product development programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Termination Rights.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Unless earlier terminated, the license the Company received under the ADVA-Tec License Agreement continues on a country-by-country basis until the later of the life of the licensed patents or the Company's last commercial sale of Ovaprene. In addition to customary termination rights for both parties: (A) the Company may terminate the agreement with or without cause in whole or on a country-by-country basis upon &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; days prior written notice; and (B) ADVA-Tec may terminate the agreement if the Company develops or commercializes any non-hormonal ring-based vaginal contraceptive device competitive to Ovaprene or if the Company fails to: (1) in certain limited circumstances, commercialize Ovaprene in certain designated countries within three years of the first commercial sale of Ovaprene, (2) satisfy the annual spending obligation described above, (3) use commercially reasonable efforts to complete all necessary pre-clinical and clinical studies required to support and submit a PMA, (4) conduct clinical trials as set forth in the development plan that is agreed by the Company and ADVA-Tec, and as may be modified by a joint research committee, unless such failure is caused by events outside of the Company&amp;#8217;s reasonable control, or (5) enroll a patient in the first non-significant risk medical device study or clinical trial as allowed by an institutional review board within &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;six months&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the production and release of Ovaprene, unless such failure is caused by events outside of its reasonable control.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;SST License and Collaboration Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In February 2018, the Company entered into a license and collaboration agreement, or the SST License Agreement, with Strategic Science &amp;amp;&amp;#160;Technologies-D,&amp;#160;LLC and Strategic Science &amp;amp; Technologies, LLC, referred to collectively as SST. The SST License Agreement provides the Company with an exclusive, royalty-bearing, sublicensable license to develop and commercialize, in all countries and geographic territories of the world, for all indications for women related to female sexual dysfunction and/or female reproductive health, including treatment of female sexual arousal disorder, or the Field of Use, SST&amp;#8217;s topical formulation of Sildenafil Cream, 3.6% as it exists as of the effective date of the SST License Agreement, or any other topically applied pharmaceutical product containing sildenafil or a salt thereof as a pharmaceutically active ingredient, alone or with other active ingredients, but specifically excluding any product containing ibuprofen or any salt derivative of ibuprofen, or the Licensed Products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following is a summary of other terms of the SST License Agreement:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Invention &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Ownership&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company retains rights to inventions made by its employees, SST retains rights to inventions made by its employees, and each party shall own a &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; undivided interest in all joint inventions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Joint &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Development&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt; Committee&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The parties will collaborate through a joint development committee that will determine the strategic objectives for, and generally oversee, the development efforts of both parties under the SST License Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Development&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company must use commercially reasonable efforts to develop the Licensed Products in the Field of Use in accordance with a development plan in the SST License Agreement, and to commercialize the Licensed Products in the Field of Use. The Company is responsible for all reasonable internal and external costs and expenses incurred by SST in its performance of the development activities it must perform under the SST License Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Royalty &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Payments.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;SST will be eligible to receive (1) tiered royalties based on percentages of annual net sales of Licensed Products in the single digits to the mid double digits, subject to customary royalty reductions and offsets, and (2) a percentage of sublicense revenue.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Milestone Payments.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;SST will be eligible to receive payments (1) ranging from &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$18.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate on achieving certain clinical and regulatory milestones in the U.S. and worldwide, and (2) between &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$100 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate upon achieving certain commercial sales milestones. If the Company enters into strategic development or distribution partnerships related to the Licensed Products, additional milestone payments would be due to SST.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;License Term.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company&amp;#8217;s license received under the SST License Agreement continues on a country-by-country basis until the later of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10 years&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; from the date of the first commercial sale of such Licensed Product or the expiration of the last valid claim of patent rights covering the Licensed Product in the Field of Use. Upon expiration (but not termination) of the SST License Agreement in a particular country, the Company will have a fully paid-up license under the licensed intellectual property to develop and commercialize the applicable Licensed Products in the applicable country on a non-exclusive basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Termination.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In addition to customary termination rights for both parties: (1) prior to receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including New Drug Application Approval, or NDA Approval, the Company may terminate the SST License Agreement without cause upon &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; days prior written notice to SST; (2)&amp;#160;following receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including NDA Approval, the Company may terminate the SST License Agreement without cause upon &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;180&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;days prior written notice; and (3) SST may terminate the SST License Agreement with respect to the applicable Licensed Product(s) in the applicable country(ies) upon &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;days&amp;#8217; notice to the Company if the Company fails to use commercially reasonable efforts to perform development activities in substantial accordance with the development plan and does not cure such failure within &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;days of receipt of SST&amp;#8217;s notice thereof.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Orbis Development and Option Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In March 2018, the Company entered into an exclusive development and option agreement, or the Orbis Agreement, with Orbis Biosciences, or Orbis, for the development of long-acting injectable etonogestrel contraceptive with 6- and 12-month durations (ORB-204 and ORB-214, respectively). Under the Orbis Agreement, the  Company paid Orbis &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$300,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to conduct the first stage of development work, Stage 1, as follows: &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$150,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; upon signing the Orbis Agreement, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; at the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; completion point, not later than 6 months following the date the Orbis Agreement was signed (which the Company paid in September 2018), and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; upon delivery by Orbis of the 6-month batch, not later than 11 months following the date the Orbis Agreement was signed (which the Company paid in January 2019). Upon Orbis successfully completing Stage 1 of the development program and achieving the predetermined target milestones for Stage 1, the Company will have &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; days to instruct Orbis whether to commence the second stage of development work, Stage 2. Should the Company execute its option to proceed to Stage 2, it will have to provide additional funding to Orbis for such activities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Pre-clinical studies for the 6- and 12-month formulations have been completed, including establishing pharmacokinetics and pharmacodynamics profiles. The collaboration with Orbis will continue to advance the program through formulation optimization with the goal of achieving sustained release over the target time period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Orbis Agreement provides the Company with an option to enter into a license agreement for ORB-204 and ORB-214 should development efforts be successful.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Juniper Pharmaceuticals - License Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In April 2018,&amp;#160;the Company entered into an Exclusive License Agreement, or the Juniper License Agreement, with Juniper Pharmaceuticals, Inc., or Juniper, under which Juniper granted the Company (a) an exclusive, royalty-bearing worldwide license under certain patent rights, either owned by or exclusively licensed to Juniper, to make, have made, use, have used, sell, have sold, import and have imported products and processes; and (b) a non-exclusive, royalty-bearing worldwide license to use certain technological information owned by Juniper to make, have made, use, have used, sell, have sold, import and have imported products and processes. The Company is entitled to sublicense the rights granted to it under the Juniper License Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:94px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following is a summary of certain terms of the Juniper License Agreement:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Upfront Fee.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company paid a &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$250,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; non-creditable upfront license fee to Juniper in connection with the execution of the Juniper License Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Annual Maintenance Fee&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Company will pay an annual license maintenance fee to Juniper on each anniversary of the date of the Juniper License Agreement, the amount of which will be &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$50,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for the first two years and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$100,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; thereafter, and which will be creditable against royalties and other payments due to Juniper in the same calendar year but may not be carried forward to any other year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Milestone &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Payments.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company must make potential future development and sales milestone payments of (1) up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$13.5 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate upon achieving certain clinical and regulatory milestones, and (2) up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$30.3 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate upon achieving certain commercial sales milestones for each product or process covered by the licenses granted under the Juniper License Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Royalty Payments&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. During the royalty term, the Company will pay Juniper mid-single-digit to low double-digit royalties based on worldwide net sales of products and processes covered by the licenses granted under the Juniper&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;License&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Agreement. In lieu of such royalty payments, the Company will pay Juniper a low double-digit percentage of all sublicense income the Company receives for the sublicense of rights under the Juniper License Agreement to a third party. The royalty term, which is determined on a country-by-country basis and product-by-product basis (or process-by-process basis), begins with the first commercial sale of a product or process in a country and terminates on the latest of (1) the expiration date of the last valid claim within the licensed patent rights with respect to such product or process in such country, (2) &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10 years&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; following the first commercial sale of such product or process in such country, and (3) when one or more generic products for such product or process are commercially available in such country, except that if there is no such generic product by the 10th year following the first commercial sale in such country, then the royalty term will terminate on the 10-year anniversary of the first commercial sale in such country.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Efforts&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Company must use commercially reasonable efforts to develop and make at least one product or process available to the public, which efforts include achieving specific diligence requirements by specific dates specified in the Juniper License Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;T&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;erm. Unless earlier terminated, the term of the Juniper License Agreement will continue on a country-by-country basis until the later of (1) the expiration date of the last valid claim within such country, or (2) 10 years from the date of first commercial sale of a product or process in such country. Upon expiration (but not early termination) of the Juniper License Agreement, the licenses granted thereunder will convert automatically to fully-paid irrevocable licenses. Juniper may terminate the Juniper License Agreement (1) upon &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; days&amp;#8217; notice for the Company&amp;#8217;s uncured breach of any payment obligation under the Juniper License Agreement, (2) if the Company fails to maintain required insurance, (3) immediately upon the Company&amp;#8217;s insolvency or the making of an assignment for the benefit of the Company&amp;#8217;s creditors or if a bankruptcy petition is filed for or against the Company, which petition is not dismissed within &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;90 days&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, or (4) upon &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; days&amp;#8217; notice for any uncured material breach by the Company of any of its other obligations under the Juniper License Agreement. The Company may terminate the Juniper License Agreement on a country-by-country basis for any reason by giving &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;180&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; days&amp;#8217; notice (or &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;90 days&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8217; notice if such termination occurs prior to receipt of marketing approval in the United States). If Juniper terminates the Juniper License Agreement for the reason described in clause (4) above or if the Company terminates the Juniper License Agreement, Juniper will have full access including the right to use and reference all product data generated during the term of the Juniper License Agreement that is owned by the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Pear Tree Acquisition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company may be required to make certain royalty and milestone payments under the Merger Agreement (see Note 4).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Hammock/MilanaPharm Assignment and License Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On December 5, 2018, the Company entered into (a) an Assignment Agreement with Hammock Pharmaceuticals, Inc., or the Assignment Agreement, and (b) a First Amendment to License Agreement with TriLogic Pharma, LLC and MilanaPharm LLC, or the License Amendment. Both agreements relate to the Exclusive License Agreement among Hammock, TriLogic and MilanaPharm dated as of January 9, 2017, or the MilanaPharm License Agreement. Under the Assignment Agreement and the MilanaPharm License Agreement, as amended by the License Amendment, the Company acquired an exclusive, worldwide license under certain intellectual property to, among other things, develop and commercialize products for the diagnosis, treatment and prevention of human diseases or conditions in or through any intravaginal or urological applications. The licensed intellectual property relates to the hydrogel drug delivery platform of TriLogic and MilanaPharm known as TRI-726. In DARE-BV1, this proprietary technology is formulated with clindamycin, an antibiotic used to treat certain bacterial infections, including BV, and has been engineered to produce a dual release pattern after vaginal application, providing maximum duration of exposure to clindamycin at the site of infection.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following is a summary of other terms of the License Amendment:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;License Fees.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; The Company paid &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$25,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to MilanaPharm in connection with the execution of the License Amendment and must pay &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$200,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to MilanaPharm (in the Company's discretion, either in cash or with shares of the Company's common stock) within 15 days of the first to occur of December 5, 2019 or the closing of an equity financing in which the Company raises aggregate proceeds of at least &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Milestone Payments.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; The Company will pay to MilanaPharm (1) up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$300,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate upon achievement of certain development milestones; and (2) up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.75 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate upon achieving certain commercial sales milestones. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Foreign Sublicense Income.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; The Company will pay MilanaPharm a low double-digit percentage of all income received by the Company or its affiliates in connection with any sublicense granted to a third party for use outside of the United States, subject to certain exclusions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Royalty Payments.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; During the royalty term, the Company will pay MilanaPharm high single-digit to low double-digit royalties based on annual worldwide net sales of licensed products and processes. The royalty term, which is determined on a country-by-country basis and licensed product-by-product basis (or process-by-process basis), begins with the first commercial sale of a licensed product or process in a country and terminates on the latest of (a) the expiration date of the last valid claim of the licensed patent rights that cover the method of use of such product or process in such country, or (b) 10 years following the first commercial sale of such product or process in such country. Royalty payments are subject to reduction in certain circumstances, including as a result of generic competition, patent prosecution expenses incurred by the Company, or payments to third parties for rights or know-how that are required for the Company to exercise the licenses granted to it under the MilanaPharm License Agreement or that are strategically important or could add value to a licensed product or process in a manner expected to materially generate or increase sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Efforts&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Company must use commercially reasonable efforts and resources to (1) develop and commercialize at least one licensed product or process in the United States and at least one licensed product or process in at least one of Canada, the United Kingdom, France, Germany, Italy or Spain, and (2) continue to commercialize that product or process following the first commercial sale of a licensed product or process in the applicable jurisdiction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Term&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. Unless earlier terminated, the term of the MilanaPharm License Agreement will continue until (1) on a licensed product-by-product (or process-by-process basis) and country-by-country basis, the date of expiration of the royalty term with respect to such licensed product in such country, and (2) the expiration of all applicable royalty terms under the MilanaPharm License Agreement with respect to all licensed products and processes in all countries. Upon expiration of the term with respect to any licensed product or process in a country (but not upon earlier termination of the MilanaPharm License Agreement), the licenses granted to the Company under the MilanaPharm License Agreement will convert automatically to an exclusive, fully paid-up, royalty-free, perpetual, non-terminable and irrevocable right and license under the licensed intellectual property. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In addition to customary termination rights for all parties, MilanaPharm may terminate the license granted to the Company solely with respect to a licensed product or process in a country if, after having launched such product or process in such country, (1) the Company, or its affiliates or sublicensees, discontinue the sale of such product or process in such country and MilanaPharm notifies the Company of such termination within 60 days of having first been notified by the Company of such discontinuation, or (2) the Company, or its affiliates or sublicensees, (A) discontinues all commercially reasonable marketing efforts to sell, and discontinues all sales of, such product or process in such country for nine months or more, (B) fails to resume such commercially reasonable marketing efforts within 120 days of having been notified of such failure by MilanaPharm, (C) fails to reasonably demonstrate a strategic justification for the discontinuation and failure to resume to MilanaPharm, and (D) MilanaPharm gives 90 days&amp;#8217; notice to the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following is a summary of other terms of the Assignment Agreement with Hammock:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Assignment; Technology Transfer&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. Hammock assigned and transferred to the Company all of its right, title and interest in and to the MilanaPharm License Agreement and agreed to cooperate to transfer to the Company all of the data, materials and the licensed technology in its possession pursuant to a technology transfer plan to be agreed upon by the parties, with a goal for the Company to independently practice the licensed intellectual property as soon as commercially practical in order to develop and commercialize the licensed products and processes. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Fees&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Company paid &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$250,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to Hammock in connection with the execution of the Assignment Agreement and must pay &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$250,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to Hammock (in the Company's discretion either in cash or with shares of the Company's common stock) within 15 days of the first to occur of December 5, 2019 or the closing of an equity financing in which the Company raises aggregate proceeds of at least &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Milestone Payments&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Company will pay Hammock up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate upon achievement of certain clinical and regulatory development milestones.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Term&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Assignment Agreement will terminate upon the later of (1) completion of the parties&amp;#8217; technology transfer plan, and (2) payment to Hammock of the last of the payments described above, including the milestone payments.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2019Q2YTD" id="Fact-BABFFCD02B675AA8A704AB07382B690F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;STOCK-BASED COMPENSATION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;The 2015 Employee, Director and Consultant Equity Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Prior to the Cerulean/Private Dar&amp;#233; stock purchase transaction, Private Dar&amp;#233; maintained the 2015 Employee, Director and Consultant Equity Incentive Plan, or the 2015 Private Dar&amp;#233; Plan. Upon closing of the Cerulean/Private Dar&amp;#233; stock purchase transaction, the Company assumed the 2015 Private Dar&amp;#233; Plan and each then outstanding award granted thereunder, which consisted of options and restricted stock. Based on the exchange ratio for the Cerulean/Private Dar&amp;#233; stock purchase transaction and after giving effect to the reverse stock split effected in connection with the closing of that transaction, the outstanding options and restricted stock awards granted under the  2015 Private Dar&amp;#233; Plan were replaced with options to purchase &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10,149&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock with a correspondingly adjusted exercise price, all of which were outstanding as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;223,295&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; restricted shares of the Company&amp;#8217;s common stock. Those options are fully vested and expire in December 2025.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;No further awards may be granted under the 2015 Private Dar&amp;#233; Plan following the closing of the Cerulean/Private Dar&amp;#233; stock purchase transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;2014 Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company&amp;#8217;s 2014 Employee Stock Purchase Plan, or the ESPP, became effective in April 2014, but no offering period has been initiated thereunder since January 2017 and there was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; stock-based compensation related to the ESPP for the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Amended and Restated 2014 Stock Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company maintains the Amended and Restated 2014 Plan, or the Amended 2014 Plan. There were &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,046,885&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of common stock authorized for issuance under the Amended 2014 Plan when it was approved by the Company's stockholders in July 2018. The number of authorized shares increases annually on the first day of each fiscal year until, and including, the fiscal year ending December 31, 2024 by the least of (i) &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,000,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, (ii) &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the number of outstanding shares of common stock on such date, or (iii) an amount determined by the Company&amp;#8217;s board of directors. On January 1, 2019, the number of authorized shares increased by &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;456,886&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,503,771&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which increase represented &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the number of outstanding shares of common stock on such date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Summary of Stock Option Activity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The table below summarizes stock option activity under the Amended 2014 Plan, and related information for the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The exercise price of all options granted during the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; was equal to the market value of the Company&amp;#8217;s common stock on the date of the grant. As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, unamortized stock-based compensation expense of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1,348,159&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; will be amortized over a weighted average period of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2.9 years&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;497,032&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of common stock were reserved for future issuance under the Amended 2014 Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Number of Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Weighted Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Outstanding at December 31, 2018 (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,635,790&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;698,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Canceled/forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(316,832&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;24.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;59.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Outstanding at June 30, 2019 (unaudited) (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,016,888&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Exercisable at June&amp;#160;30, 2019 (unaudited)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;427,702&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;21.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;padding-top:8px;text-indent:0px;"&gt;&lt;font style="padding-top:8px;font-family:Arial;font-size:10pt;padding-right:48px;"&gt;(1)&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Includes &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10,149&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares subject to options granted under the 2015 Private Dar&amp;#233; Plan assumed in connection with the Cerulean/Private Dar&amp;#233; stock purchase transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Compensation Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total stock-based compensation expense related to stock options granted to employees and directors recognized in the consolidated statement of operations is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:46%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Six Months Ended&lt;br clear="none"/&gt;June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;26,996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;51,699&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;84,355&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;157,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;18,547&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;111,351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;209,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;18,547&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:24px;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;June 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Six Months Ended&lt;br clear="none"/&gt;June 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Expected life in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2.09%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2.58%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;123%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;121%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Forfeiture rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Weighted-average fair value of options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2019Q2YTD" id="Fact-C9A6DE3FAB8B5361950C56B354BDC335">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;NET LOSS PER SHARE&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under outstanding options and warrants to purchase shares of the Company&amp;#8217;s common stock. Common share equivalents are excluded from the diluted net loss per share calculation if their effect is anti-dilutive.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Potentially dilutive securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Six Months Ended&lt;br clear="none"/&gt;June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,190,360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;547,571&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,190,360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;547,571&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,750,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,751,002&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,750,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,751,002&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,941,193&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4,298,573&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,941,193&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4,298,573&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="FD2019Q2YTD" id="Fact-D0FEA2D5566752508FAC1836CA82D348">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 2: inputs other than level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Cash and cash equivalents of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$5.6 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$6.8 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; are measured at fair value as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively, and are classified within Level 1 of the fair value hierarchy. Other receivables are financial assets with carrying values that approximate fair value due to the short-term nature of these assets. Accounts payable and accrued expenses and other liabilities are financial liabilities with carrying values that approximate fair value due to the short-term nature of these liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:LesseeLeasesPolicyTextBlock contextRef="FD2019Q2YTD" id="Fact-C38ED85748F553E9A758342D80BED7E5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use, or ROU, lease assets, current portion of lease obligations, and long-term lease obligations on the Company's balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. If the lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease and the related payments are only included in the lease liability when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
	<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="FD2019Q2YTD" id="Fact-97E9DBA8288A5286B85D6D79EBE3154F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, future minimum lease payments for the Company's corporate headquarters are:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Years ending December 31:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Remainder of 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;55,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;112,943&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;67,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Total future minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;236,069&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Less: Difference between future minimum lease payments and discounted operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;42,669&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Total operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;193,400&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
	<us-gaap:LesseeOperatingLeasesTextBlock contextRef="FD2019Q2YTD" id="Fact-2FA5BB401EAD52C78885237A300B0232">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;LEASED PROPERTIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Effective January 1, 2019, the Company adopted ASC 842, which requires recognition of a right-of-use asset and lease liability for all leases at the commencement date based on the present value of lease payments over the lease term. Additional qualitative and quantitative disclosures regarding the Company's leasing arrangements are also required. The Company adopted ASC 842 prospectively and elected the package of transition practical expedients that does not require reassessment of: (1) whether any existing or expired contracts are or contain leases, (2) lease classification and (3) initial direct costs. In addition, the Company has elected other available practical expedients to not separate lease and nonlease components, which consist principally of common area maintenance charges, for all classes of underlying assets and to exclude leases with an initial term of 12 months or less.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company's lease for its corporate headquarters (&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,169&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; square feet of office space) commenced on July 1, 2018, has term of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;37 months&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, and terminates on July 31, 2021. The Company has the option to extend the term of the lease for &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;one year&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; at the Company's discretion. The gross monthly base rent is &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$8,873&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which increases approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per year, subject to certain future adjustments. The base rent was abated during the second month of the lease. The Company evaluates renewal options at lease inception and on an ongoing basis, and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The lease does not require material variable lease payments, a residual value guarantee or restrictive covenants. This is the Company&amp;#8217;s only lease.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The lease does not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company used an incremental borrowing rate of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;7%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; as of January 1, 2019 for the operating lease that commenced prior to that date. The depreciable lives of operating lease assets and leasehold improvements are limited by the expected lease term.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company recorded a right of use asset of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$193,399&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in other non-current assets, and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$87,859&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$116,089&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively, in current and non-current other liabilities on the consolidated balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, future minimum lease payments for the Company's corporate headquarters are:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Years ending December 31:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Remainder of 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;55,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;112,943&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;67,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Total future minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;236,069&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Less: Difference between future minimum lease payments and discounted operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;42,669&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Total operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;193,400&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Operating lease costs were&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$27,038&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$54,076&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for the three and six months ended&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively. Operating lease costs are included in general and administrative expenses in the condensed consolidated statement of operations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of operating lease liabilities were&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$26,620&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$53,240&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for the three and six months ended&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively, and these amounts are included in operating activities in the condensed consolidated statements of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2019Q2YTD" id="Fact-1F343C06D4355532AEF065453E985EE9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In May 2014, FASB issued Accounting Standards Update, or ASU, 2014-09, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which impacts the way in which some entities recognize revenue for certain types of transactions. The new standard became effective beginning in 2018 for public companies. Because the Company does not currently have any contracts with customers, the Company&amp;#8217;s adoption of this accounting standard did not impact the Company&amp;#8217;s interim consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In February 2016, FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The new standard is effective for public companies for fiscal years beginning after December&amp;#160;15, 2018, with early adoption permitted. ASU 2016-02 became effective for the Company on January 1, 2019 and was adopted using a modified retrospective approach and the effective date is as of the initial application. Consequently, financial information was not updated, and the disclosures required under ASU 2016-02 are not provided for dates and periods prior to January 1, 2019. ASU 2016-02 provides a number of optional practical expedients and accounting policy elections. The Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases. The Company recorded approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$232,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; right-of-use assets and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$241,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; lease liabilities related to its lease of office space as of the adoption date in the consolidated balance sheets. There are no changes to the statement of operations or cash flows as a result of the adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In January 2017, FASB issued ASU 2017-01, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which intended to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The standard became effective for the Company on January 1, 2018. The Company&amp;#8217;s early adoption of this standard did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Disclosure Update and Simplification,&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements relating to the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of income is required to be filed. This final rule was effective November 5, 2018. In accordance with the new rule, the Company added a Consolidated Statement of Stockholders' Equity in this report and elected to present a reconciliation in a single statement that shows the changes in stockholders' equity for each interim period, as well as each comparable period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="FD2019Q2YTD" id="Fact-33F9ABF3DA9252D78B9BF05F268BD74A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;ORGANIZATION AND DESCRIPTION OF THE BUSINESS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Dar&amp;#233; Bioscience, Inc. is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women&amp;#8217;s health. Dar&amp;#233; Bioscience, Inc. and its wholly owned subsidiaries operate in &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; segment. In this report, the &amp;#8220;Company&amp;#8221; refers collectively to Dar&amp;#233; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company is driven by a mission to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. The Company's business strategy is to license or otherwise acquire the rights to differentiated product candidates in women's health, some of which have existing clinical proof-of-concept data, and to advance those candidates through clinical development and regulatory approval alone or in collaboration with strategic partners.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company has assembled a portfolio of clinical-stage and pre-clinical-stage candidates addressing unmet needs in women&amp;#8217;s health. The Company&amp;#8217;s portfolio includes these six clinical-stage candidates:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:144px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:120px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;DARE-BV1, a novel solution-to-gel formulation containing clindamycin phosphate 2% to treat bacterial vaginosis, or BV; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:144px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:120px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Ovaprene, a non-hormonal monthly contraceptive intravaginal ring; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:144px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:120px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder, or FSAD; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:144px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:120px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:144px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:120px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy, or VVA, in patients with hormone-receptor positive breast cancer; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:144px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:120px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and for fertility support as part of an &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;in vitro&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; fertilization, or IVF, treatment plan.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company's portfolio also includes several pre-clinical stage product candidates:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:144px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:120px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;ORB-204 and ORB-214, 6-month and 12-month formulations of injectable etonogestrel for contraception;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:144px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:120px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;DARE-RH1, a novel approach to non-hormonal contraception for both men and women by targeting the CatSper ion channel; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:144px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:120px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;DARE-OAB1, an intravaginal ring containing oxybutynin for the treatment of overactive bladder. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company&amp;#8217;s primary operations have consisted of, and are expected to continue to consist of, product research and development and advancing its portfolio of product candidates through clinical development and regulatory approval. We expect that the bulk of our development expenses over the next two years will support the advancement of our clinical-stage product candidates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;To date, the Company has not obtained any regulatory approvals for any of its product candidates, commercialized any of its product candidates or generated any product revenue. The Company is subject to several risks common to clinical-stage biopharmaceutical companies, including dependence on key individuals, competition from other companies, the need to develop commercially viable products in a timely and cost-effective manner, and the need to obtain adequate additional capital to fund the development of product candidates. The Company is also subject to several risks common to other companies in the industry, including rapid technology change, regulatory approval of products, uncertainty of market acceptance of products, competition from substitute products, competition from larger companies with recognized brands, greater capital resources and higher levels of dedicated staff, and compliance with government regulations, protection of proprietary technology, dependence on third parties, and product liability.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2019Q2YTD" id="Fact-91C5C4050C945C5894E9D2DBA4E780BB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Potentially dilutive securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Six Months Ended&lt;br clear="none"/&gt;June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,190,360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;547,571&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,190,360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;547,571&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,750,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,751,002&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,750,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,751,002&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,941,193&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4,298,573&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,941,193&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4,298,573&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2019Q2YTD" id="Fact-39B2BA9DD21C5A069FAF60397B4842D5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total stock-based compensation expense related to stock options granted to employees and directors recognized in the consolidated statement of operations is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:46%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Six Months Ended&lt;br clear="none"/&gt;June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;26,996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;51,699&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;84,355&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;157,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;18,547&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;111,351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;209,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;18,547&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2019Q2YTD" id="Fact-39B2E38F6AD85A388AA649F8759BD10C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The table below summarizes stock option activity under the Amended 2014 Plan, and related information for the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The exercise price of all options granted during the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; was equal to the market value of the Company&amp;#8217;s common stock on the date of the grant. As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, unamortized stock-based compensation expense of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1,348,159&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; will be amortized over a weighted average period of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2.9 years&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;497,032&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of common stock were reserved for future issuance under the Amended 2014 Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Number of Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Weighted Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Outstanding at December 31, 2018 (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,635,790&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;698,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Canceled/forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(316,832&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;24.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;59.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Outstanding at June 30, 2019 (unaudited) (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,016,888&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Exercisable at June&amp;#160;30, 2019 (unaudited)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;427,702&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;21.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;padding-top:8px;text-indent:0px;"&gt;&lt;font style="padding-top:8px;font-family:Arial;font-size:10pt;padding-right:48px;"&gt;(1)&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Includes &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10,149&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares subject to options granted under the 2015 Private Dar&amp;#233; Plan assumed in connection with the Cerulean/Private Dar&amp;#233; stock purchase transaction.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2019Q2YTD" id="Fact-5923B72EA1625D669266AD53BAAC6798">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:24px;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;June 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Six Months Ended&lt;br clear="none"/&gt;June 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Expected life in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2.09%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2.58%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;123%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;121%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Forfeiture rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Weighted-average fair value of options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="FD2019Q2YTD" id="Fact-6034C874434E51F888723F28DFFD8715">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company had the following warrants outstanding:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Shares Underlying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Outstanding Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Expiration Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,906&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;120.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;1, 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;120.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;6, 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;17,190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;60.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;January&amp;#160;8, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;6,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;April&amp;#160;4, 2026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,720,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;February&amp;#160;15, 2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,750,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2019Q2YTD" id="Fact-3C9E584FA2BC5B7C85CAE5CEB312199B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company&amp;#8217;s significant accounting policies are described in Note 1 to the interim consolidated financial statements included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, filed with the Securities and Exchange Commission, or SEC on April 1, 2019. Since the date of those consolidated financial statements, there have been no material changes to the Company&amp;#8217;s significant accounting policies, except as described below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X.&amp;#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&amp;#8217;s opinion, the accompanying interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying interim consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use, or ROU, lease assets, current portion of lease obligations, and long-term lease obligations on the Company's balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. If the lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease and the related payments are only included in the lease liability when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. (See Note 7, Leased Properties.)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 2: inputs other than level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Cash and cash equivalents of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$5.6 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$6.8 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; are measured at fair value as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively, and are classified within Level 1 of the fair value hierarchy. Other receivables are financial assets with carrying values that approximate fair value due to the short-term nature of these assets. Accounts payable and accrued expenses and other liabilities are financial liabilities with carrying values that approximate fair value due to the short-term nature of these liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In May 2014, FASB issued Accounting Standards Update, or ASU, 2014-09, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which impacts the way in which some entities recognize revenue for certain types of transactions. The new standard became effective beginning in 2018 for public companies. Because the Company does not currently have any contracts with customers, the Company&amp;#8217;s adoption of this accounting standard did not impact the Company&amp;#8217;s interim consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In February 2016, FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The new standard is effective for public companies for fiscal years beginning after December&amp;#160;15, 2018, with early adoption permitted. ASU 2016-02 became effective for the Company on January 1, 2019 and was adopted using a modified retrospective approach and the effective date is as of the initial application. Consequently, financial information was not updated, and the disclosures required under ASU 2016-02 are not provided for dates and periods prior to January 1, 2019. ASU 2016-02 provides a number of optional practical expedients and accounting policy elections. The Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases. The Company recorded approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$232,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; right-of-use assets and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$241,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; lease liabilities related to its lease of office space as of the adoption date in the consolidated balance sheets. There are no changes to the statement of operations or cash flows as a result of the adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In January 2017, FASB issued ASU 2017-01, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which intended to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The standard became effective for the Company on January 1, 2018. The Company&amp;#8217;s early adoption of this standard did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Disclosure Update and Simplification,&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements relating to the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of income is required to be filed. This final rule was effective November 5, 2018. In accordance with the new rule, the Company added a Consolidated Statement of Stockholders' Equity in this report and elected to present a reconciliation in a single statement that shows the changes in stockholders' equity for each interim period, as well as each comparable period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2019Q2YTD" id="Fact-2CD9D711B6135384A60A20ABD05DB2B4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;STOCKHOLDERS&amp;#8217; EQUITY&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ATM Sales Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In January 2018, the Company entered into a common stock sales agreement under which the Company may sell up to an aggregate of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$10 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in gross proceeds through the sale of shares of common stock from time to time in &amp;#8220;at-the-market&amp;#8221; equity offerings (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended). The Company will pay a commission of up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the gross proceeds of any common stock sold under this agreement plus certain legal expenses. This agreement was amended in August 2018 to refer to the Company&amp;#8217;s shelf registration statement on Form S-3 (File No. 333-227019) that was filed to replace the Company&amp;#8217;s shelf registration statement on Form S-3 (File No. 333-206396) that expired on August 28, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company sold &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares under this agreement during either the three or six months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; or the three months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. During the six months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company sold an aggregate of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;375,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares common stock under this agreement for gross proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and incurred issuance costs of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$237,403&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;February 2018 Underwritten Public Offering&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In February 2018, the Company closed an underwritten public offering of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of its common stock and warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3.5 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of its common stock. Each share of common stock was sold with a warrant to purchase up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.70&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of a share of the Company&amp;#8217;s common stock. The Company granted the underwriter a &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;-day over-allotment option to purchase up to an additional &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;750,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of common stock and/or warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;525,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of common stock.&amp;#160; The underwriter exercised the option with respect to warrants to purchase &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;220,500&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of common stock. The Company received gross proceeds of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$10.3 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, including the proceeds from the sale of the warrants upon exercise of the underwriter&amp;#8217;s over-allotment option, and net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$9.4 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The warrants issued in the February 2018 underwritten offering initially had an exercise price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share and&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;are exercisable through February 2023.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The warrants include a price-based anti-dilution provision, which provides that, subject to certain limited exceptions, the exercise price of the warrants will be reduced each time the Company issues or sells securities for a consideration per share less than a price equal to the exercise price of those warrants in effect immediately prior to such issuance or sale. In addition, subject to certain exceptions, if the Company issues, sells or enters into any agreement to issue or sell securities at a price which varies or may vary with the market price of the shares of the Company&amp;#8217;s common stock, the warrant holders have the right to substitute such variable price for the exercise price of the warrant then in effect. These warrants are exercisable only for cash, unless a registration statement covering the shares issued upon exercise of the warrants is not effective, in which case the warrants may be exercised on a cashless basis. A registration statement covering the shares issued upon exercise of the warrants is currently effective. The Company estimated the fair value of the warrants as of February 15, 2018 to be approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; which has been recorded in equity as of the grant date. The Company early adopted ASU 2017-11 as of January 1, 2018 and recorded the fair value of the warrants as equity. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On April 11, 2019, in accordance with the anti-dilution provision of these warrants and as a result of the sale of shares in the public offering that closed on that date and which is discussed below, the exercise price of these warrants was automatically reduced to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0.98&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share. For the three and six months ended June 30, 2019 the Company recorded &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to additional paid in capital as a result of the triggering of the anti-dilution provisions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In addition to the warrants issued in the February 2018 underwritten offering, as of June 30, 2019, there are outstanding warrants to purchase &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;30,333&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock, which are further described in the table below. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; warrants were exercised during the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company had the following warrants outstanding:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Shares Underlying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Outstanding Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Expiration Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,906&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;120.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;1, 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;120.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;6, 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;17,190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;60.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;January&amp;#160;8, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;6,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;April&amp;#160;4, 2026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,720,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;February&amp;#160;15, 2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,750,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;April 2019 Underwritten Public Offering&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On April 11, 2019, the Company closed an underwritten public offering of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4,575,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of its common stock at a public offering price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.10&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share. The Company granted the underwriters a &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;-day over-allotment option to purchase up to an additional &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;686,250&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares which was exercised in full on April 12, 2019. Including the over-allotment shares, the Company issued a total of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,261,250&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares in the underwritten public offering, and received gross proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$5.8 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; after deducting underwriting discounts and offering expenses.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="FD2019Q2YTD" id="Fact-E8D441F7665F58C3AFF376390609E592">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;GOING CONCERN&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company had an accumulated deficit of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$36.8 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and had cash and cash equivalents of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$5.6 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Company also had negative cash flow from operations of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$6.3 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; during the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; In March of 2019, the Company announced that it received a second Notice of Award for an additional &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$982,851&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the anticipated &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or the NIH Grant, which is being applied to the clinical development efforts supporting Ovaprene. As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company recorded a receivable in the amount of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$456,484&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for expenses eligible for reimbursement under the NIH Grant that were incurred through &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;June&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. See Note 9, "Grant Award," herein. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In April of 2019, the Company completed a sale of common stock raising net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. See Note 6, "Stockholders' Equity," herein. The Company needs to raise additional capital to continue to fund its operations and to successfully execute its current operating plan, including the development of its current product candidates. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company has a history of losses from operations, expects negative cash flows from its operations will continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops its existing product candidates and seeks to acquire, license or develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company is focused primarily on the development and commercialization of innovative products in women&amp;#8217;s health. The Company will continue to incur significant research and development and other expenses related to these activities. If the clinical trials for any of the Company&amp;#8217;s product candidates fail to produce successful results such that those product candidates do not advance in clinical development, then the Company&amp;#8217;s business and prospects may suffer. Even if the product candidates advance in clinical development, they may fail to gain regulatory approval. Even if the product candidates are approved, they may fail to achieve market acceptance, and the Company may never become profitable. Even if the Company becomes profitable, it may not sustain profitability.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company believes that its current available cash resources will be sufficient to fund planned operations into the first quarter of 2020. For the foreseeable future, the Company's ability to continue its operations will depend on its ability to obtain additional capital.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company is currently evaluating a variety of capital raising options, including financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements to cover its operating expenses, including the development of its product candidates and any future product candidates it may license or otherwise acquire. The amount and timing of the Company's capital needs have been and will continue to depend highly on many factors, including the product development programs the Company chooses to pursue and the pace and results of its clinical development efforts. If the Company raises capital through collaborations, strategic alliances or other similar types of arrangements, it may have to relinquish, on terms that are not favorable to the Company, rights to some of its technologies or product candidates it would otherwise seek to develop or commercialize. There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. Additionally, equity or debt financings may have a dilutive effect on the holdings of the Company's existing stockholders. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>dare-20190630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://darebioscience.com/20190630" xmlns:dare="http://darebioscience.com/20190630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20190630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20190630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20190630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20190630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="Acquisitions" roleURI="http://darebioscience.com/role/Acquisitions">
        <link:definition>2104100 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAdditionalInformationDetail" roleURI="http://darebioscience.com/role/AcquisitionsAdditionalInformationDetail">
        <link:definition>2404402 - Disclosure - Acquisitions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://darebioscience.com/role/CommitmentsAndContingencies">
        <link:definition>2109100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://darebioscience.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>2409401 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1002000 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfStockholdersEquity" roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1003000 - Statement - Consolidated Statements of Stockholders Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://darebioscience.com/role/DocumentAndEntityInformation">
        <link:definition>0002000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoingConcern" roleURI="http://darebioscience.com/role/GoingConcern">
        <link:definition>2102100 - Disclosure - Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoingConcernAdditionalInformationDetail" roleURI="http://darebioscience.com/role/GoingConcernAdditionalInformationDetail">
        <link:definition>2402401 - Disclosure - Going Concern - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantAward" roleURI="http://darebioscience.com/role/GrantAward">
        <link:definition>2110100 - Disclosure - Grant Award</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantAwardAdditionalInformationDetail" roleURI="http://darebioscience.com/role/GrantAwardAdditionalInformationDetail">
        <link:definition>2410401 - Disclosure - Grant Award - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedProperties" roleURI="http://darebioscience.com/role/LeasedProperties">
        <link:definition>2108100 - Disclosure - Leased Properties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesDetails" roleURI="http://darebioscience.com/role/LeasedPropertiesDetails">
        <link:definition>2408402 - Disclosure - Leased Properties - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" roleURI="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails">
        <link:definition>2408403 - Disclosure - Leased Properties Leased Properties - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetailsCalc2" roleURI="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetailsCalc2">
        <link:definition>2408403 - Disclosure - Leased Properties Leased Properties - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesTables" roleURI="http://darebioscience.com/role/LeasedPropertiesTables">
        <link:definition>2308301 - Disclosure - Leased Properties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://darebioscience.com/role/NetLossPerShare">
        <link:definition>2111100 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" roleURI="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail">
        <link:definition>2411402 - Disclosure - Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://darebioscience.com/role/NetLossPerShareTables">
        <link:definition>2311301 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndDescriptionOfBusiness" roleURI="http://darebioscience.com/role/OrganizationAndDescriptionOfBusiness">
        <link:definition>2101100 - Disclosure - Organization and Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" roleURI="http://darebioscience.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail">
        <link:definition>2401401 - Disclosure - Organization and Description of the Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://darebioscience.com/role/StockBasedCompensation">
        <link:definition>2106100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>2406402 - Disclosure - Stock Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail">
        <link:definition>2406405 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails">
        <link:definition>2406404 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail">
        <link:definition>2406403 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://darebioscience.com/role/StockBasedCompensationTables">
        <link:definition>2306301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://darebioscience.com/role/StockholdersEquity">
        <link:definition>2107100 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetail" roleURI="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetail">
        <link:definition>2407402 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" roleURI="http://darebioscience.com/role/StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails">
        <link:definition>2407403 - Disclosure - Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://darebioscience.com/role/StockholdersEquityTables">
        <link:definition>2307301 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2103100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2403402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="dare_ADVATecAgreementMember" name="ADVATecAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued" name="AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" name="AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease" name="AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries" name="AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_AssignmentAgreementMember" name="AssignmentAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_BusinessCombinationReverseMergerLineItems" name="BusinessCombinationReverseMergerLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" name="BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost" name="BusinessCombinationReverseMergerStockPurchaseTransactionCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions" name="BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="dare_ClassOfWarrantOrRightsWarrantsExpirationDate" name="ClassOfWarrantOrRightsWarrantsExpirationDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:dateItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_ClinicalAndRegulatoryMilestonesMember" name="ClinicalAndRegulatoryMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_CommencementPeriodForStageTwoUponAchievementOfStageOne" name="CommencementPeriodForStageTwoUponAchievementOfStageOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_DevelopmentAndOptionAgreementMember" name="DevelopmentAndOptionAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_EstimatedFairValueOfWarrantsRecordedInEquity" name="EstimatedFairValueOfWarrantsRecordedInEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember" name="EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_FutureMilestonePaymentsBasedOnCommercializationMember" name="FutureMilestonePaymentsBasedOnCommercializationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember" name="FutureMilestonePaymentsBasedOnProductDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_GrantAwardTextBlock" name="GrantAwardTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dare_GrossProceedsFromOfferingOfCommonStockAndWarrants" name="GrossProceedsFromOfferingOfCommonStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_HammockPharmaceuticalsInc.Member" name="HammockPharmaceuticalsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" name="IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_JuniperPharmaceuticalsInc.Member" name="JuniperPharmaceuticalsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_JuniperPharmaceuticalsMember" name="JuniperPharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseAgreementExpirationPeriod" name="LicenseAgreementExpirationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseAgreementNoticePeriodOfTermination" name="LicenseAgreementNoticePeriodOfTermination" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation" name="LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation" name="LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess" name="LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval" name="LicenseAgreementTerminationPeriodAfterReceiptOfApproval" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" name="LicenseAgreementTerminationPeriodDueToPerformanceFailure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries" name="LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval" name="LicenseAgreementTerminationPeriodPriorToReceiptOfApproval" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_LicenseAndCollaborationAgreementMember" name="LicenseAndCollaborationAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseFee" name="LicenseFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseFeeToBePaidUponContingency" name="LicenseFeeToBePaidUponContingency" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="dare_MaximumPotentialMilestonePayments" name="MaximumPotentialMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_MilanaPharmMember" name="MilanaPharmMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_MilestonePaymentsContingentAmount" name="MilestonePaymentsContingentAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_NationalInstitutesOfHealthMember" name="NationalInstitutesOfHealthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" name="NetProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dare_NonCashLeaseExpense" name="NonCashLeaseExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dare_NoticePeriodForTerminationOfAgreementForBothParties" name="NoticePeriodForTerminationOfAgreementForBothParties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_NumberOfCommonStockWarrantsExercised" name="NumberOfCommonStockWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_NumberOfDesignatedCountries" name="NumberOfDesignatedCountries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_NumberOfPatentApplications" name="NumberOfPatentApplications" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="dare_NumberOfPatentsGranted" name="NumberOfPatentsGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="dare_NumberOfPatentsIssued" name="NumberOfPatentsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="dare_NumberOfPendingPatents" name="NumberOfPendingPatents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="dare_OrbisMember" name="OrbisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_OvapreneMember" name="OvapreneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_PearTreePharmaceuticalsIncMember" name="PearTreePharmaceuticalsIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_PercentageOfAggregateCommission" name="PercentageOfAggregateCommission" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_PercentageOfIncreaseInAnnualBaseRent" name="PercentageOfIncreaseInAnnualBaseRent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" name="PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_PercentageOfRoyaltyRate" name="PercentageOfRoyaltyRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_PeriodOfDismissalOfBankruptcyPetition" name="PeriodOfDismissalOfBankruptcyPetition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" name="PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" name="PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dare_PotentialCashPaymentsToAcquireBusiness" name="PotentialCashPaymentsToAcquireBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="dare_PrivateDareMember" name="PrivateDareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_ProceedsRaisedFromEquityFinancing" name="ProceedsRaisedFromEquityFinancing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_PublicStockOfferingMember" name="PublicStockOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_ReimbursementOfGrantExpensesReceivable" name="ReimbursementOfGrantExpensesReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember" name="RemainingPortionOfResearchAndAvailabilityOfFundsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_ResearchAndDevelopmentMilestonePayment" name="ResearchAndDevelopmentMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_SalesMilestonesMember" name="SalesMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_ScheduleOfBusinessCombinationReverseMergerTable" name="ScheduleOfBusinessCombinationReverseMergerTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember" name="SecondPhaseOfResearchAndAvailabilityOfFundsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_SecuredInvestmentRequiredForLicenseAgreement" name="SecuredInvestmentRequiredForLicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_StockholdersEquityLineItems" name="StockholdersEquityLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_StockholdersEquityTable" name="StockholdersEquityTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" name="StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_TwoThousandAndFifteenStockIncentivePlanMember" name="TwoThousandAndFifteenStockIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" name="TwoThousandAndFourteenEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_UnderwritersOptionToPurchaseAdditionalShares" name="UnderwritersOptionToPurchaseAdditionalShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" name="UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_UpfrontLicenseFeePaid" name="UpfrontLicenseFeePaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" name="UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" name="UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_UponAchievingCertainCommercialMilestonesMember" name="UponAchievingCertainCommercialMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember" name="UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_UponReachingCertainWorldwideNetSalesMilestonesMember" name="UponReachingCertainWorldwideNetSalesMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_UponSigningOfDevelopmentAndOptionAgreementMember" name="UponSigningOfDevelopmentAndOptionAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" name="WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" name="WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" name="WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" name="WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember" name="WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_WeightedAverageAmortizationPeriod" name="WeightedAverageAmortizationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>dare-20190630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://darebioscience.com/role/Acquisitions" xlink:href="dare-20190630.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/AcquisitionsAdditionalInformationDetail" xlink:href="dare-20190630.xsd#AcquisitionsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsAndContingencies" xlink:href="dare-20190630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="dare-20190630.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheets" xlink:href="dare-20190630.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="dare-20190630.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="dare-20190630.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="dare-20190630.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="dare-20190630.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/DocumentAndEntityInformation" xlink:href="dare-20190630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GoingConcern" xlink:href="dare-20190630.xsd#GoingConcern" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GoingConcernAdditionalInformationDetail" xlink:href="dare-20190630.xsd#GoingConcernAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAward" xlink:href="dare-20190630.xsd#GrantAward" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAwardAdditionalInformationDetail" xlink:href="dare-20190630.xsd#GrantAwardAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedProperties" xlink:href="dare-20190630.xsd#LeasedProperties" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesDetails" xlink:href="dare-20190630.xsd#LeasedPropertiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:href="dare-20190630.xsd#LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetailsCalc2" xlink:href="dare-20190630.xsd#LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesTables" xlink:href="dare-20190630.xsd#LeasedPropertiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShare" xlink:href="dare-20190630.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" xlink:href="dare-20190630.xsd#NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShareTables" xlink:href="dare-20190630.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="dare-20190630.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:href="dare-20190630.xsd#OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensation" xlink:href="dare-20190630.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="dare-20190630.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" xlink:href="dare-20190630.xsd#StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" xlink:href="dare-20190630.xsd#StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" xlink:href="dare-20190630.xsd#StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationTables" xlink:href="dare-20190630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquity" xlink:href="dare-20190630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="dare-20190630.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" xlink:href="dare-20190630.xsd#StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityTables" xlink:href="dare-20190630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="dare-20190630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="dare-20190630.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="dare-20190630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/Acquisitions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/AcquisitionsAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_dbfa1e75-5ca7-c18e-328b-85edddaeec4f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_dbfa1e75-5ca7-c18e-328b-85edddaeec4f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_b69fa2fe-d7f6-024f-39fb-29cad0c95853" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_b69fa2fe-d7f6-024f-39fb-29cad0c95853" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_47ecca60-0dc8-25b2-6295-72031a21e0cb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_47ecca60-0dc8-25b2-6295-72031a21e0cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_38b416a4-4707-fba3-1084-9b8a37fd745a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_Depreciation_38b416a4-4707-fba3-1084-9b8a37fd745a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_0d30eb77-a66f-56df-77a0-7c7ad008c84e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_0d30eb77-a66f-56df-77a0-7c7ad008c84e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_5c03a9d6-b8ac-bbf3-746c-c7ea8b29c405" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_5c03a9d6-b8ac-bbf3-746c-c7ea8b29c405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_f2f5c0d1-023d-ee70-251c-234ad5970f07" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_f2f5c0d1-023d-ee70-251c-234ad5970f07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_30b51b02-ce1a-7a8d-83e5-0db42b6e72ce" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_30b51b02-ce1a-7a8d-83e5-0db42b6e72ce" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" xlink:label="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_92C7E166063E511EA618140790539928" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_92C7E166063E511EA618140790539928" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_91c354d1-d18f-051e-80cb-f13c01058b9d" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_91c354d1-d18f-051e-80cb-f13c01058b9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a039d388-4db8-a076-4618-28899f6ce801" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a039d388-4db8-a076-4618-28899f6ce801" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c85c86db-a830-0e07-1d7a-6fc2a37081a4" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c85c86db-a830-0e07-1d7a-6fc2a37081a4" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NonCashLeaseExpense" xlink:label="loc_dare_NonCashLeaseExpense_F79D2514A01FE8144D70A2E5D457459F" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_dare_NonCashLeaseExpense_F79D2514A01FE8144D70A2E5D457459F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_1AC12F3F591158C2BD54E93554218F98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_1AC12F3F591158C2BD54E93554218F98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_e0089888-8677-d95e-95e6-00fe630f2dcb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_e0089888-8677-d95e-95e6-00fe630f2dcb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_78ba68d7-f289-318f-e37f-e4831b34f534" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_78ba68d7-f289-318f-e37f-e4831b34f534" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseFee" xlink:label="loc_dare_LicenseFee_91568da7-7f44-9303-515a-72c0b1c0b502" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_dare_LicenseFee_91568da7-7f44-9303-515a-72c0b1c0b502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_0d30eb77-a66f-56df-77a0-7c7ad008c84e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_0d30eb77-a66f-56df-77a0-7c7ad008c84e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_bbef3c21-7a75-6f04-27f9-5fb5867dce81" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_bbef3c21-7a75-6f04-27f9-5fb5867dce81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b087c8bb-e0f6-4c7f-883c-027f52d32745" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b087c8bb-e0f6-4c7f-883c-027f52d32745" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/GoingConcern" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/GoingConcernAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/GrantAward" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/GrantAwardAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedProperties" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8446B7E126A65CB3A990BD3907F84526" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_E8732C4282A65F3CABF73D82180A7248" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8446B7E126A65CB3A990BD3907F84526" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_E8732C4282A65F3CABF73D82180A7248" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9B77BF8343C257B5AE6296AD990A600F" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8446B7E126A65CB3A990BD3907F84526" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9B77BF8343C257B5AE6296AD990A600F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_31ADD0E112355A78A7C9D89CC09E7156" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8446B7E126A65CB3A990BD3907F84526" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_31ADD0E112355A78A7C9D89CC09E7156" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_28A824392AAD084C3186A2C976AAF1D3_8446B7E126A65CB3A990BD3907F84526" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_28A824392AAD084C3186A2C976AAF1D3_964B5DBD1D1D53DEA944D377C2907858" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_28A824392AAD084C3186A2C976AAF1D3_8446B7E126A65CB3A990BD3907F84526" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_28A824392AAD084C3186A2C976AAF1D3_964B5DBD1D1D53DEA944D377C2907858" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_28A824392AAD084C3186A2C976AAF1D3_DF675A8F21D15DB18EA58BEB1CF49E28" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_28A824392AAD084C3186A2C976AAF1D3_8446B7E126A65CB3A990BD3907F84526" xlink:to="loc_us-gaap_OperatingLeaseLiability_28A824392AAD084C3186A2C976AAF1D3_DF675A8F21D15DB18EA58BEB1CF49E28" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/NetLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>dare-20190630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://darebioscience.com/role/Acquisitions" xlink:href="dare-20190630.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/AcquisitionsAdditionalInformationDetail" xlink:href="dare-20190630.xsd#AcquisitionsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsAndContingencies" xlink:href="dare-20190630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="dare-20190630.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheets" xlink:href="dare-20190630.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="dare-20190630.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="dare-20190630.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="dare-20190630.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="dare-20190630.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/DocumentAndEntityInformation" xlink:href="dare-20190630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GoingConcern" xlink:href="dare-20190630.xsd#GoingConcern" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GoingConcernAdditionalInformationDetail" xlink:href="dare-20190630.xsd#GoingConcernAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAward" xlink:href="dare-20190630.xsd#GrantAward" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAwardAdditionalInformationDetail" xlink:href="dare-20190630.xsd#GrantAwardAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedProperties" xlink:href="dare-20190630.xsd#LeasedProperties" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesDetails" xlink:href="dare-20190630.xsd#LeasedPropertiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:href="dare-20190630.xsd#LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesTables" xlink:href="dare-20190630.xsd#LeasedPropertiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShare" xlink:href="dare-20190630.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" xlink:href="dare-20190630.xsd#NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShareTables" xlink:href="dare-20190630.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="dare-20190630.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:href="dare-20190630.xsd#OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensation" xlink:href="dare-20190630.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="dare-20190630.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" xlink:href="dare-20190630.xsd#StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" xlink:href="dare-20190630.xsd#StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" xlink:href="dare-20190630.xsd#StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationTables" xlink:href="dare-20190630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquity" xlink:href="dare-20190630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="dare-20190630.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" xlink:href="dare-20190630.xsd#StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityTables" xlink:href="dare-20190630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="dare-20190630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="dare-20190630.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="dare-20190630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/Acquisitions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/AcquisitionsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="dare-20190630.xsd#dare_BusinessCombinationReverseMergerLineItems" xlink:label="loc_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:type="locator" />
    <link:loc xlink:href="dare-20190630.xsd#dare_ScheduleOfBusinessCombinationReverseMergerTable" xlink:label="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:to="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2D5D82A228207C7BEE9578071B332A20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092" xlink:to="loc_dei_LegalEntityAxis_2D5D82A228207C7BEE9578071B332A20" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_0D613F3323383CF311EA78071B3355C4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2D5D82A228207C7BEE9578071B332A20" xlink:to="loc_dei_EntityDomain_0D613F3323383CF311EA78071B3355C4_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_0D613F3323383CF311EA78071B3355C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2D5D82A228207C7BEE9578071B332A20" xlink:to="loc_dei_EntityDomain_0D613F3323383CF311EA78071B3355C4" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PrivateDareMember" xlink:label="loc_dare_PrivateDareMember_51385BB4DC243FD1FD5D78071B33789C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0D613F3323383CF311EA78071B3355C4" xlink:to="loc_dare_PrivateDareMember_51385BB4DC243FD1FD5D78071B33789C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_31D0CB3D18C15FFF496478071B349120" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_31D0CB3D18C15FFF496478071B349120" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B69EE32EB395B172742778071B3409FD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_31D0CB3D18C15FFF496478071B349120" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_B69EE32EB395B172742778071B3409FD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B69EE32EB395B172742778071B3409FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_31D0CB3D18C15FFF496478071B349120" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_B69EE32EB395B172742778071B3409FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5EFCDD3DD570538B187D78071B34F4B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B69EE32EB395B172742778071B3409FD" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5EFCDD3DD570538B187D78071B34F4B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_94AE358BA8FA391976FA78071B35F281" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_94AE358BA8FA391976FA78071B35F281" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_50AA83230792B766CB6E78071B35BD04_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_94AE358BA8FA391976FA78071B35F281" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_50AA83230792B766CB6E78071B35BD04_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_50AA83230792B766CB6E78071B35BD04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_94AE358BA8FA391976FA78071B35F281" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_50AA83230792B766CB6E78071B35BD04" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PearTreePharmaceuticalsIncMember" xlink:label="loc_dare_PearTreePharmaceuticalsIncMember_E43C6D1B2DEFDA4BD42678071B3508D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_50AA83230792B766CB6E78071B35BD04" xlink:to="loc_dare_PearTreePharmaceuticalsIncMember_E43C6D1B2DEFDA4BD42678071B3508D7" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_91314AC76F46EC58227C78071B367392" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:to="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_91314AC76F46EC58227C78071B367392" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions" xlink:label="loc_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_3EEE1C3BE117D05B931C78071B363A56" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:to="loc_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_3EEE1C3BE117D05B931C78071B363A56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_16AE243469526DBBAC9278071B361CA2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_16AE243469526DBBAC9278071B361CA2" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost" xlink:label="loc_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_17C634478ABBE254F63F78071B36F77D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:to="loc_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_17C634478ABBE254F63F78071B36F77D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PotentialCashPaymentsToAcquireBusiness" xlink:label="loc_dare_PotentialCashPaymentsToAcquireBusiness_968E61EDF481090A4BA678071B379F45" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:to="loc_dare_PotentialCashPaymentsToAcquireBusiness_968E61EDF481090A4BA678071B379F45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_558AF06E9A39988580D378071B3637DA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_558AF06E9A39988580D378071B3637DA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="dare-20190630.xsd#dare_CommitmentsAndContingenciesLineItems" xlink:label="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:type="locator" />
    <link:loc xlink:href="dare-20190630.xsd#dare_CommitmentsAndContingenciesTable" xlink:label="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D25F1F1D0BF2DC03B48B720E1C25ED65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D25F1F1D0BF2DC03B48B720E1C25ED65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D25F1F1D0BF2DC03B48B720E1C25ED65" xlink:to="loc_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D25F1F1D0BF2DC03B48B720E1C25ED65" xlink:to="loc_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_A72C35F79E69282B6837720E1C261189" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189" xlink:to="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_A72C35F79E69282B6837720E1C261189" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:label="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_84B1512373E5946AF257720E1C261AB6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189" xlink:to="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_84B1512373E5946AF257720E1C261AB6" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember" xlink:label="loc_dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember_8DD6B9085A618E8DB92E7215FDBADEC3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189" xlink:to="loc_dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember_8DD6B9085A618E8DB92E7215FDBADEC3" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_FutureMilestonePaymentsBasedOnCommercializationMember" xlink:label="loc_dare_FutureMilestonePaymentsBasedOnCommercializationMember_667B5EE6168008B41A1F721678E97197" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189" xlink:to="loc_dare_FutureMilestonePaymentsBasedOnCommercializationMember_667B5EE6168008B41A1F721678E97197" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_E44AAEFB6E0F915DCF61720E1C26F1F2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_E44AAEFB6E0F915DCF61720E1C26F1F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E44AAEFB6E0F915DCF61720E1C26F1F2" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E44AAEFB6E0F915DCF61720E1C26F1F2" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_UponAchievingCertainCommercialMilestonesMember" xlink:label="loc_dare_UponAchievingCertainCommercialMilestonesMember_EB5B5D7312F21BC78993720E1C27AA3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750" xlink:to="loc_dare_UponAchievingCertainCommercialMilestonesMember_EB5B5D7312F21BC78993720E1C27AA3F" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_UponSigningOfDevelopmentAndOptionAgreementMember" xlink:label="loc_dare_UponSigningOfDevelopmentAndOptionAgreementMember_46FAF28F5A9E7FA57356720E1C275A40" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750" xlink:to="loc_dare_UponSigningOfDevelopmentAndOptionAgreementMember_46FAF28F5A9E7FA57356720E1C275A40" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember" xlink:label="loc_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_D5F6C1747ACD5AB86DCB720E1C28D305" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750" xlink:to="loc_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_D5F6C1747ACD5AB86DCB720E1C28D305" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:label="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_BF1822E529A6428D8621720E1C286B81" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750" xlink:to="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_BF1822E529A6428D8621720E1C286B81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_33BFA660C11DBCD8B660720E1C285693" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_33BFA660C11DBCD8B660720E1C285693" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_E0A0BA01A6D07415477F720E1C2811BA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_33BFA660C11DBCD8B660720E1C285693" xlink:to="loc_us-gaap_RelatedPartyDomain_E0A0BA01A6D07415477F720E1C2811BA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_E0A0BA01A6D07415477F720E1C2811BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_33BFA660C11DBCD8B660720E1C285693" xlink:to="loc_us-gaap_RelatedPartyDomain_E0A0BA01A6D07415477F720E1C2811BA" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:label="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_A9153B2B0DEA56385509720E1C28E6BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_E0A0BA01A6D07415477F720E1C2811BA" xlink:to="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_A9153B2B0DEA56385509720E1C28E6BF" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_OrbisMember" xlink:label="loc_dare_OrbisMember_6C858185A7CD5A0A7A7F720E1C2949EB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_E0A0BA01A6D07415477F720E1C2811BA" xlink:to="loc_dare_OrbisMember_6C858185A7CD5A0A7A7F720E1C2949EB" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_MilanaPharmMember" xlink:label="loc_dare_MilanaPharmMember_F8B6EBFED2E14641207F720E1C296A97" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_E0A0BA01A6D07415477F720E1C2811BA" xlink:to="loc_dare_MilanaPharmMember_F8B6EBFED2E14641207F720E1C296A97" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_HammockPharmaceuticalsInc.Member" xlink:label="loc_dare_HammockPharmaceuticalsInc.Member_FA0DF05BBC852E4D6732720E1C2905C4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_E0A0BA01A6D07415477F720E1C2811BA" xlink:to="loc_dare_HammockPharmaceuticalsInc.Member_FA0DF05BBC852E4D6732720E1C2905C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_314BFD22D11D6EFA7B4A720E1C294E06" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_314BFD22D11D6EFA7B4A720E1C294E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_314BFD22D11D6EFA7B4A720E1C294E06" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_314BFD22D11D6EFA7B4A720E1C294E06" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_CF68F6EDABAE306ED9C6720E1C2A8150" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:to="loc_us-gaap_LicensingAgreementsMember_CF68F6EDABAE306ED9C6720E1C2A8150" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_AssignmentAgreementMember" xlink:label="loc_dare_AssignmentAgreementMember_340589595C152C4A9797720E1C2A8B5E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:to="loc_dare_AssignmentAgreementMember_340589595C152C4A9797720E1C2A8B5E" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAndCollaborationAgreementMember" xlink:label="loc_dare_LicenseAndCollaborationAgreementMember_57C63C1FD973C896CFC9720E1C2A798D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:to="loc_dare_LicenseAndCollaborationAgreementMember_57C63C1FD973C896CFC9720E1C2A798D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_DevelopmentAndOptionAgreementMember" xlink:label="loc_dare_DevelopmentAndOptionAgreementMember_53B16A4503175560998F720E1C2B1BEC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:to="loc_dare_DevelopmentAndOptionAgreementMember_53B16A4503175560998F720E1C2B1BEC" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_JuniperPharmaceuticalsInc.Member" xlink:label="loc_dare_JuniperPharmaceuticalsInc.Member_C669DECFBE7E4C9B1722720E1C2B059B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:to="loc_dare_JuniperPharmaceuticalsInc.Member_C669DECFBE7E4C9B1722720E1C2B059B" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_JuniperPharmaceuticalsMember" xlink:label="loc_dare_JuniperPharmaceuticalsMember_B5E44CE6DC6E200959C4720E1C2B9189" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:to="loc_dare_JuniperPharmaceuticalsMember_B5E44CE6DC6E200959C4720E1C2B9189" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_17C97A0B2D467DFC5029720E1C2C00FE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_17C97A0B2D467DFC5029720E1C2C00FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_F1A27082EB7FD4E36874720E1C2C52DB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_17C97A0B2D467DFC5029720E1C2C00FE" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_F1A27082EB7FD4E36874720E1C2C52DB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_F1A27082EB7FD4E36874720E1C2C52DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_17C97A0B2D467DFC5029720E1C2C00FE" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_F1A27082EB7FD4E36874720E1C2C52DB" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_ADVATecAgreementMember" xlink:label="loc_dare_ADVATecAgreementMember_6B4FAF095DBE9F8EA93A720E1C2C4235" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_F1A27082EB7FD4E36874720E1C2C52DB" xlink:to="loc_dare_ADVATecAgreementMember_6B4FAF095DBE9F8EA93A720E1C2C4235" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_ClinicalAndRegulatoryMilestonesMember" xlink:label="loc_dare_ClinicalAndRegulatoryMilestonesMember_E0F632337C5682F377BE720E1C2C7442" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_F1A27082EB7FD4E36874720E1C2C52DB" xlink:to="loc_dare_ClinicalAndRegulatoryMilestonesMember_E0F632337C5682F377BE720E1C2C7442" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_SalesMilestonesMember" xlink:label="loc_dare_SalesMilestonesMember_7E93522D4E5A566BA157720E1C2DBBE1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_F1A27082EB7FD4E36874720E1C2C52DB" xlink:to="loc_dare_SalesMilestonesMember_7E93522D4E5A566BA157720E1C2DBBE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6DB419DE9465D9775C20720E1C2DBF4D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:to="loc_srt_RangeAxis_6DB419DE9465D9775C20720E1C2DBF4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_108BCB3D27EA514E41BB720E1C2D6661_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6DB419DE9465D9775C20720E1C2DBF4D" xlink:to="loc_srt_RangeMember_108BCB3D27EA514E41BB720E1C2D6661_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_108BCB3D27EA514E41BB720E1C2D6661" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6DB419DE9465D9775C20720E1C2DBF4D" xlink:to="loc_srt_RangeMember_108BCB3D27EA514E41BB720E1C2D6661" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_F8C594F496E0AD8867C1720E1C2E1FA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_108BCB3D27EA514E41BB720E1C2D6661" xlink:to="loc_srt_MinimumMember_F8C594F496E0AD8867C1720E1C2E1FA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_A47D8BB2B75CA86BDFE4720E1C2F07E1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_108BCB3D27EA514E41BB720E1C2D6661" xlink:to="loc_srt_MaximumMember_A47D8BB2B75CA86BDFE4720E1C2F07E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_CC91522DFFB65E8551BE720E1C30F63B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:to="loc_srt_ProductOrServiceAxis_CC91522DFFB65E8551BE720E1C30F63B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_8871E537A9ACC680495A720E1C30BCC3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_CC91522DFFB65E8551BE720E1C30F63B" xlink:to="loc_srt_ProductsAndServicesDomain_8871E537A9ACC680495A720E1C30BCC3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_8871E537A9ACC680495A720E1C30BCC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_CC91522DFFB65E8551BE720E1C30F63B" xlink:to="loc_srt_ProductsAndServicesDomain_8871E537A9ACC680495A720E1C30BCC3" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_OvapreneMember" xlink:label="loc_dare_OvapreneMember_972EAC232AF68E34625B720E1C318C87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8871E537A9ACC680495A720E1C30BCC3" xlink:to="loc_dare_OvapreneMember_972EAC232AF68E34625B720E1C318C87" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NumberOfPatentsIssued" xlink:label="loc_dare_NumberOfPatentsIssued_DC3759BF5CBAF4FB05A8720E1C32EFDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_NumberOfPatentsIssued_DC3759BF5CBAF4FB05A8720E1C32EFDC" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NumberOfPendingPatents" xlink:label="loc_dare_NumberOfPendingPatents_091BCD5571D073B6E088720E1C32F0C1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_NumberOfPendingPatents_091BCD5571D073B6E088720E1C32F0C1" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NumberOfPatentsGranted" xlink:label="loc_dare_NumberOfPatentsGranted_C09ED940D44D9DFCACAE720E1C328B60" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_NumberOfPatentsGranted_C09ED940D44D9DFCACAE720E1C328B60" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NumberOfPatentApplications" xlink:label="loc_dare_NumberOfPatentApplications_AE419E1CED16AD89560B720E1C339342" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_NumberOfPatentApplications_AE419E1CED16AD89560B720E1C339342" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_12566402C85BBDBBF934720E1C33B332" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_us-gaap_ContractualObligation_12566402C85BBDBBF934720E1C33B332" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries" xlink:label="loc_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_39239BFC16A9EA2F225F720E1C33F8D1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_39239BFC16A9EA2F225F720E1C33F8D1" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NumberOfDesignatedCountries" xlink:label="loc_dare_NumberOfDesignatedCountries_6F550C419C7157CAA2A1720E1C339D1B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_NumberOfDesignatedCountries_6F550C419C7157CAA2A1720E1C339D1B" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PercentageOfRoyaltyRate" xlink:label="loc_dare_PercentageOfRoyaltyRate_53BE2ACF30C4616D0082720E1C34ED4A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_PercentageOfRoyaltyRate_53BE2ACF30C4616D0082720E1C34ED4A" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" xlink:label="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_921A9CEE5A93503856E3720E1C342EBC" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_921A9CEE5A93503856E3720E1C342EBC" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease" xlink:label="loc_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_A61483944156CEFC28B0720E1C34C7EF" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_A61483944156CEFC28B0720E1C34C7EF" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" xlink:label="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_A2215BC3F6476F40CA36720E1C34514D" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_A2215BC3F6476F40CA36720E1C34514D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_MilestonePaymentsContingentAmount" xlink:label="loc_dare_MilestonePaymentsContingentAmount_016410222CF3C4AC264A720E1C359D10" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_MilestonePaymentsContingentAmount_016410222CF3C4AC264A720E1C359D10" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_SecuredInvestmentRequiredForLicenseAgreement" xlink:label="loc_dare_SecuredInvestmentRequiredForLicenseAgreement_21821E41A96414ED1831720E1C3566D9" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_SecuredInvestmentRequiredForLicenseAgreement_21821E41A96414ED1831720E1C3566D9" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementExpirationPeriod" xlink:label="loc_dare_LicenseAgreementExpirationPeriod_32F365D4A7C0277864A4720E1C355CCA" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseAgreementExpirationPeriod_32F365D4A7C0277864A4720E1C355CCA" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval" xlink:label="loc_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_839B01738675A05CB4C6720E1C3520C3" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_839B01738675A05CB4C6720E1C3520C3" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval" xlink:label="loc_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_0F186928003DEFE63BD0720E1C3515F3" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_0F186928003DEFE63BD0720E1C3515F3" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries" xlink:label="loc_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_FB09EFBEF29880AC234A720E1C361E22" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_FB09EFBEF29880AC234A720E1C361E22" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NoticePeriodForTerminationOfAgreementForBothParties" xlink:label="loc_dare_NoticePeriodForTerminationOfAgreementForBothParties_FCA851E45049B2E03A7F720E1C36A3AC" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_NoticePeriodForTerminationOfAgreementForBothParties_FCA851E45049B2E03A7F720E1C36A3AC" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_ResearchAndDevelopmentMilestonePayment" xlink:label="loc_dare_ResearchAndDevelopmentMilestonePayment_FFB065DC5477EF1F92B3720E1C361D21" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_ResearchAndDevelopmentMilestonePayment_FFB065DC5477EF1F92B3720E1C361D21" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_CommencementPeriodForStageTwoUponAchievementOfStageOne" xlink:label="loc_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_6BF65CAE4EB51023B960720E1C368B0C" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_6BF65CAE4EB51023B960720E1C368B0C" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_UpfrontLicenseFeePaid" xlink:label="loc_dare_UpfrontLicenseFeePaid_B24534E7ABB0A7E59847720E1C37FB2D" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_UpfrontLicenseFeePaid_B24534E7ABB0A7E59847720E1C37FB2D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_D9BE6B1057B91F64F1BD720E1C3743AD" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_D9BE6B1057B91F64F1BD720E1C3743AD" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_D0E5C5B61A6D20252032720E1C376C29" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_D0E5C5B61A6D20252032720E1C376C29" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_MaximumPotentialMilestonePayments" xlink:label="loc_dare_MaximumPotentialMilestonePayments_530439A9C6E9058269CF720E1C376DAF" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_MaximumPotentialMilestonePayments_530439A9C6E9058269CF720E1C376DAF" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess" xlink:label="loc_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_65139A6CCD39FE9D42F0720E1C372815" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_65139A6CCD39FE9D42F0720E1C372815" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_224C8E87C7DAB371E449720E1C38A77B" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_224C8E87C7DAB371E449720E1C38A77B" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PeriodOfDismissalOfBankruptcyPetition" xlink:label="loc_dare_PeriodOfDismissalOfBankruptcyPetition_BC42B900241BBC0C011C720E1C388CC9" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_PeriodOfDismissalOfBankruptcyPetition_BC42B900241BBC0C011C720E1C388CC9" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_866B4CBEDF3BE825A323720E1C387990" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_866B4CBEDF3BE825A323720E1C387990" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementNoticePeriodOfTermination" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTermination_2C4FBB033C3F176251B4720E1C38B453" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseAgreementNoticePeriodOfTermination_2C4FBB033C3F176251B4720E1C38B453" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseFee" xlink:label="loc_dare_LicenseFee_A171B0D4889E8B0951BD720E1C392A40" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseFee_A171B0D4889E8B0951BD720E1C392A40" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseFeeToBePaidUponContingency" xlink:label="loc_dare_LicenseFeeToBePaidUponContingency_B72D6C752DFE7374A0C1720E1C39F57D" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseFeeToBePaidUponContingency_B72D6C752DFE7374A0C1720E1C39F57D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_ProceedsRaisedFromEquityFinancing" xlink:label="loc_dare_ProceedsRaisedFromEquityFinancing_80637EDC7C0C9433F246720E1C392191" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_ProceedsRaisedFromEquityFinancing_80637EDC7C0C9433F246720E1C392191" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6F60125553199E0B09B38B6FAE9EEE06" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A3F4F4A457B43093822A8B6FAE9B5F37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6F60125553199E0B09B38B6FAE9EEE06" xlink:to="loc_us-gaap_StatementTable_A3F4F4A457B43093822A8B6FAE9B5F37" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7E0C3649329E9CAEBA818B6FAE9CA943" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_A3F4F4A457B43093822A8B6FAE9B5F37" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7E0C3649329E9CAEBA818B6FAE9CA943" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7E0C3649329E9CAEBA818B6FAE9CA943" xlink:to="loc_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7E0C3649329E9CAEBA818B6FAE9CA943" xlink:to="loc_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_EE9975C36A926F29A43E8B6FAE9D4D9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C" xlink:to="loc_us-gaap_CommonStockMember_EE9975C36A926F29A43E8B6FAE9D4D9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9793BC4FE667D4DF62678B6FAE9D57B7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9793BC4FE667D4DF62678B6FAE9D57B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B669CDE737E161FC0BC88B6FAE9D1409" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B669CDE737E161FC0BC88B6FAE9D1409" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_2B051ED87000BB590A598B6FAE9EAE51" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C" xlink:to="loc_us-gaap_RetainedEarningsMember_2B051ED87000BB590A598B6FAE9EAE51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6F60125553199E0B09B38B6FAE9EEE06" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_CCB4EAD7BD5493BFE97E8B6FAE9E50E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_SharesOutstanding_CCB4EAD7BD5493BFE97E8B6FAE9E50E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_920381340E2E372311AE8B6FAE9F6821" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_StockholdersEquity_920381340E2E372311AE8B6FAE9F6821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2940A599692ECC79E2DD8B6FAE9FF2B6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2940A599692ECC79E2DD8B6FAE9FF2B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B08BF7F5BA4C4B4E7D428B6FB25CF7AA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B08BF7F5BA4C4B4E7D428B6FB25CF7AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4BFB2238736FE5BB8DBF8B6FAEA11DC3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4BFB2238736FE5BB8DBF8B6FAEA11DC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_60358D4FEE3F9CE4A6EE8B6FAEA1776C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_60358D4FEE3F9CE4A6EE8B6FAEA1776C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_8AA05A60ADC4B0A0E75D8B6FAEA2BC73" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_8AA05A60ADC4B0A0E75D8B6FAEA2BC73" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_02EE51BC72EE44F23ACA8B6FAEA236D0" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_02EE51BC72EE44F23ACA8B6FAEA236D0" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_863F0428610B7AD5EBD38B6FAEA260F2" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_863F0428610B7AD5EBD38B6FAEA260F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4FBA5B9F086B6C03DD768B6FAEA2CE65" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_NetIncomeLoss_4FBA5B9F086B6C03DD768B6FAEA2CE65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_B0E091BBFECD596837438B6FAEA2B4BD" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_B0E091BBFECD596837438B6FAEA2B4BD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/GoingConcern" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/GoingConcernAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7CEFFF5465D919DDC8916D52EA5B734B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA" xlink:to="loc_srt_ProductOrServiceAxis_7CEFFF5465D919DDC8916D52EA5B734B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_9EECFEEFA666A9A4A7506D52EA5B5235_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7CEFFF5465D919DDC8916D52EA5B734B" xlink:to="loc_srt_ProductsAndServicesDomain_9EECFEEFA666A9A4A7506D52EA5B5235_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_9EECFEEFA666A9A4A7506D52EA5B5235" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7CEFFF5465D919DDC8916D52EA5B734B" xlink:to="loc_srt_ProductsAndServicesDomain_9EECFEEFA666A9A4A7506D52EA5B5235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_91FA625B5AA197D1BBAA6D52EA5B54E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9EECFEEFA666A9A4A7506D52EA5B5235" xlink:to="loc_us-gaap_GrantMember_91FA625B5AA197D1BBAA6D52EA5B54E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8A7BA3A6C2CC1CCB7E036D52EA5B2B80" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8A7BA3A6C2CC1CCB7E036D52EA5B2B80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_D728D2DFBCC6381234FA6D52EA5B7E8E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8A7BA3A6C2CC1CCB7E036D52EA5B2B80" xlink:to="loc_us-gaap_RelatedPartyDomain_D728D2DFBCC6381234FA6D52EA5B7E8E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_D728D2DFBCC6381234FA6D52EA5B7E8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8A7BA3A6C2CC1CCB7E036D52EA5B2B80" xlink:to="loc_us-gaap_RelatedPartyDomain_D728D2DFBCC6381234FA6D52EA5B7E8E" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NationalInstitutesOfHealthMember" xlink:label="loc_dare_NationalInstitutesOfHealthMember_508495C41378D0FC8B686D52EA5B0048" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_D728D2DFBCC6381234FA6D52EA5B7E8E" xlink:to="loc_dare_NationalInstitutesOfHealthMember_508495C41378D0FC8B686D52EA5B0048" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundAxis" xlink:label="loc_us-gaap_HealthCareTrustFundAxis_9024E697C6EEF9EEF45F6D52EA5BC69E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA" xlink:to="loc_us-gaap_HealthCareTrustFundAxis_9024E697C6EEF9EEF45F6D52EA5BC69E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain" xlink:label="loc_us-gaap_HealthCareTrustFundNameDomain_CEFC5E1803BF6046AD196D52EA5BA5F7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HealthCareTrustFundAxis_9024E697C6EEF9EEF45F6D52EA5BC69E" xlink:to="loc_us-gaap_HealthCareTrustFundNameDomain_CEFC5E1803BF6046AD196D52EA5BA5F7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain" xlink:label="loc_us-gaap_HealthCareTrustFundNameDomain_CEFC5E1803BF6046AD196D52EA5BA5F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HealthCareTrustFundAxis_9024E697C6EEF9EEF45F6D52EA5BC69E" xlink:to="loc_us-gaap_HealthCareTrustFundNameDomain_CEFC5E1803BF6046AD196D52EA5BA5F7" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember" xlink:label="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_12D40397C4A8580A15106D52EA632555" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareTrustFundNameDomain_CEFC5E1803BF6046AD196D52EA5BA5F7" xlink:to="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_12D40397C4A8580A15106D52EA632555" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3558151A87F073611B636D52EA637928" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3558151A87F073611B636D52EA637928" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_B93577EA87FA69C5A75D6D52EA63811A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3558151A87F073611B636D52EA637928" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_B93577EA87FA69C5A75D6D52EA63811A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_B93577EA87FA69C5A75D6D52EA63811A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3558151A87F073611B636D52EA637928" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_B93577EA87FA69C5A75D6D52EA63811A" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember" xlink:label="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_DF450E5A27D6B8FA488C6D52EA63B7AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_B93577EA87FA69C5A75D6D52EA63811A" xlink:to="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_DF450E5A27D6B8FA488C6D52EA63B7AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9E4D11A2D13C7455FC476D52EA64E91D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9E4D11A2D13C7455FC476D52EA64E91D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DF0FAA86DAD4E600AFA36D52EA64F688" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DF0FAA86DAD4E600AFA36D52EA64F688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C6383C3A9AD9746E849C6D52EA64D4EC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C6383C3A9AD9746E849C6D52EA64D4EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C69E4D2F7126695CD38E6D52EA64A59D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C69E4D2F7126695CD38E6D52EA64A59D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable_D5E64146DD92E00E0C1D6D52EA642C56" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:to="loc_us-gaap_GrantsReceivable_D5E64146DD92E00E0C1D6D52EA642C56" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_ReimbursementOfGrantExpensesReceivable" xlink:label="loc_dare_ReimbursementOfGrantExpensesReceivable_82D663772CEE1F2578786D52EA647669" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:to="loc_dare_ReimbursementOfGrantExpensesReceivable_82D663772CEE1F2578786D52EA647669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_C078979A20F8332065206D52EA64F3C7" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_C078979A20F8332065206D52EA64F3C7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/GrantAward" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/GrantAwardAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_8DCF5FB7D002ACDE54A678071A9DF0C0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_8DCF5FB7D002ACDE54A678071A9DF0C0" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_F277B3843F86B08B689B78071A9ABC8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94" xlink:to="loc_srt_ProductOrServiceAxis_F277B3843F86B08B689B78071A9ABC8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_9FF123669E71341C3E5878071A9A0359_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_F277B3843F86B08B689B78071A9ABC8D" xlink:to="loc_srt_ProductsAndServicesDomain_9FF123669E71341C3E5878071A9A0359_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_9FF123669E71341C3E5878071A9A0359" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_F277B3843F86B08B689B78071A9ABC8D" xlink:to="loc_srt_ProductsAndServicesDomain_9FF123669E71341C3E5878071A9A0359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_535B6950653C3CB0D76878071A9B275F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9FF123669E71341C3E5878071A9A0359" xlink:to="loc_us-gaap_GrantMember_535B6950653C3CB0D76878071A9B275F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundAxis" xlink:label="loc_us-gaap_HealthCareTrustFundAxis_1830BCA3919CD5B3402A78071A9B4127" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94" xlink:to="loc_us-gaap_HealthCareTrustFundAxis_1830BCA3919CD5B3402A78071A9B4127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain" xlink:label="loc_us-gaap_HealthCareTrustFundNameDomain_D24BE27C4ACE19EC368C78071A9BDB2C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HealthCareTrustFundAxis_1830BCA3919CD5B3402A78071A9B4127" xlink:to="loc_us-gaap_HealthCareTrustFundNameDomain_D24BE27C4ACE19EC368C78071A9BDB2C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain" xlink:label="loc_us-gaap_HealthCareTrustFundNameDomain_D24BE27C4ACE19EC368C78071A9BDB2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HealthCareTrustFundAxis_1830BCA3919CD5B3402A78071A9B4127" xlink:to="loc_us-gaap_HealthCareTrustFundNameDomain_D24BE27C4ACE19EC368C78071A9BDB2C" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember" xlink:label="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_612F83A37AD7C0A1506378071A9B6D90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareTrustFundNameDomain_D24BE27C4ACE19EC368C78071A9BDB2C" xlink:to="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_612F83A37AD7C0A1506378071A9B6D90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_F3D37C904704783795E078071A9C38BE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_F3D37C904704783795E078071A9C38BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_076D258F647EC3CAB6BE78071A9CF74D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_F3D37C904704783795E078071A9C38BE" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_076D258F647EC3CAB6BE78071A9CF74D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_076D258F647EC3CAB6BE78071A9CF74D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_F3D37C904704783795E078071A9C38BE" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_076D258F647EC3CAB6BE78071A9CF74D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember" xlink:label="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_C8C5003CF6E2C5E1895878071A9C940C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_076D258F647EC3CAB6BE78071A9CF74D" xlink:to="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_C8C5003CF6E2C5E1895878071A9C940C" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember" xlink:label="loc_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_F8C3157919E0751B775978071A9CD738" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_076D258F647EC3CAB6BE78071A9CF74D" xlink:to="loc_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_F8C3157919E0751B775978071A9CD738" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_47DF55D11E5E40B7DBCD78071A9DC328" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_47DF55D11E5E40B7DBCD78071A9DC328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6345B2EE67E3C86B791378071A9D8811_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_47DF55D11E5E40B7DBCD78071A9DC328" xlink:to="loc_us-gaap_RelatedPartyDomain_6345B2EE67E3C86B791378071A9D8811_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6345B2EE67E3C86B791378071A9D8811" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_47DF55D11E5E40B7DBCD78071A9DC328" xlink:to="loc_us-gaap_RelatedPartyDomain_6345B2EE67E3C86B791378071A9D8811" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NationalInstitutesOfHealthMember" xlink:label="loc_dare_NationalInstitutesOfHealthMember_D95D11A6E5184A962CDB78071A9DBD1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6345B2EE67E3C86B791378071A9D8811" xlink:to="loc_dare_NationalInstitutesOfHealthMember_D95D11A6E5184A962CDB78071A9DBD1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8E39C881385A31E8D52878071A9D2B52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_8DCF5FB7D002ACDE54A678071A9DF0C0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8E39C881385A31E8D52878071A9D2B52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable_587FD73E2F59C11C343078071A9EB0BD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_8DCF5FB7D002ACDE54A678071A9DF0C0" xlink:to="loc_us-gaap_GrantsReceivable_587FD73E2F59C11C343078071A9EB0BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_8CE9F1F05363B064D33E78071A9ED29B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_8DCF5FB7D002ACDE54A678071A9DF0C0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_8CE9F1F05363B064D33E78071A9ED29B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/LeasedProperties" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/LeasedPropertiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/LeasedPropertiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/NetLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E7C252C5678F2865C8246D52E9547967" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9BDB42DBDA238E4DBB596D52E953A6CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E7C252C5678F2865C8246D52E9547967" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9BDB42DBDA238E4DBB596D52E953A6CB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54BB2834DB4DBD6BCA1F6D52E953F13C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9BDB42DBDA238E4DBB596D52E953A6CB" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54BB2834DB4DBD6BCA1F6D52E953F13C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_447AF40BE95F649A9D386D52E95471FB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54BB2834DB4DBD6BCA1F6D52E953F13C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_447AF40BE95F649A9D386D52E95471FB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_447AF40BE95F649A9D386D52E95471FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54BB2834DB4DBD6BCA1F6D52E953F13C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_447AF40BE95F649A9D386D52E95471FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_63898290C78FD7CAEC566D52E954E914" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_447AF40BE95F649A9D386D52E95471FB" xlink:to="loc_us-gaap_EmployeeStockOptionMember_63898290C78FD7CAEC566D52E954E914" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_B71BE63BEEE944C2367D6D52E954DFF8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_447AF40BE95F649A9D386D52E95471FB" xlink:to="loc_us-gaap_WarrantMember_B71BE63BEEE944C2367D6D52E954DFF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5105188C94B7735FA6A16D52E954CC08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E7C252C5678F2865C8246D52E9547967" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5105188C94B7735FA6A16D52E954CC08" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_514665E902E8CF33929878071B0E0532" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_514665E902E8CF33929878071B0E0532" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D976E7AE2CF00232181978071B0E68D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_514665E902E8CF33929878071B0E0532" xlink:to="loc_us-gaap_PlanNameAxis_D976E7AE2CF00232181978071B0E68D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_9DDC3B35686E55DA0D6178071B0E1D41_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_D976E7AE2CF00232181978071B0E68D2" xlink:to="loc_us-gaap_PlanNameDomain_9DDC3B35686E55DA0D6178071B0E1D41_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_9DDC3B35686E55DA0D6178071B0E1D41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_D976E7AE2CF00232181978071B0E68D2" xlink:to="loc_us-gaap_PlanNameDomain_9DDC3B35686E55DA0D6178071B0E1D41" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_TwoThousandAndFifteenStockIncentivePlanMember" xlink:label="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_5C57066E292D285B3E1978071B0E4656" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9DDC3B35686E55DA0D6178071B0E1D41" xlink:to="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_5C57066E292D285B3E1978071B0E4656" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:label="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_31829F82667CBF8C8AFD78071B0FDCD4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9DDC3B35686E55DA0D6178071B0E1D41" xlink:to="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_31829F82667CBF8C8AFD78071B0FDCD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_F8F39A5165424763C5F778071B0F89C9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_514665E902E8CF33929878071B0E0532" xlink:to="loc_us-gaap_AwardTypeAxis_F8F39A5165424763C5F778071B0F89C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_478BFA23697F50EA512578071B0F6C27_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_F8F39A5165424763C5F778071B0F89C9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_478BFA23697F50EA512578071B0F6C27_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_478BFA23697F50EA512578071B0F6C27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_F8F39A5165424763C5F778071B0F89C9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_478BFA23697F50EA512578071B0F6C27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_D2425F7E8F4F2379525678071B10340B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_478BFA23697F50EA512578071B0F6C27" xlink:to="loc_us-gaap_EmployeeStockOptionMember_D2425F7E8F4F2379525678071B10340B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_E098B8DA014F08AA312A78071B10512E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_478BFA23697F50EA512578071B0F6C27" xlink:to="loc_us-gaap_RestrictedStockMember_E098B8DA014F08AA312A78071B10512E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_AEE17DCE38D004C30D4C78071B10E487" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_514665E902E8CF33929878071B0E0532" xlink:to="loc_dei_LegalEntityAxis_AEE17DCE38D004C30D4C78071B10E487" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_50B3045CE0B52741848478071B1057F1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_AEE17DCE38D004C30D4C78071B10E487" xlink:to="loc_dei_EntityDomain_50B3045CE0B52741848478071B1057F1_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_50B3045CE0B52741848478071B1057F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_AEE17DCE38D004C30D4C78071B10E487" xlink:to="loc_dei_EntityDomain_50B3045CE0B52741848478071B1057F1" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PrivateDareMember" xlink:label="loc_dare_PrivateDareMember_DCE39D2318ADB58E9AC178071B109D47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_50B3045CE0B52741848478071B1057F1" xlink:to="loc_dare_PrivateDareMember_DCE39D2318ADB58E9AC178071B109D47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60FCE851A61B0D22ACA878071B11A1A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60FCE851A61B0D22ACA878071B11A1A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_BBDD03E2CE24EED34C7C78071B119E9F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_BBDD03E2CE24EED34C7C78071B119E9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1C7ADDA2E8185CEC996D78071B11420F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1C7ADDA2E8185CEC996D78071B11420F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2CDF900943E7B604507C78071B119F62" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2CDF900943E7B604507C78071B119F62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_DBB491C57AF1DEBE0FF678071B120A20" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_DBB491C57AF1DEBE0FF678071B120A20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_215A3D22D1652520B45D78071B12BC27" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_215A3D22D1652520B45D78071B12BC27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_2FBB9910BBEAB761386C78071B1237E3" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_2FBB9910BBEAB761386C78071B1237E3" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_WeightedAverageAmortizationPeriod" xlink:label="loc_dare_WeightedAverageAmortizationPeriod_A0396191BCF261CEB98A78071B1296F8" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_dare_WeightedAverageAmortizationPeriod_A0396191BCF261CEB98A78071B1296F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_DC7B422A8ADED2C5F2CE78071B12B8C9" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_DC7B422A8ADED2C5F2CE78071B12B8C9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69482650FDEAD6C154116D52E9B872D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A37D537168FC2631BB636D52E9B6B68A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69482650FDEAD6C154116D52E9B872D0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A37D537168FC2631BB636D52E9B6B68A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7B7CBA4A3F9F3A9E8DFC6D52E9B65984" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A37D537168FC2631BB636D52E9B6B68A" xlink:to="loc_us-gaap_AwardTypeAxis_7B7CBA4A3F9F3A9E8DFC6D52E9B65984" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4A449490693E6C995BF6D52E9B76D8D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7B7CBA4A3F9F3A9E8DFC6D52E9B65984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4A449490693E6C995BF6D52E9B76D8D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4A449490693E6C995BF6D52E9B76D8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7B7CBA4A3F9F3A9E8DFC6D52E9B65984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4A449490693E6C995BF6D52E9B76D8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_F9683919EFCF79397B776D52E9B7EF92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4A449490693E6C995BF6D52E9B76D8D" xlink:to="loc_us-gaap_EmployeeStockOptionMember_F9683919EFCF79397B776D52E9B7EF92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_E57AF9FA462BDF24F9806D52E9B7FDD5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A37D537168FC2631BB636D52E9B6B68A" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_E57AF9FA462BDF24F9806D52E9B7FDD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D5174071889B94C41D236D52E9B76728_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E57AF9FA462BDF24F9806D52E9B7FDD5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_D5174071889B94C41D236D52E9B76728_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D5174071889B94C41D236D52E9B76728" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E57AF9FA462BDF24F9806D52E9B7FDD5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_D5174071889B94C41D236D52E9B76728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9A3F78E83DDAF94383416D52E9B8BD46" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D5174071889B94C41D236D52E9B76728" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9A3F78E83DDAF94383416D52E9B8BD46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9DE0FCC49AFA4099BDD76D52E9B8EB66" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D5174071889B94C41D236D52E9B76728" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9DE0FCC49AFA4099BDD76D52E9B8EB66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_720A5EAA695713175DA46D52E9B8D0CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69482650FDEAD6C154116D52E9B872D0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_720A5EAA695713175DA46D52E9B8D0CF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB49971B6B7754989465865C0E0F7241" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BA443E41EFE503DE841865C0E0CDA2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB49971B6B7754989465865C0E0F7241" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BA443E41EFE503DE841865C0E0CDA2D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_B0632701CF95A2384886865C0E0C207D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BA443E41EFE503DE841865C0E0CDA2D" xlink:to="loc_dei_LegalEntityAxis_B0632701CF95A2384886865C0E0C207D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_203CF7377A77E2D5394A865C0E0C49AA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_B0632701CF95A2384886865C0E0C207D" xlink:to="loc_dei_EntityDomain_203CF7377A77E2D5394A865C0E0C49AA_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_203CF7377A77E2D5394A865C0E0C49AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_B0632701CF95A2384886865C0E0C207D" xlink:to="loc_dei_EntityDomain_203CF7377A77E2D5394A865C0E0C49AA" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PrivateDareMember" xlink:label="loc_dare_PrivateDareMember_0BDA779B5B444FE258BA865C0E0D5053" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_203CF7377A77E2D5394A865C0E0C49AA" xlink:to="loc_dare_PrivateDareMember_0BDA779B5B444FE258BA865C0E0D5053" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_A265480F395B83DDBC55865C0E0DA7DF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BA443E41EFE503DE841865C0E0CDA2D" xlink:to="loc_us-gaap_PlanNameAxis_A265480F395B83DDBC55865C0E0DA7DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_F2A0F307C5F736625AF5865C0E0D7EA4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_A265480F395B83DDBC55865C0E0DA7DF" xlink:to="loc_us-gaap_PlanNameDomain_F2A0F307C5F736625AF5865C0E0D7EA4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_F2A0F307C5F736625AF5865C0E0D7EA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_A265480F395B83DDBC55865C0E0DA7DF" xlink:to="loc_us-gaap_PlanNameDomain_F2A0F307C5F736625AF5865C0E0D7EA4" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_TwoThousandAndFifteenStockIncentivePlanMember" xlink:label="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_A09A6196A725CD7522BD865C0E0D9B1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_F2A0F307C5F736625AF5865C0E0D7EA4" xlink:to="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_A09A6196A725CD7522BD865C0E0D9B1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_12F9273A4AE1D453DD5F865C0E0E8D25" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BA443E41EFE503DE841865C0E0CDA2D" xlink:to="loc_us-gaap_AwardTypeAxis_12F9273A4AE1D453DD5F865C0E0E8D25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1C3AE6BDC8E4BF34F01B865C0E0EB8B5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_12F9273A4AE1D453DD5F865C0E0E8D25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1C3AE6BDC8E4BF34F01B865C0E0EB8B5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1C3AE6BDC8E4BF34F01B865C0E0EB8B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_12F9273A4AE1D453DD5F865C0E0E8D25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1C3AE6BDC8E4BF34F01B865C0E0EB8B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C0D2D786D7C1A5363C62865C0E0FD86C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1C3AE6BDC8E4BF34F01B865C0E0EB8B5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C0D2D786D7C1A5363C62865C0E0FD86C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB49971B6B7754989465865C0E0F7241" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7B91F1F506B83CD2AECB865C0E0FFDBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7B91F1F506B83CD2AECB865C0E0FFDBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EDB7F6D4101931318769865C0E108ABE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EDB7F6D4101931318769865C0E108ABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2B03E75D60AAB7B38FC3865C0E10581F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2B03E75D60AAB7B38FC3865C0E10581F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5868494C6DFFBA84B9E6865C0E105BC0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5868494C6DFFBA84B9E6865C0E105BC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_DB654CF8009A0FA37AE4865C0E10A77A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_DB654CF8009A0FA37AE4865C0E10A77A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B95FC75F6B5EB2296166865C0E110005" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B95FC75F6B5EB2296166865C0E110005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB49971B6B7754989465865C0E0F7241" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5D0F747F18C3941C0547865C0E11D9BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5D0F747F18C3941C0547865C0E11D9BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7C3903BFC828FF19F5DA865C0E11799D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7C3903BFC828FF19F5DA865C0E11799D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_26EF1CFE6198804D4251865C0E11BA73" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_26EF1CFE6198804D4251865C0E11BA73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_64F83E078EA7BFE8FE96865C0E124874" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_64F83E078EA7BFE8FE96865C0E124874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_A0499CB2AF341A040FCE865C0E12BD3E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_A0499CB2AF341A040FCE865C0E12BD3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E7791DF4D39EF7B74E8C865C0E129A70" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E7791DF4D39EF7B74E8C865C0E129A70" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="dare-20190630.xsd#dare_StockholdersEquityLineItems" xlink:label="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:type="locator" />
    <link:loc xlink:href="dare-20190630.xsd#dare_StockholdersEquityTable" xlink:label="loc_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C4D21A9C27F1C21938E08B6FD36D8181" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C4D21A9C27F1C21938E08B6FD36D8181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_A22A502617E824B33A8E8B6FD36DBDDA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C4D21A9C27F1C21938E08B6FD36D8181" xlink:to="loc_us-gaap_TypeOfAdoptionMember_A22A502617E824B33A8E8B6FD36DBDDA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_A22A502617E824B33A8E8B6FD36DBDDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C4D21A9C27F1C21938E08B6FD36D8181" xlink:to="loc_us-gaap_TypeOfAdoptionMember_A22A502617E824B33A8E8B6FD36DBDDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201711Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201711Member_A0146588574C7621B0D28B6FD36DC100" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A22A502617E824B33A8E8B6FD36DBDDA" xlink:to="loc_us-gaap_AccountingStandardsUpdate201711Member_A0146588574C7621B0D28B6FD36DC100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_323D23335B44D181BC6F8B6FD36D93C8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_323D23335B44D181BC6F8B6FD36D93C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_EAC28790EB64CA571DEB8B6FD36D8B1B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_323D23335B44D181BC6F8B6FD36D93C8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_EAC28790EB64CA571DEB8B6FD36D8B1B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_EAC28790EB64CA571DEB8B6FD36D8B1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_323D23335B44D181BC6F8B6FD36D93C8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_EAC28790EB64CA571DEB8B6FD36D8B1B" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:label="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_E965608F9764FB087E408B6FD36DD8A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EAC28790EB64CA571DEB8B6FD36D8B1B" xlink:to="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_E965608F9764FB087E408B6FD36DD8A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_714ED3D5617F28201EAF8B6FD36DCA40" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_714ED3D5617F28201EAF8B6FD36DCA40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743F5CB0BDF0B773F4E68B6FD36D0179_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_714ED3D5617F28201EAF8B6FD36DCA40" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743F5CB0BDF0B773F4E68B6FD36D0179_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743F5CB0BDF0B773F4E68B6FD36D0179" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_714ED3D5617F28201EAF8B6FD36DCA40" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743F5CB0BDF0B773F4E68B6FD36D0179" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_8E0E9910F744357DE0388B6FD36D788D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743F5CB0BDF0B773F4E68B6FD36D0179" xlink:to="loc_us-gaap_OverAllotmentOptionMember_8E0E9910F744357DE0388B6FD36D788D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PublicStockOfferingMember" xlink:label="loc_dare_PublicStockOfferingMember_B7A0DA44E04EE01018C58B6FD36D31F8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743F5CB0BDF0B773F4E68B6FD36D0179" xlink:to="loc_dare_PublicStockOfferingMember_B7A0DA44E04EE01018C58B6FD36D31F8" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_dare_GrossProceedsFromIssuanceOfCommonStock_5AF9D10A9736F08F38638B6FD36D4F27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_dare_GrossProceedsFromIssuanceOfCommonStock_5AF9D10A9736F08F38638B6FD36D4F27" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PercentageOfAggregateCommission" xlink:label="loc_dare_PercentageOfAggregateCommission_F6F73243D93E3C2980088B6FD36D9837" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_dare_PercentageOfAggregateCommission_F6F73243D93E3C2980088B6FD36D9837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7D931EBDCEE712349F3C8B6FD36DCDF2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7D931EBDCEE712349F3C8B6FD36DCDF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_8C3D3A6C3F9CE19D44FA8B6FD36D0206" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_8C3D3A6C3F9CE19D44FA8B6FD36D0206" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_87AA5F3BA749CB1A18548B6FD36D4777" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_87AA5F3BA749CB1A18548B6FD36D4777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_10DA379D4E459D6FC60E8B6FD36D25C4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_10DA379D4E459D6FC60E8B6FD36D25C4" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" xlink:label="loc_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_A8C439607C34AC537A8B8B6FD36D6A55" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_A8C439607C34AC537A8B8B6FD36D6A55" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_UnderwritersOptionToPurchaseAdditionalShares" xlink:label="loc_dare_UnderwritersOptionToPurchaseAdditionalShares_E475BDC2875473EA85A58B6FD36DF2C2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_dare_UnderwritersOptionToPurchaseAdditionalShares_E475BDC2875473EA85A58B6FD36DF2C2" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_GrossProceedsFromOfferingOfCommonStockAndWarrants" xlink:label="loc_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_496FA365D812DD499E298B6FD36D0025" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_496FA365D812DD499E298B6FD36D0025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_FD29875E61840CFADAF68B6FD36D09D1" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_FD29875E61840CFADAF68B6FD36D09D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5F4F281DD89E3CD706758B6FD36D0CA0" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5F4F281DD89E3CD706758B6FD36D0CA0" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:label="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_30857EFADD67571259728B6FD36DCE36" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_30857EFADD67571259728B6FD36DCE36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_09F24EB06E9082A95BAB8B6FD36D5D21" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_09F24EB06E9082A95BAB8B6FD36D5D21" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NumberOfCommonStockWarrantsExercised" xlink:label="loc_dare_NumberOfCommonStockWarrantsExercised_F3F6567BFBB804B7728E8B6FD36D38E7" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_dare_NumberOfCommonStockWarrantsExercised_F3F6567BFBB804B7728E8B6FD36D38E7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_BD37FE611C764357EC6C6D52E99A27E3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_894F467B9053467DE1956D52E998F00A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BD37FE611C764357EC6C6D52E99A27E3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_894F467B9053467DE1956D52E998F00A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5EA6D1172A73F93A42A86D52E998D5FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_894F467B9053467DE1956D52E998F00A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5EA6D1172A73F93A42A86D52E998D5FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5EA6D1172A73F93A42A86D52E998D5FA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5EA6D1172A73F93A42A86D52E998D5FA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" xlink:label="loc_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_0024FA9F0FCE3B3D334B6D52E999D19B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:to="loc_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_0024FA9F0FCE3B3D334B6D52E999D19B" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" xlink:label="loc_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_48F387ED3BCC11EAAB356D52E9995787" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:to="loc_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_48F387ED3BCC11EAAB356D52E9995787" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember" xlink:label="loc_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_EC1FF5ACCCD5D5F45B706D52E9998301" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:to="loc_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_EC1FF5ACCCD5D5F45B706D52E9998301" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:label="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_D07B800AD32050182F536D52E99A4403" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:to="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_D07B800AD32050182F536D52E99A4403" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:label="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C0BDD88798ECE3558C866D52E99A55BA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:to="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C0BDD88798ECE3558C866D52E99A55BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_529FB235BCCE9DDDF0606D52E99A9280" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BD37FE611C764357EC6C6D52E99A27E3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_529FB235BCCE9DDDF0606D52E99A9280" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_611770AE143C190FE3946D52E99A1C2B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BD37FE611C764357EC6C6D52E99A27E3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_611770AE143C190FE3946D52E99A1C2B" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:label="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_C89B1CD0EB99D3470BC46D52E99AF597" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BD37FE611C764357EC6C6D52E99A27E3" xlink:to="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_C89B1CD0EB99D3470BC46D52E99AF597" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="dare-20190630.xsd#dare_SignificantAccountingPoliciesLineItems" xlink:label="loc_dare_SignificantAccountingPoliciesLineItems_AB1FA72B72255C4BBD63C9710624E4F1" xlink:type="locator" />
    <link:loc xlink:href="dare-20190630.xsd#dare_SignificantAccountingPoliciesTable" xlink:label="loc_dare_SignificantAccountingPoliciesTable_40577E5A38E154DCAD75C5B130F9614D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_AB1FA72B72255C4BBD63C9710624E4F1" xlink:to="loc_dare_SignificantAccountingPoliciesTable_40577E5A38E154DCAD75C5B130F9614D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_209AC45F5E755D4099BC7980989D7CAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_SignificantAccountingPoliciesTable_40577E5A38E154DCAD75C5B130F9614D" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_209AC45F5E755D4099BC7980989D7CAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0_1D306014DC86566A9D92F5030596FCA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_209AC45F5E755D4099BC7980989D7CAF" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0_1D306014DC86566A9D92F5030596FCA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_CFC94E094EDC5E2C97061DE81812010D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_209AC45F5E755D4099BC7980989D7CAF" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_CFC94E094EDC5E2C97061DE81812010D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1EDEC70169415366995BBC3415215316" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_CFC94E094EDC5E2C97061DE81812010D" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1EDEC70169415366995BBC3415215316" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B6C4AA5F53135D578EB929FDCDC002F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_AB1FA72B72255C4BBD63C9710624E4F1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B6C4AA5F53135D578EB929FDCDC002F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_E29D27230F9559618B917803F6FF7BFE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_AB1FA72B72255C4BBD63C9710624E4F1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_E29D27230F9559618B917803F6FF7BFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_8607D7D599C95535911B7476F183D0F3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_AB1FA72B72255C4BBD63C9710624E4F1" xlink:to="loc_us-gaap_OperatingLeaseLiability_8607D7D599C95535911B7476F183D0F3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>dare-20190630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40205D1A594686018594865C0E0C98F6_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40205D1A594686018594865C0E0C98F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40205D1A594686018594865C0E0C98F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40205D1A594686018594865C0E0C98F6" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40205D1A594686018594865C0E0C98F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BA443E41EFE503DE841865C0E0CDA2D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BA443E41EFE503DE841865C0E0CDA2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BA443E41EFE503DE841865C0E0CDA2D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BA443E41EFE503DE841865C0E0CDA2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BA443E41EFE503DE841865C0E0CDA2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BA443E41EFE503DE841865C0E0CDA2D" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BA443E41EFE503DE841865C0E0CDA2D" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_B0632701CF95A2384886865C0E0C207D_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_B0632701CF95A2384886865C0E0C207D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_B0632701CF95A2384886865C0E0C207D_label_en-US" xlink:label="lab_dei_LegalEntityAxis_B0632701CF95A2384886865C0E0C207D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_B0632701CF95A2384886865C0E0C207D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_B0632701CF95A2384886865C0E0C207D" xlink:to="lab_dei_LegalEntityAxis_B0632701CF95A2384886865C0E0C207D" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_203CF7377A77E2D5394A865C0E0C49AA_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_203CF7377A77E2D5394A865C0E0C49AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_203CF7377A77E2D5394A865C0E0C49AA_label_en-US" xlink:label="lab_dei_EntityDomain_203CF7377A77E2D5394A865C0E0C49AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_203CF7377A77E2D5394A865C0E0C49AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_203CF7377A77E2D5394A865C0E0C49AA" xlink:to="lab_dei_EntityDomain_203CF7377A77E2D5394A865C0E0C49AA" xlink:type="arc" />
    <link:label id="lab_dare_PrivateDareMember_0BDA779B5B444FE258BA865C0E0D5053_terseLabel_en-US" xlink:label="lab_dare_PrivateDareMember_0BDA779B5B444FE258BA865C0E0D5053" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Dare</link:label>
    <link:label id="lab_dare_PrivateDareMember_0BDA779B5B444FE258BA865C0E0D5053_label_en-US" xlink:label="lab_dare_PrivateDareMember_0BDA779B5B444FE258BA865C0E0D5053" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Dare [Member]</link:label>
    <link:label id="lab_dare_PrivateDareMember_0BDA779B5B444FE258BA865C0E0D5053_documentation_en-US" xlink:label="lab_dare_PrivateDareMember_0BDA779B5B444FE258BA865C0E0D5053" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Dare.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_PrivateDareMember" xlink:label="loc_dare_PrivateDareMember_0BDA779B5B444FE258BA865C0E0D5053" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PrivateDareMember_0BDA779B5B444FE258BA865C0E0D5053" xlink:to="lab_dare_PrivateDareMember_0BDA779B5B444FE258BA865C0E0D5053" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_A265480F395B83DDBC55865C0E0DA7DF_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_A265480F395B83DDBC55865C0E0DA7DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_A265480F395B83DDBC55865C0E0DA7DF_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_A265480F395B83DDBC55865C0E0DA7DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_A265480F395B83DDBC55865C0E0DA7DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_A265480F395B83DDBC55865C0E0DA7DF" xlink:to="lab_us-gaap_PlanNameAxis_A265480F395B83DDBC55865C0E0DA7DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_F2A0F307C5F736625AF5865C0E0D7EA4_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_F2A0F307C5F736625AF5865C0E0D7EA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_F2A0F307C5F736625AF5865C0E0D7EA4_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_F2A0F307C5F736625AF5865C0E0D7EA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_F2A0F307C5F736625AF5865C0E0D7EA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_F2A0F307C5F736625AF5865C0E0D7EA4" xlink:to="lab_us-gaap_PlanNameDomain_F2A0F307C5F736625AF5865C0E0D7EA4" xlink:type="arc" />
    <link:label id="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember_A09A6196A725CD7522BD865C0E0D9B1A_terseLabel_en-US" xlink:label="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember_A09A6196A725CD7522BD865C0E0D9B1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 Stock Incentive Plan</link:label>
    <link:label id="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember_A09A6196A725CD7522BD865C0E0D9B1A_label_en-US" xlink:label="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember_A09A6196A725CD7522BD865C0E0D9B1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Fifteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember_A09A6196A725CD7522BD865C0E0D9B1A_documentation_en-US" xlink:label="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember_A09A6196A725CD7522BD865C0E0D9B1A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand And Fifteen Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_TwoThousandAndFifteenStockIncentivePlanMember" xlink:label="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_A09A6196A725CD7522BD865C0E0D9B1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_A09A6196A725CD7522BD865C0E0D9B1A" xlink:to="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember_A09A6196A725CD7522BD865C0E0D9B1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_12F9273A4AE1D453DD5F865C0E0E8D25_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_12F9273A4AE1D453DD5F865C0E0E8D25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_12F9273A4AE1D453DD5F865C0E0E8D25_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_12F9273A4AE1D453DD5F865C0E0E8D25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_12F9273A4AE1D453DD5F865C0E0E8D25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_12F9273A4AE1D453DD5F865C0E0E8D25" xlink:to="lab_us-gaap_AwardTypeAxis_12F9273A4AE1D453DD5F865C0E0E8D25" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1C3AE6BDC8E4BF34F01B865C0E0EB8B5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1C3AE6BDC8E4BF34F01B865C0E0EB8B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1C3AE6BDC8E4BF34F01B865C0E0EB8B5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1C3AE6BDC8E4BF34F01B865C0E0EB8B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1C3AE6BDC8E4BF34F01B865C0E0EB8B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1C3AE6BDC8E4BF34F01B865C0E0EB8B5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1C3AE6BDC8E4BF34F01B865C0E0EB8B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_C0D2D786D7C1A5363C62865C0E0FD86C_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_C0D2D786D7C1A5363C62865C0E0FD86C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_C0D2D786D7C1A5363C62865C0E0FD86C_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_C0D2D786D7C1A5363C62865C0E0FD86C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C0D2D786D7C1A5363C62865C0E0FD86C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_C0D2D786D7C1A5363C62865C0E0FD86C" xlink:to="lab_us-gaap_EmployeeStockOptionMember_C0D2D786D7C1A5363C62865C0E0FD86C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB49971B6B7754989465865C0E0F7241_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB49971B6B7754989465865C0E0F7241" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB49971B6B7754989465865C0E0F7241_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB49971B6B7754989465865C0E0F7241" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB49971B6B7754989465865C0E0F7241" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB49971B6B7754989465865C0E0F7241" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB49971B6B7754989465865C0E0F7241" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7B91F1F506B83CD2AECB865C0E0FFDBC_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7B91F1F506B83CD2AECB865C0E0FFDBC" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7B91F1F506B83CD2AECB865C0E0FFDBC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7B91F1F506B83CD2AECB865C0E0FFDBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7B91F1F506B83CD2AECB865C0E0FFDBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7B91F1F506B83CD2AECB865C0E0FFDBC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7B91F1F506B83CD2AECB865C0E0FFDBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EDB7F6D4101931318769865C0E108ABE_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EDB7F6D4101931318769865C0E108ABE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EDB7F6D4101931318769865C0E108ABE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EDB7F6D4101931318769865C0E108ABE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EDB7F6D4101931318769865C0E108ABE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EDB7F6D4101931318769865C0E108ABE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EDB7F6D4101931318769865C0E108ABE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2B03E75D60AAB7B38FC3865C0E10581F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2B03E75D60AAB7B38FC3865C0E10581F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2B03E75D60AAB7B38FC3865C0E10581F_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2B03E75D60AAB7B38FC3865C0E10581F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2B03E75D60AAB7B38FC3865C0E10581F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2B03E75D60AAB7B38FC3865C0E10581F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2B03E75D60AAB7B38FC3865C0E10581F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5868494C6DFFBA84B9E6865C0E105BC0_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5868494C6DFFBA84B9E6865C0E105BC0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Canceled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5868494C6DFFBA84B9E6865C0E105BC0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5868494C6DFFBA84B9E6865C0E105BC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5868494C6DFFBA84B9E6865C0E105BC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5868494C6DFFBA84B9E6865C0E105BC0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5868494C6DFFBA84B9E6865C0E105BC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_DB654CF8009A0FA37AE4865C0E10A77A_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_DB654CF8009A0FA37AE4865C0E10A77A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_DB654CF8009A0FA37AE4865C0E10A77A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_DB654CF8009A0FA37AE4865C0E10A77A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_DB654CF8009A0FA37AE4865C0E10A77A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_DB654CF8009A0FA37AE4865C0E10A77A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_DB654CF8009A0FA37AE4865C0E10A77A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_93D22FAF60337B8881E2865C0E10E746_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_93D22FAF60337B8881E2865C0E10E746" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_93D22FAF60337B8881E2865C0E10E746" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_93D22FAF60337B8881E2865C0E10E746" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_93D22FAF60337B8881E2865C0E10E746" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B95FC75F6B5EB2296166865C0E110005_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B95FC75F6B5EB2296166865C0E110005" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B95FC75F6B5EB2296166865C0E110005_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B95FC75F6B5EB2296166865C0E110005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B95FC75F6B5EB2296166865C0E110005" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B95FC75F6B5EB2296166865C0E110005" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B95FC75F6B5EB2296166865C0E110005" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5D0F747F18C3941C0547865C0E11D9BC_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5D0F747F18C3941C0547865C0E11D9BC" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5D0F747F18C3941C0547865C0E11D9BC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5D0F747F18C3941C0547865C0E11D9BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5D0F747F18C3941C0547865C0E11D9BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5D0F747F18C3941C0547865C0E11D9BC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5D0F747F18C3941C0547865C0E11D9BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7C3903BFC828FF19F5DA865C0E11799D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7C3903BFC828FF19F5DA865C0E11799D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7C3903BFC828FF19F5DA865C0E11799D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7C3903BFC828FF19F5DA865C0E11799D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7C3903BFC828FF19F5DA865C0E11799D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7C3903BFC828FF19F5DA865C0E11799D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7C3903BFC828FF19F5DA865C0E11799D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_26EF1CFE6198804D4251865C0E11BA73_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_26EF1CFE6198804D4251865C0E11BA73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_26EF1CFE6198804D4251865C0E11BA73_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_26EF1CFE6198804D4251865C0E11BA73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_26EF1CFE6198804D4251865C0E11BA73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_26EF1CFE6198804D4251865C0E11BA73" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_26EF1CFE6198804D4251865C0E11BA73" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_64F83E078EA7BFE8FE96865C0E124874_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_64F83E078EA7BFE8FE96865C0E124874" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canceled/forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_64F83E078EA7BFE8FE96865C0E124874_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_64F83E078EA7BFE8FE96865C0E124874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_64F83E078EA7BFE8FE96865C0E124874" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_64F83E078EA7BFE8FE96865C0E124874" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_64F83E078EA7BFE8FE96865C0E124874" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_A0499CB2AF341A040FCE865C0E12BD3E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_A0499CB2AF341A040FCE865C0E12BD3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_A0499CB2AF341A040FCE865C0E12BD3E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_A0499CB2AF341A040FCE865C0E12BD3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_A0499CB2AF341A040FCE865C0E12BD3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_A0499CB2AF341A040FCE865C0E12BD3E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_A0499CB2AF341A040FCE865C0E12BD3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3C8273D8CBA5A4824CF5865C0E12125A_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3C8273D8CBA5A4824CF5865C0E12125A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding ending balance (in usd per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3C8273D8CBA5A4824CF5865C0E12125A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3C8273D8CBA5A4824CF5865C0E12125A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3C8273D8CBA5A4824CF5865C0E12125A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E7791DF4D39EF7B74E8C865C0E129A70_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E7791DF4D39EF7B74E8C865C0E129A70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E7791DF4D39EF7B74E8C865C0E129A70_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E7791DF4D39EF7B74E8C865C0E129A70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E7791DF4D39EF7B74E8C865C0E129A70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E7791DF4D39EF7B74E8C865C0E129A70" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E7791DF4D39EF7B74E8C865C0E129A70" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_14B5BFFB0214C67A644B6D52E9986F8C_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_14B5BFFB0214C67A644B6D52E9986F8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_14B5BFFB0214C67A644B6D52E9986F8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_14B5BFFB0214C67A644B6D52E9986F8C" xlink:to="lab_us-gaap_EquityAbstract_14B5BFFB0214C67A644B6D52E9986F8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_894F467B9053467DE1956D52E998F00A_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_894F467B9053467DE1956D52E998F00A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_894F467B9053467DE1956D52E998F00A_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_894F467B9053467DE1956D52E998F00A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_894F467B9053467DE1956D52E998F00A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_894F467B9053467DE1956D52E998F00A" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_894F467B9053467DE1956D52E998F00A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_5EA6D1172A73F93A42A86D52E998D5FA_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_5EA6D1172A73F93A42A86D52E998D5FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_5EA6D1172A73F93A42A86D52E998D5FA_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_5EA6D1172A73F93A42A86D52E998D5FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5EA6D1172A73F93A42A86D52E998D5FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5EA6D1172A73F93A42A86D52E998D5FA" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_5EA6D1172A73F93A42A86D52E998D5FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:type="arc" />
    <link:label id="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_0024FA9F0FCE3B3D334B6D52E999D19B_terseLabel_en-US" xlink:label="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_0024FA9F0FCE3B3D334B6D52E999D19B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring on December 1, 2021</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_0024FA9F0FCE3B3D334B6D52E999D19B_label_en-US" xlink:label="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_0024FA9F0FCE3B3D334B6D52E999D19B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring On December One Two Thousand Twenty One [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_0024FA9F0FCE3B3D334B6D52E999D19B_documentation_en-US" xlink:label="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_0024FA9F0FCE3B3D334B6D52E999D19B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants expiring on december one two thousand twenty one.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" xlink:label="loc_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_0024FA9F0FCE3B3D334B6D52E999D19B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_0024FA9F0FCE3B3D334B6D52E999D19B" xlink:to="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_0024FA9F0FCE3B3D334B6D52E999D19B" xlink:type="arc" />
    <link:label id="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_48F387ED3BCC11EAAB356D52E9995787_terseLabel_en-US" xlink:label="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_48F387ED3BCC11EAAB356D52E9995787" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring on December 6, 2021</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_48F387ED3BCC11EAAB356D52E9995787_label_en-US" xlink:label="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_48F387ED3BCC11EAAB356D52E9995787" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring On December Six Two Thousand Twenty One [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_48F387ED3BCC11EAAB356D52E9995787_documentation_en-US" xlink:label="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_48F387ED3BCC11EAAB356D52E9995787" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants expiring on december six two thousand twenty one.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" xlink:label="loc_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_48F387ED3BCC11EAAB356D52E9995787" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_48F387ED3BCC11EAAB356D52E9995787" xlink:to="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_48F387ED3BCC11EAAB356D52E9995787" xlink:type="arc" />
    <link:label id="lab_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_EC1FF5ACCCD5D5F45B706D52E9998301_terseLabel_en-US" xlink:label="lab_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_EC1FF5ACCCD5D5F45B706D52E9998301" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring on January 8, 2020</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_EC1FF5ACCCD5D5F45B706D52E9998301_label_en-US" xlink:label="lab_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_EC1FF5ACCCD5D5F45B706D52E9998301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring On January Eight Two Thousand Twenty [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_EC1FF5ACCCD5D5F45B706D52E9998301_documentation_en-US" xlink:label="lab_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_EC1FF5ACCCD5D5F45B706D52E9998301" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants expiring on january eight two thousand twenty.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember" xlink:label="loc_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_EC1FF5ACCCD5D5F45B706D52E9998301" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_EC1FF5ACCCD5D5F45B706D52E9998301" xlink:to="lab_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_EC1FF5ACCCD5D5F45B706D52E9998301" xlink:type="arc" />
    <link:label id="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_D07B800AD32050182F536D52E99A4403_terseLabel_en-US" xlink:label="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_D07B800AD32050182F536D52E99A4403" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring on April 4, 2026</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_D07B800AD32050182F536D52E99A4403_label_en-US" xlink:label="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_D07B800AD32050182F536D52E99A4403" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring On April Four Two Thousand Twenty Six [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_D07B800AD32050182F536D52E99A4403_documentation_en-US" xlink:label="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_D07B800AD32050182F536D52E99A4403" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants expiring on april four two thousand twenty six.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:label="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_D07B800AD32050182F536D52E99A4403" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_D07B800AD32050182F536D52E99A4403" xlink:to="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_D07B800AD32050182F536D52E99A4403" xlink:type="arc" />
    <link:label id="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C0BDD88798ECE3558C866D52E99A55BA_terseLabel_en-US" xlink:label="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C0BDD88798ECE3558C866D52E99A55BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring on February 15, 2023</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C0BDD88798ECE3558C866D52E99A55BA_label_en-US" xlink:label="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C0BDD88798ECE3558C866D52E99A55BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C0BDD88798ECE3558C866D52E99A55BA_documentation_en-US" xlink:label="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C0BDD88798ECE3558C866D52E99A55BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:label="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C0BDD88798ECE3558C866D52E99A55BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C0BDD88798ECE3558C866D52E99A55BA" xlink:to="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C0BDD88798ECE3558C866D52E99A55BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_BD37FE611C764357EC6C6D52E99A27E3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_BD37FE611C764357EC6C6D52E99A27E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_BD37FE611C764357EC6C6D52E99A27E3_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_BD37FE611C764357EC6C6D52E99A27E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_BD37FE611C764357EC6C6D52E99A27E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BD37FE611C764357EC6C6D52E99A27E3" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_BD37FE611C764357EC6C6D52E99A27E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_529FB235BCCE9DDDF0606D52E99A9280_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_529FB235BCCE9DDDF0606D52E99A9280" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Underlying Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_529FB235BCCE9DDDF0606D52E99A9280_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_529FB235BCCE9DDDF0606D52E99A9280" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_529FB235BCCE9DDDF0606D52E99A9280" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_529FB235BCCE9DDDF0606D52E99A9280" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_529FB235BCCE9DDDF0606D52E99A9280" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_611770AE143C190FE3946D52E99A1C2B_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_611770AE143C190FE3946D52E99A1C2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_611770AE143C190FE3946D52E99A1C2B_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_611770AE143C190FE3946D52E99A1C2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_611770AE143C190FE3946D52E99A1C2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_611770AE143C190FE3946D52E99A1C2B" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_611770AE143C190FE3946D52E99A1C2B" xlink:type="arc" />
    <link:label id="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_C89B1CD0EB99D3470BC46D52E99AF597_terseLabel_en-US" xlink:label="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_C89B1CD0EB99D3470BC46D52E99AF597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_C89B1CD0EB99D3470BC46D52E99AF597_label_en-US" xlink:label="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_C89B1CD0EB99D3470BC46D52E99AF597" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Rights Warrants Expiration Date</link:label>
    <link:label id="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_C89B1CD0EB99D3470BC46D52E99AF597_documentation_en-US" xlink:label="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_C89B1CD0EB99D3470BC46D52E99AF597" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of warrant or rights warrants expiration date.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:label="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_C89B1CD0EB99D3470BC46D52E99AF597" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_C89B1CD0EB99D3470BC46D52E99AF597" xlink:to="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_C89B1CD0EB99D3470BC46D52E99AF597" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_5D0E7B7B0D915F63682678071B324D6E_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_5D0E7B7B0D915F63682678071B324D6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_5D0E7B7B0D915F63682678071B324D6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5D0E7B7B0D915F63682678071B324D6E" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_5D0E7B7B0D915F63682678071B324D6E" xlink:type="arc" />
    <link:label id="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092_terseLabel_en-US" xlink:label="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Business Combination Reverse Merger [Table]</link:label>
    <link:label id="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092_label_en-US" xlink:label="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Business Combination Reverse Merger [Table]</link:label>
    <link:label id="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092_documentation_en-US" xlink:label="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of business combination reverse merger.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_ScheduleOfBusinessCombinationReverseMergerTable" xlink:label="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092" xlink:to="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_31D0CB3D18C15FFF496478071B349120_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_31D0CB3D18C15FFF496478071B349120" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_31D0CB3D18C15FFF496478071B349120_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_31D0CB3D18C15FFF496478071B349120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_31D0CB3D18C15FFF496478071B349120" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_31D0CB3D18C15FFF496478071B349120" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_31D0CB3D18C15FFF496478071B349120" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_B69EE32EB395B172742778071B3409FD_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_B69EE32EB395B172742778071B3409FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_B69EE32EB395B172742778071B3409FD_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_B69EE32EB395B172742778071B3409FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B69EE32EB395B172742778071B3409FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B69EE32EB395B172742778071B3409FD" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_B69EE32EB395B172742778071B3409FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5EFCDD3DD570538B187D78071B34F4B7_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5EFCDD3DD570538B187D78071B34F4B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5EFCDD3DD570538B187D78071B34F4B7_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5EFCDD3DD570538B187D78071B34F4B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5EFCDD3DD570538B187D78071B34F4B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5EFCDD3DD570538B187D78071B34F4B7" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5EFCDD3DD570538B187D78071B34F4B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_94AE358BA8FA391976FA78071B35F281_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_94AE358BA8FA391976FA78071B35F281" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_94AE358BA8FA391976FA78071B35F281_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_94AE358BA8FA391976FA78071B35F281" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_94AE358BA8FA391976FA78071B35F281" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_94AE358BA8FA391976FA78071B35F281" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_94AE358BA8FA391976FA78071B35F281" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_50AA83230792B766CB6E78071B35BD04_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_50AA83230792B766CB6E78071B35BD04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_50AA83230792B766CB6E78071B35BD04_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_50AA83230792B766CB6E78071B35BD04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_50AA83230792B766CB6E78071B35BD04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_50AA83230792B766CB6E78071B35BD04" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_50AA83230792B766CB6E78071B35BD04" xlink:type="arc" />
    <link:label id="lab_dare_PearTreePharmaceuticalsIncMember_E43C6D1B2DEFDA4BD42678071B3508D7_terseLabel_en-US" xlink:label="lab_dare_PearTreePharmaceuticalsIncMember_E43C6D1B2DEFDA4BD42678071B3508D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pear Tree Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_dare_PearTreePharmaceuticalsIncMember_E43C6D1B2DEFDA4BD42678071B3508D7_label_en-US" xlink:label="lab_dare_PearTreePharmaceuticalsIncMember_E43C6D1B2DEFDA4BD42678071B3508D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pear Tree Pharmaceuticals Inc [Member]</link:label>
    <link:label id="lab_dare_PearTreePharmaceuticalsIncMember_E43C6D1B2DEFDA4BD42678071B3508D7_documentation_en-US" xlink:label="lab_dare_PearTreePharmaceuticalsIncMember_E43C6D1B2DEFDA4BD42678071B3508D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pear Tree Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_PearTreePharmaceuticalsIncMember" xlink:label="loc_dare_PearTreePharmaceuticalsIncMember_E43C6D1B2DEFDA4BD42678071B3508D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PearTreePharmaceuticalsIncMember_E43C6D1B2DEFDA4BD42678071B3508D7" xlink:to="lab_dare_PearTreePharmaceuticalsIncMember_E43C6D1B2DEFDA4BD42678071B3508D7" xlink:type="arc" />
    <link:label id="lab_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA_terseLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination Reverse Merger [Line Items]</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA_label_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Reverse Merger [Line Items]</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA_documentation_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination reverse merger.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_BusinessCombinationReverseMergerLineItems" xlink:label="loc_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:to="lab_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:type="arc" />
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_91314AC76F46EC58227C78071B367392_terseLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_91314AC76F46EC58227C78071B367392" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_91314AC76F46EC58227C78071B367392_label_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_91314AC76F46EC58227C78071B367392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_91314AC76F46EC58227C78071B367392_documentation_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_91314AC76F46EC58227C78071B367392" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_91314AC76F46EC58227C78071B367392" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_91314AC76F46EC58227C78071B367392" xlink:to="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_91314AC76F46EC58227C78071B367392" xlink:type="arc" />
    <link:label id="lab_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_3EEE1C3BE117D05B931C78071B363A56_terseLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_3EEE1C3BE117D05B931C78071B363A56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized fair value of stock options</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_3EEE1C3BE117D05B931C78071B363A56_label_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_3EEE1C3BE117D05B931C78071B363A56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Reverse Merger Unamortized Fair Value Of Stock Options</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_3EEE1C3BE117D05B931C78071B363A56_documentation_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_3EEE1C3BE117D05B931C78071B363A56" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination reverse merger unamortized fair value of stock options.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions" xlink:label="loc_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_3EEE1C3BE117D05B931C78071B363A56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_3EEE1C3BE117D05B931C78071B363A56" xlink:to="lab_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_3EEE1C3BE117D05B931C78071B363A56" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_16AE243469526DBBAC9278071B361CA2_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_16AE243469526DBBAC9278071B361CA2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment charge</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_16AE243469526DBBAC9278071B361CA2_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_16AE243469526DBBAC9278071B361CA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_16AE243469526DBBAC9278071B361CA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_16AE243469526DBBAC9278071B361CA2" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_16AE243469526DBBAC9278071B361CA2" xlink:type="arc" />
    <link:label id="lab_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_17C634478ABBE254F63F78071B36F77D_terseLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_17C634478ABBE254F63F78071B36F77D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_17C634478ABBE254F63F78071B36F77D_label_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_17C634478ABBE254F63F78071B36F77D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Reverse Merger Stock Purchase Transaction Cost</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_17C634478ABBE254F63F78071B36F77D_documentation_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_17C634478ABBE254F63F78071B36F77D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination reverses merger stock purchase transaction cost.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost" xlink:label="loc_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_17C634478ABBE254F63F78071B36F77D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_17C634478ABBE254F63F78071B36F77D" xlink:to="lab_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_17C634478ABBE254F63F78071B36F77D" xlink:type="arc" />
    <link:label id="lab_dare_PotentialCashPaymentsToAcquireBusiness_968E61EDF481090A4BA678071B379F45_terseLabel_en-US" xlink:label="lab_dare_PotentialCashPaymentsToAcquireBusiness_968E61EDF481090A4BA678071B379F45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential cash payments to acquire business</link:label>
    <link:label id="lab_dare_PotentialCashPaymentsToAcquireBusiness_968E61EDF481090A4BA678071B379F45_label_en-US" xlink:label="lab_dare_PotentialCashPaymentsToAcquireBusiness_968E61EDF481090A4BA678071B379F45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Cash Payments To Acquire Business</link:label>
    <link:label id="lab_dare_PotentialCashPaymentsToAcquireBusiness_968E61EDF481090A4BA678071B379F45_documentation_en-US" xlink:label="lab_dare_PotentialCashPaymentsToAcquireBusiness_968E61EDF481090A4BA678071B379F45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Cash Payments To Acquire Business</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_PotentialCashPaymentsToAcquireBusiness" xlink:label="loc_dare_PotentialCashPaymentsToAcquireBusiness_968E61EDF481090A4BA678071B379F45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PotentialCashPaymentsToAcquireBusiness_968E61EDF481090A4BA678071B379F45" xlink:to="lab_dare_PotentialCashPaymentsToAcquireBusiness_968E61EDF481090A4BA678071B379F45" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_558AF06E9A39988580D378071B3637DA_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_558AF06E9A39988580D378071B3637DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration amount</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_558AF06E9A39988580D378071B3637DA_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_558AF06E9A39988580D378071B3637DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_558AF06E9A39988580D378071B3637DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_558AF06E9A39988580D378071B3637DA" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_558AF06E9A39988580D378071B3637DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_55FB50A9CEAF28AF60C8A2CAE899C09B_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_C72CBFCA958858BBAF465D9DCCABA0A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_C72CBFCA958858BBAF465D9DCCABA0A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_C72CBFCA958858BBAF465D9DCCABA0A3" xlink:to="lab_us-gaap_LeasesAbstract_C72CBFCA958858BBAF465D9DCCABA0A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1E9A5BEA833D05630757A2CBCDE0C7A2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_C114029E7B17513681D7960F75ED5594" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2019</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1E9A5BEA833D05630757A2CBCDE0C7A2_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_C114029E7B17513681D7960F75ED5594" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_C114029E7B17513681D7960F75ED5594" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_C114029E7B17513681D7960F75ED5594" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_C114029E7B17513681D7960F75ED5594" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_98FD05DB67D25A812E16A2CAE89DDC2E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E960AAE60F40556EA85F7349097F00F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_98FD05DB67D25A812E16A2CAE89DDC2E_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E960AAE60F40556EA85F7349097F00F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E960AAE60F40556EA85F7349097F00F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E960AAE60F40556EA85F7349097F00F2" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E960AAE60F40556EA85F7349097F00F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D077CEB697C13FF63BABA2CAE89EECA1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_040CAB722AC255B088BC89FEE170BB61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D077CEB697C13FF63BABA2CAE89EECA1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_040CAB722AC255B088BC89FEE170BB61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_040CAB722AC255B088BC89FEE170BB61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_040CAB722AC255B088BC89FEE170BB61" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_040CAB722AC255B088BC89FEE170BB61" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_09EBD0CC9160696B4F95A2CAE89ED71C_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_D086BA805C1F56C581CFAAB23A4D76CA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_09EBD0CC9160696B4F95A2CAE89ED71C_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_D086BA805C1F56C581CFAAB23A4D76CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_D086BA805C1F56C581CFAAB23A4D76CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_D086BA805C1F56C581CFAAB23A4D76CA" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_D086BA805C1F56C581CFAAB23A4D76CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1ED25BCFE2168B004790A2CAE89EBBFB_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2CBF8640BC605DFB9B88506239A08E63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Difference between future minimum lease payments and discounted operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1ED25BCFE2168B004790A2CAE89EBBFB_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2CBF8640BC605DFB9B88506239A08E63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2CBF8640BC605DFB9B88506239A08E63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2CBF8640BC605DFB9B88506239A08E63" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2CBF8640BC605DFB9B88506239A08E63" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_CA9AC81015DDC2FC3169A2CAE89E149B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_072D13B4B9EF5FA38754E9ABA2E065C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_CA9AC81015DDC2FC3169A2CAE89E149B_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_072D13B4B9EF5FA38754E9ABA2E065C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_072D13B4B9EF5FA38754E9ABA2E065C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_072D13B4B9EF5FA38754E9ABA2E065C6" xlink:to="lab_us-gaap_OperatingLeaseLiability_072D13B4B9EF5FA38754E9ABA2E065C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8AD112719732F8A08E325B0CFD6148C9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_0F170CA403F552A4AD51E9DB2E0294A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8AD112719732F8A08E325B0CFD6148C9_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_0F170CA403F552A4AD51E9DB2E0294A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_0F170CA403F552A4AD51E9DB2E0294A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_0F170CA403F552A4AD51E9DB2E0294A3" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_0F170CA403F552A4AD51E9DB2E0294A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7FBDC5C72597ACF2265F5B0CFC90854B_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1BCF9F685E4B58B6989B4E5A56E13C8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7FBDC5C72597ACF2265F5B0CFC90854B_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1BCF9F685E4B58B6989B4E5A56E13C8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1BCF9F685E4B58B6989B4E5A56E13C8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1BCF9F685E4B58B6989B4E5A56E13C8F" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1BCF9F685E4B58B6989B4E5A56E13C8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6B6BE9B4D81E6B05C7B66D52EA5B2091_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6B6BE9B4D81E6B05C7B66D52EA5B2091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6B6BE9B4D81E6B05C7B66D52EA5B2091" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6B6BE9B4D81E6B05C7B66D52EA5B2091" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6B6BE9B4D81E6B05C7B66D52EA5B2091" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_7CEFFF5465D919DDC8916D52EA5B734B_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_7CEFFF5465D919DDC8916D52EA5B734B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_7CEFFF5465D919DDC8916D52EA5B734B_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_7CEFFF5465D919DDC8916D52EA5B734B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7CEFFF5465D919DDC8916D52EA5B734B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_7CEFFF5465D919DDC8916D52EA5B734B" xlink:to="lab_srt_ProductOrServiceAxis_7CEFFF5465D919DDC8916D52EA5B734B" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_9EECFEEFA666A9A4A7506D52EA5B5235_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_9EECFEEFA666A9A4A7506D52EA5B5235" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_9EECFEEFA666A9A4A7506D52EA5B5235_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_9EECFEEFA666A9A4A7506D52EA5B5235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_9EECFEEFA666A9A4A7506D52EA5B5235" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_9EECFEEFA666A9A4A7506D52EA5B5235" xlink:to="lab_srt_ProductsAndServicesDomain_9EECFEEFA666A9A4A7506D52EA5B5235" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrantMember_91FA625B5AA197D1BBAA6D52EA5B54E6_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember_91FA625B5AA197D1BBAA6D52EA5B54E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_us-gaap_GrantMember_91FA625B5AA197D1BBAA6D52EA5B54E6_label_en-US" xlink:label="lab_us-gaap_GrantMember_91FA625B5AA197D1BBAA6D52EA5B54E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_91FA625B5AA197D1BBAA6D52EA5B54E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember_91FA625B5AA197D1BBAA6D52EA5B54E6" xlink:to="lab_us-gaap_GrantMember_91FA625B5AA197D1BBAA6D52EA5B54E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8A7BA3A6C2CC1CCB7E036D52EA5B2B80_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8A7BA3A6C2CC1CCB7E036D52EA5B2B80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8A7BA3A6C2CC1CCB7E036D52EA5B2B80_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8A7BA3A6C2CC1CCB7E036D52EA5B2B80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8A7BA3A6C2CC1CCB7E036D52EA5B2B80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8A7BA3A6C2CC1CCB7E036D52EA5B2B80" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8A7BA3A6C2CC1CCB7E036D52EA5B2B80" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_D728D2DFBCC6381234FA6D52EA5B7E8E_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_D728D2DFBCC6381234FA6D52EA5B7E8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_D728D2DFBCC6381234FA6D52EA5B7E8E_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_D728D2DFBCC6381234FA6D52EA5B7E8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_D728D2DFBCC6381234FA6D52EA5B7E8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_D728D2DFBCC6381234FA6D52EA5B7E8E" xlink:to="lab_us-gaap_RelatedPartyDomain_D728D2DFBCC6381234FA6D52EA5B7E8E" xlink:type="arc" />
    <link:label id="lab_dare_NationalInstitutesOfHealthMember_508495C41378D0FC8B686D52EA5B0048_terseLabel_en-US" xlink:label="lab_dare_NationalInstitutesOfHealthMember_508495C41378D0FC8B686D52EA5B0048" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">National Institutes Of Health</link:label>
    <link:label id="lab_dare_NationalInstitutesOfHealthMember_508495C41378D0FC8B686D52EA5B0048_label_en-US" xlink:label="lab_dare_NationalInstitutesOfHealthMember_508495C41378D0FC8B686D52EA5B0048" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institutes Of Health [Member]</link:label>
    <link:label id="lab_dare_NationalInstitutesOfHealthMember_508495C41378D0FC8B686D52EA5B0048_documentation_en-US" xlink:label="lab_dare_NationalInstitutesOfHealthMember_508495C41378D0FC8B686D52EA5B0048" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">National Institutes Of Health [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_NationalInstitutesOfHealthMember" xlink:label="loc_dare_NationalInstitutesOfHealthMember_508495C41378D0FC8B686D52EA5B0048" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NationalInstitutesOfHealthMember_508495C41378D0FC8B686D52EA5B0048" xlink:to="lab_dare_NationalInstitutesOfHealthMember_508495C41378D0FC8B686D52EA5B0048" xlink:type="arc" />
    <link:label id="lab_us-gaap_HealthCareTrustFundAxis_9024E697C6EEF9EEF45F6D52EA5BC69E_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareTrustFundAxis_9024E697C6EEF9EEF45F6D52EA5BC69E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Health Care Trust Fund</link:label>
    <link:label id="lab_us-gaap_HealthCareTrustFundAxis_9024E697C6EEF9EEF45F6D52EA5BC69E_label_en-US" xlink:label="lab_us-gaap_HealthCareTrustFundAxis_9024E697C6EEF9EEF45F6D52EA5BC69E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Health Care Trust Fund [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundAxis" xlink:label="loc_us-gaap_HealthCareTrustFundAxis_9024E697C6EEF9EEF45F6D52EA5BC69E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareTrustFundAxis_9024E697C6EEF9EEF45F6D52EA5BC69E" xlink:to="lab_us-gaap_HealthCareTrustFundAxis_9024E697C6EEF9EEF45F6D52EA5BC69E" xlink:type="arc" />
    <link:label id="lab_us-gaap_HealthCareTrustFundNameDomain_CEFC5E1803BF6046AD196D52EA5BA5F7_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareTrustFundNameDomain_CEFC5E1803BF6046AD196D52EA5BA5F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Health Care Trust Fund, Name</link:label>
    <link:label id="lab_us-gaap_HealthCareTrustFundNameDomain_CEFC5E1803BF6046AD196D52EA5BA5F7_label_en-US" xlink:label="lab_us-gaap_HealthCareTrustFundNameDomain_CEFC5E1803BF6046AD196D52EA5BA5F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Health Care Trust Fund, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain" xlink:label="loc_us-gaap_HealthCareTrustFundNameDomain_CEFC5E1803BF6046AD196D52EA5BA5F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareTrustFundNameDomain_CEFC5E1803BF6046AD196D52EA5BA5F7" xlink:to="lab_us-gaap_HealthCareTrustFundNameDomain_CEFC5E1803BF6046AD196D52EA5BA5F7" xlink:type="arc" />
    <link:label id="lab_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_12D40397C4A8580A15106D52EA632555_terseLabel_en-US" xlink:label="lab_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_12D40397C4A8580A15106D52EA632555" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eunice Kennedy Shriver National Institute Of Child Health And Human Development</link:label>
    <link:label id="lab_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_12D40397C4A8580A15106D52EA632555_label_en-US" xlink:label="lab_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_12D40397C4A8580A15106D52EA632555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eunice Kennedy Shriver National Institute Of Child Health And Human Development [Member]</link:label>
    <link:label id="lab_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_12D40397C4A8580A15106D52EA632555_documentation_en-US" xlink:label="lab_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_12D40397C4A8580A15106D52EA632555" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eunice Kennedy Shriver National Institute Of Child Health And Human Development [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember" xlink:label="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_12D40397C4A8580A15106D52EA632555" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_12D40397C4A8580A15106D52EA632555" xlink:to="lab_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_12D40397C4A8580A15106D52EA632555" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3558151A87F073611B636D52EA637928_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3558151A87F073611B636D52EA637928" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3558151A87F073611B636D52EA637928_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3558151A87F073611B636D52EA637928" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3558151A87F073611B636D52EA637928" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3558151A87F073611B636D52EA637928" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3558151A87F073611B636D52EA637928" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_B93577EA87FA69C5A75D6D52EA63811A_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_B93577EA87FA69C5A75D6D52EA63811A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_B93577EA87FA69C5A75D6D52EA63811A_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_B93577EA87FA69C5A75D6D52EA63811A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_B93577EA87FA69C5A75D6D52EA63811A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_B93577EA87FA69C5A75D6D52EA63811A" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_B93577EA87FA69C5A75D6D52EA63811A" xlink:type="arc" />
    <link:label id="lab_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_DF450E5A27D6B8FA488C6D52EA63B7AB_terseLabel_en-US" xlink:label="lab_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_DF450E5A27D6B8FA488C6D52EA63B7AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Phase Of Research And Availability Of Funds</link:label>
    <link:label id="lab_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_DF450E5A27D6B8FA488C6D52EA63B7AB_label_en-US" xlink:label="lab_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_DF450E5A27D6B8FA488C6D52EA63B7AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second Phase Of Research And Availability Of Funds [Member]</link:label>
    <link:label id="lab_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_DF450E5A27D6B8FA488C6D52EA63B7AB_documentation_en-US" xlink:label="lab_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_DF450E5A27D6B8FA488C6D52EA63B7AB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second Phase Of Research And Availability Of Funds [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember" xlink:label="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_DF450E5A27D6B8FA488C6D52EA63B7AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_DF450E5A27D6B8FA488C6D52EA63B7AB" xlink:to="lab_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_DF450E5A27D6B8FA488C6D52EA63B7AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9E4D11A2D13C7455FC476D52EA64E91D_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9E4D11A2D13C7455FC476D52EA64E91D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9E4D11A2D13C7455FC476D52EA64E91D_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9E4D11A2D13C7455FC476D52EA64E91D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9E4D11A2D13C7455FC476D52EA64E91D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9E4D11A2D13C7455FC476D52EA64E91D" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9E4D11A2D13C7455FC476D52EA64E91D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DF0FAA86DAD4E600AFA36D52EA64F688_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DF0FAA86DAD4E600AFA36D52EA64F688" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DF0FAA86DAD4E600AFA36D52EA64F688_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DF0FAA86DAD4E600AFA36D52EA64F688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DF0FAA86DAD4E600AFA36D52EA64F688" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DF0FAA86DAD4E600AFA36D52EA64F688" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DF0FAA86DAD4E600AFA36D52EA64F688" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C6383C3A9AD9746E849C6D52EA64D4EC_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C6383C3A9AD9746E849C6D52EA64D4EC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash flow from operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C6383C3A9AD9746E849C6D52EA64D4EC_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C6383C3A9AD9746E849C6D52EA64D4EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C6383C3A9AD9746E849C6D52EA64D4EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C6383C3A9AD9746E849C6D52EA64D4EC" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C6383C3A9AD9746E849C6D52EA64D4EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C69E4D2F7126695CD38E6D52EA64A59D_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C69E4D2F7126695CD38E6D52EA64A59D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from grant for notice of award</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C69E4D2F7126695CD38E6D52EA64A59D_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C69E4D2F7126695CD38E6D52EA64A59D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C69E4D2F7126695CD38E6D52EA64A59D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C69E4D2F7126695CD38E6D52EA64A59D" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C69E4D2F7126695CD38E6D52EA64A59D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrantsReceivable_D5E64146DD92E00E0C1D6D52EA642C56_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable_D5E64146DD92E00E0C1D6D52EA642C56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants receivable</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_D5E64146DD92E00E0C1D6D52EA642C56_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable_D5E64146DD92E00E0C1D6D52EA642C56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable_D5E64146DD92E00E0C1D6D52EA642C56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable_D5E64146DD92E00E0C1D6D52EA642C56" xlink:to="lab_us-gaap_GrantsReceivable_D5E64146DD92E00E0C1D6D52EA642C56" xlink:type="arc" />
    <link:label id="lab_dare_ReimbursementOfGrantExpensesReceivable_82D663772CEE1F2578786D52EA647669_terseLabel_en-US" xlink:label="lab_dare_ReimbursementOfGrantExpensesReceivable_82D663772CEE1F2578786D52EA647669" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement of grant expenses receivable</link:label>
    <link:label id="lab_dare_ReimbursementOfGrantExpensesReceivable_82D663772CEE1F2578786D52EA647669_label_en-US" xlink:label="lab_dare_ReimbursementOfGrantExpensesReceivable_82D663772CEE1F2578786D52EA647669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Of Grant Expenses Receivable</link:label>
    <link:label id="lab_dare_ReimbursementOfGrantExpensesReceivable_82D663772CEE1F2578786D52EA647669_documentation_en-US" xlink:label="lab_dare_ReimbursementOfGrantExpensesReceivable_82D663772CEE1F2578786D52EA647669" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement of grant expenses receivable.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_ReimbursementOfGrantExpensesReceivable" xlink:label="loc_dare_ReimbursementOfGrantExpensesReceivable_82D663772CEE1F2578786D52EA647669" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ReimbursementOfGrantExpensesReceivable_82D663772CEE1F2578786D52EA647669" xlink:to="lab_dare_ReimbursementOfGrantExpensesReceivable_82D663772CEE1F2578786D52EA647669" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_C078979A20F8332065206D52EA64F3C7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_C078979A20F8332065206D52EA64F3C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate net proceeds on sales of shares of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_C078979A20F8332065206D52EA64F3C7_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_C078979A20F8332065206D52EA64F3C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_C078979A20F8332065206D52EA64F3C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_C078979A20F8332065206D52EA64F3C7" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_C078979A20F8332065206D52EA64F3C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_863B1DB00957354336AF51507FDC3C5E_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7932F9E7D6055092815608A5A42F9353" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_863B1DB00957354336AF51507FDC3C5E_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7932F9E7D6055092815608A5A42F9353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7932F9E7D6055092815608A5A42F9353" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7932F9E7D6055092815608A5A42F9353" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7932F9E7D6055092815608A5A42F9353" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_A315F35486D3CC7A787D51507FDCAFF8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_701DB48913EF5357B77F7FDCD401B7C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_A315F35486D3CC7A787D51507FDCAFF8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_701DB48913EF5357B77F7FDCD401B7C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_701DB48913EF5357B77F7FDCD401B7C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_701DB48913EF5357B77F7FDCD401B7C2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_701DB48913EF5357B77F7FDCD401B7C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_FCE4F1390870D2BD510B51507FDCDA55_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9C1A5A001D4B54B88E70024467A72FE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_FCE4F1390870D2BD510B51507FDCDA55_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9C1A5A001D4B54B88E70024467A72FE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9C1A5A001D4B54B88E70024467A72FE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9C1A5A001D4B54B88E70024467A72FE5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9C1A5A001D4B54B88E70024467A72FE5" xlink:type="arc" />
    <link:label id="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_FB72D966C540A0AC1FA951507FDC9B8C_terseLabel_en-US" xlink:label="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_F826AB7414D552319F2D1DAC9D0346BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_FB72D966C540A0AC1FA951507FDC9B8C_label_en-US" xlink:label="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_F826AB7414D552319F2D1DAC9D0346BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate</link:label>
    <link:label id="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_FB72D966C540A0AC1FA951507FDC9B8C_documentation_en-US" xlink:label="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_F826AB7414D552319F2D1DAC9D0346BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by Share-based payment award fair value assumptions forfeiture rate.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:label="loc_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_F826AB7414D552319F2D1DAC9D0346BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_F826AB7414D552319F2D1DAC9D0346BD" xlink:to="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_F826AB7414D552319F2D1DAC9D0346BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E97C4932FE6B27D49D8651507FDDC2E3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A29D32EA88695212A0ED8830FAA82625" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E97C4932FE6B27D49D8651507FDDC2E3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A29D32EA88695212A0ED8830FAA82625" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A29D32EA88695212A0ED8830FAA82625" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A29D32EA88695212A0ED8830FAA82625" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A29D32EA88695212A0ED8830FAA82625" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0A9423F6C891813EEE251507FDD0D94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5C72EE9B53655FD4ABD53DC5D5534431" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average fair value of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0A9423F6C891813EEE251507FDD0D94_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5C72EE9B53655FD4ABD53DC5D5534431" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5C72EE9B53655FD4ABD53DC5D5534431" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5C72EE9B53655FD4ABD53DC5D5534431" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5C72EE9B53655FD4ABD53DC5D5534431" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_FFAC18AD972FBB106C0D865C0ED00189_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_FFAC18AD972FBB106C0D865C0ED00189" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_FFAC18AD972FBB106C0D865C0ED00189" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_FFAC18AD972FBB106C0D865C0ED00189" xlink:to="lab_us-gaap_IncomeStatementAbstract_FFAC18AD972FBB106C0D865C0ED00189" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_D848ECCCE25A8214DCB2865C0ED0F7C1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_D848ECCCE25A8214DCB2865C0ED0F7C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_D848ECCCE25A8214DCB2865C0ED0F7C1_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_D848ECCCE25A8214DCB2865C0ED0F7C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_D848ECCCE25A8214DCB2865C0ED0F7C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D848ECCCE25A8214DCB2865C0ED0F7C1" xlink:to="lab_us-gaap_OperatingExpensesAbstract_D848ECCCE25A8214DCB2865C0ED0F7C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_629622F28590C0B5D6A2865C0ED0282C_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_629622F28590C0B5D6A2865C0ED0282C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_629622F28590C0B5D6A2865C0ED0282C_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_629622F28590C0B5D6A2865C0ED0282C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_629622F28590C0B5D6A2865C0ED0282C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_629622F28590C0B5D6A2865C0ED0282C" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_629622F28590C0B5D6A2865C0ED0282C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_F1E45B9767D3A9D30683865C0ED16A74_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_F1E45B9767D3A9D30683865C0ED16A74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_F1E45B9767D3A9D30683865C0ED16A74_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_F1E45B9767D3A9D30683865C0ED16A74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_F1E45B9767D3A9D30683865C0ED16A74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_F1E45B9767D3A9D30683865C0ED16A74" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_F1E45B9767D3A9D30683865C0ED16A74" xlink:type="arc" />
    <link:label id="lab_dare_LicenseFee_1BB820BBA1EA3C425A26865C0ED1C108_terseLabel_en-US" xlink:label="lab_dare_LicenseFee_1BB820BBA1EA3C425A26865C0ED1C108" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License expenses</link:label>
    <link:label id="lab_dare_LicenseFee_1BB820BBA1EA3C425A26865C0ED1C108_label_en-US" xlink:label="lab_dare_LicenseFee_1BB820BBA1EA3C425A26865C0ED1C108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_dare_LicenseFee_1BB820BBA1EA3C425A26865C0ED1C108_documentation_en-US" xlink:label="lab_dare_LicenseFee_1BB820BBA1EA3C425A26865C0ED1C108" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseFee" xlink:label="loc_dare_LicenseFee_1BB820BBA1EA3C425A26865C0ED1C108" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseFee_1BB820BBA1EA3C425A26865C0ED1C108" xlink:to="lab_dare_LicenseFee_1BB820BBA1EA3C425A26865C0ED1C108" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_2B100490F037264070B2865C0ED10374_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_2B100490F037264070B2865C0ED10374" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2B100490F037264070B2865C0ED10374" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_2B100490F037264070B2865C0ED10374" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_2B100490F037264070B2865C0ED10374" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_7D42BB96CEA2211160C6865C0ED11288_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_7D42BB96CEA2211160C6865C0ED11288" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_7D42BB96CEA2211160C6865C0ED11288_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_7D42BB96CEA2211160C6865C0ED11288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7D42BB96CEA2211160C6865C0ED11288" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_7D42BB96CEA2211160C6865C0ED11288" xlink:to="lab_us-gaap_OperatingExpenses_7D42BB96CEA2211160C6865C0ED11288" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_FC79F388FABE172B0836865C0ED11ADA_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_FC79F388FABE172B0836865C0ED11ADA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_FC79F388FABE172B0836865C0ED11ADA_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_FC79F388FABE172B0836865C0ED11ADA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_FC79F388FABE172B0836865C0ED11ADA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_FC79F388FABE172B0836865C0ED11ADA" xlink:to="lab_us-gaap_OperatingIncomeLoss_FC79F388FABE172B0836865C0ED11ADA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_0C2351D81EEECAAA2416865C0ED1FDB4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_0C2351D81EEECAAA2416865C0ED1FDB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_0C2351D81EEECAAA2416865C0ED1FDB4_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_0C2351D81EEECAAA2416865C0ED1FDB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0C2351D81EEECAAA2416865C0ED1FDB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_0C2351D81EEECAAA2416865C0ED1FDB4" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_0C2351D81EEECAAA2416865C0ED1FDB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_1111AE1DB781476263A6865C0ED2AC92_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_1111AE1DB781476263A6865C0ED2AC92" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1111AE1DB781476263A6865C0ED2AC92_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_1111AE1DB781476263A6865C0ED2AC92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1111AE1DB781476263A6865C0ED2AC92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_1111AE1DB781476263A6865C0ED2AC92" xlink:to="lab_us-gaap_NetIncomeLoss_1111AE1DB781476263A6865C0ED2AC92" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_B4E75DA51F98FAE56AD486AB39E0E43A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_B4E75DA51F98FAE56AD486AB39E0E43A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend from trigger of down round provision feature</link:label>
    <link:label id="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_B4E75DA51F98FAE56AD486AB39E0E43A_label_en-US" xlink:label="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_B4E75DA51F98FAE56AD486AB39E0E43A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_B4E75DA51F98FAE56AD486AB39E0E43A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_B4E75DA51F98FAE56AD486AB39E0E43A" xlink:to="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_B4E75DA51F98FAE56AD486AB39E0E43A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9567D9B2A2711228827386914CA4F232_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9567D9B2A2711228827386914CA4F232" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9567D9B2A2711228827386914CA4F232_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9567D9B2A2711228827386914CA4F232" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9567D9B2A2711228827386914CA4F232" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9567D9B2A2711228827386914CA4F232" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9567D9B2A2711228827386914CA4F232" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_C7189E3550A83E89BC95865C0ED2CE99_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_C7189E3550A83E89BC95865C0ED2CE99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_C7189E3550A83E89BC95865C0ED2CE99_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_C7189E3550A83E89BC95865C0ED2CE99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_C7189E3550A83E89BC95865C0ED2CE99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_C7189E3550A83E89BC95865C0ED2CE99" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_C7189E3550A83E89BC95865C0ED2CE99" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0C9641B9443865DFBAB8865C0ED23650_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_0C9641B9443865DFBAB8865C0ED23650" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0C9641B9443865DFBAB8865C0ED23650_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_0C9641B9443865DFBAB8865C0ED23650" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0C9641B9443865DFBAB8865C0ED23650" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0C9641B9443865DFBAB8865C0ED23650" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_0C9641B9443865DFBAB8865C0ED23650" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_312DC196293A22866922865C0ED27BE8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_312DC196293A22866922865C0ED27BE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per common share - basic and diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_312DC196293A22866922865C0ED27BE8_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_312DC196293A22866922865C0ED27BE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_312DC196293A22866922865C0ED27BE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_312DC196293A22866922865C0ED27BE8" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_312DC196293A22866922865C0ED27BE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C81B30B32E57107C7338865C0ED3B632_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C81B30B32E57107C7338865C0ED3B632" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C81B30B32E57107C7338865C0ED3B632_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C81B30B32E57107C7338865C0ED3B632" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C81B30B32E57107C7338865C0ED3B632" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C81B30B32E57107C7338865C0ED3B632" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C81B30B32E57107C7338865C0ED3B632" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_465BD153D06885C13AE7865C0ED35C9F_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_465BD153D06885C13AE7865C0ED35C9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_465BD153D06885C13AE7865C0ED35C9F_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_465BD153D06885C13AE7865C0ED35C9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_465BD153D06885C13AE7865C0ED35C9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_465BD153D06885C13AE7865C0ED35C9F" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_465BD153D06885C13AE7865C0ED35C9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_EF1CBE6C5DF2AE997A2C51508016A937_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8B6D6B437E975B46959BB2D0E246A1D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock Option Activity for Amended 2014 Plan and Related Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_EF1CBE6C5DF2AE997A2C51508016A937_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8B6D6B437E975B46959BB2D0E246A1D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8B6D6B437E975B46959BB2D0E246A1D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8B6D6B437E975B46959BB2D0E246A1D1" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8B6D6B437E975B46959BB2D0E246A1D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_90468317243DAE17ED18515080167C98_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_52B102DEDA16541F89C5D0E6CEFA6201" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_90468317243DAE17ED18515080167C98_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_52B102DEDA16541F89C5D0E6CEFA6201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_52B102DEDA16541F89C5D0E6CEFA6201" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_52B102DEDA16541F89C5D0E6CEFA6201" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_52B102DEDA16541F89C5D0E6CEFA6201" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3449CFDA6F4155D3C1351508017F697_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_EAC054E600655DE9AEAB3E5F480A3079" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3449CFDA6F4155D3C1351508017F697_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_EAC054E600655DE9AEAB3E5F480A3079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_EAC054E600655DE9AEAB3E5F480A3079" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_EAC054E600655DE9AEAB3E5F480A3079" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_EAC054E600655DE9AEAB3E5F480A3079" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_C0E3988C3FB3112DCC6C865C0EB2EC53_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_C0E3988C3FB3112DCC6C865C0EB2EC53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_C0E3988C3FB3112DCC6C865C0EB2EC53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C0E3988C3FB3112DCC6C865C0EB2EC53" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_C0E3988C3FB3112DCC6C865C0EB2EC53" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_16972476295511CD7A75865C0EB3E259_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_16972476295511CD7A75865C0EB3E259" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_16972476295511CD7A75865C0EB3E259_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_16972476295511CD7A75865C0EB3E259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_16972476295511CD7A75865C0EB3E259" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_16972476295511CD7A75865C0EB3E259" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_16972476295511CD7A75865C0EB3E259" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_620C0BC18DA801B7469C865C0EB34A89_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_620C0BC18DA801B7469C865C0EB34A89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_620C0BC18DA801B7469C865C0EB34A89_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_620C0BC18DA801B7469C865C0EB34A89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_620C0BC18DA801B7469C865C0EB34A89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_620C0BC18DA801B7469C865C0EB34A89" xlink:to="lab_us-gaap_ProfitLoss_620C0BC18DA801B7469C865C0EB34A89" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D37B5AD5040C0F2BD86F865C0EB326A6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D37B5AD5040C0F2BD86F865C0EB326A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash adjustments reconciling net loss to operating cash flows:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D37B5AD5040C0F2BD86F865C0EB326A6_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D37B5AD5040C0F2BD86F865C0EB326A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D37B5AD5040C0F2BD86F865C0EB326A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D37B5AD5040C0F2BD86F865C0EB326A6" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D37B5AD5040C0F2BD86F865C0EB326A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_A364D76AC133B044A03E865C0EB3413C_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_A364D76AC133B044A03E865C0EB3413C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_A364D76AC133B044A03E865C0EB3413C_label_en-US" xlink:label="lab_us-gaap_Depreciation_A364D76AC133B044A03E865C0EB3413C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_A364D76AC133B044A03E865C0EB3413C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_A364D76AC133B044A03E865C0EB3413C" xlink:to="lab_us-gaap_Depreciation_A364D76AC133B044A03E865C0EB3413C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_066B05341720AF00368E865C0EB42790_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_066B05341720AF00368E865C0EB42790" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_066B05341720AF00368E865C0EB42790_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_066B05341720AF00368E865C0EB42790" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_066B05341720AF00368E865C0EB42790" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_066B05341720AF00368E865C0EB42790" xlink:to="lab_us-gaap_ShareBasedCompensation_066B05341720AF00368E865C0EB42790" xlink:type="arc" />
    <link:label id="lab_dare_NonCashLeaseExpense_2CD7AADB31880E3037E4865C0EB481E5_terseLabel_en-US" xlink:label="lab_dare_NonCashLeaseExpense_2CD7AADB31880E3037E4865C0EB481E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expenses</link:label>
    <link:label id="lab_dare_NonCashLeaseExpense_2CD7AADB31880E3037E4865C0EB481E5_label_en-US" xlink:label="lab_dare_NonCashLeaseExpense_2CD7AADB31880E3037E4865C0EB481E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:label id="lab_dare_NonCashLeaseExpense_2CD7AADB31880E3037E4865C0EB481E5_documentation_en-US" xlink:label="lab_dare_NonCashLeaseExpense_2CD7AADB31880E3037E4865C0EB481E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_NonCashLeaseExpense" xlink:label="loc_dare_NonCashLeaseExpense_2CD7AADB31880E3037E4865C0EB481E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NonCashLeaseExpense_2CD7AADB31880E3037E4865C0EB481E5" xlink:to="lab_dare_NonCashLeaseExpense_2CD7AADB31880E3037E4865C0EB481E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_755130D369778C742CC9865C0EB5FBC1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_755130D369778C742CC9865C0EB5FBC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_755130D369778C742CC9865C0EB5FBC1_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_755130D369778C742CC9865C0EB5FBC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_755130D369778C742CC9865C0EB5FBC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess_755130D369778C742CC9865C0EB5FBC1" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess_755130D369778C742CC9865C0EB5FBC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_769A39BCCB12D2B98427865C0EB6D9E9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_769A39BCCB12D2B98427865C0EB6D9E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_769A39BCCB12D2B98427865C0EB6D9E9_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_769A39BCCB12D2B98427865C0EB6D9E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_769A39BCCB12D2B98427865C0EB6D9E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_769A39BCCB12D2B98427865C0EB6D9E9" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_769A39BCCB12D2B98427865C0EB6D9E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_C03F2D63848BF65558B9865C0EB6D00F_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables_C03F2D63848BF65558B9865C0EB6D00F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_C03F2D63848BF65558B9865C0EB6D00F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables_C03F2D63848BF65558B9865C0EB6D00F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_C03F2D63848BF65558B9865C0EB6D00F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables_C03F2D63848BF65558B9865C0EB6D00F" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables_C03F2D63848BF65558B9865C0EB6D00F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_58CA6CE0CA381CDCC8FF865C0EB6C76E_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_58CA6CE0CA381CDCC8FF865C0EB6C76E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_58CA6CE0CA381CDCC8FF865C0EB6C76E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_58CA6CE0CA381CDCC8FF865C0EB6C76E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_58CA6CE0CA381CDCC8FF865C0EB6C76E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_58CA6CE0CA381CDCC8FF865C0EB6C76E" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_58CA6CE0CA381CDCC8FF865C0EB6C76E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_FB6A38E9742573596440865C0EB6FB64_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_FB6A38E9742573596440865C0EB6FB64" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_FB6A38E9742573596440865C0EB6FB64_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_FB6A38E9742573596440865C0EB6FB64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_FB6A38E9742573596440865C0EB6FB64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_FB6A38E9742573596440865C0EB6FB64" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_FB6A38E9742573596440865C0EB6FB64" xlink:type="arc" />
    <link:label id="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_CA0D50C67A7FAA55812D865C0EB7D5B5_negatedLabel_en-US" xlink:label="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_CA0D50C67A7FAA55812D865C0EB7D5B5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_CA0D50C67A7FAA55812D865C0EB7D5B5_label_en-US" xlink:label="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_CA0D50C67A7FAA55812D865C0EB7D5B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Other Non Current Assets And Deferred Charges</link:label>
    <link:label id="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_CA0D50C67A7FAA55812D865C0EB7D5B5_documentation_en-US" xlink:label="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_CA0D50C67A7FAA55812D865C0EB7D5B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease in other non-current assets and deferred charges.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" xlink:label="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_CA0D50C67A7FAA55812D865C0EB7D5B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_CA0D50C67A7FAA55812D865C0EB7D5B5" xlink:to="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_CA0D50C67A7FAA55812D865C0EB7D5B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9FE3805882EC9BA94673865C0EB7372B_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9FE3805882EC9BA94673865C0EB7372B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9FE3805882EC9BA94673865C0EB7372B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9FE3805882EC9BA94673865C0EB7372B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9FE3805882EC9BA94673865C0EB7372B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9FE3805882EC9BA94673865C0EB7372B" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9FE3805882EC9BA94673865C0EB7372B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_E84AB8DE84DB0F7875E3865C0EB788EB_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_E84AB8DE84DB0F7875E3865C0EB788EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_E84AB8DE84DB0F7875E3865C0EB788EB_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_E84AB8DE84DB0F7875E3865C0EB788EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_E84AB8DE84DB0F7875E3865C0EB788EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_E84AB8DE84DB0F7875E3865C0EB788EB" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_E84AB8DE84DB0F7875E3865C0EB788EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_FA15B10455EECDC31AD1865C0EB747AF_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_FA15B10455EECDC31AD1865C0EB747AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_FA15B10455EECDC31AD1865C0EB747AF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_FA15B10455EECDC31AD1865C0EB747AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_FA15B10455EECDC31AD1865C0EB747AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_FA15B10455EECDC31AD1865C0EB747AF" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_FA15B10455EECDC31AD1865C0EB747AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8EAA7732079C86B534D1865C0EB8CAB8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8EAA7732079C86B534D1865C0EB8CAB8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8EAA7732079C86B534D1865C0EB8CAB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8EAA7732079C86B534D1865C0EB8CAB8" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8EAA7732079C86B534D1865C0EB8CAB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EF31235DDBF306CC6E92865C0EB8A1FF_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EF31235DDBF306CC6E92865C0EB8A1FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EF31235DDBF306CC6E92865C0EB8A1FF_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EF31235DDBF306CC6E92865C0EB8A1FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EF31235DDBF306CC6E92865C0EB8A1FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EF31235DDBF306CC6E92865C0EB8A1FF" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EF31235DDBF306CC6E92865C0EB8A1FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_876F124365D5C2842445865C0EB83AA8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_876F124365D5C2842445865C0EB83AA8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_876F124365D5C2842445865C0EB83AA8_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_876F124365D5C2842445865C0EB83AA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_876F124365D5C2842445865C0EB83AA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_876F124365D5C2842445865C0EB83AA8" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_876F124365D5C2842445865C0EB83AA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_A71BA714FA255AECF143865C0EB95CA2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_A71BA714FA255AECF143865C0EB95CA2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of Pear Tree and Hydra asset</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_A71BA714FA255AECF143865C0EB95CA2_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_A71BA714FA255AECF143865C0EB95CA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_A71BA714FA255AECF143865C0EB95CA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_A71BA714FA255AECF143865C0EB95CA2" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_A71BA714FA255AECF143865C0EB95CA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_53FC9781EE88117692FF865C0EB9C36E_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_53FC9781EE88117692FF865C0EB9C36E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_53FC9781EE88117692FF865C0EB9C36E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_53FC9781EE88117692FF865C0EB9C36E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_53FC9781EE88117692FF865C0EB9C36E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_53FC9781EE88117692FF865C0EB9C36E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_53FC9781EE88117692FF865C0EB9C36E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3851664C657ABFE32FFA865C0EB96BB1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3851664C657ABFE32FFA865C0EB96BB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3851664C657ABFE32FFA865C0EB96BB1_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3851664C657ABFE32FFA865C0EB96BB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3851664C657ABFE32FFA865C0EB96BB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3851664C657ABFE32FFA865C0EB96BB1" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3851664C657ABFE32FFA865C0EB96BB1" xlink:type="arc" />
    <link:label id="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_1D5D56E72D42D37B74AB865C0EB9BBEF_terseLabel_en-US" xlink:label="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_1D5D56E72D42D37B74AB865C0EB9BBEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock and warrants</link:label>
    <link:label id="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_1D5D56E72D42D37B74AB865C0EB9BBEF_label_en-US" xlink:label="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_1D5D56E72D42D37B74AB865C0EB9BBEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Proceeds From Issuance Of Common Stock And Warrants</link:label>
    <link:label id="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_1D5D56E72D42D37B74AB865C0EB9BBEF_documentation_en-US" xlink:label="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_1D5D56E72D42D37B74AB865C0EB9BBEF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock and warrants.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_1D5D56E72D42D37B74AB865C0EB9BBEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_1D5D56E72D42D37B74AB865C0EB9BBEF" xlink:to="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_1D5D56E72D42D37B74AB865C0EB9BBEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E502396634C97380F5A5865C0EBA4768_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E502396634C97380F5A5865C0EBA4768" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E502396634C97380F5A5865C0EBA4768_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E502396634C97380F5A5865C0EBA4768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E502396634C97380F5A5865C0EBA4768" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E502396634C97380F5A5865C0EBA4768" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E502396634C97380F5A5865C0EBA4768" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_6F23FE7432EB29FB1D65865C0EBA0326_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_6F23FE7432EB29FB1D65865C0EBA0326" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_6F23FE7432EB29FB1D65865C0EBA0326_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_6F23FE7432EB29FB1D65865C0EBA0326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_6F23FE7432EB29FB1D65865C0EBA0326" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_6F23FE7432EB29FB1D65865C0EBA0326" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_6F23FE7432EB29FB1D65865C0EBA0326" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8DCD5C130DBBBAE88F52865C0EBA0354_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8DCD5C130DBBBAE88F52865C0EBA0354" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8DCD5C130DBBBAE88F52865C0EBA0354_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8DCD5C130DBBBAE88F52865C0EBA0354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8DCD5C130DBBBAE88F52865C0EBA0354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8DCD5C130DBBBAE88F52865C0EBA0354" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8DCD5C130DBBBAE88F52865C0EBA0354" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639D75E9B23F8FDBC847865C0EBA67D2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639D75E9B23F8FDBC847865C0EBA67D2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639D75E9B23F8FDBC847865C0EBA67D2_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639D75E9B23F8FDBC847865C0EBA67D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639D75E9B23F8FDBC847865C0EBA67D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639D75E9B23F8FDBC847865C0EBA67D2" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639D75E9B23F8FDBC847865C0EBA67D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6E4A42D6C3DFA49D294B865C0EBB491A_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6E4A42D6C3DFA49D294B865C0EBB491A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6E4A42D6C3DFA49D294B865C0EBB491A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6E4A42D6C3DFA49D294B865C0EBB491A" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6E4A42D6C3DFA49D294B865C0EBB491A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_37DFFB45CF61497CED0C865C0EBB4429_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_37DFFB45CF61497CED0C865C0EBB4429" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash operating and financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_37DFFB45CF61497CED0C865C0EBB4429_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_37DFFB45CF61497CED0C865C0EBB4429" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_37DFFB45CF61497CED0C865C0EBB4429" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_37DFFB45CF61497CED0C865C0EBB4429" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_37DFFB45CF61497CED0C865C0EBB4429" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_A4625E645EE86A2872CB865C0EBB4CD9_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_A4625E645EE86A2872CB865C0EBB4CD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_A4625E645EE86A2872CB865C0EBB4CD9_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_A4625E645EE86A2872CB865C0EBB4CD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_A4625E645EE86A2872CB865C0EBB4CD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_A4625E645EE86A2872CB865C0EBB4CD9" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_A4625E645EE86A2872CB865C0EBB4CD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_F2B6276AC516CC96708486AA97B642B3_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_F2B6276AC516CC96708486AA97B642B3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend from trigger of down round provision</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_F2B6276AC516CC96708486AA97B642B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_F2B6276AC516CC96708486AA97B642B3" xlink:to="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_F2B6276AC516CC96708486AA97B642B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_5A7709594452461163625E776967FDB0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_5A7709594452461163625E776967FDB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_5A7709594452461163625E776967FDB0_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_5A7709594452461163625E776967FDB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_5A7709594452461163625E776967FDB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_5A7709594452461163625E776967FDB0" xlink:to="lab_us-gaap_NumberOfOperatingSegments_5A7709594452461163625E776967FDB0" xlink:type="arc" />
    <link:label id="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_31829F82667CBF8C8AFD78071B0FDCD4_terseLabel_en-US" xlink:label="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_31829F82667CBF8C8AFD78071B0FDCD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_31829F82667CBF8C8AFD78071B0FDCD4_label_en-US" xlink:label="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_31829F82667CBF8C8AFD78071B0FDCD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Fourteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_31829F82667CBF8C8AFD78071B0FDCD4_documentation_en-US" xlink:label="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_31829F82667CBF8C8AFD78071B0FDCD4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand and fourteen employee stock purchase plan.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:label="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_31829F82667CBF8C8AFD78071B0FDCD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_31829F82667CBF8C8AFD78071B0FDCD4" xlink:to="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_31829F82667CBF8C8AFD78071B0FDCD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockMember_E098B8DA014F08AA312A78071B10512E_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_E098B8DA014F08AA312A78071B10512E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_E098B8DA014F08AA312A78071B10512E_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_E098B8DA014F08AA312A78071B10512E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_E098B8DA014F08AA312A78071B10512E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_E098B8DA014F08AA312A78071B10512E" xlink:to="lab_us-gaap_RestrictedStockMember_E098B8DA014F08AA312A78071B10512E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60FCE851A61B0D22ACA878071B11A1A7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60FCE851A61B0D22ACA878071B11A1A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60FCE851A61B0D22ACA878071B11A1A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60FCE851A61B0D22ACA878071B11A1A7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60FCE851A61B0D22ACA878071B11A1A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_BBDD03E2CE24EED34C7C78071B119E9F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_BBDD03E2CE24EED34C7C78071B119E9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_BBDD03E2CE24EED34C7C78071B119E9F_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_BBDD03E2CE24EED34C7C78071B119E9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_BBDD03E2CE24EED34C7C78071B119E9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_BBDD03E2CE24EED34C7C78071B119E9F" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_BBDD03E2CE24EED34C7C78071B119E9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_1C7ADDA2E8185CEC996D78071B11420F_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_1C7ADDA2E8185CEC996D78071B11420F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_1C7ADDA2E8185CEC996D78071B11420F_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_1C7ADDA2E8185CEC996D78071B11420F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1C7ADDA2E8185CEC996D78071B11420F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_1C7ADDA2E8185CEC996D78071B11420F" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_1C7ADDA2E8185CEC996D78071B11420F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2CDF900943E7B604507C78071B119F62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2CDF900943E7B604507C78071B119F62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase number of outstanding shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2CDF900943E7B604507C78071B119F62_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2CDF900943E7B604507C78071B119F62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2CDF900943E7B604507C78071B119F62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2CDF900943E7B604507C78071B119F62" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2CDF900943E7B604507C78071B119F62" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_DBB491C57AF1DEBE0FF678071B120A20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_DBB491C57AF1DEBE0FF678071B120A20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual percentage increase in outstanding number of common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_DBB491C57AF1DEBE0FF678071B120A20_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_DBB491C57AF1DEBE0FF678071B120A20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_DBB491C57AF1DEBE0FF678071B120A20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_DBB491C57AF1DEBE0FF678071B120A20" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_DBB491C57AF1DEBE0FF678071B120A20" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_215A3D22D1652520B45D78071B12BC27_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_215A3D22D1652520B45D78071B12BC27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_215A3D22D1652520B45D78071B12BC27_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_215A3D22D1652520B45D78071B12BC27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_215A3D22D1652520B45D78071B12BC27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_215A3D22D1652520B45D78071B12BC27" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_215A3D22D1652520B45D78071B12BC27" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_2FBB9910BBEAB761386C78071B1237E3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_2FBB9910BBEAB761386C78071B1237E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_2FBB9910BBEAB761386C78071B1237E3_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_2FBB9910BBEAB761386C78071B1237E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_2FBB9910BBEAB761386C78071B1237E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_2FBB9910BBEAB761386C78071B1237E3" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_2FBB9910BBEAB761386C78071B1237E3" xlink:type="arc" />
    <link:label id="lab_dare_WeightedAverageAmortizationPeriod_A0396191BCF261CEB98A78071B1296F8_terseLabel_en-US" xlink:label="lab_dare_WeightedAverageAmortizationPeriod_A0396191BCF261CEB98A78071B1296F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized weighted average period</link:label>
    <link:label id="lab_dare_WeightedAverageAmortizationPeriod_A0396191BCF261CEB98A78071B1296F8_label_en-US" xlink:label="lab_dare_WeightedAverageAmortizationPeriod_A0396191BCF261CEB98A78071B1296F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Amortization Period</link:label>
    <link:label id="lab_dare_WeightedAverageAmortizationPeriod_A0396191BCF261CEB98A78071B1296F8_documentation_en-US" xlink:label="lab_dare_WeightedAverageAmortizationPeriod_A0396191BCF261CEB98A78071B1296F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Amortization Period</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_WeightedAverageAmortizationPeriod" xlink:label="loc_dare_WeightedAverageAmortizationPeriod_A0396191BCF261CEB98A78071B1296F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WeightedAverageAmortizationPeriod_A0396191BCF261CEB98A78071B1296F8" xlink:to="lab_dare_WeightedAverageAmortizationPeriod_A0396191BCF261CEB98A78071B1296F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_DC7B422A8ADED2C5F2CE78071B12B8C9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_DC7B422A8ADED2C5F2CE78071B12B8C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_DC7B422A8ADED2C5F2CE78071B12B8C9_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_DC7B422A8ADED2C5F2CE78071B12B8C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_DC7B422A8ADED2C5F2CE78071B12B8C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_DC7B422A8ADED2C5F2CE78071B12B8C9" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_DC7B422A8ADED2C5F2CE78071B12B8C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_711C30A4F92B7D190CED6D52E9535AA0_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_711C30A4F92B7D190CED6D52E9535AA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_711C30A4F92B7D190CED6D52E9535AA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_711C30A4F92B7D190CED6D52E9535AA0" xlink:to="lab_us-gaap_EarningsPerShareAbstract_711C30A4F92B7D190CED6D52E9535AA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9BDB42DBDA238E4DBB596D52E953A6CB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9BDB42DBDA238E4DBB596D52E953A6CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9BDB42DBDA238E4DBB596D52E953A6CB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9BDB42DBDA238E4DBB596D52E953A6CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9BDB42DBDA238E4DBB596D52E953A6CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9BDB42DBDA238E4DBB596D52E953A6CB" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9BDB42DBDA238E4DBB596D52E953A6CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54BB2834DB4DBD6BCA1F6D52E953F13C_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54BB2834DB4DBD6BCA1F6D52E953F13C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54BB2834DB4DBD6BCA1F6D52E953F13C_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54BB2834DB4DBD6BCA1F6D52E953F13C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54BB2834DB4DBD6BCA1F6D52E953F13C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54BB2834DB4DBD6BCA1F6D52E953F13C" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54BB2834DB4DBD6BCA1F6D52E953F13C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_447AF40BE95F649A9D386D52E95471FB_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_447AF40BE95F649A9D386D52E95471FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_447AF40BE95F649A9D386D52E95471FB_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_447AF40BE95F649A9D386D52E95471FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_447AF40BE95F649A9D386D52E95471FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_447AF40BE95F649A9D386D52E95471FB" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_447AF40BE95F649A9D386D52E95471FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_B71BE63BEEE944C2367D6D52E954DFF8_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_B71BE63BEEE944C2367D6D52E954DFF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_B71BE63BEEE944C2367D6D52E954DFF8_label_en-US" xlink:label="lab_us-gaap_WarrantMember_B71BE63BEEE944C2367D6D52E954DFF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_B71BE63BEEE944C2367D6D52E954DFF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_B71BE63BEEE944C2367D6D52E954DFF8" xlink:to="lab_us-gaap_WarrantMember_B71BE63BEEE944C2367D6D52E954DFF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E7C252C5678F2865C8246D52E9547967_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E7C252C5678F2865C8246D52E9547967" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E7C252C5678F2865C8246D52E9547967_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E7C252C5678F2865C8246D52E9547967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E7C252C5678F2865C8246D52E9547967" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E7C252C5678F2865C8246D52E9547967" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E7C252C5678F2865C8246D52E9547967" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5105188C94B7735FA6A16D52E954CC08_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5105188C94B7735FA6A16D52E954CC08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5105188C94B7735FA6A16D52E954CC08_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5105188C94B7735FA6A16D52E954CC08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5105188C94B7735FA6A16D52E954CC08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5105188C94B7735FA6A16D52E954CC08" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5105188C94B7735FA6A16D52E954CC08" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_005EC5BF97AA5459CAEE8B6FAE986326_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_005EC5BF97AA5459CAEE8B6FAE986326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_005EC5BF97AA5459CAEE8B6FAE986326" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_005EC5BF97AA5459CAEE8B6FAE986326" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_005EC5BF97AA5459CAEE8B6FAE986326" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_A3F4F4A457B43093822A8B6FAE9B5F37_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_A3F4F4A457B43093822A8B6FAE9B5F37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_A3F4F4A457B43093822A8B6FAE9B5F37_label_en-US" xlink:label="lab_us-gaap_StatementTable_A3F4F4A457B43093822A8B6FAE9B5F37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A3F4F4A457B43093822A8B6FAE9B5F37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_A3F4F4A457B43093822A8B6FAE9B5F37" xlink:to="lab_us-gaap_StatementTable_A3F4F4A457B43093822A8B6FAE9B5F37" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7E0C3649329E9CAEBA818B6FAE9CA943_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_7E0C3649329E9CAEBA818B6FAE9CA943" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7E0C3649329E9CAEBA818B6FAE9CA943_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_7E0C3649329E9CAEBA818B6FAE9CA943" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7E0C3649329E9CAEBA818B6FAE9CA943" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7E0C3649329E9CAEBA818B6FAE9CA943" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_7E0C3649329E9CAEBA818B6FAE9CA943" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C" xlink:to="lab_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_EE9975C36A926F29A43E8B6FAE9D4D9C_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_EE9975C36A926F29A43E8B6FAE9D4D9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_EE9975C36A926F29A43E8B6FAE9D4D9C_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_EE9975C36A926F29A43E8B6FAE9D4D9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_EE9975C36A926F29A43E8B6FAE9D4D9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_EE9975C36A926F29A43E8B6FAE9D4D9C" xlink:to="lab_us-gaap_CommonStockMember_EE9975C36A926F29A43E8B6FAE9D4D9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_9793BC4FE667D4DF62678B6FAE9D57B7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_9793BC4FE667D4DF62678B6FAE9D57B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital [Member]</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_9793BC4FE667D4DF62678B6FAE9D57B7_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_9793BC4FE667D4DF62678B6FAE9D57B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9793BC4FE667D4DF62678B6FAE9D57B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_9793BC4FE667D4DF62678B6FAE9D57B7" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_9793BC4FE667D4DF62678B6FAE9D57B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B669CDE737E161FC0BC88B6FAE9D1409_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B669CDE737E161FC0BC88B6FAE9D1409" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B669CDE737E161FC0BC88B6FAE9D1409_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B669CDE737E161FC0BC88B6FAE9D1409" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B669CDE737E161FC0BC88B6FAE9D1409" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B669CDE737E161FC0BC88B6FAE9D1409" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B669CDE737E161FC0BC88B6FAE9D1409" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_2B051ED87000BB590A598B6FAE9EAE51_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_2B051ED87000BB590A598B6FAE9EAE51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2B051ED87000BB590A598B6FAE9EAE51_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_2B051ED87000BB590A598B6FAE9EAE51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_2B051ED87000BB590A598B6FAE9EAE51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_2B051ED87000BB590A598B6FAE9EAE51" xlink:to="lab_us-gaap_RetainedEarningsMember_2B051ED87000BB590A598B6FAE9EAE51" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_6F60125553199E0B09B38B6FAE9EEE06_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_6F60125553199E0B09B38B6FAE9EEE06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_6F60125553199E0B09B38B6FAE9EEE06_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_6F60125553199E0B09B38B6FAE9EEE06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6F60125553199E0B09B38B6FAE9EEE06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_6F60125553199E0B09B38B6FAE9EEE06" xlink:to="lab_us-gaap_StatementLineItems_6F60125553199E0B09B38B6FAE9EEE06" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_CCB4EAD7BD5493BFE97E8B6FAE9E50E6_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_CCB4EAD7BD5493BFE97E8B6FAE9E50E6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_CCB4EAD7BD5493BFE97E8B6FAE9E50E6_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_CCB4EAD7BD5493BFE97E8B6FAE9E50E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_CCB4EAD7BD5493BFE97E8B6FAE9E50E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_CCB4EAD7BD5493BFE97E8B6FAE9E50E6" xlink:to="lab_us-gaap_SharesOutstanding_CCB4EAD7BD5493BFE97E8B6FAE9E50E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_920381340E2E372311AE8B6FAE9F6821_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_920381340E2E372311AE8B6FAE9F6821" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_920381340E2E372311AE8B6FAE9F6821_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_920381340E2E372311AE8B6FAE9F6821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_920381340E2E372311AE8B6FAE9F6821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_920381340E2E372311AE8B6FAE9F6821" xlink:to="lab_us-gaap_StockholdersEquity_920381340E2E372311AE8B6FAE9F6821" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2940A599692ECC79E2DD8B6FAE9FF2B6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2940A599692ECC79E2DD8B6FAE9FF2B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2940A599692ECC79E2DD8B6FAE9FF2B6_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2940A599692ECC79E2DD8B6FAE9FF2B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2940A599692ECC79E2DD8B6FAE9FF2B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2940A599692ECC79E2DD8B6FAE9FF2B6" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2940A599692ECC79E2DD8B6FAE9FF2B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B08BF7F5BA4C4B4E7D428B6FB25CF7AA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B08BF7F5BA4C4B4E7D428B6FB25CF7AA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Public offering costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B08BF7F5BA4C4B4E7D428B6FB25CF7AA_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B08BF7F5BA4C4B4E7D428B6FB25CF7AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B08BF7F5BA4C4B4E7D428B6FB25CF7AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B08BF7F5BA4C4B4E7D428B6FB25CF7AA" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B08BF7F5BA4C4B4E7D428B6FB25CF7AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4BFB2238736FE5BB8DBF8B6FAEA11DC3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4BFB2238736FE5BB8DBF8B6FAEA11DC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4BFB2238736FE5BB8DBF8B6FAEA11DC3_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4BFB2238736FE5BB8DBF8B6FAEA11DC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4BFB2238736FE5BB8DBF8B6FAEA11DC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4BFB2238736FE5BB8DBF8B6FAEA11DC3" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4BFB2238736FE5BB8DBF8B6FAEA11DC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_60358D4FEE3F9CE4A6EE8B6FAEA1776C_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_60358D4FEE3F9CE4A6EE8B6FAEA1776C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_60358D4FEE3F9CE4A6EE8B6FAEA1776C_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_60358D4FEE3F9CE4A6EE8B6FAEA1776C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_60358D4FEE3F9CE4A6EE8B6FAEA1776C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_60358D4FEE3F9CE4A6EE8B6FAEA1776C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_60358D4FEE3F9CE4A6EE8B6FAEA1776C" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_8AA05A60ADC4B0A0E75D8B6FAEA2BC73_negatedLabel_en-US" xlink:label="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_8AA05A60ADC4B0A0E75D8B6FAEA2BC73" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend from trigger of down round provision</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_8AA05A60ADC4B0A0E75D8B6FAEA2BC73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_8AA05A60ADC4B0A0E75D8B6FAEA2BC73" xlink:to="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_8AA05A60ADC4B0A0E75D8B6FAEA2BC73" xlink:type="arc" />
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_02EE51BC72EE44F23ACA8B6FAEA236D0_terseLabel_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_02EE51BC72EE44F23ACA8B6FAEA236D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock and warrants (in shares)</link:label>
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_02EE51BC72EE44F23ACA8B6FAEA236D0_label_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_02EE51BC72EE44F23ACA8B6FAEA236D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares</link:label>
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_02EE51BC72EE44F23ACA8B6FAEA236D0_documentation_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_02EE51BC72EE44F23ACA8B6FAEA236D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_02EE51BC72EE44F23ACA8B6FAEA236D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_02EE51BC72EE44F23ACA8B6FAEA236D0" xlink:to="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_02EE51BC72EE44F23ACA8B6FAEA236D0" xlink:type="arc" />
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_863F0428610B7AD5EBD38B6FAEA260F2_terseLabel_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_863F0428610B7AD5EBD38B6FAEA260F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public offering costs</link:label>
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_863F0428610B7AD5EBD38B6FAEA260F2_label_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_863F0428610B7AD5EBD38B6FAEA260F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued</link:label>
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_863F0428610B7AD5EBD38B6FAEA260F2_documentation_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_863F0428610B7AD5EBD38B6FAEA260F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_863F0428610B7AD5EBD38B6FAEA260F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_863F0428610B7AD5EBD38B6FAEA260F2" xlink:to="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_863F0428610B7AD5EBD38B6FAEA260F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_4FBA5B9F086B6C03DD768B6FAEA2CE65_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_4FBA5B9F086B6C03DD768B6FAEA2CE65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4FBA5B9F086B6C03DD768B6FAEA2CE65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_4FBA5B9F086B6C03DD768B6FAEA2CE65" xlink:to="lab_us-gaap_NetIncomeLoss_4FBA5B9F086B6C03DD768B6FAEA2CE65" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_B0E091BBFECD596837438B6FAEA2B4BD_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_B0E091BBFECD596837438B6FAEA2B4BD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_B0E091BBFECD596837438B6FAEA2B4BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_B0E091BBFECD596837438B6FAEA2B4BD" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_B0E091BBFECD596837438B6FAEA2B4BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_B1C979487A100BB111688B6FAEA2F36D_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_B1C979487A100BB111688B6FAEA2F36D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_B1C979487A100BB111688B6FAEA2F36D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_B1C979487A100BB111688B6FAEA2F36D" xlink:to="lab_us-gaap_SharesOutstanding_B1C979487A100BB111688B6FAEA2F36D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_CCBCDFDC95C9C86BCB308B6FAEA3BF14_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_CCBCDFDC95C9C86BCB308B6FAEA3BF14" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CCBCDFDC95C9C86BCB308B6FAEA3BF14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_CCBCDFDC95C9C86BCB308B6FAEA3BF14" xlink:to="lab_us-gaap_StockholdersEquity_CCBCDFDC95C9C86BCB308B6FAEA3BF14" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_4FB4D6512B5C76E839AE5B0CFD7D0553_terseLabel_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_774791C3ED2057D08400EF7FA2C6A932" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Going Concern</link:label>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_4FB4D6512B5C76E839AE5B0CFD7D0553_label_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_774791C3ED2057D08400EF7FA2C6A932" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_774791C3ED2057D08400EF7FA2C6A932" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_774791C3ED2057D08400EF7FA2C6A932" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_774791C3ED2057D08400EF7FA2C6A932" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_FCE03DF4CC270DAEA778B9F088A2FB53_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ED7AE697A5025E8B929ED9C53E407454" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_FCE03DF4CC270DAEA778B9F088A2FB53_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ED7AE697A5025E8B929ED9C53E407454" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ED7AE697A5025E8B929ED9C53E407454" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ED7AE697A5025E8B929ED9C53E407454" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ED7AE697A5025E8B929ED9C53E407454" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesAbstract_F3ADC89DCC63EEF2AC485B0CFBCC2937_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract_A2FB7F44FAFF509AA836C4BE72D78A68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_A2FB7F44FAFF509AA836C4BE72D78A68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract_A2FB7F44FAFF509AA836C4BE72D78A68" xlink:to="lab_us-gaap_ReceivablesAbstract_A2FB7F44FAFF509AA836C4BE72D78A68" xlink:type="arc" />
    <link:label id="lab_dare_GrantAwardTextBlock_60E5F4A97C48CE4E8EFC5B0CFBCCFC45_terseLabel_en-US" xlink:label="lab_dare_GrantAwardTextBlock_6876CE8B016D5220A983CCD5C3DD1E43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant Award</link:label>
    <link:label id="lab_dare_GrantAwardTextBlock_60E5F4A97C48CE4E8EFC5B0CFBCCFC45_label_en-US" xlink:label="lab_dare_GrantAwardTextBlock_6876CE8B016D5220A983CCD5C3DD1E43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Award [Text Block]</link:label>
    <link:label id="lab_dare_GrantAwardTextBlock_60E5F4A97C48CE4E8EFC5B0CFBCCFC45_documentation_en-US" xlink:label="lab_dare_GrantAwardTextBlock_6876CE8B016D5220A983CCD5C3DD1E43" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Award [Text Block]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_GrantAwardTextBlock" xlink:label="loc_dare_GrantAwardTextBlock_6876CE8B016D5220A983CCD5C3DD1E43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_GrantAwardTextBlock_6876CE8B016D5220A983CCD5C3DD1E43" xlink:to="lab_dare_GrantAwardTextBlock_6876CE8B016D5220A983CCD5C3DD1E43" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_AD5490C1229320B2C5E9BA4E6F926D3E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_01CE7DEDA6645C2295761A6575145B93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_AD5490C1229320B2C5E9BA4E6F926D3E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_01CE7DEDA6645C2295761A6575145B93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_01CE7DEDA6645C2295761A6575145B93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_01CE7DEDA6645C2295761A6575145B93" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_01CE7DEDA6645C2295761A6575145B93" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_66D586C4FD1C123940795B0CFD3B80D5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_43B32258FEB757DC965CFFCCFA9A6124" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_66D586C4FD1C123940795B0CFD3B80D5_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_43B32258FEB757DC965CFFCCFA9A6124" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_43B32258FEB757DC965CFFCCFA9A6124" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_43B32258FEB757DC965CFFCCFA9A6124" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_43B32258FEB757DC965CFFCCFA9A6124" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A37D537168FC2631BB636D52E9B6B68A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A37D537168FC2631BB636D52E9B6B68A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A37D537168FC2631BB636D52E9B6B68A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A37D537168FC2631BB636D52E9B6B68A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A37D537168FC2631BB636D52E9B6B68A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A37D537168FC2631BB636D52E9B6B68A" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A37D537168FC2631BB636D52E9B6B68A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_9A3F78E83DDAF94383416D52E9B8BD46_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_9A3F78E83DDAF94383416D52E9B8BD46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9A3F78E83DDAF94383416D52E9B8BD46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9A3F78E83DDAF94383416D52E9B8BD46" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_9A3F78E83DDAF94383416D52E9B8BD46" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_9DE0FCC49AFA4099BDD76D52E9B8EB66_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_9DE0FCC49AFA4099BDD76D52E9B8EB66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_9DE0FCC49AFA4099BDD76D52E9B8EB66_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_9DE0FCC49AFA4099BDD76D52E9B8EB66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9DE0FCC49AFA4099BDD76D52E9B8EB66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9DE0FCC49AFA4099BDD76D52E9B8EB66" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_9DE0FCC49AFA4099BDD76D52E9B8EB66" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69482650FDEAD6C154116D52E9B872D0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69482650FDEAD6C154116D52E9B872D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69482650FDEAD6C154116D52E9B872D0_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69482650FDEAD6C154116D52E9B872D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69482650FDEAD6C154116D52E9B872D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69482650FDEAD6C154116D52E9B872D0" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69482650FDEAD6C154116D52E9B872D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_2085522664A62DCCA89A6D22BA93EABF_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_2085522664A62DCCA89A6D22BA93EABF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2085522664A62DCCA89A6D22BA93EABF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2085522664A62DCCA89A6D22BA93EABF" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_2085522664A62DCCA89A6D22BA93EABF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_6E17FAD2BC86770A4A2A6D22BA932AD2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_6E17FAD2BC86770A4A2A6D22BA932AD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_6E17FAD2BC86770A4A2A6D22BA932AD2_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_6E17FAD2BC86770A4A2A6D22BA932AD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_6E17FAD2BC86770A4A2A6D22BA932AD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_6E17FAD2BC86770A4A2A6D22BA932AD2" xlink:to="lab_us-gaap_AssetsAbstract_6E17FAD2BC86770A4A2A6D22BA932AD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_A3BD2B7392438E2F94B36D22BA933FE6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_A3BD2B7392438E2F94B36D22BA933FE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_A3BD2B7392438E2F94B36D22BA933FE6_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_A3BD2B7392438E2F94B36D22BA933FE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_A3BD2B7392438E2F94B36D22BA933FE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A3BD2B7392438E2F94B36D22BA933FE6" xlink:to="lab_us-gaap_AssetsCurrentAbstract_A3BD2B7392438E2F94B36D22BA933FE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_ACA77A1BBCC7FAF845106D22BA9330DE_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_ACA77A1BBCC7FAF845106D22BA9330DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_ACA77A1BBCC7FAF845106D22BA9330DE_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_ACA77A1BBCC7FAF845106D22BA9330DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_ACA77A1BBCC7FAF845106D22BA9330DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent_ACA77A1BBCC7FAF845106D22BA9330DE" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent_ACA77A1BBCC7FAF845106D22BA9330DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_686E43C0C9032871E1666D22BA93E687_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_686E43C0C9032871E1666D22BA93E687" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_686E43C0C9032871E1666D22BA93E687_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_686E43C0C9032871E1666D22BA93E687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_686E43C0C9032871E1666D22BA93E687" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_686E43C0C9032871E1666D22BA93E687" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_686E43C0C9032871E1666D22BA93E687" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_1A0AC4428FBF92B7DEF86D22BA9357EC_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_1A0AC4428FBF92B7DEF86D22BA9357EC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_1A0AC4428FBF92B7DEF86D22BA9357EC_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_1A0AC4428FBF92B7DEF86D22BA9357EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1A0AC4428FBF92B7DEF86D22BA9357EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_1A0AC4428FBF92B7DEF86D22BA9357EC" xlink:to="lab_us-gaap_AssetsCurrent_1A0AC4428FBF92B7DEF86D22BA9357EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_879C785C0BA92F60F32B6D22BA937783_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_879C785C0BA92F60F32B6D22BA937783" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_879C785C0BA92F60F32B6D22BA937783_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_879C785C0BA92F60F32B6D22BA937783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_879C785C0BA92F60F32B6D22BA937783" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_879C785C0BA92F60F32B6D22BA937783" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_879C785C0BA92F60F32B6D22BA937783" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_D45DFB766DECCD3E49126D22BA93A7D3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_D45DFB766DECCD3E49126D22BA93A7D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_D45DFB766DECCD3E49126D22BA93A7D3_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_D45DFB766DECCD3E49126D22BA93A7D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_D45DFB766DECCD3E49126D22BA93A7D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_D45DFB766DECCD3E49126D22BA93A7D3" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_D45DFB766DECCD3E49126D22BA93A7D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_00B4019C7331E002C2FE6D22BAA3A3CE_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_00B4019C7331E002C2FE6D22BAA3A3CE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_00B4019C7331E002C2FE6D22BAA3A3CE_label_en-US" xlink:label="lab_us-gaap_Assets_00B4019C7331E002C2FE6D22BAA3A3CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_00B4019C7331E002C2FE6D22BAA3A3CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_00B4019C7331E002C2FE6D22BAA3A3CE" xlink:to="lab_us-gaap_Assets_00B4019C7331E002C2FE6D22BAA3A3CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2EBDB0A497D24D0DA3406D22BAA375DB_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2EBDB0A497D24D0DA3406D22BAA375DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2EBDB0A497D24D0DA3406D22BAA375DB_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2EBDB0A497D24D0DA3406D22BAA375DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2EBDB0A497D24D0DA3406D22BAA375DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2EBDB0A497D24D0DA3406D22BAA375DB" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2EBDB0A497D24D0DA3406D22BAA375DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_DA10F9684FAFDE2214476D22BAA3091C_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_DA10F9684FAFDE2214476D22BAA3091C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_DA10F9684FAFDE2214476D22BAA3091C_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_DA10F9684FAFDE2214476D22BAA3091C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_DA10F9684FAFDE2214476D22BAA3091C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DA10F9684FAFDE2214476D22BAA3091C" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_DA10F9684FAFDE2214476D22BAA3091C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_A3714DA41BC27E3C25A16D22BAA348B1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_A3714DA41BC27E3C25A16D22BAA348B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_A3714DA41BC27E3C25A16D22BAA348B1_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_A3714DA41BC27E3C25A16D22BAA348B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_A3714DA41BC27E3C25A16D22BAA348B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_A3714DA41BC27E3C25A16D22BAA348B1" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_A3714DA41BC27E3C25A16D22BAA348B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4A87FA7AAB34F7548DE26D22BAA34977_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_4A87FA7AAB34F7548DE26D22BAA34977" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4A87FA7AAB34F7548DE26D22BAA34977_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_4A87FA7AAB34F7548DE26D22BAA34977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4A87FA7AAB34F7548DE26D22BAA34977" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4A87FA7AAB34F7548DE26D22BAA34977" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_4A87FA7AAB34F7548DE26D22BAA34977" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_97F4F879AB059FF9FDC26D22BAA36C39_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_97F4F879AB059FF9FDC26D22BAA36C39" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_97F4F879AB059FF9FDC26D22BAA36C39_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_97F4F879AB059FF9FDC26D22BAA36C39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_97F4F879AB059FF9FDC26D22BAA36C39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_97F4F879AB059FF9FDC26D22BAA36C39" xlink:to="lab_us-gaap_LiabilitiesCurrent_97F4F879AB059FF9FDC26D22BAA36C39" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_6C54E53169E7D4C2F6786D22BAA3BF0F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_6C54E53169E7D4C2F6786D22BAA3BF0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_6C54E53169E7D4C2F6786D22BAA3BF0F_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_6C54E53169E7D4C2F6786D22BAA3BF0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6C54E53169E7D4C2F6786D22BAA3BF0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_6C54E53169E7D4C2F6786D22BAA3BF0F" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_6C54E53169E7D4C2F6786D22BAA3BF0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_F2034829B5396D6E934A6D22BAA3CC6E_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_F2034829B5396D6E934A6D22BAA3CC6E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_F2034829B5396D6E934A6D22BAA3CC6E_label_en-US" xlink:label="lab_us-gaap_Liabilities_F2034829B5396D6E934A6D22BAA3CC6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_F2034829B5396D6E934A6D22BAA3CC6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_F2034829B5396D6E934A6D22BAA3CC6E" xlink:to="lab_us-gaap_Liabilities_F2034829B5396D6E934A6D22BAA3CC6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_5CE4EEE5F306A0E9E3C66D22BAA3D841_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_5CE4EEE5F306A0E9E3C66D22BAA3D841" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_5CE4EEE5F306A0E9E3C66D22BAA3D841_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_5CE4EEE5F306A0E9E3C66D22BAA3D841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5CE4EEE5F306A0E9E3C66D22BAA3D841" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_5CE4EEE5F306A0E9E3C66D22BAA3D841" xlink:to="lab_us-gaap_CommitmentsAndContingencies_5CE4EEE5F306A0E9E3C66D22BAA3D841" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_571C2B8C5329D30343326D22BAA310E5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_571C2B8C5329D30343326D22BAA310E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_571C2B8C5329D30343326D22BAA310E5_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_571C2B8C5329D30343326D22BAA310E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_571C2B8C5329D30343326D22BAA310E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_571C2B8C5329D30343326D22BAA310E5" xlink:to="lab_us-gaap_StockholdersEquityAbstract_571C2B8C5329D30343326D22BAA310E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_924DE14A8C3359FDA4196D22BAA384C4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_924DE14A8C3359FDA4196D22BAA384C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_924DE14A8C3359FDA4196D22BAA384C4_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_924DE14A8C3359FDA4196D22BAA384C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_924DE14A8C3359FDA4196D22BAA384C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_924DE14A8C3359FDA4196D22BAA384C4" xlink:to="lab_us-gaap_PreferredStockValue_924DE14A8C3359FDA4196D22BAA384C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_49367BEC90C65C60C9E86D22BAA3EDA2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_49367BEC90C65C60C9E86D22BAA3EDA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 120,000,000 shares authorized; 16,683,411 and 11,422,161 shares issued and outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_49367BEC90C65C60C9E86D22BAA3EDA2_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_49367BEC90C65C60C9E86D22BAA3EDA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_49367BEC90C65C60C9E86D22BAA3EDA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_49367BEC90C65C60C9E86D22BAA3EDA2" xlink:to="lab_us-gaap_CommonStockValue_49367BEC90C65C60C9E86D22BAA3EDA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F37D532F138E083470BE6D22BAA3A7D0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F37D532F138E083470BE6D22BAA3A7D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F37D532F138E083470BE6D22BAA3A7D0_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F37D532F138E083470BE6D22BAA3A7D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F37D532F138E083470BE6D22BAA3A7D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F37D532F138E083470BE6D22BAA3A7D0" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F37D532F138E083470BE6D22BAA3A7D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_7873F9EF5D1DA4606B966D22BAA39747_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_7873F9EF5D1DA4606B966D22BAA39747" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_7873F9EF5D1DA4606B966D22BAA39747_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_7873F9EF5D1DA4606B966D22BAA39747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7873F9EF5D1DA4606B966D22BAA39747" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7873F9EF5D1DA4606B966D22BAA39747" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_7873F9EF5D1DA4606B966D22BAA39747" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_31C635E80DFFF1CBCC0E6D22BAA38E60_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_31C635E80DFFF1CBCC0E6D22BAA38E60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_31C635E80DFFF1CBCC0E6D22BAA38E60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_31C635E80DFFF1CBCC0E6D22BAA38E60" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_31C635E80DFFF1CBCC0E6D22BAA38E60" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_B187C728BE30E56855CD6D22BAA3E156_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_B187C728BE30E56855CD6D22BAA3E156" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B187C728BE30E56855CD6D22BAA3E156" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_B187C728BE30E56855CD6D22BAA3E156" xlink:to="lab_us-gaap_StockholdersEquity_B187C728BE30E56855CD6D22BAA3E156" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_353611D57C1197C8F34C6D22BAA33B8F_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_353611D57C1197C8F34C6D22BAA33B8F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_353611D57C1197C8F34C6D22BAA33B8F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_353611D57C1197C8F34C6D22BAA33B8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_353611D57C1197C8F34C6D22BAA33B8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_353611D57C1197C8F34C6D22BAA33B8F" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_353611D57C1197C8F34C6D22BAA33B8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94" xlink:type="arc" />
    <link:label id="lab_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_F8C3157919E0751B775978071A9CD738_terseLabel_en-US" xlink:label="lab_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_F8C3157919E0751B775978071A9CD738" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining Portion Of Research And Availability Of Funds</link:label>
    <link:label id="lab_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_F8C3157919E0751B775978071A9CD738_label_en-US" xlink:label="lab_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_F8C3157919E0751B775978071A9CD738" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining Portion Of Research And Availability Of Funds [Member]</link:label>
    <link:label id="lab_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_F8C3157919E0751B775978071A9CD738_documentation_en-US" xlink:label="lab_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_F8C3157919E0751B775978071A9CD738" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remaining Portion Of Research And Availability Of Funds [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember" xlink:label="loc_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_F8C3157919E0751B775978071A9CD738" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_F8C3157919E0751B775978071A9CD738" xlink:to="lab_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_F8C3157919E0751B775978071A9CD738" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_8DCF5FB7D002ACDE54A678071A9DF0C0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_8DCF5FB7D002ACDE54A678071A9DF0C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_8DCF5FB7D002ACDE54A678071A9DF0C0_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_8DCF5FB7D002ACDE54A678071A9DF0C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_8DCF5FB7D002ACDE54A678071A9DF0C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_8DCF5FB7D002ACDE54A678071A9DF0C0" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_8DCF5FB7D002ACDE54A678071A9DF0C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_8CE9F1F05363B064D33E78071A9ED29B_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_8CE9F1F05363B064D33E78071A9ED29B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received from federal grant</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_8CE9F1F05363B064D33E78071A9ED29B_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_8CE9F1F05363B064D33E78071A9ED29B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_8CE9F1F05363B064D33E78071A9ED29B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_8CE9F1F05363B064D33E78071A9ED29B" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_8CE9F1F05363B064D33E78071A9ED29B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9011CCD548C94268B8655B0CFC3E571D_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E2D11AC3FA485A1CA8CED1CFC621C30A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E2D11AC3FA485A1CA8CED1CFC621C30A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E2D11AC3FA485A1CA8CED1CFC621C30A" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E2D11AC3FA485A1CA8CED1CFC621C30A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_EC017C87C964FC242A865B0CFC3FE23B_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock_EE0D071AB3325E62B047371FB6DA0136" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_EC017C87C964FC242A865B0CFC3FE23B_label_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock_EE0D071AB3325E62B047371FB6DA0136" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_EE0D071AB3325E62B047371FB6DA0136" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock_EE0D071AB3325E62B047371FB6DA0136" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock_EE0D071AB3325E62B047371FB6DA0136" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0B0438353097CFA219695B0CFBA33C24_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_F9037B3123D052DCA0C5CD48F59DF8EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0B0438353097CFA219695B0CFBA33C24_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_F9037B3123D052DCA0C5CD48F59DF8EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_F9037B3123D052DCA0C5CD48F59DF8EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_F9037B3123D052DCA0C5CD48F59DF8EF" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_F9037B3123D052DCA0C5CD48F59DF8EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_DE883CE1F5ACA9FB28AB4AFD87A90115_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_B885B9A8FB7C5B6291545489DB7952F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_DE883CE1F5ACA9FB28AB4AFD87A90115_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_B885B9A8FB7C5B6291545489DB7952F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_B885B9A8FB7C5B6291545489DB7952F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_B885B9A8FB7C5B6291545489DB7952F0" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_B885B9A8FB7C5B6291545489DB7952F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_42774BA14B3F9AE466784AFD87A944E4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_1F9AD6BE0BCE5D39AE1926043E22F56F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_42774BA14B3F9AE466784AFD87A944E4_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_1F9AD6BE0BCE5D39AE1926043E22F56F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1F9AD6BE0BCE5D39AE1926043E22F56F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_1F9AD6BE0BCE5D39AE1926043E22F56F" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_1F9AD6BE0BCE5D39AE1926043E22F56F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_445473AEC3E5D80A9CE84AFD87A9C16C_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_6A151FF0BCD6537EB59523EB4EDCAD13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_445473AEC3E5D80A9CE84AFD87A9C16C_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_6A151FF0BCD6537EB59523EB4EDCAD13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6A151FF0BCD6537EB59523EB4EDCAD13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_6A151FF0BCD6537EB59523EB4EDCAD13" xlink:to="lab_us-gaap_PreferredStockSharesIssued_6A151FF0BCD6537EB59523EB4EDCAD13" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_E0B9F9ACB71325C4A9524AFD87A9DC4E_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_B348AC900BBD5E9A970356B181784E3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_E0B9F9ACB71325C4A9524AFD87A9DC4E_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_B348AC900BBD5E9A970356B181784E3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_B348AC900BBD5E9A970356B181784E3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_B348AC900BBD5E9A970356B181784E3F" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_B348AC900BBD5E9A970356B181784E3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_4C203616CB1F8C6B2BA24AFD87AA0329_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_08299D1A3C7956C4A2BEDA557E28B274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_4C203616CB1F8C6B2BA24AFD87AA0329_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_08299D1A3C7956C4A2BEDA557E28B274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_08299D1A3C7956C4A2BEDA557E28B274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_08299D1A3C7956C4A2BEDA557E28B274" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_08299D1A3C7956C4A2BEDA557E28B274" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4D5F6671C099F82A84E94AFD87AA93B5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_37C00890D6FD56DDB1DE1EE0F276A769" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4D5F6671C099F82A84E94AFD87AA93B5_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_37C00890D6FD56DDB1DE1EE0F276A769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_37C00890D6FD56DDB1DE1EE0F276A769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_37C00890D6FD56DDB1DE1EE0F276A769" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_37C00890D6FD56DDB1DE1EE0F276A769" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3BC28C6E72004E449D8A4AFD87AAA191_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_E9ADA20987D05A6EAE9628438D86EA55" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3BC28C6E72004E449D8A4AFD87AAA191_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_E9ADA20987D05A6EAE9628438D86EA55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_E9ADA20987D05A6EAE9628438D86EA55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_E9ADA20987D05A6EAE9628438D86EA55" xlink:to="lab_us-gaap_CommonStockSharesIssued_E9ADA20987D05A6EAE9628438D86EA55" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_063C4D0132B9EB441DD29A56022F952C_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_63A6FD055EF8564FB487B59EA17378C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_63A6FD055EF8564FB487B59EA17378C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_63A6FD055EF8564FB487B59EA17378C5" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_63A6FD055EF8564FB487B59EA17378C5" xlink:type="arc" />
    <link:label id="lab_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D_terseLabel_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesTable_40577E5A38E154DCAD75C5B130F9614D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D_label_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesTable_40577E5A38E154DCAD75C5B130F9614D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D_documentation_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesTable_40577E5A38E154DCAD75C5B130F9614D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_SignificantAccountingPoliciesTable" xlink:label="loc_dare_SignificantAccountingPoliciesTable_40577E5A38E154DCAD75C5B130F9614D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SignificantAccountingPoliciesTable_40577E5A38E154DCAD75C5B130F9614D" xlink:to="lab_dare_SignificantAccountingPoliciesTable_40577E5A38E154DCAD75C5B130F9614D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5CD7E0215C0D939117539A56022FE9CD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_209AC45F5E755D4099BC7980989D7CAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5CD7E0215C0D939117539A56022FE9CD_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_209AC45F5E755D4099BC7980989D7CAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_209AC45F5E755D4099BC7980989D7CAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_209AC45F5E755D4099BC7980989D7CAF" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_209AC45F5E755D4099BC7980989D7CAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_CFC94E094EDC5E2C97061DE81812010D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_CFC94E094EDC5E2C97061DE81812010D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_CFC94E094EDC5E2C97061DE81812010D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_CFC94E094EDC5E2C97061DE81812010D" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_CFC94E094EDC5E2C97061DE81812010D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_E3ADFD332D5C8729B5279A56022F6093_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_1EDEC70169415366995BBC3415215316" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_E3ADFD332D5C8729B5279A56022F6093_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_1EDEC70169415366995BBC3415215316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1EDEC70169415366995BBC3415215316" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_1EDEC70169415366995BBC3415215316" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_1EDEC70169415366995BBC3415215316" xlink:type="arc" />
    <link:label id="lab_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4_terseLabel_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesLineItems_AB1FA72B72255C4BBD63C9710624E4F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4_label_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesLineItems_AB1FA72B72255C4BBD63C9710624E4F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4_documentation_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesLineItems_AB1FA72B72255C4BBD63C9710624E4F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_SignificantAccountingPoliciesLineItems" xlink:label="loc_dare_SignificantAccountingPoliciesLineItems_AB1FA72B72255C4BBD63C9710624E4F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_AB1FA72B72255C4BBD63C9710624E4F1" xlink:to="lab_dare_SignificantAccountingPoliciesLineItems_AB1FA72B72255C4BBD63C9710624E4F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_75CC75E42D13BA9B5A639A56022FEC60_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B6C4AA5F53135D578EB929FDCDC002F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_75CC75E42D13BA9B5A639A56022FEC60_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B6C4AA5F53135D578EB929FDCDC002F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B6C4AA5F53135D578EB929FDCDC002F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B6C4AA5F53135D578EB929FDCDC002F3" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B6C4AA5F53135D578EB929FDCDC002F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_E9DCD4DE6780D18E00819A56022F191E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_E29D27230F9559618B917803F6FF7BFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_E9DCD4DE6780D18E00819A56022F191E_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_E29D27230F9559618B917803F6FF7BFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_E29D27230F9559618B917803F6FF7BFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_E29D27230F9559618B917803F6FF7BFE" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_E29D27230F9559618B917803F6FF7BFE" xlink:type="arc" />
    <link:label id="lab_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11_terseLabel_en-US" xlink:label="lab_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:label id="lab_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11_label_en-US" xlink:label="lab_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:label id="lab_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11_documentation_en-US" xlink:label="lab_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders' equity.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_StockholdersEquityTable" xlink:label="loc_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11" xlink:to="lab_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C4D21A9C27F1C21938E08B6FD36D8181_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C4D21A9C27F1C21938E08B6FD36D8181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C4D21A9C27F1C21938E08B6FD36D8181_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C4D21A9C27F1C21938E08B6FD36D8181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C4D21A9C27F1C21938E08B6FD36D8181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C4D21A9C27F1C21938E08B6FD36D8181" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C4D21A9C27F1C21938E08B6FD36D8181" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_A22A502617E824B33A8E8B6FD36DBDDA_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_A22A502617E824B33A8E8B6FD36DBDDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_A22A502617E824B33A8E8B6FD36DBDDA_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_A22A502617E824B33A8E8B6FD36DBDDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_A22A502617E824B33A8E8B6FD36DBDDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A22A502617E824B33A8E8B6FD36DBDDA" xlink:to="lab_us-gaap_TypeOfAdoptionMember_A22A502617E824B33A8E8B6FD36DBDDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201711Member_A0146588574C7621B0D28B6FD36DC100_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201711Member_A0146588574C7621B0D28B6FD36DC100" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2017-11</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201711Member_A0146588574C7621B0D28B6FD36DC100_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201711Member_A0146588574C7621B0D28B6FD36DC100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2017-11 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201711Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201711Member_A0146588574C7621B0D28B6FD36DC100" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201711Member_A0146588574C7621B0D28B6FD36DC100" xlink:to="lab_us-gaap_AccountingStandardsUpdate201711Member_A0146588574C7621B0D28B6FD36DC100" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_714ED3D5617F28201EAF8B6FD36DCA40_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_714ED3D5617F28201EAF8B6FD36DCA40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_714ED3D5617F28201EAF8B6FD36DCA40_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_714ED3D5617F28201EAF8B6FD36DCA40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_714ED3D5617F28201EAF8B6FD36DCA40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_714ED3D5617F28201EAF8B6FD36DCA40" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_714ED3D5617F28201EAF8B6FD36DCA40" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_743F5CB0BDF0B773F4E68B6FD36D0179_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_743F5CB0BDF0B773F4E68B6FD36D0179" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_743F5CB0BDF0B773F4E68B6FD36D0179_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_743F5CB0BDF0B773F4E68B6FD36D0179" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743F5CB0BDF0B773F4E68B6FD36D0179" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743F5CB0BDF0B773F4E68B6FD36D0179" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_743F5CB0BDF0B773F4E68B6FD36D0179" xlink:type="arc" />
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_8E0E9910F744357DE0388B6FD36D788D_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_8E0E9910F744357DE0388B6FD36D788D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwritten Offering</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_8E0E9910F744357DE0388B6FD36D788D_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_8E0E9910F744357DE0388B6FD36D788D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_8E0E9910F744357DE0388B6FD36D788D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember_8E0E9910F744357DE0388B6FD36D788D" xlink:to="lab_us-gaap_OverAllotmentOptionMember_8E0E9910F744357DE0388B6FD36D788D" xlink:type="arc" />
    <link:label id="lab_dare_PublicStockOfferingMember_B7A0DA44E04EE01018C58B6FD36D31F8_terseLabel_en-US" xlink:label="lab_dare_PublicStockOfferingMember_B7A0DA44E04EE01018C58B6FD36D31F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Stock Offering</link:label>
    <link:label id="lab_dare_PublicStockOfferingMember_B7A0DA44E04EE01018C58B6FD36D31F8_label_en-US" xlink:label="lab_dare_PublicStockOfferingMember_B7A0DA44E04EE01018C58B6FD36D31F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_dare_PublicStockOfferingMember_B7A0DA44E04EE01018C58B6FD36D31F8_documentation_en-US" xlink:label="lab_dare_PublicStockOfferingMember_B7A0DA44E04EE01018C58B6FD36D31F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_PublicStockOfferingMember" xlink:label="loc_dare_PublicStockOfferingMember_B7A0DA44E04EE01018C58B6FD36D31F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PublicStockOfferingMember_B7A0DA44E04EE01018C58B6FD36D31F8" xlink:to="lab_dare_PublicStockOfferingMember_B7A0DA44E04EE01018C58B6FD36D31F8" xlink:type="arc" />
    <link:label id="lab_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919_terseLabel_en-US" xlink:label="lab_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders Equity [Line Items]</link:label>
    <link:label id="lab_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919_label_en-US" xlink:label="lab_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity [Line Items]</link:label>
    <link:label id="lab_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919_documentation_en-US" xlink:label="lab_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders' equity.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_StockholdersEquityLineItems" xlink:label="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="lab_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:type="arc" />
    <link:label id="lab_dare_GrossProceedsFromIssuanceOfCommonStock_5AF9D10A9736F08F38638B6FD36D4F27_verboseLabel_en-US" xlink:label="lab_dare_GrossProceedsFromIssuanceOfCommonStock_5AF9D10A9736F08F38638B6FD36D4F27" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds on sale of shares of common stock</link:label>
    <link:label id="lab_dare_GrossProceedsFromIssuanceOfCommonStock_5AF9D10A9736F08F38638B6FD36D4F27_label_en-US" xlink:label="lab_dare_GrossProceedsFromIssuanceOfCommonStock_5AF9D10A9736F08F38638B6FD36D4F27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Issuance Of Common Stock</link:label>
    <link:label id="lab_dare_GrossProceedsFromIssuanceOfCommonStock_5AF9D10A9736F08F38638B6FD36D4F27_documentation_en-US" xlink:label="lab_dare_GrossProceedsFromIssuanceOfCommonStock_5AF9D10A9736F08F38638B6FD36D4F27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_dare_GrossProceedsFromIssuanceOfCommonStock_5AF9D10A9736F08F38638B6FD36D4F27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_GrossProceedsFromIssuanceOfCommonStock_5AF9D10A9736F08F38638B6FD36D4F27" xlink:to="lab_dare_GrossProceedsFromIssuanceOfCommonStock_5AF9D10A9736F08F38638B6FD36D4F27" xlink:type="arc" />
    <link:label id="lab_dare_PercentageOfAggregateCommission_F6F73243D93E3C2980088B6FD36D9837_terseLabel_en-US" xlink:label="lab_dare_PercentageOfAggregateCommission_F6F73243D93E3C2980088B6FD36D9837" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate commission rate</link:label>
    <link:label id="lab_dare_PercentageOfAggregateCommission_F6F73243D93E3C2980088B6FD36D9837_label_en-US" xlink:label="lab_dare_PercentageOfAggregateCommission_F6F73243D93E3C2980088B6FD36D9837" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Aggregate Commission</link:label>
    <link:label id="lab_dare_PercentageOfAggregateCommission_F6F73243D93E3C2980088B6FD36D9837_documentation_en-US" xlink:label="lab_dare_PercentageOfAggregateCommission_F6F73243D93E3C2980088B6FD36D9837" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of aggregate commission.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_PercentageOfAggregateCommission" xlink:label="loc_dare_PercentageOfAggregateCommission_F6F73243D93E3C2980088B6FD36D9837" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PercentageOfAggregateCommission_F6F73243D93E3C2980088B6FD36D9837" xlink:to="lab_dare_PercentageOfAggregateCommission_F6F73243D93E3C2980088B6FD36D9837" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7D931EBDCEE712349F3C8B6FD36DCDF2_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7D931EBDCEE712349F3C8B6FD36DCDF2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued and sold (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7D931EBDCEE712349F3C8B6FD36DCDF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7D931EBDCEE712349F3C8B6FD36DCDF2" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7D931EBDCEE712349F3C8B6FD36DCDF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_8C3D3A6C3F9CE19D44FA8B6FD36D0206_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_8C3D3A6C3F9CE19D44FA8B6FD36D0206" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Public offering price in the Offering (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_8C3D3A6C3F9CE19D44FA8B6FD36D0206_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_8C3D3A6C3F9CE19D44FA8B6FD36D0206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_8C3D3A6C3F9CE19D44FA8B6FD36D0206" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_8C3D3A6C3F9CE19D44FA8B6FD36D0206" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_8C3D3A6C3F9CE19D44FA8B6FD36D0206" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_87AA5F3BA749CB1A18548B6FD36D4777_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_87AA5F3BA749CB1A18548B6FD36D4777" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs incurred</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_87AA5F3BA749CB1A18548B6FD36D4777_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_87AA5F3BA749CB1A18548B6FD36D4777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_87AA5F3BA749CB1A18548B6FD36D4777" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_87AA5F3BA749CB1A18548B6FD36D4777" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_87AA5F3BA749CB1A18548B6FD36D4777" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_10DA379D4E459D6FC60E8B6FD36D25C4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_10DA379D4E459D6FC60E8B6FD36D25C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_10DA379D4E459D6FC60E8B6FD36D25C4_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_10DA379D4E459D6FC60E8B6FD36D25C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_10DA379D4E459D6FC60E8B6FD36D25C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_10DA379D4E459D6FC60E8B6FD36D25C4" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_10DA379D4E459D6FC60E8B6FD36D25C4" xlink:type="arc" />
    <link:label id="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_A8C439607C34AC537A8B8B6FD36D6A55_terseLabel_en-US" xlink:label="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_A8C439607C34AC537A8B8B6FD36D6A55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriters overallotment option to purchase additional shares of common stock and warrants period</link:label>
    <link:label id="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_A8C439607C34AC537A8B8B6FD36D6A55_label_en-US" xlink:label="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_A8C439607C34AC537A8B8B6FD36D6A55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwriters Option To Purchase Additional Shares Of Common Stock Period</link:label>
    <link:label id="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_A8C439607C34AC537A8B8B6FD36D6A55_documentation_en-US" xlink:label="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_A8C439607C34AC537A8B8B6FD36D6A55" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwriters option to purchase additional shares of common stock period.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" xlink:label="loc_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_A8C439607C34AC537A8B8B6FD36D6A55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_A8C439607C34AC537A8B8B6FD36D6A55" xlink:to="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_A8C439607C34AC537A8B8B6FD36D6A55" xlink:type="arc" />
    <link:label id="lab_dare_UnderwritersOptionToPurchaseAdditionalShares_E475BDC2875473EA85A58B6FD36DF2C2_terseLabel_en-US" xlink:label="lab_dare_UnderwritersOptionToPurchaseAdditionalShares_E475BDC2875473EA85A58B6FD36DF2C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriters option to purchase additional shares (in shares)</link:label>
    <link:label id="lab_dare_UnderwritersOptionToPurchaseAdditionalShares_E475BDC2875473EA85A58B6FD36DF2C2_label_en-US" xlink:label="lab_dare_UnderwritersOptionToPurchaseAdditionalShares_E475BDC2875473EA85A58B6FD36DF2C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwriters Option To Purchase Additional Shares</link:label>
    <link:label id="lab_dare_UnderwritersOptionToPurchaseAdditionalShares_E475BDC2875473EA85A58B6FD36DF2C2_documentation_en-US" xlink:label="lab_dare_UnderwritersOptionToPurchaseAdditionalShares_E475BDC2875473EA85A58B6FD36DF2C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwriters option to purchase additional shares.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_UnderwritersOptionToPurchaseAdditionalShares" xlink:label="loc_dare_UnderwritersOptionToPurchaseAdditionalShares_E475BDC2875473EA85A58B6FD36DF2C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UnderwritersOptionToPurchaseAdditionalShares_E475BDC2875473EA85A58B6FD36DF2C2" xlink:to="lab_dare_UnderwritersOptionToPurchaseAdditionalShares_E475BDC2875473EA85A58B6FD36DF2C2" xlink:type="arc" />
    <link:label id="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_496FA365D812DD499E298B6FD36D0025_terseLabel_en-US" xlink:label="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_496FA365D812DD499E298B6FD36D0025" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from offering of common stock and warrants</link:label>
    <link:label id="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_496FA365D812DD499E298B6FD36D0025_label_en-US" xlink:label="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_496FA365D812DD499E298B6FD36D0025" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Offering Of Common Stock And Warrants</link:label>
    <link:label id="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_496FA365D812DD499E298B6FD36D0025_documentation_en-US" xlink:label="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_496FA365D812DD499E298B6FD36D0025" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Offering Of Common Stock And Warrants</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_GrossProceedsFromOfferingOfCommonStockAndWarrants" xlink:label="loc_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_496FA365D812DD499E298B6FD36D0025" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_496FA365D812DD499E298B6FD36D0025" xlink:to="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_496FA365D812DD499E298B6FD36D0025" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_FD29875E61840CFADAF68B6FD36D09D1_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_FD29875E61840CFADAF68B6FD36D09D1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds received in public offering, net of underwriting discounts and offering expenses</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_FD29875E61840CFADAF68B6FD36D09D1_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_FD29875E61840CFADAF68B6FD36D09D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_FD29875E61840CFADAF68B6FD36D09D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_FD29875E61840CFADAF68B6FD36D09D1" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_FD29875E61840CFADAF68B6FD36D09D1" xlink:type="arc" />
    <link:label id="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_30857EFADD67571259728B6FD36DCE36_terseLabel_en-US" xlink:label="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_30857EFADD67571259728B6FD36DCE36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value of warrants recorded in equity</link:label>
    <link:label id="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_30857EFADD67571259728B6FD36DCE36_label_en-US" xlink:label="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_30857EFADD67571259728B6FD36DCE36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Fair Value Of Warrants Recorded In Equity</link:label>
    <link:label id="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_30857EFADD67571259728B6FD36DCE36_documentation_en-US" xlink:label="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_30857EFADD67571259728B6FD36DCE36" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Fair Value Of Warrants Recorded In Equity</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:label="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_30857EFADD67571259728B6FD36DCE36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_30857EFADD67571259728B6FD36DCE36" xlink:to="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_30857EFADD67571259728B6FD36DCE36" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_09F24EB06E9082A95BAB8B6FD36D5D21_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_09F24EB06E9082A95BAB8B6FD36D5D21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount recorded to additional paid in capital as a result of triggered anti-diluted provisions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_09F24EB06E9082A95BAB8B6FD36D5D21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_09F24EB06E9082A95BAB8B6FD36D5D21" xlink:to="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_09F24EB06E9082A95BAB8B6FD36D5D21" xlink:type="arc" />
    <link:label id="lab_dare_NumberOfCommonStockWarrantsExercised_F3F6567BFBB804B7728E8B6FD36D38E7_terseLabel_en-US" xlink:label="lab_dare_NumberOfCommonStockWarrantsExercised_F3F6567BFBB804B7728E8B6FD36D38E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_dare_NumberOfCommonStockWarrantsExercised_F3F6567BFBB804B7728E8B6FD36D38E7_label_en-US" xlink:label="lab_dare_NumberOfCommonStockWarrantsExercised_F3F6567BFBB804B7728E8B6FD36D38E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Common Stock Warrants Exercised</link:label>
    <link:label id="lab_dare_NumberOfCommonStockWarrantsExercised_F3F6567BFBB804B7728E8B6FD36D38E7_documentation_en-US" xlink:label="lab_dare_NumberOfCommonStockWarrantsExercised_F3F6567BFBB804B7728E8B6FD36D38E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of common stock warrants exercised.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_NumberOfCommonStockWarrantsExercised" xlink:label="loc_dare_NumberOfCommonStockWarrantsExercised_F3F6567BFBB804B7728E8B6FD36D38E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NumberOfCommonStockWarrantsExercised_F3F6567BFBB804B7728E8B6FD36D38E7" xlink:to="lab_dare_NumberOfCommonStockWarrantsExercised_F3F6567BFBB804B7728E8B6FD36D38E7" xlink:type="arc" />
    <link:label id="lab_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B_terseLabel_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B_label_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B_documentation_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_CommitmentsAndContingenciesTable" xlink:label="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:to="lab_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D25F1F1D0BF2DC03B48B720E1C25ED65_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D25F1F1D0BF2DC03B48B720E1C25ED65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D25F1F1D0BF2DC03B48B720E1C25ED65_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D25F1F1D0BF2DC03B48B720E1C25ED65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D25F1F1D0BF2DC03B48B720E1C25ED65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D25F1F1D0BF2DC03B48B720E1C25ED65" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D25F1F1D0BF2DC03B48B720E1C25ED65" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project</link:label>
    <link:label id="lab_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189_label_en-US" xlink:label="lab_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189" xlink:to="lab_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189" xlink:type="arc" />
    <link:label id="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_A72C35F79E69282B6837720E1C261189_terseLabel_en-US" xlink:label="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_A72C35F79E69282B6837720E1C261189" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon Achievement Of Specified Development And Regulatory Milestones</link:label>
    <link:label id="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_A72C35F79E69282B6837720E1C261189_label_en-US" xlink:label="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_A72C35F79E69282B6837720E1C261189" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Achievement Of Specified Development And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_A72C35F79E69282B6837720E1C261189_documentation_en-US" xlink:label="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_A72C35F79E69282B6837720E1C261189" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upon achievement of specified development and regulatory milestones.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_A72C35F79E69282B6837720E1C261189" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_A72C35F79E69282B6837720E1C261189" xlink:to="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_A72C35F79E69282B6837720E1C261189" xlink:type="arc" />
    <link:label id="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_84B1512373E5946AF257720E1C261AB6_terseLabel_en-US" xlink:label="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_84B1512373E5946AF257720E1C261AB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon Reaching Certain Worldwide Net Sales Milestones</link:label>
    <link:label id="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_84B1512373E5946AF257720E1C261AB6_label_en-US" xlink:label="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_84B1512373E5946AF257720E1C261AB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Reaching Certain Worldwide Net Sales Milestones [Member]</link:label>
    <link:label id="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_84B1512373E5946AF257720E1C261AB6_documentation_en-US" xlink:label="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_84B1512373E5946AF257720E1C261AB6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upon reaching certain worldwide net sales milestones.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:label="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_84B1512373E5946AF257720E1C261AB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_84B1512373E5946AF257720E1C261AB6" xlink:to="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_84B1512373E5946AF257720E1C261AB6" xlink:type="arc" />
    <link:label id="lab_dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember_8DD6B9085A618E8DB92E7215FDBADEC3_terseLabel_en-US" xlink:label="lab_dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember_8DD6B9085A618E8DB92E7215FDBADEC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Milestone Payments Based On Product Development [Member]</link:label>
    <link:label id="lab_dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember_8DD6B9085A618E8DB92E7215FDBADEC3_label_en-US" xlink:label="lab_dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember_8DD6B9085A618E8DB92E7215FDBADEC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Milestone Payments Based On Product Development [Member]</link:label>
    <link:label id="lab_dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember_8DD6B9085A618E8DB92E7215FDBADEC3_documentation_en-US" xlink:label="lab_dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember_8DD6B9085A618E8DB92E7215FDBADEC3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Milestone Payments Based On Product Development [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember" xlink:label="loc_dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember_8DD6B9085A618E8DB92E7215FDBADEC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember_8DD6B9085A618E8DB92E7215FDBADEC3" xlink:to="lab_dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember_8DD6B9085A618E8DB92E7215FDBADEC3" xlink:type="arc" />
    <link:label id="lab_dare_FutureMilestonePaymentsBasedOnCommercializationMember_667B5EE6168008B41A1F721678E97197_terseLabel_en-US" xlink:label="lab_dare_FutureMilestonePaymentsBasedOnCommercializationMember_667B5EE6168008B41A1F721678E97197" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Milestone Payments Based On Commercialization [Member]</link:label>
    <link:label id="lab_dare_FutureMilestonePaymentsBasedOnCommercializationMember_667B5EE6168008B41A1F721678E97197_label_en-US" xlink:label="lab_dare_FutureMilestonePaymentsBasedOnCommercializationMember_667B5EE6168008B41A1F721678E97197" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Milestone Payments Based On Commercialization [Member]</link:label>
    <link:label id="lab_dare_FutureMilestonePaymentsBasedOnCommercializationMember_667B5EE6168008B41A1F721678E97197_documentation_en-US" xlink:label="lab_dare_FutureMilestonePaymentsBasedOnCommercializationMember_667B5EE6168008B41A1F721678E97197" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Milestone Payments Based On Commercialization [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_FutureMilestonePaymentsBasedOnCommercializationMember" xlink:label="loc_dare_FutureMilestonePaymentsBasedOnCommercializationMember_667B5EE6168008B41A1F721678E97197" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_FutureMilestonePaymentsBasedOnCommercializationMember_667B5EE6168008B41A1F721678E97197" xlink:to="lab_dare_FutureMilestonePaymentsBasedOnCommercializationMember_667B5EE6168008B41A1F721678E97197" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_E44AAEFB6E0F915DCF61720E1C26F1F2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_E44AAEFB6E0F915DCF61720E1C26F1F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_E44AAEFB6E0F915DCF61720E1C26F1F2_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_E44AAEFB6E0F915DCF61720E1C26F1F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_E44AAEFB6E0F915DCF61720E1C26F1F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E44AAEFB6E0F915DCF61720E1C26F1F2" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_E44AAEFB6E0F915DCF61720E1C26F1F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750" xlink:type="arc" />
    <link:label id="lab_dare_UponAchievingCertainCommercialMilestonesMember_EB5B5D7312F21BC78993720E1C27AA3F_terseLabel_en-US" xlink:label="lab_dare_UponAchievingCertainCommercialMilestonesMember_EB5B5D7312F21BC78993720E1C27AA3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon Achieving Certain Commercial Milestones</link:label>
    <link:label id="lab_dare_UponAchievingCertainCommercialMilestonesMember_EB5B5D7312F21BC78993720E1C27AA3F_label_en-US" xlink:label="lab_dare_UponAchievingCertainCommercialMilestonesMember_EB5B5D7312F21BC78993720E1C27AA3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Achieving Certain Commercial Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievingCertainCommercialMilestonesMember_EB5B5D7312F21BC78993720E1C27AA3F_documentation_en-US" xlink:label="lab_dare_UponAchievingCertainCommercialMilestonesMember_EB5B5D7312F21BC78993720E1C27AA3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upon Achieving Certain Commercial Milestones [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_UponAchievingCertainCommercialMilestonesMember" xlink:label="loc_dare_UponAchievingCertainCommercialMilestonesMember_EB5B5D7312F21BC78993720E1C27AA3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievingCertainCommercialMilestonesMember_EB5B5D7312F21BC78993720E1C27AA3F" xlink:to="lab_dare_UponAchievingCertainCommercialMilestonesMember_EB5B5D7312F21BC78993720E1C27AA3F" xlink:type="arc" />
    <link:label id="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember_46FAF28F5A9E7FA57356720E1C275A40_terseLabel_en-US" xlink:label="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember_46FAF28F5A9E7FA57356720E1C275A40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon Signing Of Development And Option Agreement</link:label>
    <link:label id="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember_46FAF28F5A9E7FA57356720E1C275A40_label_en-US" xlink:label="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember_46FAF28F5A9E7FA57356720E1C275A40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Signing Of Development And Option Agreement [Member]</link:label>
    <link:label id="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember_46FAF28F5A9E7FA57356720E1C275A40_documentation_en-US" xlink:label="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember_46FAF28F5A9E7FA57356720E1C275A40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upon Signing Of Development And Option Agreement [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_UponSigningOfDevelopmentAndOptionAgreementMember" xlink:label="loc_dare_UponSigningOfDevelopmentAndOptionAgreementMember_46FAF28F5A9E7FA57356720E1C275A40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponSigningOfDevelopmentAndOptionAgreementMember_46FAF28F5A9E7FA57356720E1C275A40" xlink:to="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember_46FAF28F5A9E7FA57356720E1C275A40" xlink:type="arc" />
    <link:label id="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_D5F6C1747ACD5AB86DCB720E1C28D305_terseLabel_en-US" xlink:label="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_D5F6C1747ACD5AB86DCB720E1C28D305" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon Completion Of Fifty Percent Development Not Later Than Six Months</link:label>
    <link:label id="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_D5F6C1747ACD5AB86DCB720E1C28D305_label_en-US" xlink:label="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_D5F6C1747ACD5AB86DCB720E1C28D305" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member]</link:label>
    <link:label id="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_D5F6C1747ACD5AB86DCB720E1C28D305_documentation_en-US" xlink:label="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_D5F6C1747ACD5AB86DCB720E1C28D305" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember" xlink:label="loc_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_D5F6C1747ACD5AB86DCB720E1C28D305" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_D5F6C1747ACD5AB86DCB720E1C28D305" xlink:to="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_D5F6C1747ACD5AB86DCB720E1C28D305" xlink:type="arc" />
    <link:label id="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_BF1822E529A6428D8621720E1C286B81_terseLabel_en-US" xlink:label="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_BF1822E529A6428D8621720E1C286B81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon Achieving Certain Clinical And Regulatory Development Milestones</link:label>
    <link:label id="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_BF1822E529A6428D8621720E1C286B81_label_en-US" xlink:label="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_BF1822E529A6428D8621720E1C286B81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_BF1822E529A6428D8621720E1C286B81_documentation_en-US" xlink:label="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_BF1822E529A6428D8621720E1C286B81" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:label="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_BF1822E529A6428D8621720E1C286B81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_BF1822E529A6428D8621720E1C286B81" xlink:to="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_BF1822E529A6428D8621720E1C286B81" xlink:type="arc" />
    <link:label id="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_A9153B2B0DEA56385509720E1C28E6BF_terseLabel_en-US" xlink:label="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_A9153B2B0DEA56385509720E1C28E6BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SST</link:label>
    <link:label id="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_A9153B2B0DEA56385509720E1C28E6BF_label_en-US" xlink:label="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_A9153B2B0DEA56385509720E1C28E6BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Science And Technologies D Limited Liability Company And Strategic Science Technologies Limited Liability Company [Member]</link:label>
    <link:label id="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_A9153B2B0DEA56385509720E1C28E6BF_documentation_en-US" xlink:label="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_A9153B2B0DEA56385509720E1C28E6BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:label="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_A9153B2B0DEA56385509720E1C28E6BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_A9153B2B0DEA56385509720E1C28E6BF" xlink:to="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_A9153B2B0DEA56385509720E1C28E6BF" xlink:type="arc" />
    <link:label id="lab_dare_OrbisMember_6C858185A7CD5A0A7A7F720E1C2949EB_terseLabel_en-US" xlink:label="lab_dare_OrbisMember_6C858185A7CD5A0A7A7F720E1C2949EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Orbis</link:label>
    <link:label id="lab_dare_OrbisMember_6C858185A7CD5A0A7A7F720E1C2949EB_label_en-US" xlink:label="lab_dare_OrbisMember_6C858185A7CD5A0A7A7F720E1C2949EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Orbis [Member]</link:label>
    <link:label id="lab_dare_OrbisMember_6C858185A7CD5A0A7A7F720E1C2949EB_documentation_en-US" xlink:label="lab_dare_OrbisMember_6C858185A7CD5A0A7A7F720E1C2949EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Orbis [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_OrbisMember" xlink:label="loc_dare_OrbisMember_6C858185A7CD5A0A7A7F720E1C2949EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_OrbisMember_6C858185A7CD5A0A7A7F720E1C2949EB" xlink:to="lab_dare_OrbisMember_6C858185A7CD5A0A7A7F720E1C2949EB" xlink:type="arc" />
    <link:label id="lab_dare_MilanaPharmMember_F8B6EBFED2E14641207F720E1C296A97_terseLabel_en-US" xlink:label="lab_dare_MilanaPharmMember_F8B6EBFED2E14641207F720E1C296A97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MilanaPharm</link:label>
    <link:label id="lab_dare_MilanaPharmMember_F8B6EBFED2E14641207F720E1C296A97_label_en-US" xlink:label="lab_dare_MilanaPharmMember_F8B6EBFED2E14641207F720E1C296A97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MilanaPharm [Member]</link:label>
    <link:label id="lab_dare_MilanaPharmMember_F8B6EBFED2E14641207F720E1C296A97_documentation_en-US" xlink:label="lab_dare_MilanaPharmMember_F8B6EBFED2E14641207F720E1C296A97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MilanaPharm [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_MilanaPharmMember" xlink:label="loc_dare_MilanaPharmMember_F8B6EBFED2E14641207F720E1C296A97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MilanaPharmMember_F8B6EBFED2E14641207F720E1C296A97" xlink:to="lab_dare_MilanaPharmMember_F8B6EBFED2E14641207F720E1C296A97" xlink:type="arc" />
    <link:label id="lab_dare_HammockPharmaceuticalsInc.Member_FA0DF05BBC852E4D6732720E1C2905C4_terseLabel_en-US" xlink:label="lab_dare_HammockPharmaceuticalsInc.Member_FA0DF05BBC852E4D6732720E1C2905C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hammock Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_dare_HammockPharmaceuticalsInc.Member_FA0DF05BBC852E4D6732720E1C2905C4_label_en-US" xlink:label="lab_dare_HammockPharmaceuticalsInc.Member_FA0DF05BBC852E4D6732720E1C2905C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hammock Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_dare_HammockPharmaceuticalsInc.Member_FA0DF05BBC852E4D6732720E1C2905C4_documentation_en-US" xlink:label="lab_dare_HammockPharmaceuticalsInc.Member_FA0DF05BBC852E4D6732720E1C2905C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hammock Pharmaceuticals, Inc. [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_HammockPharmaceuticalsInc.Member" xlink:label="loc_dare_HammockPharmaceuticalsInc.Member_FA0DF05BBC852E4D6732720E1C2905C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_HammockPharmaceuticalsInc.Member_FA0DF05BBC852E4D6732720E1C2905C4" xlink:to="lab_dare_HammockPharmaceuticalsInc.Member_FA0DF05BBC852E4D6732720E1C2905C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_314BFD22D11D6EFA7B4A720E1C294E06_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_314BFD22D11D6EFA7B4A720E1C294E06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_314BFD22D11D6EFA7B4A720E1C294E06_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_314BFD22D11D6EFA7B4A720E1C294E06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_314BFD22D11D6EFA7B4A720E1C294E06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_314BFD22D11D6EFA7B4A720E1C294E06" xlink:to="lab_us-gaap_TypeOfArrangementAxis_314BFD22D11D6EFA7B4A720E1C294E06" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensingAgreementsMember_CF68F6EDABAE306ED9C6720E1C2A8150_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_CF68F6EDABAE306ED9C6720E1C2A8150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_CF68F6EDABAE306ED9C6720E1C2A8150_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_CF68F6EDABAE306ED9C6720E1C2A8150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_CF68F6EDABAE306ED9C6720E1C2A8150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember_CF68F6EDABAE306ED9C6720E1C2A8150" xlink:to="lab_us-gaap_LicensingAgreementsMember_CF68F6EDABAE306ED9C6720E1C2A8150" xlink:type="arc" />
    <link:label id="lab_dare_AssignmentAgreementMember_340589595C152C4A9797720E1C2A8B5E_terseLabel_en-US" xlink:label="lab_dare_AssignmentAgreementMember_340589595C152C4A9797720E1C2A8B5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assignment Agreement</link:label>
    <link:label id="lab_dare_AssignmentAgreementMember_340589595C152C4A9797720E1C2A8B5E_label_en-US" xlink:label="lab_dare_AssignmentAgreementMember_340589595C152C4A9797720E1C2A8B5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assignment Agreement [Member]</link:label>
    <link:label id="lab_dare_AssignmentAgreementMember_340589595C152C4A9797720E1C2A8B5E_documentation_en-US" xlink:label="lab_dare_AssignmentAgreementMember_340589595C152C4A9797720E1C2A8B5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assignment Agreement [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_AssignmentAgreementMember" xlink:label="loc_dare_AssignmentAgreementMember_340589595C152C4A9797720E1C2A8B5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AssignmentAgreementMember_340589595C152C4A9797720E1C2A8B5E" xlink:to="lab_dare_AssignmentAgreementMember_340589595C152C4A9797720E1C2A8B5E" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAndCollaborationAgreementMember_57C63C1FD973C896CFC9720E1C2A798D_terseLabel_en-US" xlink:label="lab_dare_LicenseAndCollaborationAgreementMember_57C63C1FD973C896CFC9720E1C2A798D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreement</link:label>
    <link:label id="lab_dare_LicenseAndCollaborationAgreementMember_57C63C1FD973C896CFC9720E1C2A798D_label_en-US" xlink:label="lab_dare_LicenseAndCollaborationAgreementMember_57C63C1FD973C896CFC9720E1C2A798D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_dare_LicenseAndCollaborationAgreementMember_57C63C1FD973C896CFC9720E1C2A798D_documentation_en-US" xlink:label="lab_dare_LicenseAndCollaborationAgreementMember_57C63C1FD973C896CFC9720E1C2A798D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAndCollaborationAgreementMember" xlink:label="loc_dare_LicenseAndCollaborationAgreementMember_57C63C1FD973C896CFC9720E1C2A798D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAndCollaborationAgreementMember_57C63C1FD973C896CFC9720E1C2A798D" xlink:to="lab_dare_LicenseAndCollaborationAgreementMember_57C63C1FD973C896CFC9720E1C2A798D" xlink:type="arc" />
    <link:label id="lab_dare_DevelopmentAndOptionAgreementMember_53B16A4503175560998F720E1C2B1BEC_terseLabel_en-US" xlink:label="lab_dare_DevelopmentAndOptionAgreementMember_53B16A4503175560998F720E1C2B1BEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development And Option Agreement</link:label>
    <link:label id="lab_dare_DevelopmentAndOptionAgreementMember_53B16A4503175560998F720E1C2B1BEC_label_en-US" xlink:label="lab_dare_DevelopmentAndOptionAgreementMember_53B16A4503175560998F720E1C2B1BEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Option Agreement [Member]</link:label>
    <link:label id="lab_dare_DevelopmentAndOptionAgreementMember_53B16A4503175560998F720E1C2B1BEC_documentation_en-US" xlink:label="lab_dare_DevelopmentAndOptionAgreementMember_53B16A4503175560998F720E1C2B1BEC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Option Agreement [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_DevelopmentAndOptionAgreementMember" xlink:label="loc_dare_DevelopmentAndOptionAgreementMember_53B16A4503175560998F720E1C2B1BEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_DevelopmentAndOptionAgreementMember_53B16A4503175560998F720E1C2B1BEC" xlink:to="lab_dare_DevelopmentAndOptionAgreementMember_53B16A4503175560998F720E1C2B1BEC" xlink:type="arc" />
    <link:label id="lab_dare_JuniperPharmaceuticalsInc.Member_C669DECFBE7E4C9B1722720E1C2B059B_terseLabel_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsInc.Member_C669DECFBE7E4C9B1722720E1C2B059B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Juniper Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_dare_JuniperPharmaceuticalsInc.Member_C669DECFBE7E4C9B1722720E1C2B059B_label_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsInc.Member_C669DECFBE7E4C9B1722720E1C2B059B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Juniper Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_dare_JuniperPharmaceuticalsInc.Member_C669DECFBE7E4C9B1722720E1C2B059B_documentation_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsInc.Member_C669DECFBE7E4C9B1722720E1C2B059B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Juniper Pharmaceuticals, Inc. [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_JuniperPharmaceuticalsInc.Member" xlink:label="loc_dare_JuniperPharmaceuticalsInc.Member_C669DECFBE7E4C9B1722720E1C2B059B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_JuniperPharmaceuticalsInc.Member_C669DECFBE7E4C9B1722720E1C2B059B" xlink:to="lab_dare_JuniperPharmaceuticalsInc.Member_C669DECFBE7E4C9B1722720E1C2B059B" xlink:type="arc" />
    <link:label id="lab_dare_JuniperPharmaceuticalsMember_B5E44CE6DC6E200959C4720E1C2B9189_terseLabel_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsMember_B5E44CE6DC6E200959C4720E1C2B9189" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Juniper Pharmaceuticals</link:label>
    <link:label id="lab_dare_JuniperPharmaceuticalsMember_B5E44CE6DC6E200959C4720E1C2B9189_label_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsMember_B5E44CE6DC6E200959C4720E1C2B9189" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Juniper Pharmaceuticals [Member]</link:label>
    <link:label id="lab_dare_JuniperPharmaceuticalsMember_B5E44CE6DC6E200959C4720E1C2B9189_documentation_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsMember_B5E44CE6DC6E200959C4720E1C2B9189" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Juniper Pharmaceuticals.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_JuniperPharmaceuticalsMember" xlink:label="loc_dare_JuniperPharmaceuticalsMember_B5E44CE6DC6E200959C4720E1C2B9189" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_JuniperPharmaceuticalsMember_B5E44CE6DC6E200959C4720E1C2B9189" xlink:to="lab_dare_JuniperPharmaceuticalsMember_B5E44CE6DC6E200959C4720E1C2B9189" xlink:type="arc" />
    <link:label id="lab_dare_ADVATecAgreementMember_6B4FAF095DBE9F8EA93A720E1C2C4235_terseLabel_en-US" xlink:label="lab_dare_ADVATecAgreementMember_6B4FAF095DBE9F8EA93A720E1C2C4235" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ADVA Tec Agreement</link:label>
    <link:label id="lab_dare_ADVATecAgreementMember_6B4FAF095DBE9F8EA93A720E1C2C4235_label_en-US" xlink:label="lab_dare_ADVATecAgreementMember_6B4FAF095DBE9F8EA93A720E1C2C4235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">A D V A Tec Agreement [Member]</link:label>
    <link:label id="lab_dare_ADVATecAgreementMember_6B4FAF095DBE9F8EA93A720E1C2C4235_documentation_en-US" xlink:label="lab_dare_ADVATecAgreementMember_6B4FAF095DBE9F8EA93A720E1C2C4235" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ADVA Tec agreement.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_ADVATecAgreementMember" xlink:label="loc_dare_ADVATecAgreementMember_6B4FAF095DBE9F8EA93A720E1C2C4235" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ADVATecAgreementMember_6B4FAF095DBE9F8EA93A720E1C2C4235" xlink:to="lab_dare_ADVATecAgreementMember_6B4FAF095DBE9F8EA93A720E1C2C4235" xlink:type="arc" />
    <link:label id="lab_dare_ClinicalAndRegulatoryMilestonesMember_E0F632337C5682F377BE720E1C2C7442_terseLabel_en-US" xlink:label="lab_dare_ClinicalAndRegulatoryMilestonesMember_E0F632337C5682F377BE720E1C2C7442" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical And Regulatory Milestones</link:label>
    <link:label id="lab_dare_ClinicalAndRegulatoryMilestonesMember_E0F632337C5682F377BE720E1C2C7442_label_en-US" xlink:label="lab_dare_ClinicalAndRegulatoryMilestonesMember_E0F632337C5682F377BE720E1C2C7442" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_dare_ClinicalAndRegulatoryMilestonesMember_E0F632337C5682F377BE720E1C2C7442_documentation_en-US" xlink:label="lab_dare_ClinicalAndRegulatoryMilestonesMember_E0F632337C5682F377BE720E1C2C7442" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical And Regulatory Milestones [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_ClinicalAndRegulatoryMilestonesMember" xlink:label="loc_dare_ClinicalAndRegulatoryMilestonesMember_E0F632337C5682F377BE720E1C2C7442" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ClinicalAndRegulatoryMilestonesMember_E0F632337C5682F377BE720E1C2C7442" xlink:to="lab_dare_ClinicalAndRegulatoryMilestonesMember_E0F632337C5682F377BE720E1C2C7442" xlink:type="arc" />
    <link:label id="lab_dare_SalesMilestonesMember_7E93522D4E5A566BA157720E1C2DBBE1_terseLabel_en-US" xlink:label="lab_dare_SalesMilestonesMember_7E93522D4E5A566BA157720E1C2DBBE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Milestones</link:label>
    <link:label id="lab_dare_SalesMilestonesMember_7E93522D4E5A566BA157720E1C2DBBE1_label_en-US" xlink:label="lab_dare_SalesMilestonesMember_7E93522D4E5A566BA157720E1C2DBBE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Milestones [Member]</link:label>
    <link:label id="lab_dare_SalesMilestonesMember_7E93522D4E5A566BA157720E1C2DBBE1_documentation_en-US" xlink:label="lab_dare_SalesMilestonesMember_7E93522D4E5A566BA157720E1C2DBBE1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Milestones [Member]</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_SalesMilestonesMember" xlink:label="loc_dare_SalesMilestonesMember_7E93522D4E5A566BA157720E1C2DBBE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SalesMilestonesMember_7E93522D4E5A566BA157720E1C2DBBE1" xlink:to="lab_dare_SalesMilestonesMember_7E93522D4E5A566BA157720E1C2DBBE1" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_6DB419DE9465D9775C20720E1C2DBF4D_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_6DB419DE9465D9775C20720E1C2DBF4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_6DB419DE9465D9775C20720E1C2DBF4D_label_en-US" xlink:label="lab_srt_RangeAxis_6DB419DE9465D9775C20720E1C2DBF4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6DB419DE9465D9775C20720E1C2DBF4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_6DB419DE9465D9775C20720E1C2DBF4D" xlink:to="lab_srt_RangeAxis_6DB419DE9465D9775C20720E1C2DBF4D" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_108BCB3D27EA514E41BB720E1C2D6661_terseLabel_en-US" xlink:label="lab_srt_RangeMember_108BCB3D27EA514E41BB720E1C2D6661" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_108BCB3D27EA514E41BB720E1C2D6661_label_en-US" xlink:label="lab_srt_RangeMember_108BCB3D27EA514E41BB720E1C2D6661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_108BCB3D27EA514E41BB720E1C2D6661" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_108BCB3D27EA514E41BB720E1C2D6661" xlink:to="lab_srt_RangeMember_108BCB3D27EA514E41BB720E1C2D6661" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_F8C594F496E0AD8867C1720E1C2E1FA0_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_F8C594F496E0AD8867C1720E1C2E1FA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_F8C594F496E0AD8867C1720E1C2E1FA0_label_en-US" xlink:label="lab_srt_MinimumMember_F8C594F496E0AD8867C1720E1C2E1FA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_F8C594F496E0AD8867C1720E1C2E1FA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_F8C594F496E0AD8867C1720E1C2E1FA0" xlink:to="lab_srt_MinimumMember_F8C594F496E0AD8867C1720E1C2E1FA0" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_A47D8BB2B75CA86BDFE4720E1C2F07E1_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_A47D8BB2B75CA86BDFE4720E1C2F07E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_A47D8BB2B75CA86BDFE4720E1C2F07E1_label_en-US" xlink:label="lab_srt_MaximumMember_A47D8BB2B75CA86BDFE4720E1C2F07E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_A47D8BB2B75CA86BDFE4720E1C2F07E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_A47D8BB2B75CA86BDFE4720E1C2F07E1" xlink:to="lab_srt_MaximumMember_A47D8BB2B75CA86BDFE4720E1C2F07E1" xlink:type="arc" />
    <link:label id="lab_dare_OvapreneMember_972EAC232AF68E34625B720E1C318C87_terseLabel_en-US" xlink:label="lab_dare_OvapreneMember_972EAC232AF68E34625B720E1C318C87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ovaprene</link:label>
    <link:label id="lab_dare_OvapreneMember_972EAC232AF68E34625B720E1C318C87_label_en-US" xlink:label="lab_dare_OvapreneMember_972EAC232AF68E34625B720E1C318C87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ovaprene [Member]</link:label>
    <link:label id="lab_dare_OvapreneMember_972EAC232AF68E34625B720E1C318C87_documentation_en-US" xlink:label="lab_dare_OvapreneMember_972EAC232AF68E34625B720E1C318C87" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ovaprene.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_OvapreneMember" xlink:label="loc_dare_OvapreneMember_972EAC232AF68E34625B720E1C318C87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_OvapreneMember_972EAC232AF68E34625B720E1C318C87" xlink:to="lab_dare_OvapreneMember_972EAC232AF68E34625B720E1C318C87" xlink:type="arc" />
    <link:label id="lab_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC_terseLabel_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC_label_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC_documentation_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_CommitmentsAndContingenciesLineItems" xlink:label="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="lab_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:type="arc" />
    <link:label id="lab_dare_NumberOfPatentsIssued_DC3759BF5CBAF4FB05A8720E1C32EFDC_terseLabel_en-US" xlink:label="lab_dare_NumberOfPatentsIssued_DC3759BF5CBAF4FB05A8720E1C32EFDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents issued</link:label>
    <link:label id="lab_dare_NumberOfPatentsIssued_DC3759BF5CBAF4FB05A8720E1C32EFDC_label_en-US" xlink:label="lab_dare_NumberOfPatentsIssued_DC3759BF5CBAF4FB05A8720E1C32EFDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Patents Issued</link:label>
    <link:label id="lab_dare_NumberOfPatentsIssued_DC3759BF5CBAF4FB05A8720E1C32EFDC_documentation_en-US" xlink:label="lab_dare_NumberOfPatentsIssued_DC3759BF5CBAF4FB05A8720E1C32EFDC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of patents issued.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_NumberOfPatentsIssued" xlink:label="loc_dare_NumberOfPatentsIssued_DC3759BF5CBAF4FB05A8720E1C32EFDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NumberOfPatentsIssued_DC3759BF5CBAF4FB05A8720E1C32EFDC" xlink:to="lab_dare_NumberOfPatentsIssued_DC3759BF5CBAF4FB05A8720E1C32EFDC" xlink:type="arc" />
    <link:label id="lab_dare_NumberOfPendingPatents_091BCD5571D073B6E088720E1C32F0C1_terseLabel_en-US" xlink:label="lab_dare_NumberOfPendingPatents_091BCD5571D073B6E088720E1C32F0C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of pending US patent applications</link:label>
    <link:label id="lab_dare_NumberOfPendingPatents_091BCD5571D073B6E088720E1C32F0C1_label_en-US" xlink:label="lab_dare_NumberOfPendingPatents_091BCD5571D073B6E088720E1C32F0C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Pending Patents</link:label>
    <link:label id="lab_dare_NumberOfPendingPatents_091BCD5571D073B6E088720E1C32F0C1_documentation_en-US" xlink:label="lab_dare_NumberOfPendingPatents_091BCD5571D073B6E088720E1C32F0C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Pending Patents</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_NumberOfPendingPatents" xlink:label="loc_dare_NumberOfPendingPatents_091BCD5571D073B6E088720E1C32F0C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NumberOfPendingPatents_091BCD5571D073B6E088720E1C32F0C1" xlink:to="lab_dare_NumberOfPendingPatents_091BCD5571D073B6E088720E1C32F0C1" xlink:type="arc" />
    <link:label id="lab_dare_NumberOfPatentsGranted_C09ED940D44D9DFCACAE720E1C328B60_terseLabel_en-US" xlink:label="lab_dare_NumberOfPatentsGranted_C09ED940D44D9DFCACAE720E1C328B60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents granted</link:label>
    <link:label id="lab_dare_NumberOfPatentsGranted_C09ED940D44D9DFCACAE720E1C328B60_label_en-US" xlink:label="lab_dare_NumberOfPatentsGranted_C09ED940D44D9DFCACAE720E1C328B60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Patents Granted</link:label>
    <link:label id="lab_dare_NumberOfPatentsGranted_C09ED940D44D9DFCACAE720E1C328B60_documentation_en-US" xlink:label="lab_dare_NumberOfPatentsGranted_C09ED940D44D9DFCACAE720E1C328B60" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Patents Granted</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_NumberOfPatentsGranted" xlink:label="loc_dare_NumberOfPatentsGranted_C09ED940D44D9DFCACAE720E1C328B60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NumberOfPatentsGranted_C09ED940D44D9DFCACAE720E1C328B60" xlink:to="lab_dare_NumberOfPatentsGranted_C09ED940D44D9DFCACAE720E1C328B60" xlink:type="arc" />
    <link:label id="lab_dare_NumberOfPatentApplications_AE419E1CED16AD89560B720E1C339342_terseLabel_en-US" xlink:label="lab_dare_NumberOfPatentApplications_AE419E1CED16AD89560B720E1C339342" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patent applications in other major markets</link:label>
    <link:label id="lab_dare_NumberOfPatentApplications_AE419E1CED16AD89560B720E1C339342_label_en-US" xlink:label="lab_dare_NumberOfPatentApplications_AE419E1CED16AD89560B720E1C339342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Patent Applications</link:label>
    <link:label id="lab_dare_NumberOfPatentApplications_AE419E1CED16AD89560B720E1C339342_documentation_en-US" xlink:label="lab_dare_NumberOfPatentApplications_AE419E1CED16AD89560B720E1C339342" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of patent applications.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_NumberOfPatentApplications" xlink:label="loc_dare_NumberOfPatentApplications_AE419E1CED16AD89560B720E1C339342" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NumberOfPatentApplications_AE419E1CED16AD89560B720E1C339342" xlink:to="lab_dare_NumberOfPatentApplications_AE419E1CED16AD89560B720E1C339342" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligation_12566402C85BBDBBF934720E1C33B332_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation_12566402C85BBDBBF934720E1C33B332" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum spending amounts per year</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_12566402C85BBDBBF934720E1C33B332_label_en-US" xlink:label="lab_us-gaap_ContractualObligation_12566402C85BBDBBF934720E1C33B332" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_12566402C85BBDBBF934720E1C33B332" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation_12566402C85BBDBBF934720E1C33B332" xlink:to="lab_us-gaap_ContractualObligation_12566402C85BBDBBF934720E1C33B332" xlink:type="arc" />
    <link:label id="lab_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_39239BFC16A9EA2F225F720E1C33F8D1_terseLabel_en-US" xlink:label="lab_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_39239BFC16A9EA2F225F720E1C33F8D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement termination period on failing to commercialize in certain designated countries</link:label>
    <link:label id="lab_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_39239BFC16A9EA2F225F720E1C33F8D1_label_en-US" xlink:label="lab_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_39239BFC16A9EA2F225F720E1C33F8D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement Termination Period On Failing To Commercialize In Certain Designated Countries</link:label>
    <link:label id="lab_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_39239BFC16A9EA2F225F720E1C33F8D1_documentation_en-US" xlink:label="lab_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_39239BFC16A9EA2F225F720E1C33F8D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement termination period on failing to commercialize in certain designated countries.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries" xlink:label="loc_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_39239BFC16A9EA2F225F720E1C33F8D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_39239BFC16A9EA2F225F720E1C33F8D1" xlink:to="lab_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_39239BFC16A9EA2F225F720E1C33F8D1" xlink:type="arc" />
    <link:label id="lab_dare_NumberOfDesignatedCountries_6F550C419C7157CAA2A1720E1C339D1B_terseLabel_en-US" xlink:label="lab_dare_NumberOfDesignatedCountries_6F550C419C7157CAA2A1720E1C339D1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of designated European countries</link:label>
    <link:label id="lab_dare_NumberOfDesignatedCountries_6F550C419C7157CAA2A1720E1C339D1B_label_en-US" xlink:label="lab_dare_NumberOfDesignatedCountries_6F550C419C7157CAA2A1720E1C339D1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Designated Countries</link:label>
    <link:label id="lab_dare_NumberOfDesignatedCountries_6F550C419C7157CAA2A1720E1C339D1B_documentation_en-US" xlink:label="lab_dare_NumberOfDesignatedCountries_6F550C419C7157CAA2A1720E1C339D1B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of designated countries.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_NumberOfDesignatedCountries" xlink:label="loc_dare_NumberOfDesignatedCountries_6F550C419C7157CAA2A1720E1C339D1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NumberOfDesignatedCountries_6F550C419C7157CAA2A1720E1C339D1B" xlink:to="lab_dare_NumberOfDesignatedCountries_6F550C419C7157CAA2A1720E1C339D1B" xlink:type="arc" />
    <link:label id="lab_dare_PercentageOfRoyaltyRate_53BE2ACF30C4616D0082720E1C34ED4A_terseLabel_en-US" xlink:label="lab_dare_PercentageOfRoyaltyRate_53BE2ACF30C4616D0082720E1C34ED4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of royalty rate</link:label>
    <link:label id="lab_dare_PercentageOfRoyaltyRate_53BE2ACF30C4616D0082720E1C34ED4A_label_en-US" xlink:label="lab_dare_PercentageOfRoyaltyRate_53BE2ACF30C4616D0082720E1C34ED4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Royalty Rate</link:label>
    <link:label id="lab_dare_PercentageOfRoyaltyRate_53BE2ACF30C4616D0082720E1C34ED4A_documentation_en-US" xlink:label="lab_dare_PercentageOfRoyaltyRate_53BE2ACF30C4616D0082720E1C34ED4A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of royalty rate.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_PercentageOfRoyaltyRate" xlink:label="loc_dare_PercentageOfRoyaltyRate_53BE2ACF30C4616D0082720E1C34ED4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PercentageOfRoyaltyRate_53BE2ACF30C4616D0082720E1C34ED4A" xlink:to="lab_dare_PercentageOfRoyaltyRate_53BE2ACF30C4616D0082720E1C34ED4A" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_921A9CEE5A93503856E3720E1C342EBC_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_921A9CEE5A93503856E3720E1C342EBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, termination period due to performance failure</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_921A9CEE5A93503856E3720E1C342EBC_label_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_921A9CEE5A93503856E3720E1C342EBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Termination Period Due To Performance Failure</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_921A9CEE5A93503856E3720E1C342EBC_documentation_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_921A9CEE5A93503856E3720E1C342EBC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License agreement, termination period due to performance failure.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" xlink:label="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_921A9CEE5A93503856E3720E1C342EBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_921A9CEE5A93503856E3720E1C342EBC" xlink:to="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_921A9CEE5A93503856E3720E1C342EBC" xlink:type="arc" />
    <link:label id="lab_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_A61483944156CEFC28B0720E1C34C7EF_terseLabel_en-US" xlink:label="lab_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_A61483944156CEFC28B0720E1C34C7EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement termination on failing to enroll patient within months of production and release</link:label>
    <link:label id="lab_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_A61483944156CEFC28B0720E1C34C7EF_label_en-US" xlink:label="lab_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_A61483944156CEFC28B0720E1C34C7EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement Termination On Failing To Enroll Patient Within Months Of Production And Release</link:label>
    <link:label id="lab_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_A61483944156CEFC28B0720E1C34C7EF_documentation_en-US" xlink:label="lab_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_A61483944156CEFC28B0720E1C34C7EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement termination on failing to enroll patient within months of production and release.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease" xlink:label="loc_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_A61483944156CEFC28B0720E1C34C7EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_A61483944156CEFC28B0720E1C34C7EF" xlink:to="lab_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_A61483944156CEFC28B0720E1C34C7EF" xlink:type="arc" />
    <link:label id="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_A2215BC3F6476F40CA36720E1C34514D_terseLabel_en-US" xlink:label="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_A2215BC3F6476F40CA36720E1C34514D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of rights to inventions by employees under license agreement</link:label>
    <link:label id="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_A2215BC3F6476F40CA36720E1C34514D_label_en-US" xlink:label="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_A2215BC3F6476F40CA36720E1C34514D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Rights To Inventions By Employees Under License Agreement</link:label>
    <link:label id="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_A2215BC3F6476F40CA36720E1C34514D_documentation_en-US" xlink:label="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_A2215BC3F6476F40CA36720E1C34514D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of rights to inventions by employees under license agreement.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" xlink:label="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_A2215BC3F6476F40CA36720E1C34514D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_A2215BC3F6476F40CA36720E1C34514D" xlink:to="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_A2215BC3F6476F40CA36720E1C34514D" xlink:type="arc" />
    <link:label id="lab_dare_MilestonePaymentsContingentAmount_016410222CF3C4AC264A720E1C359D10_terseLabel_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmount_016410222CF3C4AC264A720E1C359D10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments, contingent amount</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmount_016410222CF3C4AC264A720E1C359D10_label_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmount_016410222CF3C4AC264A720E1C359D10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments Contingent Amount</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmount_016410222CF3C4AC264A720E1C359D10_documentation_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmount_016410222CF3C4AC264A720E1C359D10" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payments, contingent amount.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_MilestonePaymentsContingentAmount" xlink:label="loc_dare_MilestonePaymentsContingentAmount_016410222CF3C4AC264A720E1C359D10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MilestonePaymentsContingentAmount_016410222CF3C4AC264A720E1C359D10" xlink:to="lab_dare_MilestonePaymentsContingentAmount_016410222CF3C4AC264A720E1C359D10" xlink:type="arc" />
    <link:label id="lab_dare_SecuredInvestmentRequiredForLicenseAgreement_21821E41A96414ED1831720E1C3566D9_terseLabel_en-US" xlink:label="lab_dare_SecuredInvestmentRequiredForLicenseAgreement_21821E41A96414ED1831720E1C3566D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured investment required for license agreement</link:label>
    <link:label id="lab_dare_SecuredInvestmentRequiredForLicenseAgreement_21821E41A96414ED1831720E1C3566D9_label_en-US" xlink:label="lab_dare_SecuredInvestmentRequiredForLicenseAgreement_21821E41A96414ED1831720E1C3566D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Investment Required For License Agreement</link:label>
    <link:label id="lab_dare_SecuredInvestmentRequiredForLicenseAgreement_21821E41A96414ED1831720E1C3566D9_documentation_en-US" xlink:label="lab_dare_SecuredInvestmentRequiredForLicenseAgreement_21821E41A96414ED1831720E1C3566D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Secured investment required for license agreement.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_SecuredInvestmentRequiredForLicenseAgreement" xlink:label="loc_dare_SecuredInvestmentRequiredForLicenseAgreement_21821E41A96414ED1831720E1C3566D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SecuredInvestmentRequiredForLicenseAgreement_21821E41A96414ED1831720E1C3566D9" xlink:to="lab_dare_SecuredInvestmentRequiredForLicenseAgreement_21821E41A96414ED1831720E1C3566D9" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAgreementExpirationPeriod_32F365D4A7C0277864A4720E1C355CCA_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementExpirationPeriod_32F365D4A7C0277864A4720E1C355CCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, expiration period</link:label>
    <link:label id="lab_dare_LicenseAgreementExpirationPeriod_32F365D4A7C0277864A4720E1C355CCA_label_en-US" xlink:label="lab_dare_LicenseAgreementExpirationPeriod_32F365D4A7C0277864A4720E1C355CCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Expiration Period</link:label>
    <link:label id="lab_dare_LicenseAgreementExpirationPeriod_32F365D4A7C0277864A4720E1C355CCA_documentation_en-US" xlink:label="lab_dare_LicenseAgreementExpirationPeriod_32F365D4A7C0277864A4720E1C355CCA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License agreement expiration period.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementExpirationPeriod" xlink:label="loc_dare_LicenseAgreementExpirationPeriod_32F365D4A7C0277864A4720E1C355CCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementExpirationPeriod_32F365D4A7C0277864A4720E1C355CCA" xlink:to="lab_dare_LicenseAgreementExpirationPeriod_32F365D4A7C0277864A4720E1C355CCA" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_839B01738675A05CB4C6720E1C3520C3_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_839B01738675A05CB4C6720E1C3520C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, termination period prior to receipt of approval</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_839B01738675A05CB4C6720E1C3520C3_label_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_839B01738675A05CB4C6720E1C3520C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Termination Period Prior To Receipt Of Approval</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_839B01738675A05CB4C6720E1C3520C3_documentation_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_839B01738675A05CB4C6720E1C3520C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License agreement, termination period prior to receipt of approval.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval" xlink:label="loc_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_839B01738675A05CB4C6720E1C3520C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_839B01738675A05CB4C6720E1C3520C3" xlink:to="lab_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_839B01738675A05CB4C6720E1C3520C3" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_0F186928003DEFE63BD0720E1C3515F3_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_0F186928003DEFE63BD0720E1C3515F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, termination period after receipt of approval</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_0F186928003DEFE63BD0720E1C3515F3_label_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_0F186928003DEFE63BD0720E1C3515F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Termination Period After Receipt Of Approval</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_0F186928003DEFE63BD0720E1C3515F3_documentation_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_0F186928003DEFE63BD0720E1C3515F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License agreement, termination period after receipt of approval.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval" xlink:label="loc_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_0F186928003DEFE63BD0720E1C3515F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_0F186928003DEFE63BD0720E1C3515F3" xlink:to="lab_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_0F186928003DEFE63BD0720E1C3515F3" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_FB09EFBEF29880AC234A720E1C361E22_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_FB09EFBEF29880AC234A720E1C361E22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, termination period for applicable license products of applicable countries</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_FB09EFBEF29880AC234A720E1C361E22_label_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_FB09EFBEF29880AC234A720E1C361E22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Termination Period For Applicable License Products Of Applicable Countries</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_FB09EFBEF29880AC234A720E1C361E22_documentation_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_FB09EFBEF29880AC234A720E1C361E22" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License agreement, termination period for applicable license products of applicable countries.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries" xlink:label="loc_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_FB09EFBEF29880AC234A720E1C361E22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_FB09EFBEF29880AC234A720E1C361E22" xlink:to="lab_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_FB09EFBEF29880AC234A720E1C361E22" xlink:type="arc" />
    <link:label id="lab_dare_NoticePeriodForTerminationOfAgreementForBothParties_FCA851E45049B2E03A7F720E1C36A3AC_terseLabel_en-US" xlink:label="lab_dare_NoticePeriodForTerminationOfAgreementForBothParties_FCA851E45049B2E03A7F720E1C36A3AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior written notice period for termination of agreement for both parties</link:label>
    <link:label id="lab_dare_NoticePeriodForTerminationOfAgreementForBothParties_FCA851E45049B2E03A7F720E1C36A3AC_label_en-US" xlink:label="lab_dare_NoticePeriodForTerminationOfAgreementForBothParties_FCA851E45049B2E03A7F720E1C36A3AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notice Period For Termination Of Agreement For Both Parties</link:label>
    <link:label id="lab_dare_NoticePeriodForTerminationOfAgreementForBothParties_FCA851E45049B2E03A7F720E1C36A3AC_documentation_en-US" xlink:label="lab_dare_NoticePeriodForTerminationOfAgreementForBothParties_FCA851E45049B2E03A7F720E1C36A3AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notice period for termination of agreement for both parties.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_NoticePeriodForTerminationOfAgreementForBothParties" xlink:label="loc_dare_NoticePeriodForTerminationOfAgreementForBothParties_FCA851E45049B2E03A7F720E1C36A3AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NoticePeriodForTerminationOfAgreementForBothParties_FCA851E45049B2E03A7F720E1C36A3AC" xlink:to="lab_dare_NoticePeriodForTerminationOfAgreementForBothParties_FCA851E45049B2E03A7F720E1C36A3AC" xlink:type="arc" />
    <link:label id="lab_dare_ResearchAndDevelopmentMilestonePayment_FFB065DC5477EF1F92B3720E1C361D21_terseLabel_en-US" xlink:label="lab_dare_ResearchAndDevelopmentMilestonePayment_FFB065DC5477EF1F92B3720E1C361D21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_dare_ResearchAndDevelopmentMilestonePayment_FFB065DC5477EF1F92B3720E1C361D21_label_en-US" xlink:label="lab_dare_ResearchAndDevelopmentMilestonePayment_FFB065DC5477EF1F92B3720E1C361D21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Milestone Payment</link:label>
    <link:label id="lab_dare_ResearchAndDevelopmentMilestonePayment_FFB065DC5477EF1F92B3720E1C361D21_documentation_en-US" xlink:label="lab_dare_ResearchAndDevelopmentMilestonePayment_FFB065DC5477EF1F92B3720E1C361D21" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development milestone payment.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_ResearchAndDevelopmentMilestonePayment" xlink:label="loc_dare_ResearchAndDevelopmentMilestonePayment_FFB065DC5477EF1F92B3720E1C361D21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ResearchAndDevelopmentMilestonePayment_FFB065DC5477EF1F92B3720E1C361D21" xlink:to="lab_dare_ResearchAndDevelopmentMilestonePayment_FFB065DC5477EF1F92B3720E1C361D21" xlink:type="arc" />
    <link:label id="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_6BF65CAE4EB51023B960720E1C368B0C_terseLabel_en-US" xlink:label="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_6BF65CAE4EB51023B960720E1C368B0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commencement period for stage two upon achievement of stage one</link:label>
    <link:label id="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_6BF65CAE4EB51023B960720E1C368B0C_label_en-US" xlink:label="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_6BF65CAE4EB51023B960720E1C368B0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commencement Period For Stage Two Upon Achievement Of Stage One</link:label>
    <link:label id="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_6BF65CAE4EB51023B960720E1C368B0C_documentation_en-US" xlink:label="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_6BF65CAE4EB51023B960720E1C368B0C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commencement Period For Stage Two Upon Achievement Of Stage One</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_CommencementPeriodForStageTwoUponAchievementOfStageOne" xlink:label="loc_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_6BF65CAE4EB51023B960720E1C368B0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_6BF65CAE4EB51023B960720E1C368B0C" xlink:to="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_6BF65CAE4EB51023B960720E1C368B0C" xlink:type="arc" />
    <link:label id="lab_dare_UpfrontLicenseFeePaid_B24534E7ABB0A7E59847720E1C37FB2D_terseLabel_en-US" xlink:label="lab_dare_UpfrontLicenseFeePaid_B24534E7ABB0A7E59847720E1C37FB2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront license fee paid</link:label>
    <link:label id="lab_dare_UpfrontLicenseFeePaid_B24534E7ABB0A7E59847720E1C37FB2D_label_en-US" xlink:label="lab_dare_UpfrontLicenseFeePaid_B24534E7ABB0A7E59847720E1C37FB2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront License Fee Paid</link:label>
    <link:label id="lab_dare_UpfrontLicenseFeePaid_B24534E7ABB0A7E59847720E1C37FB2D_documentation_en-US" xlink:label="lab_dare_UpfrontLicenseFeePaid_B24534E7ABB0A7E59847720E1C37FB2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront License Fee Paid</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_UpfrontLicenseFeePaid" xlink:label="loc_dare_UpfrontLicenseFeePaid_B24534E7ABB0A7E59847720E1C37FB2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UpfrontLicenseFeePaid_B24534E7ABB0A7E59847720E1C37FB2D" xlink:to="lab_dare_UpfrontLicenseFeePaid_B24534E7ABB0A7E59847720E1C37FB2D" xlink:type="arc" />
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_D9BE6B1057B91F64F1BD720E1C3743AD_terseLabel_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_D9BE6B1057B91F64F1BD720E1C3743AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential annual license maintenance fee, payments in year one</link:label>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_D9BE6B1057B91F64F1BD720E1C3743AD_label_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_D9BE6B1057B91F64F1BD720E1C3743AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Annual License Maintenance Fee, Payments In Year One</link:label>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_D9BE6B1057B91F64F1BD720E1C3743AD_documentation_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_D9BE6B1057B91F64F1BD720E1C3743AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Annual License Maintenance Fee, Payments In Year One</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_D9BE6B1057B91F64F1BD720E1C3743AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_D9BE6B1057B91F64F1BD720E1C3743AD" xlink:to="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_D9BE6B1057B91F64F1BD720E1C3743AD" xlink:type="arc" />
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_D0E5C5B61A6D20252032720E1C376C29_terseLabel_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_D0E5C5B61A6D20252032720E1C376C29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential annual license maintenance fee payments, thereafter</link:label>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_D0E5C5B61A6D20252032720E1C376C29_label_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_D0E5C5B61A6D20252032720E1C376C29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Annual License Maintenance Fee Payments, Thereafter</link:label>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_D0E5C5B61A6D20252032720E1C376C29_documentation_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_D0E5C5B61A6D20252032720E1C376C29" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Annual License Maintenance Fee Payments, Thereafter</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_D0E5C5B61A6D20252032720E1C376C29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_D0E5C5B61A6D20252032720E1C376C29" xlink:to="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_D0E5C5B61A6D20252032720E1C376C29" xlink:type="arc" />
    <link:label id="lab_dare_MaximumPotentialMilestonePayments_530439A9C6E9058269CF720E1C376DAF_terseLabel_en-US" xlink:label="lab_dare_MaximumPotentialMilestonePayments_530439A9C6E9058269CF720E1C376DAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum potential milestone payments</link:label>
    <link:label id="lab_dare_MaximumPotentialMilestonePayments_530439A9C6E9058269CF720E1C376DAF_label_en-US" xlink:label="lab_dare_MaximumPotentialMilestonePayments_530439A9C6E9058269CF720E1C376DAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Potential Milestone Payments</link:label>
    <link:label id="lab_dare_MaximumPotentialMilestonePayments_530439A9C6E9058269CF720E1C376DAF_documentation_en-US" xlink:label="lab_dare_MaximumPotentialMilestonePayments_530439A9C6E9058269CF720E1C376DAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Potential Milestone Payments</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_MaximumPotentialMilestonePayments" xlink:label="loc_dare_MaximumPotentialMilestonePayments_530439A9C6E9058269CF720E1C376DAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MaximumPotentialMilestonePayments_530439A9C6E9058269CF720E1C376DAF" xlink:to="lab_dare_MaximumPotentialMilestonePayments_530439A9C6E9058269CF720E1C376DAF" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_65139A6CCD39FE9D42F0720E1C372815_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_65139A6CCD39FE9D42F0720E1C372815" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, period of continuation from date of first commercial sale of product or process</link:label>
    <link:label id="lab_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_65139A6CCD39FE9D42F0720E1C372815_label_en-US" xlink:label="lab_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_65139A6CCD39FE9D42F0720E1C372815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Period Of Continuation From Date Of First Commercial Sale Of Product Or Process</link:label>
    <link:label id="lab_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_65139A6CCD39FE9D42F0720E1C372815_documentation_en-US" xlink:label="lab_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_65139A6CCD39FE9D42F0720E1C372815" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Period Of Continuation From Date Of First Commercial Sale Of Product Or Process</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess" xlink:label="loc_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_65139A6CCD39FE9D42F0720E1C372815" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_65139A6CCD39FE9D42F0720E1C372815" xlink:to="lab_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_65139A6CCD39FE9D42F0720E1C372815" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_224C8E87C7DAB371E449720E1C38A77B_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_224C8E87C7DAB371E449720E1C38A77B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement notice period of termination for breach of payment obligation</link:label>
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_224C8E87C7DAB371E449720E1C38A77B_label_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_224C8E87C7DAB371E449720E1C38A77B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Notice Period Of Termination For Breach Of Payment Obligation</link:label>
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_224C8E87C7DAB371E449720E1C38A77B_documentation_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_224C8E87C7DAB371E449720E1C38A77B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Notice Period Of Termination For Breach Of Payment Obligation</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_224C8E87C7DAB371E449720E1C38A77B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_224C8E87C7DAB371E449720E1C38A77B" xlink:to="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_224C8E87C7DAB371E449720E1C38A77B" xlink:type="arc" />
    <link:label id="lab_dare_PeriodOfDismissalOfBankruptcyPetition_BC42B900241BBC0C011C720E1C388CC9_terseLabel_en-US" xlink:label="lab_dare_PeriodOfDismissalOfBankruptcyPetition_BC42B900241BBC0C011C720E1C388CC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of dismissal of bankruptcy petition</link:label>
    <link:label id="lab_dare_PeriodOfDismissalOfBankruptcyPetition_BC42B900241BBC0C011C720E1C388CC9_label_en-US" xlink:label="lab_dare_PeriodOfDismissalOfBankruptcyPetition_BC42B900241BBC0C011C720E1C388CC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Dismissal Of Bankruptcy Petition</link:label>
    <link:label id="lab_dare_PeriodOfDismissalOfBankruptcyPetition_BC42B900241BBC0C011C720E1C388CC9_documentation_en-US" xlink:label="lab_dare_PeriodOfDismissalOfBankruptcyPetition_BC42B900241BBC0C011C720E1C388CC9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Of Dismissal Of Bankruptcy Petition</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_PeriodOfDismissalOfBankruptcyPetition" xlink:label="loc_dare_PeriodOfDismissalOfBankruptcyPetition_BC42B900241BBC0C011C720E1C388CC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PeriodOfDismissalOfBankruptcyPetition_BC42B900241BBC0C011C720E1C388CC9" xlink:to="lab_dare_PeriodOfDismissalOfBankruptcyPetition_BC42B900241BBC0C011C720E1C388CC9" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_866B4CBEDF3BE825A323720E1C387990_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_866B4CBEDF3BE825A323720E1C387990" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement notice period of termination for breach of other obligation</link:label>
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_866B4CBEDF3BE825A323720E1C387990_label_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_866B4CBEDF3BE825A323720E1C387990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Notice Period Of Termination For Breach Of Other Obligation</link:label>
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_866B4CBEDF3BE825A323720E1C387990_documentation_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_866B4CBEDF3BE825A323720E1C387990" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Notice Period Of Termination For Breach Of Other Obligation</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_866B4CBEDF3BE825A323720E1C387990" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_866B4CBEDF3BE825A323720E1C387990" xlink:to="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_866B4CBEDF3BE825A323720E1C387990" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTermination_2C4FBB033C3F176251B4720E1C38B453_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTermination_2C4FBB033C3F176251B4720E1C38B453" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, notice period of termination</link:label>
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTermination_2C4FBB033C3F176251B4720E1C38B453_label_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTermination_2C4FBB033C3F176251B4720E1C38B453" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Notice Period Of Termination</link:label>
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTermination_2C4FBB033C3F176251B4720E1C38B453_documentation_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTermination_2C4FBB033C3F176251B4720E1C38B453" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Notice Period Of Termination</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementNoticePeriodOfTermination" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTermination_2C4FBB033C3F176251B4720E1C38B453" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementNoticePeriodOfTermination_2C4FBB033C3F176251B4720E1C38B453" xlink:to="lab_dare_LicenseAgreementNoticePeriodOfTermination_2C4FBB033C3F176251B4720E1C38B453" xlink:type="arc" />
    <link:label id="lab_dare_LicenseFee_A171B0D4889E8B0951BD720E1C392A40_verboseLabel_en-US" xlink:label="lab_dare_LicenseFee_A171B0D4889E8B0951BD720E1C392A40" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">License fee</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseFee" xlink:label="loc_dare_LicenseFee_A171B0D4889E8B0951BD720E1C392A40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseFee_A171B0D4889E8B0951BD720E1C392A40" xlink:to="lab_dare_LicenseFee_A171B0D4889E8B0951BD720E1C392A40" xlink:type="arc" />
    <link:label id="lab_dare_LicenseFeeToBePaidUponContingency_B72D6C752DFE7374A0C1720E1C39F57D_terseLabel_en-US" xlink:label="lab_dare_LicenseFeeToBePaidUponContingency_B72D6C752DFE7374A0C1720E1C39F57D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License fee to be paid upon contingency</link:label>
    <link:label id="lab_dare_LicenseFeeToBePaidUponContingency_B72D6C752DFE7374A0C1720E1C39F57D_label_en-US" xlink:label="lab_dare_LicenseFeeToBePaidUponContingency_B72D6C752DFE7374A0C1720E1C39F57D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fee, To Be Paid Upon Contingency</link:label>
    <link:label id="lab_dare_LicenseFeeToBePaidUponContingency_B72D6C752DFE7374A0C1720E1C39F57D_documentation_en-US" xlink:label="lab_dare_LicenseFeeToBePaidUponContingency_B72D6C752DFE7374A0C1720E1C39F57D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fee, To Be Paid Upon Contingency</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseFeeToBePaidUponContingency" xlink:label="loc_dare_LicenseFeeToBePaidUponContingency_B72D6C752DFE7374A0C1720E1C39F57D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseFeeToBePaidUponContingency_B72D6C752DFE7374A0C1720E1C39F57D" xlink:to="lab_dare_LicenseFeeToBePaidUponContingency_B72D6C752DFE7374A0C1720E1C39F57D" xlink:type="arc" />
    <link:label id="lab_dare_ProceedsRaisedFromEquityFinancing_80637EDC7C0C9433F246720E1C392191_terseLabel_en-US" xlink:label="lab_dare_ProceedsRaisedFromEquityFinancing_80637EDC7C0C9433F246720E1C392191" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds raised from equity financing</link:label>
    <link:label id="lab_dare_ProceedsRaisedFromEquityFinancing_80637EDC7C0C9433F246720E1C392191_label_en-US" xlink:label="lab_dare_ProceedsRaisedFromEquityFinancing_80637EDC7C0C9433F246720E1C392191" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds Raised From Equity Financing</link:label>
    <link:label id="lab_dare_ProceedsRaisedFromEquityFinancing_80637EDC7C0C9433F246720E1C392191_documentation_en-US" xlink:label="lab_dare_ProceedsRaisedFromEquityFinancing_80637EDC7C0C9433F246720E1C392191" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds Raised From Equity Financing</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_ProceedsRaisedFromEquityFinancing" xlink:label="loc_dare_ProceedsRaisedFromEquityFinancing_80637EDC7C0C9433F246720E1C392191" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ProceedsRaisedFromEquityFinancing_80637EDC7C0C9433F246720E1C392191" xlink:to="lab_dare_ProceedsRaisedFromEquityFinancing_80637EDC7C0C9433F246720E1C392191" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_F6AA5EB73D169996FD475B0CFCCA9A86_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_1A5F31D46D355DC3846132FE3A63A00E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leased Properties</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_F6AA5EB73D169996FD475B0CFCCA9A86_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_1A5F31D46D355DC3846132FE3A63A00E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1A5F31D46D355DC3846132FE3A63A00E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_1A5F31D46D355DC3846132FE3A63A00E" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_1A5F31D46D355DC3846132FE3A63A00E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4FA3ED0D4EA58762368555940C2DFC09_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C80FB35C25765DC6A026019E67E3693A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4FA3ED0D4EA58762368555940C2DFC09_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C80FB35C25765DC6A026019E67E3693A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C80FB35C25765DC6A026019E67E3693A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C80FB35C25765DC6A026019E67E3693A" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C80FB35C25765DC6A026019E67E3693A" xlink:type="arc" />
    <link:label id="lab_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710_label_en-US" xlink:label="lab_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710_documentation_en-US" xlink:label="lab_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and entity information.</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_DocumentAndEntityInformationAbstract" xlink:label="loc_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:to="lab_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_1B60FC890212C3CC8FE2720C223A31CA_verboseLabel_en-US" xlink:label="lab_dei_DocumentType_1B60FC890212C3CC8FE2720C223A31CA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_1B60FC890212C3CC8FE2720C223A31CA_label_en-US" xlink:label="lab_dei_DocumentType_1B60FC890212C3CC8FE2720C223A31CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_1B60FC890212C3CC8FE2720C223A31CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_1B60FC890212C3CC8FE2720C223A31CA" xlink:to="lab_dei_DocumentType_1B60FC890212C3CC8FE2720C223A31CA" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_C91B96610588A6369F95720C223ADAEF_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_C91B96610588A6369F95720C223ADAEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_C91B96610588A6369F95720C223ADAEF_label_en-US" xlink:label="lab_dei_AmendmentFlag_C91B96610588A6369F95720C223ADAEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C91B96610588A6369F95720C223ADAEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_C91B96610588A6369F95720C223ADAEF" xlink:to="lab_dei_AmendmentFlag_C91B96610588A6369F95720C223ADAEF" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_B051D0B7A79F1107A821720C223BA228_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_B051D0B7A79F1107A821720C223BA228" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_B051D0B7A79F1107A821720C223BA228_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_B051D0B7A79F1107A821720C223BA228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_B051D0B7A79F1107A821720C223BA228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_B051D0B7A79F1107A821720C223BA228" xlink:to="lab_dei_DocumentPeriodEndDate_B051D0B7A79F1107A821720C223BA228" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_73CFAA96A126F30ABB3D720C223B6BB3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_73CFAA96A126F30ABB3D720C223B6BB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_73CFAA96A126F30ABB3D720C223B6BB3_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_73CFAA96A126F30ABB3D720C223B6BB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_73CFAA96A126F30ABB3D720C223B6BB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_73CFAA96A126F30ABB3D720C223B6BB3" xlink:to="lab_dei_DocumentFiscalYearFocus_73CFAA96A126F30ABB3D720C223B6BB3" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_71A050169DD0A9FF285F720C223B6631_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_71A050169DD0A9FF285F720C223B6631" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_71A050169DD0A9FF285F720C223B6631_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_71A050169DD0A9FF285F720C223B6631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_71A050169DD0A9FF285F720C223B6631" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_71A050169DD0A9FF285F720C223B6631" xlink:to="lab_dei_DocumentFiscalPeriodFocus_71A050169DD0A9FF285F720C223B6631" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_7AED388970DE8BC1C13B720C223B45DF_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_7AED388970DE8BC1C13B720C223B45DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_7AED388970DE8BC1C13B720C223B45DF_label_en-US" xlink:label="lab_dei_EntityRegistrantName_7AED388970DE8BC1C13B720C223B45DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_7AED388970DE8BC1C13B720C223B45DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_7AED388970DE8BC1C13B720C223B45DF" xlink:to="lab_dei_EntityRegistrantName_7AED388970DE8BC1C13B720C223B45DF" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_74B076A9F5EA8AE95318720C223CD8FB_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_74B076A9F5EA8AE95318720C223CD8FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_74B076A9F5EA8AE95318720C223CD8FB_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_74B076A9F5EA8AE95318720C223CD8FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_74B076A9F5EA8AE95318720C223CD8FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_74B076A9F5EA8AE95318720C223CD8FB" xlink:to="lab_dei_EntityCentralIndexKey_74B076A9F5EA8AE95318720C223CD8FB" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_0765B7E978DD5822FE75720C223CCFA8_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_0765B7E978DD5822FE75720C223CCFA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_0765B7E978DD5822FE75720C223CCFA8_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_0765B7E978DD5822FE75720C223CCFA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_0765B7E978DD5822FE75720C223CCFA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_0765B7E978DD5822FE75720C223CCFA8" xlink:to="lab_dei_CurrentFiscalYearEndDate_0765B7E978DD5822FE75720C223CCFA8" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_C95071695F167B8F22C1720C223C0FDA_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_C95071695F167B8F22C1720C223C0FDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_C95071695F167B8F22C1720C223C0FDA_label_en-US" xlink:label="lab_dei_EntityFilerCategory_C95071695F167B8F22C1720C223C0FDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_C95071695F167B8F22C1720C223C0FDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_C95071695F167B8F22C1720C223C0FDA" xlink:to="lab_dei_EntityFilerCategory_C95071695F167B8F22C1720C223C0FDA" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_E7A3B3432B71680FBD0B720C223CC959_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_E7A3B3432B71680FBD0B720C223CC959" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_E7A3B3432B71680FBD0B720C223CC959_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_E7A3B3432B71680FBD0B720C223CC959" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_E7A3B3432B71680FBD0B720C223CC959" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_E7A3B3432B71680FBD0B720C223CC959" xlink:to="lab_dei_EntitySmallBusiness_E7A3B3432B71680FBD0B720C223CC959" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_A8893BC5F3AE680EF2D9720C223D6896_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_A8893BC5F3AE680EF2D9720C223D6896" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_A8893BC5F3AE680EF2D9720C223D6896_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_A8893BC5F3AE680EF2D9720C223D6896" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_A8893BC5F3AE680EF2D9720C223D6896" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_A8893BC5F3AE680EF2D9720C223D6896" xlink:to="lab_dei_EntityEmergingGrowthCompany_A8893BC5F3AE680EF2D9720C223D6896" xlink:type="arc" />
    <link:label id="lab_dei_EntityExTransitionPeriod_F019616E4DCEDFAD6BE4720C223DD995_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_F019616E4DCEDFAD6BE4720C223DD995" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_F019616E4DCEDFAD6BE4720C223DD995_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_F019616E4DCEDFAD6BE4720C223DD995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_F019616E4DCEDFAD6BE4720C223DD995" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_F019616E4DCEDFAD6BE4720C223DD995" xlink:to="lab_dei_EntityExTransitionPeriod_F019616E4DCEDFAD6BE4720C223DD995" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_799446C3D5A99AEEE764720C223DC200_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_799446C3D5A99AEEE764720C223DC200" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_799446C3D5A99AEEE764720C223DC200_label_en-US" xlink:label="lab_dei_EntityShellCompany_799446C3D5A99AEEE764720C223DC200" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_799446C3D5A99AEEE764720C223DC200" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_799446C3D5A99AEEE764720C223DC200" xlink:to="lab_dei_EntityShellCompany_799446C3D5A99AEEE764720C223DC200" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_8E5AAFA6664C70D2827D720C223D7BB4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_8E5AAFA6664C70D2827D720C223D7BB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_8E5AAFA6664C70D2827D720C223D7BB4_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_8E5AAFA6664C70D2827D720C223D7BB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_8E5AAFA6664C70D2827D720C223D7BB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_8E5AAFA6664C70D2827D720C223D7BB4" xlink:to="lab_dei_EntityCurrentReportingStatus_8E5AAFA6664C70D2827D720C223D7BB4" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_03F8139EF284CF48C34B720C223EC9FC_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_03F8139EF284CF48C34B720C223EC9FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_03F8139EF284CF48C34B720C223EC9FC_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_03F8139EF284CF48C34B720C223EC9FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_03F8139EF284CF48C34B720C223EC9FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_03F8139EF284CF48C34B720C223EC9FC" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_03F8139EF284CF48C34B720C223EC9FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2724CFFD36C2CCA2FD7D5B0CFD705BD2_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8C95ABB2DF745DDBA564C38D4BAC1F14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2724CFFD36C2CCA2FD7D5B0CFD705BD2_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8C95ABB2DF745DDBA564C38D4BAC1F14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8C95ABB2DF745DDBA564C38D4BAC1F14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8C95ABB2DF745DDBA564C38D4BAC1F14" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8C95ABB2DF745DDBA564C38D4BAC1F14" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_98C7F8F7887E1B1937D9B919C3CAF639_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_FC215CD122245A0C8E3A5037040021E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Description of the Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_98C7F8F7887E1B1937D9B919C3CAF639_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_FC215CD122245A0C8E3A5037040021E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_FC215CD122245A0C8E3A5037040021E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_FC215CD122245A0C8E3A5037040021E9" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_FC215CD122245A0C8E3A5037040021E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetRentableArea_46106322944B0DF9615C87D135652A95_terseLabel_en-US" xlink:label="lab_us-gaap_NetRentableArea_46106322944B0DF9615C87D135652A95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Square footage of office space</link:label>
    <link:label id="lab_us-gaap_NetRentableArea_46106322944B0DF9615C87D135652A95_label_en-US" xlink:label="lab_us-gaap_NetRentableArea_46106322944B0DF9615C87D135652A95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Rentable Area</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetRentableArea" xlink:label="loc_us-gaap_NetRentableArea_46106322944B0DF9615C87D135652A95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetRentableArea_46106322944B0DF9615C87D135652A95" xlink:to="lab_us-gaap_NetRentableArea_46106322944B0DF9615C87D135652A95" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_1084D4EB8852CA71C68187D135657FD6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_1084D4EB8852CA71C68187D135657FD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of operating lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_1084D4EB8852CA71C68187D135657FD6_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_1084D4EB8852CA71C68187D135657FD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1084D4EB8852CA71C68187D135657FD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1084D4EB8852CA71C68187D135657FD6" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_1084D4EB8852CA71C68187D135657FD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_14D1172847189E5CF24287D135658437_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_14D1172847189E5CF24287D135658437" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal term of operating lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_14D1172847189E5CF24287D135658437_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_14D1172847189E5CF24287D135658437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_14D1172847189E5CF24287D135658437" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_14D1172847189E5CF24287D135658437" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_14D1172847189E5CF24287D135658437" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_6CA74F59CB7AF5D3808D87D13565D232_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_6CA74F59CB7AF5D3808D87D13565D232" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross monthly base rent</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_6CA74F59CB7AF5D3808D87D13565D232_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_6CA74F59CB7AF5D3808D87D13565D232" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Minimum Rentals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_6CA74F59CB7AF5D3808D87D13565D232" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_6CA74F59CB7AF5D3808D87D13565D232" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_6CA74F59CB7AF5D3808D87D13565D232" xlink:type="arc" />
    <link:label id="lab_dare_PercentageOfIncreaseInAnnualBaseRent_DDA1722093063A74768F87D13565CF6B_terseLabel_en-US" xlink:label="lab_dare_PercentageOfIncreaseInAnnualBaseRent_DDA1722093063A74768F87D13565CF6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of increase in annual base rent, each year</link:label>
    <link:label id="lab_dare_PercentageOfIncreaseInAnnualBaseRent_DDA1722093063A74768F87D13565CF6B_label_en-US" xlink:label="lab_dare_PercentageOfIncreaseInAnnualBaseRent_DDA1722093063A74768F87D13565CF6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Increase In Annual Base Rent</link:label>
    <link:label id="lab_dare_PercentageOfIncreaseInAnnualBaseRent_DDA1722093063A74768F87D13565CF6B_documentation_en-US" xlink:label="lab_dare_PercentageOfIncreaseInAnnualBaseRent_DDA1722093063A74768F87D13565CF6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Increase In Annual Base Rent</link:label>
    <link:loc xlink:href="dare-20190630.xsd#dare_PercentageOfIncreaseInAnnualBaseRent" xlink:label="loc_dare_PercentageOfIncreaseInAnnualBaseRent_DDA1722093063A74768F87D13565CF6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PercentageOfIncreaseInAnnualBaseRent_DDA1722093063A74768F87D13565CF6B" xlink:to="lab_dare_PercentageOfIncreaseInAnnualBaseRent_DDA1722093063A74768F87D13565CF6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_D62277D2A42943F0F41287D81D065160_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate_D62277D2A42943F0F41287D81D065160" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_D62277D2A42943F0F41287D81D065160_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate_D62277D2A42943F0F41287D81D065160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_D62277D2A42943F0F41287D81D065160" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate_D62277D2A42943F0F41287D81D065160" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate_D62277D2A42943F0F41287D81D065160" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6A5CA07BD61B000E42CD87D135654587_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_6A5CA07BD61B000E42CD87D135654587" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Right of use asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6A5CA07BD61B000E42CD87D135654587" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_6A5CA07BD61B000E42CD87D135654587" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_6A5CA07BD61B000E42CD87D135654587" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_A8625A5BD3C53B09E57587D13565E027_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_A8625A5BD3C53B09E57587D13565E027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, short term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_A8625A5BD3C53B09E57587D13565E027_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_A8625A5BD3C53B09E57587D13565E027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_A8625A5BD3C53B09E57587D13565E027" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_A8625A5BD3C53B09E57587D13565E027" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_A8625A5BD3C53B09E57587D13565E027" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_84A6D947C1DFFCEE01AA87D13565962C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_84A6D947C1DFFCEE01AA87D13565962C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, long term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_84A6D947C1DFFCEE01AA87D13565962C_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_84A6D947C1DFFCEE01AA87D13565962C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_84A6D947C1DFFCEE01AA87D13565962C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_84A6D947C1DFFCEE01AA87D13565962C" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_84A6D947C1DFFCEE01AA87D13565962C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_54C4EFAC4DB3779DCE9F87D135657741_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_54C4EFAC4DB3779DCE9F87D135657741" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expenses</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_54C4EFAC4DB3779DCE9F87D135657741_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_54C4EFAC4DB3779DCE9F87D135657741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_54C4EFAC4DB3779DCE9F87D135657741" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_54C4EFAC4DB3779DCE9F87D135657741" xlink:to="lab_us-gaap_OperatingLeaseCost_54C4EFAC4DB3779DCE9F87D135657741" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_021801878E381DDE7B8A87D13565802E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_021801878E381DDE7B8A87D13565802E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_021801878E381DDE7B8A87D13565802E_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_021801878E381DDE7B8A87D13565802E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_021801878E381DDE7B8A87D13565802E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_021801878E381DDE7B8A87D13565802E" xlink:to="lab_us-gaap_OperatingLeasePayments_021801878E381DDE7B8A87D13565802E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A29C5FF6D290992C9BE09A56023E9ED8_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ABE78533779F5A4DBEEE3F0E0C93A850" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A29C5FF6D290992C9BE09A56023E9ED8_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ABE78533779F5A4DBEEE3F0E0C93A850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ABE78533779F5A4DBEEE3F0E0C93A850" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ABE78533779F5A4DBEEE3F0E0C93A850" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ABE78533779F5A4DBEEE3F0E0C93A850" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_5AF23F50A920E8FC9DB19A56023E8B07_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_8E63F5C76A515033BA493C45156336DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_5AF23F50A920E8FC9DB19A56023E8B07_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_8E63F5C76A515033BA493C45156336DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_8E63F5C76A515033BA493C45156336DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_8E63F5C76A515033BA493C45156336DD" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_8E63F5C76A515033BA493C45156336DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6327697B7B3E9F63FCFD9A56023E6BA9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_52999C838DE858A2B4AC7E304CC9D7B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6327697B7B3E9F63FCFD9A56023E6BA9_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_52999C838DE858A2B4AC7E304CC9D7B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_52999C838DE858A2B4AC7E304CC9D7B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_52999C838DE858A2B4AC7E304CC9D7B0" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_52999C838DE858A2B4AC7E304CC9D7B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_82A3B5CC4C999B4214329A56023EFD36_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D41DA061D14A508F92DFD52F0629BC69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_82A3B5CC4C999B4214329A56023EFD36_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D41DA061D14A508F92DFD52F0629BC69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D41DA061D14A508F92DFD52F0629BC69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D41DA061D14A508F92DFD52F0629BC69" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D41DA061D14A508F92DFD52F0629BC69" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>dare-20190630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://darebioscience.com/role/Acquisitions" xlink:href="dare-20190630.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/AcquisitionsAdditionalInformationDetail" xlink:href="dare-20190630.xsd#AcquisitionsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsAndContingencies" xlink:href="dare-20190630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="dare-20190630.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheets" xlink:href="dare-20190630.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="dare-20190630.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="dare-20190630.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="dare-20190630.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="dare-20190630.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/DocumentAndEntityInformation" xlink:href="dare-20190630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GoingConcern" xlink:href="dare-20190630.xsd#GoingConcern" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GoingConcernAdditionalInformationDetail" xlink:href="dare-20190630.xsd#GoingConcernAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAward" xlink:href="dare-20190630.xsd#GrantAward" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAwardAdditionalInformationDetail" xlink:href="dare-20190630.xsd#GrantAwardAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedProperties" xlink:href="dare-20190630.xsd#LeasedProperties" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesDetails" xlink:href="dare-20190630.xsd#LeasedPropertiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:href="dare-20190630.xsd#LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesTables" xlink:href="dare-20190630.xsd#LeasedPropertiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShare" xlink:href="dare-20190630.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" xlink:href="dare-20190630.xsd#NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShareTables" xlink:href="dare-20190630.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="dare-20190630.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:href="dare-20190630.xsd#OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensation" xlink:href="dare-20190630.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="dare-20190630.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" xlink:href="dare-20190630.xsd#StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" xlink:href="dare-20190630.xsd#StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" xlink:href="dare-20190630.xsd#StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationTables" xlink:href="dare-20190630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquity" xlink:href="dare-20190630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="dare-20190630.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" xlink:href="dare-20190630.xsd#StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityTables" xlink:href="dare-20190630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="dare-20190630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="dare-20190630.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="dare-20190630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://darebioscience.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_F3EEE77E34E351E5AB00312CB74B7A08" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_0F170CA403F552A4AD51E9DB2E0294A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_F3EEE77E34E351E5AB00312CB74B7A08" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_0F170CA403F552A4AD51E9DB2E0294A3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/AcquisitionsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_5D0E7B7B0D915F63682678071B324D6E" xlink:type="locator" />
    <link:loc xlink:href="dare-20190630.xsd#dare_ScheduleOfBusinessCombinationReverseMergerTable" xlink:label="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5D0E7B7B0D915F63682678071B324D6E" xlink:to="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2D5D82A228207C7BEE9578071B332A20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092" xlink:to="loc_dei_LegalEntityAxis_2D5D82A228207C7BEE9578071B332A20" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_0D613F3323383CF311EA78071B3355C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2D5D82A228207C7BEE9578071B332A20" xlink:to="loc_dei_EntityDomain_0D613F3323383CF311EA78071B3355C4" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PrivateDareMember" xlink:label="loc_dare_PrivateDareMember_51385BB4DC243FD1FD5D78071B33789C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0D613F3323383CF311EA78071B3355C4" xlink:to="loc_dare_PrivateDareMember_51385BB4DC243FD1FD5D78071B33789C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_31D0CB3D18C15FFF496478071B349120" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_31D0CB3D18C15FFF496478071B349120" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B69EE32EB395B172742778071B3409FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_31D0CB3D18C15FFF496478071B349120" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_B69EE32EB395B172742778071B3409FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5EFCDD3DD570538B187D78071B34F4B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B69EE32EB395B172742778071B3409FD" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5EFCDD3DD570538B187D78071B34F4B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_94AE358BA8FA391976FA78071B35F281" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_94AE358BA8FA391976FA78071B35F281" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_50AA83230792B766CB6E78071B35BD04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_94AE358BA8FA391976FA78071B35F281" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_50AA83230792B766CB6E78071B35BD04" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PearTreePharmaceuticalsIncMember" xlink:label="loc_dare_PearTreePharmaceuticalsIncMember_E43C6D1B2DEFDA4BD42678071B3508D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_50AA83230792B766CB6E78071B35BD04" xlink:to="loc_dare_PearTreePharmaceuticalsIncMember_E43C6D1B2DEFDA4BD42678071B3508D7" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_BusinessCombinationReverseMergerLineItems" xlink:label="loc_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_86336E94DDC6C54F551B78071B32E092" xlink:to="loc_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_91314AC76F46EC58227C78071B367392" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:to="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_91314AC76F46EC58227C78071B367392" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions" xlink:label="loc_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_3EEE1C3BE117D05B931C78071B363A56" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:to="loc_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_3EEE1C3BE117D05B931C78071B363A56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_16AE243469526DBBAC9278071B361CA2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_16AE243469526DBBAC9278071B361CA2" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost" xlink:label="loc_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_17C634478ABBE254F63F78071B36F77D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:to="loc_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_17C634478ABBE254F63F78071B36F77D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PotentialCashPaymentsToAcquireBusiness" xlink:label="loc_dare_PotentialCashPaymentsToAcquireBusiness_968E61EDF481090A4BA678071B379F45" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:to="loc_dare_PotentialCashPaymentsToAcquireBusiness_968E61EDF481090A4BA678071B379F45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_558AF06E9A39988580D378071B3637DA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_0E36739B3FAEBF7A5BA878071B35FCEA" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_558AF06E9A39988580D378071B3637DA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E2D11AC3FA485A1CA8CED1CFC621C30A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_EE0D071AB3325E62B047371FB6DA0136" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E2D11AC3FA485A1CA8CED1CFC621C30A" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_EE0D071AB3325E62B047371FB6DA0136" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B893FF5D443867559F25720E1C2554D9" xlink:type="locator" />
    <link:loc xlink:href="dare-20190630.xsd#dare_CommitmentsAndContingenciesTable" xlink:label="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B893FF5D443867559F25720E1C2554D9" xlink:to="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D25F1F1D0BF2DC03B48B720E1C25ED65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D25F1F1D0BF2DC03B48B720E1C25ED65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_D25F1F1D0BF2DC03B48B720E1C25ED65" xlink:to="loc_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_A72C35F79E69282B6837720E1C261189" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189" xlink:to="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_A72C35F79E69282B6837720E1C261189" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:label="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_84B1512373E5946AF257720E1C261AB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189" xlink:to="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_84B1512373E5946AF257720E1C261AB6" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember" xlink:label="loc_dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember_8DD6B9085A618E8DB92E7215FDBADEC3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189" xlink:to="loc_dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember_8DD6B9085A618E8DB92E7215FDBADEC3" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_FutureMilestonePaymentsBasedOnCommercializationMember" xlink:label="loc_dare_FutureMilestonePaymentsBasedOnCommercializationMember_667B5EE6168008B41A1F721678E97197" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_722FBC585D3024F5315F720E1C262189" xlink:to="loc_dare_FutureMilestonePaymentsBasedOnCommercializationMember_667B5EE6168008B41A1F721678E97197" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_E44AAEFB6E0F915DCF61720E1C26F1F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_E44AAEFB6E0F915DCF61720E1C26F1F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E44AAEFB6E0F915DCF61720E1C26F1F2" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_UponAchievingCertainCommercialMilestonesMember" xlink:label="loc_dare_UponAchievingCertainCommercialMilestonesMember_EB5B5D7312F21BC78993720E1C27AA3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750" xlink:to="loc_dare_UponAchievingCertainCommercialMilestonesMember_EB5B5D7312F21BC78993720E1C27AA3F" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_UponSigningOfDevelopmentAndOptionAgreementMember" xlink:label="loc_dare_UponSigningOfDevelopmentAndOptionAgreementMember_46FAF28F5A9E7FA57356720E1C275A40" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750" xlink:to="loc_dare_UponSigningOfDevelopmentAndOptionAgreementMember_46FAF28F5A9E7FA57356720E1C275A40" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember" xlink:label="loc_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_D5F6C1747ACD5AB86DCB720E1C28D305" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750" xlink:to="loc_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_D5F6C1747ACD5AB86DCB720E1C28D305" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:label="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_BF1822E529A6428D8621720E1C286B81" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_A10CBF90CB549683B63A720E1C272750" xlink:to="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_BF1822E529A6428D8621720E1C286B81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_33BFA660C11DBCD8B660720E1C285693" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_33BFA660C11DBCD8B660720E1C285693" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_E0A0BA01A6D07415477F720E1C2811BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_33BFA660C11DBCD8B660720E1C285693" xlink:to="loc_us-gaap_RelatedPartyDomain_E0A0BA01A6D07415477F720E1C2811BA" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:label="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_A9153B2B0DEA56385509720E1C28E6BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_E0A0BA01A6D07415477F720E1C2811BA" xlink:to="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_A9153B2B0DEA56385509720E1C28E6BF" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_OrbisMember" xlink:label="loc_dare_OrbisMember_6C858185A7CD5A0A7A7F720E1C2949EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_E0A0BA01A6D07415477F720E1C2811BA" xlink:to="loc_dare_OrbisMember_6C858185A7CD5A0A7A7F720E1C2949EB" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_MilanaPharmMember" xlink:label="loc_dare_MilanaPharmMember_F8B6EBFED2E14641207F720E1C296A97" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_E0A0BA01A6D07415477F720E1C2811BA" xlink:to="loc_dare_MilanaPharmMember_F8B6EBFED2E14641207F720E1C296A97" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_HammockPharmaceuticalsInc.Member" xlink:label="loc_dare_HammockPharmaceuticalsInc.Member_FA0DF05BBC852E4D6732720E1C2905C4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_E0A0BA01A6D07415477F720E1C2811BA" xlink:to="loc_dare_HammockPharmaceuticalsInc.Member_FA0DF05BBC852E4D6732720E1C2905C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_314BFD22D11D6EFA7B4A720E1C294E06" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_314BFD22D11D6EFA7B4A720E1C294E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_314BFD22D11D6EFA7B4A720E1C294E06" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_CF68F6EDABAE306ED9C6720E1C2A8150" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:to="loc_us-gaap_LicensingAgreementsMember_CF68F6EDABAE306ED9C6720E1C2A8150" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_AssignmentAgreementMember" xlink:label="loc_dare_AssignmentAgreementMember_340589595C152C4A9797720E1C2A8B5E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:to="loc_dare_AssignmentAgreementMember_340589595C152C4A9797720E1C2A8B5E" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAndCollaborationAgreementMember" xlink:label="loc_dare_LicenseAndCollaborationAgreementMember_57C63C1FD973C896CFC9720E1C2A798D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:to="loc_dare_LicenseAndCollaborationAgreementMember_57C63C1FD973C896CFC9720E1C2A798D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_DevelopmentAndOptionAgreementMember" xlink:label="loc_dare_DevelopmentAndOptionAgreementMember_53B16A4503175560998F720E1C2B1BEC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:to="loc_dare_DevelopmentAndOptionAgreementMember_53B16A4503175560998F720E1C2B1BEC" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_JuniperPharmaceuticalsInc.Member" xlink:label="loc_dare_JuniperPharmaceuticalsInc.Member_C669DECFBE7E4C9B1722720E1C2B059B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:to="loc_dare_JuniperPharmaceuticalsInc.Member_C669DECFBE7E4C9B1722720E1C2B059B" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_JuniperPharmaceuticalsMember" xlink:label="loc_dare_JuniperPharmaceuticalsMember_B5E44CE6DC6E200959C4720E1C2B9189" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03B7A05B0221B1582680720E1C2AF8C3" xlink:to="loc_dare_JuniperPharmaceuticalsMember_B5E44CE6DC6E200959C4720E1C2B9189" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_17C97A0B2D467DFC5029720E1C2C00FE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_17C97A0B2D467DFC5029720E1C2C00FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_F1A27082EB7FD4E36874720E1C2C52DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_17C97A0B2D467DFC5029720E1C2C00FE" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_F1A27082EB7FD4E36874720E1C2C52DB" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_ADVATecAgreementMember" xlink:label="loc_dare_ADVATecAgreementMember_6B4FAF095DBE9F8EA93A720E1C2C4235" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_F1A27082EB7FD4E36874720E1C2C52DB" xlink:to="loc_dare_ADVATecAgreementMember_6B4FAF095DBE9F8EA93A720E1C2C4235" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_ClinicalAndRegulatoryMilestonesMember" xlink:label="loc_dare_ClinicalAndRegulatoryMilestonesMember_E0F632337C5682F377BE720E1C2C7442" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_F1A27082EB7FD4E36874720E1C2C52DB" xlink:to="loc_dare_ClinicalAndRegulatoryMilestonesMember_E0F632337C5682F377BE720E1C2C7442" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_SalesMilestonesMember" xlink:label="loc_dare_SalesMilestonesMember_7E93522D4E5A566BA157720E1C2DBBE1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_F1A27082EB7FD4E36874720E1C2C52DB" xlink:to="loc_dare_SalesMilestonesMember_7E93522D4E5A566BA157720E1C2DBBE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6DB419DE9465D9775C20720E1C2DBF4D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:to="loc_srt_RangeAxis_6DB419DE9465D9775C20720E1C2DBF4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_108BCB3D27EA514E41BB720E1C2D6661" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6DB419DE9465D9775C20720E1C2DBF4D" xlink:to="loc_srt_RangeMember_108BCB3D27EA514E41BB720E1C2D6661" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_F8C594F496E0AD8867C1720E1C2E1FA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_108BCB3D27EA514E41BB720E1C2D6661" xlink:to="loc_srt_MinimumMember_F8C594F496E0AD8867C1720E1C2E1FA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_A47D8BB2B75CA86BDFE4720E1C2F07E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_108BCB3D27EA514E41BB720E1C2D6661" xlink:to="loc_srt_MaximumMember_A47D8BB2B75CA86BDFE4720E1C2F07E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_CC91522DFFB65E8551BE720E1C30F63B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:to="loc_srt_ProductOrServiceAxis_CC91522DFFB65E8551BE720E1C30F63B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_8871E537A9ACC680495A720E1C30BCC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_CC91522DFFB65E8551BE720E1C30F63B" xlink:to="loc_srt_ProductsAndServicesDomain_8871E537A9ACC680495A720E1C30BCC3" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_OvapreneMember" xlink:label="loc_dare_OvapreneMember_972EAC232AF68E34625B720E1C318C87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8871E537A9ACC680495A720E1C30BCC3" xlink:to="loc_dare_OvapreneMember_972EAC232AF68E34625B720E1C318C87" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_CommitmentsAndContingenciesLineItems" xlink:label="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_C53AE5C20B07D16974A6720E1C25B34B" xlink:to="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NumberOfPatentsIssued" xlink:label="loc_dare_NumberOfPatentsIssued_DC3759BF5CBAF4FB05A8720E1C32EFDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_NumberOfPatentsIssued_DC3759BF5CBAF4FB05A8720E1C32EFDC" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NumberOfPendingPatents" xlink:label="loc_dare_NumberOfPendingPatents_091BCD5571D073B6E088720E1C32F0C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_NumberOfPendingPatents_091BCD5571D073B6E088720E1C32F0C1" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NumberOfPatentsGranted" xlink:label="loc_dare_NumberOfPatentsGranted_C09ED940D44D9DFCACAE720E1C328B60" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_NumberOfPatentsGranted_C09ED940D44D9DFCACAE720E1C328B60" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NumberOfPatentApplications" xlink:label="loc_dare_NumberOfPatentApplications_AE419E1CED16AD89560B720E1C339342" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_NumberOfPatentApplications_AE419E1CED16AD89560B720E1C339342" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_12566402C85BBDBBF934720E1C33B332" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_us-gaap_ContractualObligation_12566402C85BBDBBF934720E1C33B332" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries" xlink:label="loc_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_39239BFC16A9EA2F225F720E1C33F8D1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_39239BFC16A9EA2F225F720E1C33F8D1" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NumberOfDesignatedCountries" xlink:label="loc_dare_NumberOfDesignatedCountries_6F550C419C7157CAA2A1720E1C339D1B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_NumberOfDesignatedCountries_6F550C419C7157CAA2A1720E1C339D1B" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PercentageOfRoyaltyRate" xlink:label="loc_dare_PercentageOfRoyaltyRate_53BE2ACF30C4616D0082720E1C34ED4A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_PercentageOfRoyaltyRate_53BE2ACF30C4616D0082720E1C34ED4A" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" xlink:label="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_921A9CEE5A93503856E3720E1C342EBC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_921A9CEE5A93503856E3720E1C342EBC" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease" xlink:label="loc_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_A61483944156CEFC28B0720E1C34C7EF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_A61483944156CEFC28B0720E1C34C7EF" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" xlink:label="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_A2215BC3F6476F40CA36720E1C34514D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_A2215BC3F6476F40CA36720E1C34514D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_MilestonePaymentsContingentAmount" xlink:label="loc_dare_MilestonePaymentsContingentAmount_016410222CF3C4AC264A720E1C359D10" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_MilestonePaymentsContingentAmount_016410222CF3C4AC264A720E1C359D10" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_SecuredInvestmentRequiredForLicenseAgreement" xlink:label="loc_dare_SecuredInvestmentRequiredForLicenseAgreement_21821E41A96414ED1831720E1C3566D9" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_SecuredInvestmentRequiredForLicenseAgreement_21821E41A96414ED1831720E1C3566D9" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementExpirationPeriod" xlink:label="loc_dare_LicenseAgreementExpirationPeriod_32F365D4A7C0277864A4720E1C355CCA" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseAgreementExpirationPeriod_32F365D4A7C0277864A4720E1C355CCA" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval" xlink:label="loc_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_839B01738675A05CB4C6720E1C3520C3" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_839B01738675A05CB4C6720E1C3520C3" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval" xlink:label="loc_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_0F186928003DEFE63BD0720E1C3515F3" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_0F186928003DEFE63BD0720E1C3515F3" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries" xlink:label="loc_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_FB09EFBEF29880AC234A720E1C361E22" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_FB09EFBEF29880AC234A720E1C361E22" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NoticePeriodForTerminationOfAgreementForBothParties" xlink:label="loc_dare_NoticePeriodForTerminationOfAgreementForBothParties_FCA851E45049B2E03A7F720E1C36A3AC" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_NoticePeriodForTerminationOfAgreementForBothParties_FCA851E45049B2E03A7F720E1C36A3AC" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_ResearchAndDevelopmentMilestonePayment" xlink:label="loc_dare_ResearchAndDevelopmentMilestonePayment_FFB065DC5477EF1F92B3720E1C361D21" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_ResearchAndDevelopmentMilestonePayment_FFB065DC5477EF1F92B3720E1C361D21" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_CommencementPeriodForStageTwoUponAchievementOfStageOne" xlink:label="loc_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_6BF65CAE4EB51023B960720E1C368B0C" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_6BF65CAE4EB51023B960720E1C368B0C" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_UpfrontLicenseFeePaid" xlink:label="loc_dare_UpfrontLicenseFeePaid_B24534E7ABB0A7E59847720E1C37FB2D" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_UpfrontLicenseFeePaid_B24534E7ABB0A7E59847720E1C37FB2D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_D9BE6B1057B91F64F1BD720E1C3743AD" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_D9BE6B1057B91F64F1BD720E1C3743AD" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_D0E5C5B61A6D20252032720E1C376C29" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_D0E5C5B61A6D20252032720E1C376C29" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_MaximumPotentialMilestonePayments" xlink:label="loc_dare_MaximumPotentialMilestonePayments_530439A9C6E9058269CF720E1C376DAF" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_MaximumPotentialMilestonePayments_530439A9C6E9058269CF720E1C376DAF" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess" xlink:label="loc_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_65139A6CCD39FE9D42F0720E1C372815" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_65139A6CCD39FE9D42F0720E1C372815" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_224C8E87C7DAB371E449720E1C38A77B" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_224C8E87C7DAB371E449720E1C38A77B" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PeriodOfDismissalOfBankruptcyPetition" xlink:label="loc_dare_PeriodOfDismissalOfBankruptcyPetition_BC42B900241BBC0C011C720E1C388CC9" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_PeriodOfDismissalOfBankruptcyPetition_BC42B900241BBC0C011C720E1C388CC9" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_866B4CBEDF3BE825A323720E1C387990" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_866B4CBEDF3BE825A323720E1C387990" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseAgreementNoticePeriodOfTermination" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTermination_2C4FBB033C3F176251B4720E1C38B453" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseAgreementNoticePeriodOfTermination_2C4FBB033C3F176251B4720E1C38B453" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseFee" xlink:label="loc_dare_LicenseFee_A171B0D4889E8B0951BD720E1C392A40" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseFee_A171B0D4889E8B0951BD720E1C392A40" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseFeeToBePaidUponContingency" xlink:label="loc_dare_LicenseFeeToBePaidUponContingency_B72D6C752DFE7374A0C1720E1C39F57D" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_LicenseFeeToBePaidUponContingency_B72D6C752DFE7374A0C1720E1C39F57D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_ProceedsRaisedFromEquityFinancing" xlink:label="loc_dare_ProceedsRaisedFromEquityFinancing_80637EDC7C0C9433F246720E1C392191" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_9D561BB3FACCE0F8003B720E1C31C5FC" xlink:to="loc_dare_ProceedsRaisedFromEquityFinancing_80637EDC7C0C9433F246720E1C392191" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2085522664A62DCCA89A6D22BA93EABF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_6E17FAD2BC86770A4A2A6D22BA932AD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2085522664A62DCCA89A6D22BA93EABF" xlink:to="loc_us-gaap_AssetsAbstract_6E17FAD2BC86770A4A2A6D22BA932AD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_A3BD2B7392438E2F94B36D22BA933FE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6E17FAD2BC86770A4A2A6D22BA932AD2" xlink:to="loc_us-gaap_AssetsCurrentAbstract_A3BD2B7392438E2F94B36D22BA933FE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13E0112DEA6CD878F6806D22BA933835" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A3BD2B7392438E2F94B36D22BA933FE6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13E0112DEA6CD878F6806D22BA933835" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_ACA77A1BBCC7FAF845106D22BA9330DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A3BD2B7392438E2F94B36D22BA933FE6" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_ACA77A1BBCC7FAF845106D22BA9330DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_686E43C0C9032871E1666D22BA93E687" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A3BD2B7392438E2F94B36D22BA933FE6" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_686E43C0C9032871E1666D22BA93E687" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1A0AC4428FBF92B7DEF86D22BA9357EC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A3BD2B7392438E2F94B36D22BA933FE6" xlink:to="loc_us-gaap_AssetsCurrent_1A0AC4428FBF92B7DEF86D22BA9357EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_879C785C0BA92F60F32B6D22BA937783" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6E17FAD2BC86770A4A2A6D22BA932AD2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_879C785C0BA92F60F32B6D22BA937783" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_D45DFB766DECCD3E49126D22BA93A7D3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6E17FAD2BC86770A4A2A6D22BA932AD2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_D45DFB766DECCD3E49126D22BA93A7D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_00B4019C7331E002C2FE6D22BAA3A3CE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6E17FAD2BC86770A4A2A6D22BA932AD2" xlink:to="loc_us-gaap_Assets_00B4019C7331E002C2FE6D22BAA3A3CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2EBDB0A497D24D0DA3406D22BAA375DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2085522664A62DCCA89A6D22BA93EABF" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2EBDB0A497D24D0DA3406D22BAA375DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_DA10F9684FAFDE2214476D22BAA3091C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2EBDB0A497D24D0DA3406D22BAA375DB" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_DA10F9684FAFDE2214476D22BAA3091C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_A3714DA41BC27E3C25A16D22BAA348B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DA10F9684FAFDE2214476D22BAA3091C" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_A3714DA41BC27E3C25A16D22BAA348B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4A87FA7AAB34F7548DE26D22BAA34977" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DA10F9684FAFDE2214476D22BAA3091C" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4A87FA7AAB34F7548DE26D22BAA34977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_97F4F879AB059FF9FDC26D22BAA36C39" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DA10F9684FAFDE2214476D22BAA3091C" xlink:to="loc_us-gaap_LiabilitiesCurrent_97F4F879AB059FF9FDC26D22BAA36C39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6C54E53169E7D4C2F6786D22BAA3BF0F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2EBDB0A497D24D0DA3406D22BAA375DB" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6C54E53169E7D4C2F6786D22BAA3BF0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_F2034829B5396D6E934A6D22BAA3CC6E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2EBDB0A497D24D0DA3406D22BAA375DB" xlink:to="loc_us-gaap_Liabilities_F2034829B5396D6E934A6D22BAA3CC6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5CE4EEE5F306A0E9E3C66D22BAA3D841" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2EBDB0A497D24D0DA3406D22BAA375DB" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5CE4EEE5F306A0E9E3C66D22BAA3D841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_571C2B8C5329D30343326D22BAA310E5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2EBDB0A497D24D0DA3406D22BAA375DB" xlink:to="loc_us-gaap_StockholdersEquityAbstract_571C2B8C5329D30343326D22BAA310E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_924DE14A8C3359FDA4196D22BAA384C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_571C2B8C5329D30343326D22BAA310E5" xlink:to="loc_us-gaap_PreferredStockValue_924DE14A8C3359FDA4196D22BAA384C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_49367BEC90C65C60C9E86D22BAA3EDA2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_571C2B8C5329D30343326D22BAA310E5" xlink:to="loc_us-gaap_CommonStockValue_49367BEC90C65C60C9E86D22BAA3EDA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F37D532F138E083470BE6D22BAA3A7D0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_571C2B8C5329D30343326D22BAA310E5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F37D532F138E083470BE6D22BAA3A7D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7873F9EF5D1DA4606B966D22BAA39747" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_571C2B8C5329D30343326D22BAA310E5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7873F9EF5D1DA4606B966D22BAA39747" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_31C635E80DFFF1CBCC0E6D22BAA38E60" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_571C2B8C5329D30343326D22BAA310E5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_31C635E80DFFF1CBCC0E6D22BAA38E60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B187C728BE30E56855CD6D22BAA3E156" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_571C2B8C5329D30343326D22BAA310E5" xlink:to="loc_us-gaap_StockholdersEquity_B187C728BE30E56855CD6D22BAA3E156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_353611D57C1197C8F34C6D22BAA33B8F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2EBDB0A497D24D0DA3406D22BAA375DB" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_353611D57C1197C8F34C6D22BAA33B8F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_CA79CFD08A5C518794D8176DA72C0B4D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_B885B9A8FB7C5B6291545489DB7952F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CA79CFD08A5C518794D8176DA72C0B4D" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_B885B9A8FB7C5B6291545489DB7952F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1F9AD6BE0BCE5D39AE1926043E22F56F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CA79CFD08A5C518794D8176DA72C0B4D" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1F9AD6BE0BCE5D39AE1926043E22F56F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6A151FF0BCD6537EB59523EB4EDCAD13" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CA79CFD08A5C518794D8176DA72C0B4D" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6A151FF0BCD6537EB59523EB4EDCAD13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_B348AC900BBD5E9A970356B181784E3F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CA79CFD08A5C518794D8176DA72C0B4D" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_B348AC900BBD5E9A970356B181784E3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_08299D1A3C7956C4A2BEDA557E28B274" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CA79CFD08A5C518794D8176DA72C0B4D" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_08299D1A3C7956C4A2BEDA557E28B274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_37C00890D6FD56DDB1DE1EE0F276A769" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CA79CFD08A5C518794D8176DA72C0B4D" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_37C00890D6FD56DDB1DE1EE0F276A769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_E9ADA20987D05A6EAE9628438D86EA55" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CA79CFD08A5C518794D8176DA72C0B4D" xlink:to="loc_us-gaap_CommonStockSharesIssued_E9ADA20987D05A6EAE9628438D86EA55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1D6246BCBF67595DB12CDBBDE7F9DF4E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CA79CFD08A5C518794D8176DA72C0B4D" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1D6246BCBF67595DB12CDBBDE7F9DF4E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_C0E3988C3FB3112DCC6C865C0EB2EC53" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_16972476295511CD7A75865C0EB3E259" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C0E3988C3FB3112DCC6C865C0EB2EC53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_16972476295511CD7A75865C0EB3E259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_620C0BC18DA801B7469C865C0EB34A89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_16972476295511CD7A75865C0EB3E259" xlink:to="loc_us-gaap_ProfitLoss_620C0BC18DA801B7469C865C0EB34A89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D37B5AD5040C0F2BD86F865C0EB326A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_16972476295511CD7A75865C0EB3E259" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D37B5AD5040C0F2BD86F865C0EB326A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_A364D76AC133B044A03E865C0EB3413C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D37B5AD5040C0F2BD86F865C0EB326A6" xlink:to="loc_us-gaap_Depreciation_A364D76AC133B044A03E865C0EB3413C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_066B05341720AF00368E865C0EB42790" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D37B5AD5040C0F2BD86F865C0EB326A6" xlink:to="loc_us-gaap_ShareBasedCompensation_066B05341720AF00368E865C0EB42790" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NonCashLeaseExpense" xlink:label="loc_dare_NonCashLeaseExpense_2CD7AADB31880E3037E4865C0EB481E5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D37B5AD5040C0F2BD86F865C0EB326A6" xlink:to="loc_dare_NonCashLeaseExpense_2CD7AADB31880E3037E4865C0EB481E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_755130D369778C742CC9865C0EB5FBC1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D37B5AD5040C0F2BD86F865C0EB326A6" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_755130D369778C742CC9865C0EB5FBC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_10A06321A3CECCF04EBF865C0EB5FC18" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D37B5AD5040C0F2BD86F865C0EB326A6" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_10A06321A3CECCF04EBF865C0EB5FC18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_769A39BCCB12D2B98427865C0EB6D9E9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D37B5AD5040C0F2BD86F865C0EB326A6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_769A39BCCB12D2B98427865C0EB6D9E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_C03F2D63848BF65558B9865C0EB6D00F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_769A39BCCB12D2B98427865C0EB6D9E9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_C03F2D63848BF65558B9865C0EB6D00F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_58CA6CE0CA381CDCC8FF865C0EB6C76E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_769A39BCCB12D2B98427865C0EB6D9E9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_58CA6CE0CA381CDCC8FF865C0EB6C76E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_FB6A38E9742573596440865C0EB6FB64" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_769A39BCCB12D2B98427865C0EB6D9E9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_FB6A38E9742573596440865C0EB6FB64" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" xlink:label="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_CA0D50C67A7FAA55812D865C0EB7D5B5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_769A39BCCB12D2B98427865C0EB6D9E9" xlink:to="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_CA0D50C67A7FAA55812D865C0EB7D5B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9FE3805882EC9BA94673865C0EB7372B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_769A39BCCB12D2B98427865C0EB6D9E9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9FE3805882EC9BA94673865C0EB7372B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_E84AB8DE84DB0F7875E3865C0EB788EB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_769A39BCCB12D2B98427865C0EB6D9E9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_E84AB8DE84DB0F7875E3865C0EB788EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_FA15B10455EECDC31AD1865C0EB747AF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_769A39BCCB12D2B98427865C0EB6D9E9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_FA15B10455EECDC31AD1865C0EB747AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8EAA7732079C86B534D1865C0EB8CAB8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_16972476295511CD7A75865C0EB3E259" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8EAA7732079C86B534D1865C0EB8CAB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EF31235DDBF306CC6E92865C0EB8A1FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C0E3988C3FB3112DCC6C865C0EB2EC53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EF31235DDBF306CC6E92865C0EB8A1FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_876F124365D5C2842445865C0EB83AA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EF31235DDBF306CC6E92865C0EB8A1FF" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_876F124365D5C2842445865C0EB83AA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_A71BA714FA255AECF143865C0EB95CA2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EF31235DDBF306CC6E92865C0EB8A1FF" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_A71BA714FA255AECF143865C0EB95CA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_53FC9781EE88117692FF865C0EB9C36E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_EF31235DDBF306CC6E92865C0EB8A1FF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_53FC9781EE88117692FF865C0EB9C36E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3851664C657ABFE32FFA865C0EB96BB1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C0E3988C3FB3112DCC6C865C0EB2EC53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3851664C657ABFE32FFA865C0EB96BB1" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_1D5D56E72D42D37B74AB865C0EB9BBEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3851664C657ABFE32FFA865C0EB96BB1" xlink:to="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_1D5D56E72D42D37B74AB865C0EB9BBEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E502396634C97380F5A5865C0EBA4768" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3851664C657ABFE32FFA865C0EB96BB1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E502396634C97380F5A5865C0EBA4768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_6F23FE7432EB29FB1D65865C0EBA0326" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C0E3988C3FB3112DCC6C865C0EB2EC53" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_6F23FE7432EB29FB1D65865C0EBA0326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8DCD5C130DBBBAE88F52865C0EBA0354" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C0E3988C3FB3112DCC6C865C0EB2EC53" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8DCD5C130DBBBAE88F52865C0EBA0354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639D75E9B23F8FDBC847865C0EBA67D2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C0E3988C3FB3112DCC6C865C0EB2EC53" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639D75E9B23F8FDBC847865C0EBA67D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6E4A42D6C3DFA49D294B865C0EBB491A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C0E3988C3FB3112DCC6C865C0EB2EC53" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6E4A42D6C3DFA49D294B865C0EBB491A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_37DFFB45CF61497CED0C865C0EBB4429" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C0E3988C3FB3112DCC6C865C0EB2EC53" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_37DFFB45CF61497CED0C865C0EBB4429" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_A4625E645EE86A2872CB865C0EBB4CD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_37DFFB45CF61497CED0C865C0EBB4429" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_A4625E645EE86A2872CB865C0EBB4CD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_F2B6276AC516CC96708486AA97B642B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_37DFFB45CF61497CED0C865C0EBB4429" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_F2B6276AC516CC96708486AA97B642B3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_FFAC18AD972FBB106C0D865C0ED00189" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_D848ECCCE25A8214DCB2865C0ED0F7C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FFAC18AD972FBB106C0D865C0ED00189" xlink:to="loc_us-gaap_OperatingExpensesAbstract_D848ECCCE25A8214DCB2865C0ED0F7C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_629622F28590C0B5D6A2865C0ED0282C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D848ECCCE25A8214DCB2865C0ED0F7C1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_629622F28590C0B5D6A2865C0ED0282C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_F1E45B9767D3A9D30683865C0ED16A74" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D848ECCCE25A8214DCB2865C0ED0F7C1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_F1E45B9767D3A9D30683865C0ED16A74" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_LicenseFee" xlink:label="loc_dare_LicenseFee_1BB820BBA1EA3C425A26865C0ED1C108" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D848ECCCE25A8214DCB2865C0ED0F7C1" xlink:to="loc_dare_LicenseFee_1BB820BBA1EA3C425A26865C0ED1C108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2B100490F037264070B2865C0ED10374" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D848ECCCE25A8214DCB2865C0ED0F7C1" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2B100490F037264070B2865C0ED10374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7D42BB96CEA2211160C6865C0ED11288" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D848ECCCE25A8214DCB2865C0ED0F7C1" xlink:to="loc_us-gaap_OperatingExpenses_7D42BB96CEA2211160C6865C0ED11288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_FC79F388FABE172B0836865C0ED11ADA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FFAC18AD972FBB106C0D865C0ED00189" xlink:to="loc_us-gaap_OperatingIncomeLoss_FC79F388FABE172B0836865C0ED11ADA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0C2351D81EEECAAA2416865C0ED1FDB4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FFAC18AD972FBB106C0D865C0ED00189" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0C2351D81EEECAAA2416865C0ED1FDB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1111AE1DB781476263A6865C0ED2AC92" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FFAC18AD972FBB106C0D865C0ED00189" xlink:to="loc_us-gaap_NetIncomeLoss_1111AE1DB781476263A6865C0ED2AC92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_B4E75DA51F98FAE56AD486AB39E0E43A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FFAC18AD972FBB106C0D865C0ED00189" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_B4E75DA51F98FAE56AD486AB39E0E43A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9567D9B2A2711228827386914CA4F232" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FFAC18AD972FBB106C0D865C0ED00189" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9567D9B2A2711228827386914CA4F232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_C7189E3550A83E89BC95865C0ED2CE99" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FFAC18AD972FBB106C0D865C0ED00189" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_C7189E3550A83E89BC95865C0ED2CE99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0C9641B9443865DFBAB8865C0ED23650" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FFAC18AD972FBB106C0D865C0ED00189" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0C9641B9443865DFBAB8865C0ED23650" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_312DC196293A22866922865C0ED27BE8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FFAC18AD972FBB106C0D865C0ED00189" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_312DC196293A22866922865C0ED27BE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C81B30B32E57107C7338865C0ED3B632" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FFAC18AD972FBB106C0D865C0ED00189" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C81B30B32E57107C7338865C0ED3B632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_465BD153D06885C13AE7865C0ED35C9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_C81B30B32E57107C7338865C0ED3B632" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_465BD153D06885C13AE7865C0ED35C9F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_005EC5BF97AA5459CAEE8B6FAE986326" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A3F4F4A457B43093822A8B6FAE9B5F37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_005EC5BF97AA5459CAEE8B6FAE986326" xlink:to="loc_us-gaap_StatementTable_A3F4F4A457B43093822A8B6FAE9B5F37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7E0C3649329E9CAEBA818B6FAE9CA943" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A3F4F4A457B43093822A8B6FAE9B5F37" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7E0C3649329E9CAEBA818B6FAE9CA943" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7E0C3649329E9CAEBA818B6FAE9CA943" xlink:to="loc_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_EE9975C36A926F29A43E8B6FAE9D4D9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C" xlink:to="loc_us-gaap_CommonStockMember_EE9975C36A926F29A43E8B6FAE9D4D9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9793BC4FE667D4DF62678B6FAE9D57B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9793BC4FE667D4DF62678B6FAE9D57B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B669CDE737E161FC0BC88B6FAE9D1409" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B669CDE737E161FC0BC88B6FAE9D1409" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_2B051ED87000BB590A598B6FAE9EAE51" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_31871EDDC6D7CAF677998B6FAE9C288C" xlink:to="loc_us-gaap_RetainedEarningsMember_2B051ED87000BB590A598B6FAE9EAE51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6F60125553199E0B09B38B6FAE9EEE06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A3F4F4A457B43093822A8B6FAE9B5F37" xlink:to="loc_us-gaap_StatementLineItems_6F60125553199E0B09B38B6FAE9EEE06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6F60125553199E0B09B38B6FAE9EEE06" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_CCB4EAD7BD5493BFE97E8B6FAE9E50E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_SharesOutstanding_CCB4EAD7BD5493BFE97E8B6FAE9E50E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_920381340E2E372311AE8B6FAE9F6821" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_StockholdersEquity_920381340E2E372311AE8B6FAE9F6821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2940A599692ECC79E2DD8B6FAE9FF2B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2940A599692ECC79E2DD8B6FAE9FF2B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B08BF7F5BA4C4B4E7D428B6FB25CF7AA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_B08BF7F5BA4C4B4E7D428B6FB25CF7AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4BFB2238736FE5BB8DBF8B6FAEA11DC3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4BFB2238736FE5BB8DBF8B6FAEA11DC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_60358D4FEE3F9CE4A6EE8B6FAEA1776C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_60358D4FEE3F9CE4A6EE8B6FAEA1776C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_8AA05A60ADC4B0A0E75D8B6FAEA2BC73" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_8AA05A60ADC4B0A0E75D8B6FAEA2BC73" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_02EE51BC72EE44F23ACA8B6FAEA236D0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_02EE51BC72EE44F23ACA8B6FAEA236D0" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_863F0428610B7AD5EBD38B6FAEA260F2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_863F0428610B7AD5EBD38B6FAEA260F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4FBA5B9F086B6C03DD768B6FAEA2CE65" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_NetIncomeLoss_4FBA5B9F086B6C03DD768B6FAEA2CE65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_B0E091BBFECD596837438B6FAEA2B4BD" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_B0E091BBFECD596837438B6FAEA2B4BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_B1C979487A100BB111688B6FAEA2F36D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_SharesOutstanding_B1C979487A100BB111688B6FAEA2F36D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CCBCDFDC95C9C86BCB308B6FAEA3BF14" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3F55480ECB81D1EF6E468B6FAE9E2485" xlink:to="loc_us-gaap_StockholdersEquity_CCBCDFDC95C9C86BCB308B6FAEA3BF14" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="dare-20190630.xsd#dare_DocumentAndEntityInformationAbstract" xlink:label="loc_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_1B60FC890212C3CC8FE2720C223A31CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:to="loc_dei_DocumentType_1B60FC890212C3CC8FE2720C223A31CA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C91B96610588A6369F95720C223ADAEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:to="loc_dei_AmendmentFlag_C91B96610588A6369F95720C223ADAEF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_B051D0B7A79F1107A821720C223BA228" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:to="loc_dei_DocumentPeriodEndDate_B051D0B7A79F1107A821720C223BA228" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_73CFAA96A126F30ABB3D720C223B6BB3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:to="loc_dei_DocumentFiscalYearFocus_73CFAA96A126F30ABB3D720C223B6BB3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_71A050169DD0A9FF285F720C223B6631" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:to="loc_dei_DocumentFiscalPeriodFocus_71A050169DD0A9FF285F720C223B6631" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_7AED388970DE8BC1C13B720C223B45DF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:to="loc_dei_EntityRegistrantName_7AED388970DE8BC1C13B720C223B45DF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_74B076A9F5EA8AE95318720C223CD8FB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:to="loc_dei_EntityCentralIndexKey_74B076A9F5EA8AE95318720C223CD8FB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_0765B7E978DD5822FE75720C223CCFA8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:to="loc_dei_CurrentFiscalYearEndDate_0765B7E978DD5822FE75720C223CCFA8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_C95071695F167B8F22C1720C223C0FDA" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:to="loc_dei_EntityFilerCategory_C95071695F167B8F22C1720C223C0FDA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_E7A3B3432B71680FBD0B720C223CC959" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:to="loc_dei_EntitySmallBusiness_E7A3B3432B71680FBD0B720C223CC959" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_A8893BC5F3AE680EF2D9720C223D6896" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:to="loc_dei_EntityEmergingGrowthCompany_A8893BC5F3AE680EF2D9720C223D6896" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_F019616E4DCEDFAD6BE4720C223DD995" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:to="loc_dei_EntityExTransitionPeriod_F019616E4DCEDFAD6BE4720C223DD995" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_799446C3D5A99AEEE764720C223DC200" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:to="loc_dei_EntityShellCompany_799446C3D5A99AEEE764720C223DC200" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_8E5AAFA6664C70D2827D720C223D7BB4" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:to="loc_dei_EntityCurrentReportingStatus_8E5AAFA6664C70D2827D720C223D7BB4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_03F8139EF284CF48C34B720C223EC9FC" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_2EDCD025007315E04583720C2235A710" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_03F8139EF284CF48C34B720C223EC9FC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/GoingConcern" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DF31327ED928534F9406C4F4D10CE146" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_774791C3ED2057D08400EF7FA2C6A932" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DF31327ED928534F9406C4F4D10CE146" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_774791C3ED2057D08400EF7FA2C6A932" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/GoingConcernAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6B6BE9B4D81E6B05C7B66D52EA5B2091" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6B6BE9B4D81E6B05C7B66D52EA5B2091" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7CEFFF5465D919DDC8916D52EA5B734B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA" xlink:to="loc_srt_ProductOrServiceAxis_7CEFFF5465D919DDC8916D52EA5B734B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_9EECFEEFA666A9A4A7506D52EA5B5235" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7CEFFF5465D919DDC8916D52EA5B734B" xlink:to="loc_srt_ProductsAndServicesDomain_9EECFEEFA666A9A4A7506D52EA5B5235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_91FA625B5AA197D1BBAA6D52EA5B54E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9EECFEEFA666A9A4A7506D52EA5B5235" xlink:to="loc_us-gaap_GrantMember_91FA625B5AA197D1BBAA6D52EA5B54E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8A7BA3A6C2CC1CCB7E036D52EA5B2B80" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8A7BA3A6C2CC1CCB7E036D52EA5B2B80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_D728D2DFBCC6381234FA6D52EA5B7E8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8A7BA3A6C2CC1CCB7E036D52EA5B2B80" xlink:to="loc_us-gaap_RelatedPartyDomain_D728D2DFBCC6381234FA6D52EA5B7E8E" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NationalInstitutesOfHealthMember" xlink:label="loc_dare_NationalInstitutesOfHealthMember_508495C41378D0FC8B686D52EA5B0048" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_D728D2DFBCC6381234FA6D52EA5B7E8E" xlink:to="loc_dare_NationalInstitutesOfHealthMember_508495C41378D0FC8B686D52EA5B0048" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundAxis" xlink:label="loc_us-gaap_HealthCareTrustFundAxis_9024E697C6EEF9EEF45F6D52EA5BC69E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA" xlink:to="loc_us-gaap_HealthCareTrustFundAxis_9024E697C6EEF9EEF45F6D52EA5BC69E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain" xlink:label="loc_us-gaap_HealthCareTrustFundNameDomain_CEFC5E1803BF6046AD196D52EA5BA5F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareTrustFundAxis_9024E697C6EEF9EEF45F6D52EA5BC69E" xlink:to="loc_us-gaap_HealthCareTrustFundNameDomain_CEFC5E1803BF6046AD196D52EA5BA5F7" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember" xlink:label="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_12D40397C4A8580A15106D52EA632555" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareTrustFundNameDomain_CEFC5E1803BF6046AD196D52EA5BA5F7" xlink:to="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_12D40397C4A8580A15106D52EA632555" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3558151A87F073611B636D52EA637928" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3558151A87F073611B636D52EA637928" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_B93577EA87FA69C5A75D6D52EA63811A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3558151A87F073611B636D52EA637928" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_B93577EA87FA69C5A75D6D52EA63811A" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember" xlink:label="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_DF450E5A27D6B8FA488C6D52EA63B7AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_B93577EA87FA69C5A75D6D52EA63811A" xlink:to="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_DF450E5A27D6B8FA488C6D52EA63B7AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_51EADE8B97AC278B9AA46D52EA5B9FCA" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9E4D11A2D13C7455FC476D52EA64E91D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9E4D11A2D13C7455FC476D52EA64E91D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DF0FAA86DAD4E600AFA36D52EA64F688" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DF0FAA86DAD4E600AFA36D52EA64F688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C6383C3A9AD9746E849C6D52EA64D4EC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C6383C3A9AD9746E849C6D52EA64D4EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C69E4D2F7126695CD38E6D52EA64A59D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C69E4D2F7126695CD38E6D52EA64A59D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable_D5E64146DD92E00E0C1D6D52EA642C56" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:to="loc_us-gaap_GrantsReceivable_D5E64146DD92E00E0C1D6D52EA642C56" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_ReimbursementOfGrantExpensesReceivable" xlink:label="loc_dare_ReimbursementOfGrantExpensesReceivable_82D663772CEE1F2578786D52EA647669" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:to="loc_dare_ReimbursementOfGrantExpensesReceivable_82D663772CEE1F2578786D52EA647669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_C078979A20F8332065206D52EA64F3C7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_216F1500BD0EDBF0B0266D52EA648E15" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_C078979A20F8332065206D52EA64F3C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/GrantAward" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_A2FB7F44FAFF509AA836C4BE72D78A68" xlink:type="locator" />
    <link:loc xlink:href="dare-20190630.xsd#dare_GrantAwardTextBlock" xlink:label="loc_dare_GrantAwardTextBlock_6876CE8B016D5220A983CCD5C3DD1E43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_A2FB7F44FAFF509AA836C4BE72D78A68" xlink:to="loc_dare_GrantAwardTextBlock_6876CE8B016D5220A983CCD5C3DD1E43" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/GrantAwardAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_FC06EF96BBD77C5DE4FA78071A9A23CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_FC06EF96BBD77C5DE4FA78071A9A23CA" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_F277B3843F86B08B689B78071A9ABC8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94" xlink:to="loc_srt_ProductOrServiceAxis_F277B3843F86B08B689B78071A9ABC8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_9FF123669E71341C3E5878071A9A0359" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_F277B3843F86B08B689B78071A9ABC8D" xlink:to="loc_srt_ProductsAndServicesDomain_9FF123669E71341C3E5878071A9A0359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_535B6950653C3CB0D76878071A9B275F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9FF123669E71341C3E5878071A9A0359" xlink:to="loc_us-gaap_GrantMember_535B6950653C3CB0D76878071A9B275F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundAxis" xlink:label="loc_us-gaap_HealthCareTrustFundAxis_1830BCA3919CD5B3402A78071A9B4127" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94" xlink:to="loc_us-gaap_HealthCareTrustFundAxis_1830BCA3919CD5B3402A78071A9B4127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain" xlink:label="loc_us-gaap_HealthCareTrustFundNameDomain_D24BE27C4ACE19EC368C78071A9BDB2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareTrustFundAxis_1830BCA3919CD5B3402A78071A9B4127" xlink:to="loc_us-gaap_HealthCareTrustFundNameDomain_D24BE27C4ACE19EC368C78071A9BDB2C" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember" xlink:label="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_612F83A37AD7C0A1506378071A9B6D90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareTrustFundNameDomain_D24BE27C4ACE19EC368C78071A9BDB2C" xlink:to="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_612F83A37AD7C0A1506378071A9B6D90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_F3D37C904704783795E078071A9C38BE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_F3D37C904704783795E078071A9C38BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_076D258F647EC3CAB6BE78071A9CF74D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_F3D37C904704783795E078071A9C38BE" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_076D258F647EC3CAB6BE78071A9CF74D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember" xlink:label="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_C8C5003CF6E2C5E1895878071A9C940C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_076D258F647EC3CAB6BE78071A9CF74D" xlink:to="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_C8C5003CF6E2C5E1895878071A9C940C" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember" xlink:label="loc_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_F8C3157919E0751B775978071A9CD738" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_076D258F647EC3CAB6BE78071A9CF74D" xlink:to="loc_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_F8C3157919E0751B775978071A9CD738" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_47DF55D11E5E40B7DBCD78071A9DC328" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_47DF55D11E5E40B7DBCD78071A9DC328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6345B2EE67E3C86B791378071A9D8811" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_47DF55D11E5E40B7DBCD78071A9DC328" xlink:to="loc_us-gaap_RelatedPartyDomain_6345B2EE67E3C86B791378071A9D8811" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NationalInstitutesOfHealthMember" xlink:label="loc_dare_NationalInstitutesOfHealthMember_D95D11A6E5184A962CDB78071A9DBD1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6345B2EE67E3C86B791378071A9D8811" xlink:to="loc_dare_NationalInstitutesOfHealthMember_D95D11A6E5184A962CDB78071A9DBD1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_8DCF5FB7D002ACDE54A678071A9DF0C0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1655896E38CDAC0C103C78071A9A1D94" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_8DCF5FB7D002ACDE54A678071A9DF0C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8E39C881385A31E8D52878071A9D2B52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_8DCF5FB7D002ACDE54A678071A9DF0C0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8E39C881385A31E8D52878071A9D2B52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable_587FD73E2F59C11C343078071A9EB0BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_8DCF5FB7D002ACDE54A678071A9DF0C0" xlink:to="loc_us-gaap_GrantsReceivable_587FD73E2F59C11C343078071A9EB0BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_8CE9F1F05363B064D33E78071A9ED29B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_8DCF5FB7D002ACDE54A678071A9DF0C0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_8CE9F1F05363B064D33E78071A9ED29B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedProperties" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_4979DA12CA2B50E29C489358FF47E295" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1A5F31D46D355DC3846132FE3A63A00E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4979DA12CA2B50E29C489358FF47E295" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1A5F31D46D355DC3846132FE3A63A00E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_D3A51C7A906455CE83DE87D13565E416" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetRentableArea" xlink:label="loc_us-gaap_NetRentableArea_46106322944B0DF9615C87D135652A95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_D3A51C7A906455CE83DE87D13565E416" xlink:to="loc_us-gaap_NetRentableArea_46106322944B0DF9615C87D135652A95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1084D4EB8852CA71C68187D135657FD6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_D3A51C7A906455CE83DE87D13565E416" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1084D4EB8852CA71C68187D135657FD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_14D1172847189E5CF24287D135658437" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_D3A51C7A906455CE83DE87D13565E416" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_14D1172847189E5CF24287D135658437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_6CA74F59CB7AF5D3808D87D13565D232" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_D3A51C7A906455CE83DE87D13565E416" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_6CA74F59CB7AF5D3808D87D13565D232" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PercentageOfIncreaseInAnnualBaseRent" xlink:label="loc_dare_PercentageOfIncreaseInAnnualBaseRent_DDA1722093063A74768F87D13565CF6B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_D3A51C7A906455CE83DE87D13565E416" xlink:to="loc_dare_PercentageOfIncreaseInAnnualBaseRent_DDA1722093063A74768F87D13565CF6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_D62277D2A42943F0F41287D81D065160" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_D3A51C7A906455CE83DE87D13565E416" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_D62277D2A42943F0F41287D81D065160" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6A5CA07BD61B000E42CD87D135654587" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_D3A51C7A906455CE83DE87D13565E416" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6A5CA07BD61B000E42CD87D135654587" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_A8625A5BD3C53B09E57587D13565E027" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_D3A51C7A906455CE83DE87D13565E416" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_A8625A5BD3C53B09E57587D13565E027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_84A6D947C1DFFCEE01AA87D13565962C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_D3A51C7A906455CE83DE87D13565E416" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_84A6D947C1DFFCEE01AA87D13565962C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_54C4EFAC4DB3779DCE9F87D135657741" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_D3A51C7A906455CE83DE87D13565E416" xlink:to="loc_us-gaap_OperatingLeaseCost_54C4EFAC4DB3779DCE9F87D135657741" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_021801878E381DDE7B8A87D13565802E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_D3A51C7A906455CE83DE87D13565E416" xlink:to="loc_us-gaap_OperatingLeasePayments_021801878E381DDE7B8A87D13565802E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_C72CBFCA958858BBAF465D9DCCABA0A3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_C114029E7B17513681D7960F75ED5594" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_C72CBFCA958858BBAF465D9DCCABA0A3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_C114029E7B17513681D7960F75ED5594" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E960AAE60F40556EA85F7349097F00F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_C72CBFCA958858BBAF465D9DCCABA0A3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E960AAE60F40556EA85F7349097F00F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_040CAB722AC255B088BC89FEE170BB61" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_C72CBFCA958858BBAF465D9DCCABA0A3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_040CAB722AC255B088BC89FEE170BB61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_D086BA805C1F56C581CFAAB23A4D76CA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_C72CBFCA958858BBAF465D9DCCABA0A3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_D086BA805C1F56C581CFAAB23A4D76CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2CBF8640BC605DFB9B88506239A08E63" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_C72CBFCA958858BBAF465D9DCCABA0A3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2CBF8640BC605DFB9B88506239A08E63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_072D13B4B9EF5FA38754E9ABA2E065C6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_C72CBFCA958858BBAF465D9DCCABA0A3" xlink:to="loc_us-gaap_OperatingLeaseLiability_072D13B4B9EF5FA38754E9ABA2E065C6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_A7AFD0EFF28D5F1599CF3E6689F5D865" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C80FB35C25765DC6A026019E67E3693A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_A7AFD0EFF28D5F1599CF3E6689F5D865" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C80FB35C25765DC6A026019E67E3693A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_892B5EC6526F5B59B10039AA9DAC8452" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_F9037B3123D052DCA0C5CD48F59DF8EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_892B5EC6526F5B59B10039AA9DAC8452" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_F9037B3123D052DCA0C5CD48F59DF8EF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_711C30A4F92B7D190CED6D52E9535AA0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9BDB42DBDA238E4DBB596D52E953A6CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_711C30A4F92B7D190CED6D52E9535AA0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9BDB42DBDA238E4DBB596D52E953A6CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54BB2834DB4DBD6BCA1F6D52E953F13C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9BDB42DBDA238E4DBB596D52E953A6CB" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54BB2834DB4DBD6BCA1F6D52E953F13C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_447AF40BE95F649A9D386D52E95471FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54BB2834DB4DBD6BCA1F6D52E953F13C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_447AF40BE95F649A9D386D52E95471FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_63898290C78FD7CAEC566D52E954E914" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_447AF40BE95F649A9D386D52E95471FB" xlink:to="loc_us-gaap_EmployeeStockOptionMember_63898290C78FD7CAEC566D52E954E914" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_B71BE63BEEE944C2367D6D52E954DFF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_447AF40BE95F649A9D386D52E95471FB" xlink:to="loc_us-gaap_WarrantMember_B71BE63BEEE944C2367D6D52E954DFF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E7C252C5678F2865C8246D52E9547967" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9BDB42DBDA238E4DBB596D52E953A6CB" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E7C252C5678F2865C8246D52E9547967" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5105188C94B7735FA6A16D52E954CC08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_E7C252C5678F2865C8246D52E9547967" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5105188C94B7735FA6A16D52E954CC08" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_B3796063942255018FFFBC589346BDEC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_01CE7DEDA6645C2295761A6575145B93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B3796063942255018FFFBC589346BDEC" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_01CE7DEDA6645C2295761A6575145B93" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_78D5848595855FA7AE59DE5E2E00BE78" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_FC215CD122245A0C8E3A5037040021E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_78D5848595855FA7AE59DE5E2E00BE78" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_FC215CD122245A0C8E3A5037040021E9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BC6A65164EC3EA547A95E776956DFE2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_5A7709594452461163625E776967FDB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1BC6A65164EC3EA547A95E776956DFE2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_5A7709594452461163625E776967FDB0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_095D3B6D7C7D58299E1627EFCA77819B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_43B32258FEB757DC965CFFCCFA9A6124" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_095D3B6D7C7D58299E1627EFCA77819B" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_43B32258FEB757DC965CFFCCFA9A6124" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CD5C8E004EA075D9FA1678071B0DF24A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_514665E902E8CF33929878071B0E0532" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CD5C8E004EA075D9FA1678071B0DF24A" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_514665E902E8CF33929878071B0E0532" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D976E7AE2CF00232181978071B0E68D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_514665E902E8CF33929878071B0E0532" xlink:to="loc_us-gaap_PlanNameAxis_D976E7AE2CF00232181978071B0E68D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_9DDC3B35686E55DA0D6178071B0E1D41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_D976E7AE2CF00232181978071B0E68D2" xlink:to="loc_us-gaap_PlanNameDomain_9DDC3B35686E55DA0D6178071B0E1D41" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_TwoThousandAndFifteenStockIncentivePlanMember" xlink:label="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_5C57066E292D285B3E1978071B0E4656" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9DDC3B35686E55DA0D6178071B0E1D41" xlink:to="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_5C57066E292D285B3E1978071B0E4656" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:label="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_31829F82667CBF8C8AFD78071B0FDCD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9DDC3B35686E55DA0D6178071B0E1D41" xlink:to="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_31829F82667CBF8C8AFD78071B0FDCD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_F8F39A5165424763C5F778071B0F89C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_514665E902E8CF33929878071B0E0532" xlink:to="loc_us-gaap_AwardTypeAxis_F8F39A5165424763C5F778071B0F89C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_478BFA23697F50EA512578071B0F6C27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_F8F39A5165424763C5F778071B0F89C9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_478BFA23697F50EA512578071B0F6C27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_D2425F7E8F4F2379525678071B10340B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_478BFA23697F50EA512578071B0F6C27" xlink:to="loc_us-gaap_EmployeeStockOptionMember_D2425F7E8F4F2379525678071B10340B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_E098B8DA014F08AA312A78071B10512E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_478BFA23697F50EA512578071B0F6C27" xlink:to="loc_us-gaap_RestrictedStockMember_E098B8DA014F08AA312A78071B10512E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_AEE17DCE38D004C30D4C78071B10E487" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_514665E902E8CF33929878071B0E0532" xlink:to="loc_dei_LegalEntityAxis_AEE17DCE38D004C30D4C78071B10E487" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_50B3045CE0B52741848478071B1057F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_AEE17DCE38D004C30D4C78071B10E487" xlink:to="loc_dei_EntityDomain_50B3045CE0B52741848478071B1057F1" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PrivateDareMember" xlink:label="loc_dare_PrivateDareMember_DCE39D2318ADB58E9AC178071B109D47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_50B3045CE0B52741848478071B1057F1" xlink:to="loc_dare_PrivateDareMember_DCE39D2318ADB58E9AC178071B109D47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_514665E902E8CF33929878071B0E0532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60FCE851A61B0D22ACA878071B11A1A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60FCE851A61B0D22ACA878071B11A1A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_BBDD03E2CE24EED34C7C78071B119E9F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_BBDD03E2CE24EED34C7C78071B119E9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1C7ADDA2E8185CEC996D78071B11420F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1C7ADDA2E8185CEC996D78071B11420F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2CDF900943E7B604507C78071B119F62" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2CDF900943E7B604507C78071B119F62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_DBB491C57AF1DEBE0FF678071B120A20" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_DBB491C57AF1DEBE0FF678071B120A20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_215A3D22D1652520B45D78071B12BC27" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_215A3D22D1652520B45D78071B12BC27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_2FBB9910BBEAB761386C78071B1237E3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_2FBB9910BBEAB761386C78071B1237E3" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_WeightedAverageAmortizationPeriod" xlink:label="loc_dare_WeightedAverageAmortizationPeriod_A0396191BCF261CEB98A78071B1296F8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_dare_WeightedAverageAmortizationPeriod_A0396191BCF261CEB98A78071B1296F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_DC7B422A8ADED2C5F2CE78071B12B8C9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0AE8B6F2FF272A9F6F8978071B110CBE" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_DC7B422A8ADED2C5F2CE78071B12B8C9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FF84B4A3C9FF575AA49C2DC50163B4F5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7932F9E7D6055092815608A5A42F9353" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FF84B4A3C9FF575AA49C2DC50163B4F5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7932F9E7D6055092815608A5A42F9353" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_701DB48913EF5357B77F7FDCD401B7C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FF84B4A3C9FF575AA49C2DC50163B4F5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_701DB48913EF5357B77F7FDCD401B7C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9C1A5A001D4B54B88E70024467A72FE5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FF84B4A3C9FF575AA49C2DC50163B4F5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9C1A5A001D4B54B88E70024467A72FE5" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:label="loc_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_F826AB7414D552319F2D1DAC9D0346BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FF84B4A3C9FF575AA49C2DC50163B4F5" xlink:to="loc_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_F826AB7414D552319F2D1DAC9D0346BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A29D32EA88695212A0ED8830FAA82625" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FF84B4A3C9FF575AA49C2DC50163B4F5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A29D32EA88695212A0ED8830FAA82625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5C72EE9B53655FD4ABD53DC5D5534431" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FF84B4A3C9FF575AA49C2DC50163B4F5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5C72EE9B53655FD4ABD53DC5D5534431" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4A436152E437063225566D52E9B6640B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A37D537168FC2631BB636D52E9B6B68A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4A436152E437063225566D52E9B6640B" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A37D537168FC2631BB636D52E9B6B68A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7B7CBA4A3F9F3A9E8DFC6D52E9B65984" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A37D537168FC2631BB636D52E9B6B68A" xlink:to="loc_us-gaap_AwardTypeAxis_7B7CBA4A3F9F3A9E8DFC6D52E9B65984" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4A449490693E6C995BF6D52E9B76D8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7B7CBA4A3F9F3A9E8DFC6D52E9B65984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4A449490693E6C995BF6D52E9B76D8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_F9683919EFCF79397B776D52E9B7EF92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F4A449490693E6C995BF6D52E9B76D8D" xlink:to="loc_us-gaap_EmployeeStockOptionMember_F9683919EFCF79397B776D52E9B7EF92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_E57AF9FA462BDF24F9806D52E9B7FDD5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A37D537168FC2631BB636D52E9B6B68A" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_E57AF9FA462BDF24F9806D52E9B7FDD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D5174071889B94C41D236D52E9B76728" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E57AF9FA462BDF24F9806D52E9B7FDD5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_D5174071889B94C41D236D52E9B76728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9A3F78E83DDAF94383416D52E9B8BD46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D5174071889B94C41D236D52E9B76728" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9A3F78E83DDAF94383416D52E9B8BD46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9DE0FCC49AFA4099BDD76D52E9B8EB66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D5174071889B94C41D236D52E9B76728" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9DE0FCC49AFA4099BDD76D52E9B8EB66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69482650FDEAD6C154116D52E9B872D0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A37D537168FC2631BB636D52E9B6B68A" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69482650FDEAD6C154116D52E9B872D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_720A5EAA695713175DA46D52E9B8D0CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69482650FDEAD6C154116D52E9B872D0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_720A5EAA695713175DA46D52E9B8D0CF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40205D1A594686018594865C0E0C98F6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BA443E41EFE503DE841865C0E0CDA2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40205D1A594686018594865C0E0C98F6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BA443E41EFE503DE841865C0E0CDA2D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_B0632701CF95A2384886865C0E0C207D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BA443E41EFE503DE841865C0E0CDA2D" xlink:to="loc_dei_LegalEntityAxis_B0632701CF95A2384886865C0E0C207D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_203CF7377A77E2D5394A865C0E0C49AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_B0632701CF95A2384886865C0E0C207D" xlink:to="loc_dei_EntityDomain_203CF7377A77E2D5394A865C0E0C49AA" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PrivateDareMember" xlink:label="loc_dare_PrivateDareMember_0BDA779B5B444FE258BA865C0E0D5053" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_203CF7377A77E2D5394A865C0E0C49AA" xlink:to="loc_dare_PrivateDareMember_0BDA779B5B444FE258BA865C0E0D5053" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_A265480F395B83DDBC55865C0E0DA7DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BA443E41EFE503DE841865C0E0CDA2D" xlink:to="loc_us-gaap_PlanNameAxis_A265480F395B83DDBC55865C0E0DA7DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_F2A0F307C5F736625AF5865C0E0D7EA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_A265480F395B83DDBC55865C0E0DA7DF" xlink:to="loc_us-gaap_PlanNameDomain_F2A0F307C5F736625AF5865C0E0D7EA4" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_TwoThousandAndFifteenStockIncentivePlanMember" xlink:label="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_A09A6196A725CD7522BD865C0E0D9B1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_F2A0F307C5F736625AF5865C0E0D7EA4" xlink:to="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_A09A6196A725CD7522BD865C0E0D9B1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_12F9273A4AE1D453DD5F865C0E0E8D25" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BA443E41EFE503DE841865C0E0CDA2D" xlink:to="loc_us-gaap_AwardTypeAxis_12F9273A4AE1D453DD5F865C0E0E8D25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1C3AE6BDC8E4BF34F01B865C0E0EB8B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_12F9273A4AE1D453DD5F865C0E0E8D25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1C3AE6BDC8E4BF34F01B865C0E0EB8B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C0D2D786D7C1A5363C62865C0E0FD86C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1C3AE6BDC8E4BF34F01B865C0E0EB8B5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C0D2D786D7C1A5363C62865C0E0FD86C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB49971B6B7754989465865C0E0F7241" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BA443E41EFE503DE841865C0E0CDA2D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB49971B6B7754989465865C0E0F7241" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB49971B6B7754989465865C0E0F7241" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7B91F1F506B83CD2AECB865C0E0FFDBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7B91F1F506B83CD2AECB865C0E0FFDBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EDB7F6D4101931318769865C0E108ABE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EDB7F6D4101931318769865C0E108ABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2B03E75D60AAB7B38FC3865C0E10581F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2B03E75D60AAB7B38FC3865C0E10581F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5868494C6DFFBA84B9E6865C0E105BC0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5868494C6DFFBA84B9E6865C0E105BC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_DB654CF8009A0FA37AE4865C0E10A77A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_DB654CF8009A0FA37AE4865C0E10A77A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_93D22FAF60337B8881E2865C0E10E746" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_93D22FAF60337B8881E2865C0E10E746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B95FC75F6B5EB2296166865C0E110005" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D9A9BC320862C46A804C865C0E0F609E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_B95FC75F6B5EB2296166865C0E110005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB49971B6B7754989465865C0E0F7241" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5D0F747F18C3941C0547865C0E11D9BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5D0F747F18C3941C0547865C0E11D9BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7C3903BFC828FF19F5DA865C0E11799D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7C3903BFC828FF19F5DA865C0E11799D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_26EF1CFE6198804D4251865C0E11BA73" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_26EF1CFE6198804D4251865C0E11BA73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_64F83E078EA7BFE8FE96865C0E124874" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_64F83E078EA7BFE8FE96865C0E124874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_A0499CB2AF341A040FCE865C0E12BD3E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_A0499CB2AF341A040FCE865C0E12BD3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3C8273D8CBA5A4824CF5865C0E12125A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3C8273D8CBA5A4824CF5865C0E12125A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E7791DF4D39EF7B74E8C865C0E129A70" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C567AFAB4A1E7B2EEF65865C0E116974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_E7791DF4D39EF7B74E8C865C0E129A70" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FE80EE6FDF235208936FD9B2610A54B4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8B6D6B437E975B46959BB2D0E246A1D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FE80EE6FDF235208936FD9B2610A54B4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8B6D6B437E975B46959BB2D0E246A1D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_52B102DEDA16541F89C5D0E6CEFA6201" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FE80EE6FDF235208936FD9B2610A54B4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_52B102DEDA16541F89C5D0E6CEFA6201" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_EAC054E600655DE9AEAB3E5F480A3079" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FE80EE6FDF235208936FD9B2610A54B4" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_EAC054E600655DE9AEAB3E5F480A3079" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_DFB639E118A95852B1DC6FD590DA415C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1BCF9F685E4B58B6989B4E5A56E13C8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_DFB639E118A95852B1DC6FD590DA415C" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1BCF9F685E4B58B6989B4E5A56E13C8F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_BB1CB57381F127144D268B6FD36DD338" xlink:type="locator" />
    <link:loc xlink:href="dare-20190630.xsd#dare_StockholdersEquityTable" xlink:label="loc_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_BB1CB57381F127144D268B6FD36DD338" xlink:to="loc_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C4D21A9C27F1C21938E08B6FD36D8181" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C4D21A9C27F1C21938E08B6FD36D8181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_A22A502617E824B33A8E8B6FD36DBDDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_C4D21A9C27F1C21938E08B6FD36D8181" xlink:to="loc_us-gaap_TypeOfAdoptionMember_A22A502617E824B33A8E8B6FD36DBDDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201711Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201711Member_A0146588574C7621B0D28B6FD36DC100" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_A22A502617E824B33A8E8B6FD36DBDDA" xlink:to="loc_us-gaap_AccountingStandardsUpdate201711Member_A0146588574C7621B0D28B6FD36DC100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_323D23335B44D181BC6F8B6FD36D93C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_323D23335B44D181BC6F8B6FD36D93C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_EAC28790EB64CA571DEB8B6FD36D8B1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_323D23335B44D181BC6F8B6FD36D93C8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_EAC28790EB64CA571DEB8B6FD36D8B1B" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:label="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_E965608F9764FB087E408B6FD36DD8A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EAC28790EB64CA571DEB8B6FD36D8B1B" xlink:to="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_E965608F9764FB087E408B6FD36DD8A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_714ED3D5617F28201EAF8B6FD36DCA40" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_714ED3D5617F28201EAF8B6FD36DCA40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743F5CB0BDF0B773F4E68B6FD36D0179" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_714ED3D5617F28201EAF8B6FD36DCA40" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743F5CB0BDF0B773F4E68B6FD36D0179" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_8E0E9910F744357DE0388B6FD36D788D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743F5CB0BDF0B773F4E68B6FD36D0179" xlink:to="loc_us-gaap_OverAllotmentOptionMember_8E0E9910F744357DE0388B6FD36D788D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PublicStockOfferingMember" xlink:label="loc_dare_PublicStockOfferingMember_B7A0DA44E04EE01018C58B6FD36D31F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743F5CB0BDF0B773F4E68B6FD36D0179" xlink:to="loc_dare_PublicStockOfferingMember_B7A0DA44E04EE01018C58B6FD36D31F8" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_StockholdersEquityLineItems" xlink:label="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_5D45154D634295EFF0858B6FD36D9A11" xlink:to="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_dare_GrossProceedsFromIssuanceOfCommonStock_5AF9D10A9736F08F38638B6FD36D4F27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_dare_GrossProceedsFromIssuanceOfCommonStock_5AF9D10A9736F08F38638B6FD36D4F27" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_PercentageOfAggregateCommission" xlink:label="loc_dare_PercentageOfAggregateCommission_F6F73243D93E3C2980088B6FD36D9837" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_dare_PercentageOfAggregateCommission_F6F73243D93E3C2980088B6FD36D9837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7D931EBDCEE712349F3C8B6FD36DCDF2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7D931EBDCEE712349F3C8B6FD36DCDF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_8C3D3A6C3F9CE19D44FA8B6FD36D0206" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_8C3D3A6C3F9CE19D44FA8B6FD36D0206" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_87AA5F3BA749CB1A18548B6FD36D4777" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_87AA5F3BA749CB1A18548B6FD36D4777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_10DA379D4E459D6FC60E8B6FD36D25C4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_10DA379D4E459D6FC60E8B6FD36D25C4" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" xlink:label="loc_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_A8C439607C34AC537A8B8B6FD36D6A55" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_A8C439607C34AC537A8B8B6FD36D6A55" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_UnderwritersOptionToPurchaseAdditionalShares" xlink:label="loc_dare_UnderwritersOptionToPurchaseAdditionalShares_E475BDC2875473EA85A58B6FD36DF2C2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_dare_UnderwritersOptionToPurchaseAdditionalShares_E475BDC2875473EA85A58B6FD36DF2C2" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_GrossProceedsFromOfferingOfCommonStockAndWarrants" xlink:label="loc_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_496FA365D812DD499E298B6FD36D0025" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_496FA365D812DD499E298B6FD36D0025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_FD29875E61840CFADAF68B6FD36D09D1" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_FD29875E61840CFADAF68B6FD36D09D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5F4F281DD89E3CD706758B6FD36D0CA0" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5F4F281DD89E3CD706758B6FD36D0CA0" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:label="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_30857EFADD67571259728B6FD36DCE36" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_30857EFADD67571259728B6FD36DCE36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_09F24EB06E9082A95BAB8B6FD36D5D21" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_09F24EB06E9082A95BAB8B6FD36D5D21" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_NumberOfCommonStockWarrantsExercised" xlink:label="loc_dare_NumberOfCommonStockWarrantsExercised_F3F6567BFBB804B7728E8B6FD36D38E7" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_3C9647CD26CC617AEC828B6FD36D8919" xlink:to="loc_dare_NumberOfCommonStockWarrantsExercised_F3F6567BFBB804B7728E8B6FD36D38E7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_14B5BFFB0214C67A644B6D52E9986F8C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_894F467B9053467DE1956D52E998F00A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_14B5BFFB0214C67A644B6D52E9986F8C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_894F467B9053467DE1956D52E998F00A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5EA6D1172A73F93A42A86D52E998D5FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_894F467B9053467DE1956D52E998F00A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5EA6D1172A73F93A42A86D52E998D5FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5EA6D1172A73F93A42A86D52E998D5FA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" xlink:label="loc_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_0024FA9F0FCE3B3D334B6D52E999D19B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:to="loc_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_0024FA9F0FCE3B3D334B6D52E999D19B" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" xlink:label="loc_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_48F387ED3BCC11EAAB356D52E9995787" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:to="loc_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_48F387ED3BCC11EAAB356D52E9995787" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember" xlink:label="loc_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_EC1FF5ACCCD5D5F45B706D52E9998301" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:to="loc_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_EC1FF5ACCCD5D5F45B706D52E9998301" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:label="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_D07B800AD32050182F536D52E99A4403" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:to="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_D07B800AD32050182F536D52E99A4403" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:label="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C0BDD88798ECE3558C866D52E99A55BA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0B823F23CFAAFB9B62016D52E9998E62" xlink:to="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C0BDD88798ECE3558C866D52E99A55BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_BD37FE611C764357EC6C6D52E99A27E3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_894F467B9053467DE1956D52E998F00A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_BD37FE611C764357EC6C6D52E99A27E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_529FB235BCCE9DDDF0606D52E99A9280" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BD37FE611C764357EC6C6D52E99A27E3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_529FB235BCCE9DDDF0606D52E99A9280" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_611770AE143C190FE3946D52E99A1C2B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BD37FE611C764357EC6C6D52E99A27E3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_611770AE143C190FE3946D52E99A1C2B" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:label="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_C89B1CD0EB99D3470BC46D52E99AF597" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BD37FE611C764357EC6C6D52E99A27E3" xlink:to="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_C89B1CD0EB99D3470BC46D52E99AF597" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_477C6C5CEE755F8B84666DCE660B3720" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ED7AE697A5025E8B929ED9C53E407454" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_477C6C5CEE755F8B84666DCE660B3720" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ED7AE697A5025E8B929ED9C53E407454" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_25459F96AD1D5F90822E4F87F4E937BA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8C95ABB2DF745DDBA564C38D4BAC1F14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25459F96AD1D5F90822E4F87F4E937BA" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8C95ABB2DF745DDBA564C38D4BAC1F14" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_63A6FD055EF8564FB487B59EA17378C5" xlink:type="locator" />
    <link:loc xlink:href="dare-20190630.xsd#dare_SignificantAccountingPoliciesTable" xlink:label="loc_dare_SignificantAccountingPoliciesTable_40577E5A38E154DCAD75C5B130F9614D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_63A6FD055EF8564FB487B59EA17378C5" xlink:to="loc_dare_SignificantAccountingPoliciesTable_40577E5A38E154DCAD75C5B130F9614D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_209AC45F5E755D4099BC7980989D7CAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesTable_40577E5A38E154DCAD75C5B130F9614D" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_209AC45F5E755D4099BC7980989D7CAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_CFC94E094EDC5E2C97061DE81812010D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_209AC45F5E755D4099BC7980989D7CAF" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_CFC94E094EDC5E2C97061DE81812010D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1EDEC70169415366995BBC3415215316" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_CFC94E094EDC5E2C97061DE81812010D" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1EDEC70169415366995BBC3415215316" xlink:type="arc" />
    <link:loc xlink:href="dare-20190630.xsd#dare_SignificantAccountingPoliciesLineItems" xlink:label="loc_dare_SignificantAccountingPoliciesLineItems_AB1FA72B72255C4BBD63C9710624E4F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesTable_40577E5A38E154DCAD75C5B130F9614D" xlink:to="loc_dare_SignificantAccountingPoliciesLineItems_AB1FA72B72255C4BBD63C9710624E4F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B6C4AA5F53135D578EB929FDCDC002F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_AB1FA72B72255C4BBD63C9710624E4F1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B6C4AA5F53135D578EB929FDCDC002F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_E29D27230F9559618B917803F6FF7BFE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_AB1FA72B72255C4BBD63C9710624E4F1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_E29D27230F9559618B917803F6FF7BFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_8607D7D599C95535911B7476F183D0F3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_AB1FA72B72255C4BBD63C9710624E4F1" xlink:to="loc_us-gaap_OperatingLeaseLiability_8607D7D599C95535911B7476F183D0F3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_813630F74BB05A188BB9CB1E8A140C9C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ABE78533779F5A4DBEEE3F0E0C93A850" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_813630F74BB05A188BB9CB1E8A140C9C" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ABE78533779F5A4DBEEE3F0E0C93A850" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_8E63F5C76A515033BA493C45156336DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_813630F74BB05A188BB9CB1E8A140C9C" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_8E63F5C76A515033BA493C45156336DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_52999C838DE858A2B4AC7E304CC9D7B0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_813630F74BB05A188BB9CB1E8A140C9C" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_52999C838DE858A2B4AC7E304CC9D7B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D41DA061D14A508F92DFD52F0629BC69" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_813630F74BB05A188BB9CB1E8A140C9C" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D41DA061D14A508F92DFD52F0629BC69" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>darebioinlinefullcolorrgb.jpg
<TEXT>
begin 644 darebioinlinefullcolorrgb.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D="                  #VU@ !     -,M2% @(
M                                            $6-P<G0   %0
M,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M    %&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0
M  +$    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE
M87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (
M#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE
M='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V
M+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                                  !865H@
M    \U$  0    $6S%A96B                      6%E:(        &^B
M   X]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0
M +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M   6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                 &1E<V,         +DE%0R V,3DV
M-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M    +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@
M<U)'0@                            !D97-C         "Q2969E<F5N
M8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0                                  =FEE=P      $Z3^ !1?+@ 0
MSQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M      $                        "CP    )S:6<@     $-25"!C=7)V
M        !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0
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MBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____N  Y!9&]B90!DP
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M&?_:  P# 0 "$0,1 #\ W\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_?SS7_K7_LUG_LX_VP_(W^T3_P"D=%_ZL#^[_2/_ ,)_UM;^,']_/-?^M?\
MLUG_ +.7.Z)DKN9T?3<QDIOK.1RNJ:[DK]CVXH?K%V]B*=JU-[->.*"+W9Y7
M.[6-:QO7HB(G1"O&9T:=OF5Q;T5A1IUZD8K:\%&;26+Q;P2Z7B7_ --7=QF&
MG,OO[N7'=U[*A4G+!+BG.E&4GA%)+%MO!))="2/5GPGM@
M
M
M
M                                           BIYQ?A+YV^X]K]=HD
M3<]?LBS_ .02]*)-GAQ^W+37TE'T)F1HQ^-U   #8IRS^&S<_P"%5O[ :;U:
M ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<RP   -$_&'[M.//N-J7V!CRI>=?/%
MW\IJ^G(U4T=]4,J^C;;X&![D\PZ0
M
M
M
M                          $5/.+\)?.WW'M?KM$B;GK]D6?_ ""7I1)L
M\./VY::^DH^A,R-&/QNH   ;%.6?PV;G_"JW]@--ZM ?.&4>ZM_P1/YEN='U
M3U+\FO/RRALMN98   &B?C#]VG'GW&U+[ QY4O.OGB[^4U?3D:J:.^J&5?1M
MM\# ]R>8=(
M
M
M
M        "*GG%^$OG;[CVOUVB1-SU^R+/_D$O2B39X<?MRTU])1]"9D:,?C=
M0   V*<L_ALW/^%5O[ :;U: ^<,H]U;_ ((G\RW.CZIZE^37GY90V6W,L
M#1/QA^[3CS[C:E]@8\J7G7SQ=_*:OIR-5-'?5#*OHVV^!@>Y/,.D
M
M
M
M                                                  !%3SB_"7SM
M]Q[7Z[1(FYZ_9%G_ ,@EZ42;/#C]N6FOI*/H3,C1C\;J   &Q3EG\-FY_P *
MK?V TWJT!\X91[JW_!$_F6YT?5/4OR:\_+*&RVYE@   :)^,/W:<>?<;4OL#
M'E2\Z^>+OY35].1JIH[ZH95]&VWP,#W)YAT@
M
M
M
M                                  (J><7X2^=ON/:_7:)$W/7[(L_^
M02]*)-GAQ^W+37TE'T)F1HQ^-U   #8IRS^&S<_X56_L!IO5H#YPRCW5O^")
M_,MSH^J>I?DUY^64-EMS+    T3\8?NTX\^XVI?8&/*EYU\\7?RFKZ<C531W
MU0RKZ-MO@8'N3S#I
M
M
M
M               14\XOPE\[?<>U^NT2)N>OV19_\@EZ42;/#C]N6FOI*/H3
M,C1C\;J   &Q3EG\-FY_PJM_8#3>K0'SAE'NK?\ !$_F6YT?5/4OR:\_+*&R
MVYE@   :)^,/W:<>?<;4OL#'E2\Z^>+OY35].1JIH[ZH95]&VWP,#W)YAT@
M
M
M
M                                                         (J>
M<7X2^=ON/:_7:)$W/7[(L_\ D$O2B39X<?MRTU])1]"9D:,?C=0   V*<L_A
MLW/^%5O[ :;U: ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<RP   -$_&'[M.//N
M-J7V!CRI>=?/%W\IJ^G(U4T=]4,J^C;;X&![D\PZ0
M
M
M
M                                       $5/.+\)?.WW'M?KM$B;GK
M]D6?_()>E$FSPX_;EIKZ2CZ$S(T8_&Z@  !L4Y9_#9N?\*K?V TWJT!\X91[
MJW_!$_F6YT?5/4OR:\_+*&RVYE@   :)^,/W:<>?<;4OL#'E2\Z^>+OY35].
M1JIH[ZH95]&VWP,#W)YAT@
M
M
M
M                    (J><7X2^=ON/:_7:)$W/7[(L_P#D$O2B39X<?MRT
MU])1]"9D:,?C=0   V*<L_ALW/\ A5;^P&F]6@/G#*/=6_X(G\RW.CZIZE^3
M7GY90V6W,L   #1/QA^[3CS[C:E]@8\J7G7SQ=_*:OIR-5-'?5#*OHVV^!@>
MY/,.D
M
M
M
M   !%3SB_"7SM]Q[7Z[1(FYZ_9%G_P @EZ42;/#C]N6FOI*/H3,C1C\;J
M&Q3EG\-FY_PJM_8#3>K0'SAE'NK?\$3^9;G1]4]2_)KS\LH;+;F6   !HGXP
M_=IQY]QM2^P,>5+SKYXN_E-7TY&JFCOJAE7T;;? P/<GF'2
M
M
M
M                                              BIYQ?A+YV^X]K]
M=HD3<]?LBS_Y!+THDV>''[<M-?24?0F9&C'XW4   -BG+/X;-S_A5;^P&F]6
M@/G#*/=6_P"")_,MSH^J>I?DUY^64-EMS+    T3\8?NTX\^XVI?8&/*EYU\
M\7?RFKZ<C531WU0RKZ-MO@8'N3S#I
M
M
M
M                            14\XOPE\[?<>U^NT2)N>OV19_P#()>E$
MFSPX_;EIKZ2CZ$S(T8_&Z@  !L4Y9_#9N?\ "JW]@--ZM ?.&4>ZM_P1/YEN
M='U3U+\FO/RRALMN98   &B?C#]VG'GW&U+[ QY4O.OGB[^4U?3D:J:.^J&5
M?1MM\# ]R>8=(
M
M
M
M           "*GG%^$OG;[CVOUVB1-SU^R+/_D$O2B39X<?MRTU])1]"9D:,
M?C=0   V*<L_ALW/^%5O[ :;U: ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<RP
M  -$_&'[M.//N-J7V!CRI>=?/%W\IJ^G(U4T=]4,J^C;;X&![D\PZ0
M
M
M
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M;Y=94<OM$XVM"E"G!-MX0A%1BL7M>"2VO:^D^@?J/J
M
M
M
M                                    /,[9NNGZ%B)<_N^TZ]J&$A7M
MDRVRYC'X3'H_HJMB2UD;%>%\ST3Z+&JKW+Z(BJ>7F^=Y-I^S>89[=VUG8QWU
M*U2%*&/5Q3:6+Z$MKZ$>QD>GL^U-?1RO3EE=7^8RW4K>E.M/#KX:<9-)=+:P
M72ROCD_YJ7C5I#K%/4';/RKE(N]C%UO%NQ& ;.Q%_1V,YLG[.F=$KDZ)+4J7
M&+\454*[:I\6'+'(G*CDSNLVNEBO>8=W2Q70ZM;@>'MJ=.HNK$M-HWP4\WM1
MJ-QGRL\DLI8-_&*G>U\'TQHV_>+'VM6K2:W/!D&-E^;=S3M>>QV+T71='T+$
M7\I1JNER"Y'<=ACAL6HH')'D9Y,)A4562*J]V,<O7IT7HB]T#YGXO];YM?T[
M7(;"PR^SJ58QQGQW-9)R2V3;I4^GIHOHV[\;)91X&.7N2995O=2YEF69W]*C
M.6$.[M:#<8M[8)5JN]+=<+9CLW86T^<7X2^=ON/:_7:);SGK]D6?_()>E$HW
MX<?MRTU])1]"9D:,?C=0   V*<L_ALW/^%5O[ :;U: ^<,H]U;_@B?S+<Z/J
MGJ7Y->?EE#9;<RP !]3%YS-827W\+F,IB)^J.][%Y"WCY>J=.B^Y4FB?U3HG
MY?R'Z*UM;7,>&XIPJ1ZI14E]],^RSS',,NGWN7UZU"IUTYR@_NQ:9V+7O)KG
M;67,6CR5L-QC%]8M@E@V9CV_E8Y=@@R,J-5/3Z+FJGY%0Y^[T;IB\3[VSI1?
M7!.GZ#BCO<JYO\R<H:^+9O=5(KHK.-PGV>_JH_N--=&!(C5/F [W0=%%N.G:
MYL==O1KY\1/=UW(N3IT661TJYJA+(U?7M9!"UWPZM^*<G?<J\LJIRR^XK49]
M4TJD?)LX)+U6_5)4R3Q/ZEMFH9]86EW26^5*4Z$_*\>]@WTX*$4]VS>2KTKS
M4X3VM8J^4R63TF_(J,]G9J+DHND7X^WEL8_(48HD3^?96LG_  ?#KP^8\NM1
MV.,Z$(7-)=-.6W]K+A;?9'B)JT]X@^7F=\-*\K5LNNGLPN(>9CV5:;G!+MJ.
MF2GQ>6Q6<HP9/"Y/'YC&V6]U;(8N[6R%&PW^^@MU))H)6^OQ:Y3B*]"O;5'1
MN83IUEOC).+7E3P:)GL[ZRS&WC>9?6I5[2:QC.G.,X279*+<7ZC/H'ZCZ@
M
M
M
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MTEQ13PJ0QZ*E.6$X=G%%)]#:/>'F'2@
M
M
M
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M6E._RZK3KV56/%"<)*49)]*DL4_U-Q](_2?6
M
M
M
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M_ALW/^%5O[ :;U: ^<,H]U;_ ((G\RW.CZIZE^37GY90V6W,L
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M0GC!=I.=)!
M
M
M                                           *IO.3YAN,X<;E>*>&
M+E#.\J.CEI9[96^QD,)QZZ1LD4U>-K7O@R>YUE]4@>CJU%_1;"2/:ZN5,Y[^
M(RUT8JNDM%3IU]6-.-6MLG2L\<4TMN$[E?B/&%)_G%*2=,NUX;_"K>:^=#6_
M,&G5MM%)J=&W>,*U]A@U)[$Z=I+\=85*RQ[IQBU5,[N;SF9V7+Y+8-ARE_-Y
MS,7)K^5RV4M37LAD+MAZR3VK=NP^2:>:5Z]5<Y54SBOKZ]S.\JYAF-6I7OJT
MW.I4G)RG.3VN4I/%MOK9JSEV6Y?D]A1RO*J-*VRVWIJ%.E3BH0A"*P48QBDD
MDNA(^4?*?:       "1?"/C;SKRUF\#D= XOVO.8:+*XZS)L+Z'[)UI(:]Z%
MTZMV3-28[!RR1,:JK&RPZ3HGHU22-#<L]>ZOOK>YT]E5W7LE5A)UN#NZ&"DL
M??JKA2;74IM]A$_,7FYRUT-EUS::HSFQMLP="I%4%/O;C&4&E_)Z*J5DF]G$
MX*/::6O.+\)?.WW'M?KM$TYYZ_9%G_R"7I1,@_#C]N6FOI*/H3,C1C\;J
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MN$-L-T*ZBMM2ECN>]RI8N44G*+E%/AEH<(3>
M
M
M
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M[\F^;]#6UI'(\]G&&K:47MP48W,5[."6"51+\Y326YU(+AXHTYBD?D]
M
M
M
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M'.@
M    J]YY^:1Q3Q#OEW1-3U2[RO+A4=7V#/878Z.)P-++L?VRXC'7'8W+)F9J
M:(J6)8T9#'+^C:Y[FO1E6-?^*O2>CL_GD&46D\WG0V5:M*M&G2C4QVTX2X*G
M>./LY+",9>:G)J7#<OEEX,-;:[TS3U+G=]3R2G<>=0HUJ$ZM:=)K95G!5*7=
M*>^G&6,Y1\YJ*<>+BO\ OE=:_L$SG_>!0_ZJ'#_XT\L_L_7_ -;A_LY(?_\
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MYPD,
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MIOV-6-D.3?V4Z>^B;;X-&#//G[:-4?3=W\+(D<241*
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M,O/7GWJ7G1G?O[G:Z/MJK=I9I[([.%5J[6RI7E'';MC24I0I['.4YADS$"
M       &>OFG]\?+/\3-\_K3E2UVG?J_8?(Z'P<3+;F#]?<\^F+S^D5"X_Q2
M_#[QK_DS)_UAS!7W7'UKO/=Q^#@7VY*?9=E'[S4^'JDA3DR4P
M               #GW(?*FA\5XROE=ZV"OA8+DKX:$"PV;N0R$L:-=*VECJ$
M-FY.V%'M]R1&>W%W-[W-[DZ^KE.29IGE9T,LI.I**QD\4HQ71C*326/0L<7@
M\$\#EM4ZTTUHNTC>ZDNH6]*HVH+"4YS:W\$(*4WABN)X<,<5Q-8H^9QQS7QG
MRQ];9H^SULI=HL]VYBYZ]O&96"#O2/ZU^S\C!5L3U.]S46:))(FN>UKG(Y>T
M_?F^G,YR+A>947"G)X*2:E%OJXHMI/L>#>#:6&T^32?,+2&MN..G+R%:XIK&
M5-QE3J)8X<7!449..[SHIQ3:3:;P.J'AG:
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M;B>'KD_:\GM T<KK1@]47O#7OZBVXUFO-HQETT[>+X(]#FZE18=XT1#(>)V
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M   &Q3EG\-FY_P *K?V TWJT!\X91[JW_!$_F6YT?5/4OR:\_+*&RVYE@
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MT=J-91F-3#3N83C">+\VE6?FTZW4D]D*KV+A:E)X4TBZ4KJ:"@
M                   &1KS@_%GSM]^;?ZG2,?N>OVNY_P#+Y>C$W4\./V&Z
M:^C8^G,BH1,38; O$#\+? /\*=-^QJQLAR;^RG3WT3;?!HP9Y\_;1JCZ;N_A
M9$CB2B)0
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MNHOTOGLNYRNCC&UM(2;HV\'Y<..K/!.K6:4IM))0IQA3C)4DXB$
M &>OFG]\?+/\3-\_K3E2UVG?J_8?(Z'P<3+;F#]?<\^F+S^D5"X_Q2_#[QK_
M ),R?]8<P5]UQ]:[SW<?@X%]N2GV791^\U/AZI(4Y,E,
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MT*Y%:\>L-)JPOI\6>9;PTJC;\Z=/!]S5?6VDX2>UN<')^N1+$X4FX
M                     &1KS@_%GSM]^;?ZG2,?N>OVNY_\OEZ,3=3PX_8;
MIKZ-CZ<R*A$Q-AL"\0/PM\ _PITW[&K&R')O[*=/?1-M\&C!GGS]M&J/IN[^
M%D2.)*(E
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MHZKYLZEJ:CU16<GBU0H1;[BVI-K"G1@W@E@EQS]?4DN*;;W=O.Y(Y
M     ,]?-/[X^6?XF;Y_6G*EKM._5^P^1T/@XF6W,'Z^YY],7G](J%Q_BE^'
MWC7_ "9D_P"L.8*^ZX^M=Y[N/P<"^W)3[+LH_>:GP]4D*<F2F
M                >/W/0-,Y#QD>(W77<;L5"&;ZQ7BOQ.]VK/T[5FIVX7Q6
MZ<KV?1<Z*1BN;Z+U3T/0R[-<QRFL[C+JTZ-5K!N+WKJ:>*:\J9X6H-,9!JJS
M5CJ&TI75K&7%%36V+ZX234H-K8W%K%;'L/PZ/Q=Q]QM%;BT?5<7KWU]6K=GJ
M,EENVFL7K'%/?N2V;TD$;O5L:R>VU5541%53]F99WFN<2C+,J\ZO#N3P27:H
MI)8];PQ9\VG-&Z7TE"<-.65&U[WU[BFYRPW)SDY3:71'BP70CWQY9TP
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MS2UG=ZQSV35:O+AI4DVX6]"+?=4(8X>;!/:TEQU)3J-<4Y'9#M#@
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M.:Y$<US516N:J=45%3T5%0J^UAL>\TO336*VIG_0?Z
M         9&O.#\6?.WWYM_J=(Q^YZ_:[G_R^7HQ-U/#C]ANFOHV/IS(J$3$
MV&P+Q _"WP#_  ITW[&K&R')O[*=/?1-M\&C!GGS]M&J/IN[^%D2.)*(E
M                                                    !X_=^/\
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M?9=E'[S4^'JDA3DR4P
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M\:RL]4].U+$J)\>J_ A[,?&E>2FXY1D%.$$]DJUU*;:[8PHPX?)QR\I.V5>
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M; O$#\+? /\ "G3?L:L;(<F_LIT]]$VWP:,&>?/VT:H^F[OX61(XDHB4
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M6MKI73UU=W=.KEM.YJ2KNFY1G4K5Z:@N[A!)<-)2VK'SEMPW3,)J*_
M'_%5&HKG*B-1%555>B(B>JJJKZ(B(&TEB]Q_J3;P6\B'RQYV>,/#\UK'[!R5
MC\]GZCG1RZYHT4FW92.>-5;+5LV,6K\)C+<3DZ.BN7*[T7\A#NKN??*W1LYV
MV8YG3N,PAL=&U3N)IK?&3A[U"2Z8U*D'V$[:(\-7.37M.%WE>45;;*YK%5[Q
MJUIM/=*,:F%:I%]$J5*:?604V_YR.JUYI8M"X1V#,5^Y4@O[?MN.UN9&HJ*C
MY<3AL5M3'.<G5.U+J=%]>Y?@L"9QXT,IIS<-/Y%<5J?1.XN(47ZM.G3KKU%4
MV=;+*Y#X LZJTXSU/J.UMZN&V%K;5+A>15:M2V?JNEMZEO.*W?G$\PR3(['<
M4<:U:_9T6*[:VB_,K^YZJY)X,KC6(SL5J=OM]>J*O7UZ)Q%?QF:RE/&VRC+(
M4\-TI5YO'RJI!;L-F';CMP4AV_@'T%&GA=YWF\ZN.^$;>"PP71*G4>...WBW
M8+#9B_V8OYQG*4+T7-\/Z!D(_<55;B\OL6'>L79T1B/MR9Q$D23U5W:J*WT[
M47U/W6GC.U7!_P NR;+ZD<?W.I6I[,.N3J[<>G#=LPZ3]%[X!=%U(_\ =V?9
MI2EA^Z4J%58X[\(JCLPZ,=^W'H)!Z1\X7BO*20P\@<5[KI[I9$C?:UW*8C=*
M,"+T3WYUM1ZC?2)/BY(H)GHGP1RDBY%XR])W4HPU#E-]9MO!RHU*=S%=KXE;
MSPZ^&,GU)D5ZC\!.M;*,JFE\[RZ_26*C7IU;2<NR/"[J&/5Q3BNMHL%XF\H^
M N;_ &8>-^3=<S66FC]Q-:M3R8/:F]K%?,C=;SD6/S%AE;HJ22PQ2PI\4>J*
MU5L1I#FKR^UUPPTUFEM7O)+'N9-TJ_;[S54*DN'IE&,H^V::;JUKGDQS/Y<\
M535V3W=O8Q>'QB,56MM^"_E%%SI1<O8QG*,_:III=^)!(P            ,]
M?-/[X^6?XF;Y_6G*EKM._5^P^1T/@XF6W,'Z^YY],7G](J%Q_BE^'WC7_)F3
M_K#F"ONN/K7>>[C\' OMR4^R[*/WFI\/5)"G)DI@ _!D\KC,+1L9/,Y*AB<;
M48LEK(9.Y7H4:T:?&2Q;M2100L3\[G(A^VC0K7-14;>$JE:6Z,4Y-^1+%L^:
M\O;/+[>5Y?U:5"T@L93J2C"$5URE)J*7E9%'=?-GA;5GS5<1<R^[WX^K>W7:
M/MXULJ?S9,ME9*$$D2I_RE9MEOY/S].YR[EQJ*^2G<1IVU)_YR7G8>YCQ/'L
MEPD)ZA\0W+[)92HV-2OF-RMGO$,*>/;4J.":[::J(CCF_F%['*]R:WQQA*$:
M*J-?F\U?R[WIU]'.CH5L(V-53^;W.Z?G4ZZVY46<5_++RI-^TA&'I.?X$1/F
M/BES:<FLIRFWI0ZZU6=5OU(1HX>3%^4\%8\]N:IG-='BN/JB(WHK*^#S3FN7
MJJ][EM[+:?W=%Z>BHGI\#U(<K].16#G=R\LX?J4T<U5\3',&HTX4,KIK#=&C
M5^[YUQ)_?/IX_P _^5X71IDM6T&_"UK4?]7I;!0LRJBIW/=,NP7*[7.;U^$*
M(BKUZ=/0_35Y69%)/N:]U&7:X27W.[3^^?7:^)[6U.25W9995II;>&%:$GZO
M?RC]R'ZQV'5_F$:Y9?%%N/'V8Q**J,DNZ]E:F;C]>GZ5:-^#"20QM5?5J32N
M1$ZIU5>AS][RIO()RR^[IU.RI%P]3&+GC]Q'>9/XH\IJR4,^RNO06YSH5(UE
MY>":HM+L4I/JQW$NN/\ G/BOD[VXM0W#&7,C(U5_8EQS\7G45K5=(C,5D65K
M=EL2(O<^%LL:?'NZ'!9KIG/,FQE?V\XT5[->=#]M'%+'J>#["<]+\Q]%ZPPA
MD5_1J7;7YF>-.MLWX4YJ,I8=+@I1[3K1X1W
M       .'[_Y&\/<;/GJ;!N-&QEX%<U^"P*.SF69,WNZU[,./]V#&S_1_DVY
M(/R?G3KTN5:1U!G"52TMY*@_9S\R.'6G+!R7N5(CG4_-?0>DI2H9I?TYWT=]
M&C[]53_%DH8QIOLJ2A]]$3ME^85BXWR1:?QQ?N,7K[-W9<U7QSV_F63%XNME
M$=U_*B7$Z?G4[FSY45FE+,+R,7TJG!R_RI./H$)9OXI;.$G#(<IJU(]$[BK&
MF_5ITXU/A4<GO^?O+DZO;0UKC^A&Y$1CI,=G[EF-4=UZI*[8X:[NK>B>L*_E
M7\W3W:7*S(8X.K6NI/W4$ON=VW]\XFY\3NN:C:MK/*Z4'NQA7E)>KWZC]V/_
M "?BK>>_-$"N6;$<?74=V]&V,)FV=G15Z]BU-FK+U<B_SNY/3T/V3Y7:=EZV
MI=Q\DX?JTV?/1\3/,"FVYT,KJ)_C4:RP\G#<1^_B=#P/S"\S'(QFS\;8RW$Y
M522? YRUCI(VJ[JCV5,A3RC9E:ST[5FCZKZ]R? \JZY46[3=E>3B^J<%+[\7
M'#[C\AU.6>*6_C)1SG*:-2'3*C6E3:V[U&<:F.SHXXXO;BMQ)31_,WA+<)(:
MM[+WM*R$O1J0;9494I+)V]7]N9I37L5#"B]>C[$M?N_,B^AQV9<O-29>G.E3
MC<TETTGB_P!HU&3?9%2)<T[S_P"7F?2C1N:]3+[J71<QX88]/OL'.FEU.<H8
M]6.PE-3N4\C5@O8^W6O4K4;9JURG/%9JV(G>K98+$+GQ31N3X.:JHIQ-2G4I
M3=.K%QJ1>#3333ZFGM1,U"XH75&-Q:SA4MYK&,HM2C)/I4DVFNU,_2?@?N
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MWA=_QIHW_<WRA_LKIO\ W99?Q!<?\I;D_DKDC_7_ /ZP^0]YWW]C?ZJOV/\
MTTVW/[3^ROVC_K(_:'[-_;F0O?4?KWU&#WO:[?=]EG=U[&]+H>$/5.I]2_\
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M.NQWH^>5S(6*O17=RM:ONY%IW,]07'<6$/>UZZ<MD(>5]?5%8M]6&+.)UMS
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M,L   #1/QA^[3CS[C:E]@8\J7G7SQ=_*:OIR-5-'?5#*OHVV^!@>Y/,.D
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MG)MK$S:YE:NCKW7N;:QITYT:.87M2K"G)IRA!O"$9..";C!13:Z4=8.N.'
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MGL79%;HKLBDBXN0Z;R+3%BLNR"UHVMHL,5".#DULXIRVRG+VTW*7:>K/A/;
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M&6O>:F>:H4N*UKWTX47C_P"[T,*%#L6-*G"3PV<3;V[SOY(1%P
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MD^3%+*J5'6&K*2EFLTIV]O-;*">ZI4BUMK-;8Q:PI+:_?,.[L((H+1@
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MGX?^74-3YW+4V;4U+),OFN",ML:MS@I1BUTQI)JI)/8Y.FFI1<D7#$ %\0
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MO>"Q[<"I_C1SEY7R,NK-2P>8YA:6^]+'";NFMKQ>RV>*6+PQQ6&)IY-23&\
M            $5/.+\)?.WW'M?KM$B;GK]D6?_()>E$FSPX_;EIKZ2CZ$S(T
M8_&Z@  !L4Y9_#9N?\*K?V TWJT!\X91[JW_  1/YEN='U3U+\FO/RRALMN9
M8   &B?C#]VG'GW&U+[ QY4O.OGB[^4U?3D:J:.^J&5?1MM\# ]R>8=(
M         "A3R:PR8'GGDZBC48D^QOS/1.GJNQTZFPN=]'TZO=E.[\_KZ^I:
M'1MQ\:TO95.JCP?P;=/\DS/YOY>LMYEYQ;I8<5VZO\/"-?'U>\Q.%'3$;@
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MR3.ZY#Z1AJG75*XNX\66Y='XS-/=*<6E1@_+4:FT]DHTY)[R[<K@:'@
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M0>EJ&C=)V>GZ27>T:2=62]G6GYU67;C-M1VO"*BMR1TP\8Z\
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M=U2^[Y#-#Q^Z?A3S/3NJJ<?/K4+FTJ/#HI3IUJ*Q[>^KO#L>'278EX3.X
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MW$\'[:1IQX!-/0I9!J#5<HXU*]Y0M(O#<J%-UJB3W><[BFY+VL>M%+A28T(
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M_@PTQ_75_P#P5+]<?X^]7_V?RW^&K?K#_<Y<:_VR[Q_F# ?X0?X,-,?UU?\
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M4*C_  X$?^&2V577EU<26*I974P?5*5:A%?Y/$BWT@(O8
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MIL)YKIG,<KIQ4ZES87%)1>U2=2E."323>#;P>Q^0VQ&X1_.X
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MRZA+RNIWGJ>;47X3&WQH6=2UYZWE>?K;FPLZD?(J2I>KYU*75U=!8F6/*H@
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M<.4O,.3$+Z*VV.<6U9OI49PKV[6Y['*O'%8K:D\=F#TLFG)D&
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MIXUU&:OCZTE5C?9#KNC%NA.E4L*LL-D90E*XMXX]<U.Y:71W;ZR[<O(9T@
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M^C:D_P#)4EZI5?DOG4,CYE99<59<-"M5E;RZO?X2IPQ[%4E!^H7N%8S28
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MV)56WV(ASQ!Z=EJGDMJ/*8+BK++9UX+>W.T<;J,5OVRE145VOH->1L081
M           BIYQ?A+YV^X]K]=HD3<]?LBS_ .02]*)-GAQ^W+37TE'T)F1H
MQ^-U   #8IRS^&S<_P"%5O[ :;U: ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<R
MP   -$_&'[M.//N-J7V!CRI>=?/%W\IJ^G(U4T=]4,J^C;;X&![D\PZ0
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M*N9VB."2/OQVB8FZLL$-E.OO0R;)GZ;&Q*WT?!1LL=Z/3K3[Q;\PZ63Z9I:
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MK4E-^63;P\BQP1JMDV5V^1Y1:Y-:?S:UMZ=*/1BJ<5%-]KPQ?6VS[Q\IZ0
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M)4=OJ=*+H>!K4:ROFU<Y%5:5+-,JJPBNNM0G"O'[E*-?9OZ=R9FY,T#7
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M\@EZ42;/#C]N6FOI*/H3,C1C\;J   &Q3EG\-FY_PJM_8#3>K0'SAE'NK?\
M!$_F6YT?5/4OR:\_+*&RVYE@   :)^,/W:<>?<;4OL#'E2\Z^>+OY35].1JI
MH[ZH95]&VWP,#W)YAT@           !Q'R.W!-'X4Y S+)4BN6,'-@L:J+TE
M3(;&YF$@E@3JG=+32\ZPGQZ)$JJBHBH=)I'+_P!):CM;=K&FJJG+JX:?GM/L
M?#P^J1WS8S[_ (<Y>YIF$7A7E;.C3Z^.OA137;'C<_)%O!X%!I:,S+    !>
M/X@ZVNN<!Z;[D:16L\N4V2U]'IWIE,C8_9\B]417*_#P5O7_ /AZ="M6OKSX
MYJBXP>,*7#37[&*XO\MR-&>164O*>6>7\:PK7/>5Y=O>5)<#]6E&G_\ T),G
M&DO@     $3O-/Q_3R+X&V;3\?%&[<<*K=NT.5[(NYVS8:"PL>+]R16>U%L.
M/GGHJY7M;&^PR5W<D?:L1\[N7O\ >1H"ZR:V2>=4/Y1:MX?GJ:>%/%X8*M!R
MI8XI)S4GCPX$X>'GFB^4_,VSSZZDUD%QC:WJ3?\ -ZKCC4P6.+H34*V&#<E"
M4%@YXK)-/!/5GFJVH9:UFM+)!8KSQOAG@GA>L<L,T4B-DBEBD:K7-<B*U4Z+
MZF0E2G4I5)4JL7&K%M-----/!II[4T]C3VIFYM*K3K4XUJ,HSHSBI1E%IJ2:
MQ336QIK:FMC1]C5]FSNE['@]MUC)6,/L6MY6EFL+E*JM2>CDL=899JV&(]KH
MY$9+&G<QZ.8]O5KD5JJB_9E6:7^29E0S?*ZLJ.96U6-2G..^,X-2BUT/!K:F
MFFMC33:/@SG)\MU#E-SD><T87&57=&=*K3ENG3G%QE%X8-8I[&FFG@TTTF:P
M_$7RGU;RCXX@SU-:V+WK 14Z/(.IQND1<3EI62)'D<<DRNDGU_-+7?+4?W/6
M/HZ&1RR1.5=<.3W-?*N:NFHYA1X:6?6ZC&[MUC[W4:>$X8[71JX.5-XO#;"3
M<HLP_P">O)7.N3&K999<<=;35U*4[&Y>'OM)-8TYX;%7H\2C46"4ME2*4)I*
M5Y+9"(        !P[R$Y^T;QRXYRG(&ZVV*L3)*FN:_#-&S*[7GWQ.=3PV+B
M>JN57N3OL3=KF5J[72O]&]%X3F)S!R+EMIJKJ'/)K8G&C132J5ZK7FTX)]>^
M<L&H03D]BP<D<K.6&I.;.K*.EM.TWA)J5>NTW2MJ"?GU:C75NA#%.I-QA':\
M5DFY9Y1VSF?D+9^2MUN?7,_M&0?<G:Q7I4Q]6-K8,=B,='(Y[H,;B:,4<$#%
M552.-%<JN557(35VJLWUMJ*ZU-GD^/,+JIQ/#'AA%;(4X)[H4XI0BNI;6WBW
MN9H?1F1\OM*V>D-.T^[RNSI**QPXIR;XJE6HUAC4JS<IS>[B;P2227.3FSK#
M3[\M;QXGX4X,CVG8J2U-XY=?C]JRD,T3H[>+UF*M)_1#"V62,9+%894NS79F
M.1'1RW5B<G6(U+\,O+FIH?0:S7,H<&>YPX5YIK"4*"B_B]*6.U-1E*I)/;&5
M5Q:QB8V^+OFK2YB<R'DN55./3F1*=M3:>,:EPY+XU5BTVG%RA"E%K%2C14T\
M)EB98\JB    #+?\QCQWGX0YWRFPXBDZ+0>5Y\AM^N2PP)%3QV9GL))M>M,6
M-&Q,=C\E:2S"QK6M93N0L3JK'*95>)+EQ4T+KZKF-G!K3^;RG<46EA&%1O&X
MH[-GF3DIQ222IU(16+BS9[PG<UJ7,;EI1RJ^J)ZGR.,+6NG+&=2DHX6UP\=K
MXZ<73FVVW5I5)/!2BBO\KT6B+4_EP^9U+A7-R\/<G91M/C#;<E];P6>NR+]5
MT;:;79#(ZW(O5*VM9]6L2P]?T5.RULZ]D<EB1+8>&OG90T1?/1FJ:O!I:\J\
M5*K)^;:UY8)\3]C0J[.-^MIS2J/",JDBE/BU\/EQS#RZ.OM'474UE8T>&M1@
MO.O+:.+7"O97%';W:]=5IMTUQ2C2B:.HY&2L9+$]DD4C&R1R1N1[)&/1',>Q
M[55KF.:O5%3T5#2F,HSBIP:<6L4UM33Z49+RC*$G"::FG@T]C36]-=#1_L_T
M_$         SW_,M\SZ7(UV;@#B[+LNZ3@\C%-O^Q8Z=)*.UY_'2MEJX#'V(
M7K'<P& N,22:3UCLWXV*SJR!DDN=GB<YUT-25Y<O=*UE/(Z%1.[K0>,;BK!X
MQI0:>$J5*2XI/=.K%./FTU*>IWA!\/EQI.WCS0UI0=/45S2:LJ%183MJ-182
MK3BUC"O7@^&,?74Z,I*7G591A3^4X+Y  M6^4#^)7=_X&[+_ %^XS+9>#G[3
M;[Z!K?TNR*3^/'[(<M__ "2W_H68&CHTH,EP    4X?.-_=KPU]^,_\ 8$93
M#QG_ %8R7Y?5^"1?SP"?6_4'T;1^&9G^,]#40O(^3%_YD?\ L>_\4B]O@H_\
MS?\ AW_UQF__ .H+_P"4?_%/_MQ>07M,WP        #^%JK6O5K%*Y!%:J6X
M)JMJM/&V6"Q6L1NBG@FB>BLDBFB>K7-5%147HI^NK2IUZ4J%:*G1G%QE%K%-
M-8--/>FMC1^VC6JV]:%Q;RE"O3DI1E%X.,HO%--;4TTFFMS,B/EWP%>\<^<=
MKT3ZO.W6+4[MCT*]*KGMOZ=EIYWXUGON5736</+'+0L.=T5T]5ST3M<U5QYY
MP\OJ_+;7=WD'#)97.7?6DGMX[:HWP+'IE3:E2FW@W*FWA@UCNSR)YGVW-CEQ
M8ZEXXO.81[B]@MG!=4HI5'AT1JIQK02Q2A4C''%-*,A%Y,1=]\LSS2I8ZOC?
M&WE3+Q5(/>6+B;9<E,D<#9+4R*N@7[4G1L:RV9728E\B]%<YU3N1?JL:WH\,
M'.VA;4Z7+/5E90I\6%A6F\%C)_S2<GNQDV[=OI;HX_FHF<OC"\/5Q=U:W-S1
M5!U*O#CF=O36+PBOY["*WX12C<J.W!*OA^?F7I%\C-D         _-<N4\=3
MM9#(6JU"A0K3W+UZY/%5ITZ=6)T]FU:LSN9#7K5X6.?)(]R-8U%551$/U5JU
M&VHSN+B<:=O3BY2E)J,8QBL92E)X)123;;>"6UG[K>WKW=>%K:PG5NJLU"$(
M)RE.4FE&,8I-RE)M)))MMI)8F9#YA'F$WR*W>OI>C7I7<0:'>G=BIF^[#'N6
MQHR2I9VN:!Z,=]1KP/D@QK7M1[8))95[5L*QF7?B)YRKF1GD<DR*HWH[+ZC[
MM[4KFM@XRKM/V*3<**:Q47*;P=1QCL5X6.0KY4:=EJ'4E**UYF=-=XMC=K0Q
M4HVR:Q\^32G<-/!SC""Q5)2E7.5N+8%IORM/'>3DCER;F+8*'NZ;Q'+'-BG3
MQ]:^4Y#LQ))AH8NY$;)_1FI(N1D<UW=#9^IJJ*V12UOA3Y<2U+K"6L\QIXY+
MD[3IXK9.\DL::77W$7WS:>,9]ST2*6^-'FM#2.A8Z!RNKAJ#/8M5.%^=3L8O
M"JWU?&)+N$FL)T_C&U.)I#-+3)$      \IO.GXK?]0V'3<VSNQNPXRQCYGH
MUKY*TCT1]2_ UWT?K6.N1QSQ=?1)(VJI]V69A7RJ_I9A;?GJ4U)=O7%]DEC%
M]C9XNH\BLM3Y%=9!F*QM+JC*#>]Q;VQFO;0FHSC[:*,^&W:OFM#VK-:IG(74
M\UKN2EHV48KD19(7(^"W6D^BYU>U YDT+TZ=T;VN3XEK+"]MLTL:=];/BMZL
M$UZN]/M3Q370TT9<9YDV8::SJXR7,8NGF%K6<)8=:VQE%_BR6$X/IBTUO+IO
M&#FNOS!Q_63(V6+NNL1U\7M%=ST6>VK8U91V!K?170YB*)5>J(B,LLE;T[4:
MKJZZTTY+(,U?<Q_[NK-RIOH7XT/+!O9UQ<7OQPT%Y.\PJ6O-+P^-37_$-FHT
M[B+>V6S"%==E5)M]5136[!N2AQY+@             *;?,KFZ'D?<H--UVVE
MC4=(GL1OLP2=];-;*]%@OWXW-=[<U3&Q(M6N[IZN6=[7.9(TL'R]TW+*,O>8
M7<<+^Y2V/?"GOC'L<GYTOV*:33*#<_>8E/5F?QR#*JG%D672DG)/&-6X>R<U
MT.-->]P?7WDDW&:/;>"?$C\ULN0Y7S%7KBM7][%:U[K/H6MBMUT;=NQHY%:^
M/#XR=6(JIT]ZRUS5[HEZ>=S-SY6]G#([>7O];"53#HII[%^SDL?)%I[)'1>&
MW0\LPS>KK:_A_(K/&G;XK9*O*/GS76J5.6'NZB:>,&6N$&EUP       5>?,
M._QSQ;_DS:OUK!DU<I_YO>^[I?@F4W\4_P X9-^\W/I43F7@A^^ZU]QL]]H8
M,]GF=]6X_*8>C,Y#PU_:)/Z-K>G1+D"OA?<       %/?F]Q._3^0(M_Q=56
M:_OROFNNC;^AI[968G[2B=T149^UZZ-MM5R]9)EL=$Z,)_Y;YZLPRIY57E_*
M[78NMTGZU_L'YKZEP=90_P 1.B)9%JA:GLX897F>+GANA<Q7OB?5WL<*JQVR
MEWN&R(\+N;HM!VV;0-CN-KZINUJ):%B=R-KX?:NQE>K-(]51(JN:A8RM*Y>J
M-E9 Y5:Q)'#F)IN6:6"S6TCC?6T7Q);YTM[7:X/&2[');7@AX?N8D-,YY+3&
M:U%'),QFN"3V1I7."C%M]$:J2IR?1)4WYL5)EPA !?              $/O,
M#FV'C;19]2PMQK=UW:I/2KMB>J3X?7YD?7R>8<K'-D@GG8KJ]1WHONN=(U?T
M*HO?Z TW+.,S5_<Q_P"[K:2;QW3J+;&':EZZ79@GZX@?GOS$IZ2TW+(\OJ):
M@S&G*$<'MI4'C&I5V/%.2QA3>SSG*2_-M%37&F@Y;D[>-?TG#(YMG-7F16+?
MMNECQN.B19LEDYVMZ?HJ--CY.BJG>Y$8B]7(3KG.:4,FRVKF-QZRG'%+=Q2>
MR,5VR>"[-_04CTCIF^UAJ*UT]88JK<5$I2PQ5.FMM2H^R$$WT8O"*VM&@_7\
M'C=8P6'US#P)6Q6"QM+$X^#T58Z="O'6@1[D1O?(L<:*YW3JYRJJ^JE4[JYK
M7MS4N[AXUZLW*3[9/%_\AJ-E>6VF3Y;0RJPCP65M1A3@NJ,(J*QZW@MKZ7M/
MKGSGW                  '#_);CQW*W 7+>@0U_K5[8-(S3<-!T1WN;#C:
MZYC6TZ+^;/8^LOYTZ>GJ<+S.TX]6\OLXT]"/'7N+&KW:ZZT%WE'_ *V$"1^4
M&JUHCF?D6J*DN"VM<QH][+JH5)=U<?\ 4SJ&-\Q?-^0    :+_E*\NMVOA78
M^)[]KORW%NP26\7"]Z=RZEN$MG)UVQ-7Z<GU/8XLC[BIU1C9XD].J==(O"%K
M!9MHBYTC<2QN\JN'*FG_ /#W#E-8=?#65;'J4H+9L,GO'+H1Y)S#M-;VL,+'
M.K51J-+_ -ZM5&G+'H7%0=#AZ6X3>W!EL);@I             14\XOPE\[?
M<>U^NT2)N>OV19_\@EZ42;/#C]N6FOI*/H3,C1C\;J   &Q3EG\-FY_PJM_8
M#3>K0'SAE'NK?\$3^9;G1]4]2_)KS\LH;+;F6   !HGXP_=IQY]QM2^P,>5+
MSKYXN_E-7TY&JFCOJAE7T;;? P/<GF'2            %9WS M^:O]#.,Z<R
M*YKI=QSD;7(O:O;8Q6!B=VNZHY6NNO>QR)Z+&Y/BA,G*O*W_ "C.:BV;*4/O
M2F_02?E14+Q0:F3_ $?I"A+:F[JLOVU.BG_UK:?M&5H$QE1   #Z.'Q=O.9;
M%X3'QK+?S&1HXNC$B*JR6\A9BJ5HT1$555\TS4]$Z^I^FXKT[:A.YJO"E3@Y
M-]D4V_O(^JPLZ^8WU'+[5<5S7JPIP77*<E&*]5M&C?7L+4UO 8/7:"=*. P^
M,PM-.U&]*F+I04:Z=J*J-Z0P)Z?D*C7=S.\NJMW5_.5:DIORR;D_OLU?RO+Z
M&4Y9;95;?S:VH4Z4/<TX*$?O)'V#YS[P       9^OF>>(-G5-AO^1W'N+[M
M2V:VQ_)F,I0M1-=VFY,V)NTLBB1.F*VB>1/K3NW]#DE5[G*EI$CSR\4G)RKE
M&8U.96G:6.474T[V$5^9KR>'?X+]SKMKO'AYM;&3;[U*.HW@WY\4<[RJEREU
M56PSRS@UE]2;_/VT5C\6;?[K;Q3[M8^=02BDNY;G3H4R+]'1^*>6-[X5W;$[
M_P =YVQ@MAQ,GHYBK)1R=)[FK:Q&9HJYL.2Q-YC4;+#)Z>B/:K9&L>WI-):N
MS_1&>4=0Z;KRH9C1?EC.+]=3J1W3IRW2B^QK"237)ZVT1IKF'IVOI?5=M"YR
MJNMSV3IS7K:M*>^G5@WC&<>V+3C*47I(\5_F#\3^0=;':WL=FGQQRM(V*O)J
M^7MMBP^Q7%;T=+IN9L/;%<]YR=4HSNCO,55:QL[6+,NF/*CQ$Z2YB4Z>69E*
M&6ZM>"="I+"G6EUVU1[)8_YJ;55;HJHDYO(WG5X6=;\K*M7-\IA4S;1*;DKB
ME'&K0CU7=**QA@M]:"E1>^3IRDH*P$L*5=      (=>3/FWPYXTT;5'+Y*/;
MN1/95<?QUKURO+EV3/B9)7EV2VGOP:MCI&RL=WV&NL21KW003=%Z0QS0YY:,
MY8T)V]Y55YJ3A\RSHR3J8M8IUI;50@\4\9ISDGC3ISP9/G)[PZZ^YOW,+FQH
MNQTIQ>??UX25)I-J2MX['<U%@UA!J$9+"I4IXK'-)S[Y"<D>1V[S;KR+E&SO
MB;-5U_ 46OKX#5L5+,LR8S"TG/>K&JO;[L\KI+-ES6K+([M;VYC<P>8NIN96
M>2SS4E7BE'&-*E#92H4V\>"G'%]G%.3<YM)SD\%AK[RPY6:1Y2Z<CIW2E%QC
M)J5>O/"5>YJ)8=Y5G@L>GAA%1ITTVH16+QX><*2.63_+O\/[//&^0<D;OBGK
MQ%H63AGFCN0+]5W;9ZBQV:FMPMD3LM8NBY63Y)>CF+&K*ZI^F<K+,^'+DW5U
M]G\=2YY2?_!V7U4VI+S;FO'"4:*QV2IQV2K;UAPT_9MQJ+XK.?-'EGIF6DM.
M5U_QWF=%Q3B_.M+>6,97#PVQJ3VPM]S4N*JOS:4M-)J"8\@     $>/*'Q[U
M[R5XDSG'>7=!1RWIE]-V&6'W7Z[M5**5N/O+VM=*ZC9;*^M<C;]*2K,]&]'H
MQS8XYJ<NLNYG:0KZ<O'&G>?G+:LUBZ->*?!+KX98N%1+:Z<I8>=@U*W)KFGF
MO*'7-MJNP4JMC^:NZ">"KVTVN.'5QQ:52E)[(U(1QQCQ)Y)=^T3:>,=QV#0M
MUQ4V%V?6,C-C,K0FZ+V31]'1SUY6_H[5*Y ]DT$S%6.:&1KVJK7(ID)J#(,U
MTOG-QD&=TI4,TM:CA4@^AK<T]THR34H26R46I+8S<S3&I<EUCD%KJ;3U>-QD
MUY252E-=*>QJ2WQG"2<9P?G0FG%I-,\@>.>\6K^%GS',OPO3Q?%_,K<GM'&%
M5(:.O[#51;NRZ)5[E:RH^%[DES^KU4<G9 COK5*)%;![K&QUDMER1\2EYHFC
M2TKK7O;O2T,(T:T?.K6L>B.#VU:$>B./>4X[*?'%1IJD_B%\)ECS"KUM9\OW
M1LM93QG7H2\RWO9=,DULHW$NF>'=U9/&KP2<ZKT%:-O^E<F:Y2VW0-GP^V:Y
MD&(ZME<+<CMP=_:USZUEC52>E=@1R)+7G9'/$[Z+V-7T-#\AU#D>I\MIYOIZ
MZHWF6U%YM2G)27D?3&2]E"24HO9))F6NI-+ZAT?FU3(M3V=Q8YM2?G4ZL'%X
M=$HO=.#]C.#E"2VQDUM/7GLG@@    \UMVXZIH.OY#:MUV+#ZMKF+B]V_F<Y
M?KXZA715Z1QK/9>QLEB=_1D43.Z66148QKG*B+YF<9UE.G\OJ9MGES1M,MI+
M&=2K-0@NI8R:Q;>R,5C*3P44VTCU\BR#.]3YI2R33MI<7N;5GA"E1A*I.76\
M(IX1BMLI/",8IRDTDV4'^9OS+<CR32RW%_ 4N2U[1[C;..V+?)XWT-AVZC(Q
MT$V/P==Z):UW7[C7+[DK^R_:C5&*E=BRQRY^\ZO$[<ZFHUM+<OG5MLBGQ0K7
M37!6N(O8X4D_.HT9=,GA5FL(M4X\49Z=>'[P@VND;BAK+F?&C=:CIN,Z%DFI
MT+6:>*G6DO-KUX/#ABL:%.6,DZLN"<*A"G1>\   M6^4#^)7=_X&[+_7[C,M
MEX.?M-OOH&M_2[(I/X\?LARW_P#)+?\ H68&CHTH,EP    4X?.-_=KPU]^,
M_P#8$93#QG_5C)?E]7X)%_/ )];]0?1M'X9F?XST-1"\CY,7_F1_['O_ !2+
MV^"C_P S?^'?_7&;_P#Z@O\ Y1_\4_\ MQ>07M,WP          0I\X_%:IY
M.<5OK8>*M!R=I3;N8T#(S*R)MN:6.)V4U6[.]6MCH[%#58QCW.:V"W'#*Y>Q
MLC70ASVY3T>:.DW3LU&.J;'BJ6DW@N)M+CH2;W1K**2;:4:BA)OA4D[#^&_G
M77Y.:U5:_E.6CLQ<*5[36+<4F^[N816.,Z#DVTDW.E*I!+B<6LJN6Q.3P.4R
M6$S5"WBLQA[UO&97&7X)*UW'Y&C.^M<I6Z\K6RP6:MB)S'L<B*US513)R[M+
MJPNJMC>TYTKRC4E"I":<90G!N,HR3VJ46FFGM31M?8WUGF=E1S'+ZL*]A<4H
MU*=2#4H3IS2E"<9+8XRBTTUL:>)^!%5JHYJJCD5%147HJ*GJBHJ>J*BGSIM/
M%;SZFDU@]Q=7X;_,[_8%/%\:>2=R[<QE6*"AK_*K(9\AD*->&-D->CN]2O'+
M?R<+&,Z-R<+9;77I]8CDZOL,N]R7\4GZ.HTM,<S)U)VL$H4;])SG%))*-U%)
MSFDMBKQ4I[N\C+&519X\_O!Q^E+BMK#E%3IT[R;<Z^6MJ$)R;;E.SE)J%-MO
M%V\W&GO[J<,(TI7F8#8<#M>'Q^PZQFL5L.!RM=EO&9G"WZN3Q=^M)_(GJ7J<
MLU:Q&OYVN5.OI\2^&7YCE^;65/,<KKTKG+ZL5*%2E.,X3B^F,HMQ:\C,W,TR
MK,\DOZN59S;UK7,Z$W&I2K0E3J0DMZE":4HOL:/L'V'P     Y_R5RIQYP_K
M5G;^2MMQ&HX"MU:EO)SJD]R=&]Z4L5CH&S9',9![456UZL4TSD151O1%5.>U
M-JS3FC<LEG&I[RC9Y?'V4WMD_P 6G!8SJ3ZH4XRD]^&!U.D-%:JU[G$,ATA8
MU[_,Y^QIQV06[CJ3;5.E!=,ZDHP3V8XM&=GS0^81LWD(R[QYQW#D=-X@][MO
M1SN9#L>]^Q(U\,F?6O)*S'85DC$?'CXI'H]W1]A\BHQD6</.SQ%9IS%4].:;
M52RT;Q><G@JUU@\4ZN#:A336,:,6TWYU1R?#&&K?A\\+&3\JY4]5:KE2S#7G
M#YCBFZ%GBL&J'$DYU6GA*O**:6,:48IRE.M4K(6\.H\-<0[ESIR+KO&NBT5M
MYK/6D;-:E:],=@\5"K7Y//YB=C7?5L7BJRK)([HKY'=L437S21QNZK16CLZU
MYJ2VTQD-/CO;B>V3QX*5->OJU'[&G3CM;WMX0BI3E&+XSF!KS3_+;2=WJ_4M
M7@R^VALBL.\K57LIT*47ZZI4EYL5NBL9S<:<926N?A#AW5.!N,M8XPT^-ZXS
M7J?2SD)V,9>SF8M.6?+YW(]BN3ZYD[KW2*U%5D+.V)G2-C438+0NC,IT!I>U
MTMDR?Q6VAYTVO.JU);:E6?MIRQ>&Z*PC'S8I&%7,;7V=\S=8WFLL^:^.753S
M81;<*-*/FTJ,,?8TX)+'?)XSEC*4F^L'7'#@       @GYE>/\V]8=.2]0HN
MGVS7*:Q9S'58U=8V#7JZ.D2>"-B*ZQE<*BN<UJ)WSUE<Q%<Z.)BR;R]U5'++
MC]#W\L+"M+&$GNA4?0^J,^E[E+![$Y,K;S]Y85-26'_%V14W+/+2GA6IQ7G5
MZ$<7BDO75*6UI;YP;BL7&$767QCR5LG$^X8[<=9F:VW35T-RC,Z3ZCE\9,K%
MMXO(1QN:Z2M81B*B]>Z.1C)&]',:I,N=9/9Y[E\\OO5[W+:FM\)+=*/:OOIM
M/8V5!T?JW-M$Y[2S[)Y+OZ>R4'CP5:;PXJ<TL,8RP3ZXR49+;%%Y_$G+>J\Q
MZK7V;6;'9*SVX,UA9Y&+DL#DE9W/IW&-Z=\3^BN@G:B1SQIU3HY'-;6?/LAO
MM/WSL[Q8Q>V$UZV<>M=O6M\7V8-Z/:'UQDNO<ECF^42PFL(U:4FN\HU,-L)K
MI3WPFMDUM6#4HKJ)XIV0          *\?+'REJX6GDN,.-\FD^>LMFH;7LF/
MF:Z+!P.[X+>$QMEG=WYJ9.K)Y8U3ZFWJUJ^^JK#+&A=$SN*D,ZSB&%K'"5*G
M);9O>IR7XBWQ3]?O?F^NJQSNYS4<OH5M':2K<69S3A<UX/91CM4J-.2_=7M4
MY)^]+8GWF/=UY\5<9;#RWNF+T[7HG));?[^3R3HGR5,)B(7,^O96ZK5:B1P,
M<C8VJYJS3/9$U>YZ$L9YG-ID.73S"[>R.R,<=LYO=%>7I?0DY/8BK.BM'YIK
MC4%'(<K7G3>-2HTW&E26''4GV);$L5Q3<8)XR1?AI.G8/C_5<)I^NUOJV(P5
M*.I71W19IW]5DLW;3VHU)+EZT]\TSNB(Z1ZJB(G1$J[F687.:WU3,+MXUZLL
M7U+J2[(K!)=2-,].Y!EVE\EM\ARJ'!8VU-1CUR>^4Y/IE.3<I/IDWN6P]4?"
M>T       "KSYAW^.>+?\F;5^M8,FKE/_-[WW=+\$RF_BG^<,F_>;GTJ)S+P
M0_?=:^XV>^T,&>SS.^K<?E,/1F<AX:_M$G]&UO3HER!7PON       #P')_'
M>#Y4TG-:5GF=M;*0=U2ZQB/L8K*5U]S'Y2KU5J^]4L(BJWJB2QJZ-WT'N1?5
MR7-KG),RIYC:^O@]JZ)1?KHOL:^X\&MJ1S&L=*Y=K33UQI[,U[S6CYLTL94Z
MD=L*D>V,MZQ7%'B@_-DR@[?=&V'CC:\OI^SU%JY7$V%C<YO<M:[6?].KD:,K
MFL6>C=@5'QNZ(O1>CD1R.:EHLKS.TS>QIYA92XJ%1>JGTQDNAI[&ON;,&9EZ
MFTYFFD\ZKY#G$."]H2PZ>&<7MC.#>&,)K;%^HTFFE99XH^4]?9:V-XSY(R21
M;/7;%1UC8[LBI'L<#&=D&,RMJ5Z]N?C1J-BE>O\ SU.C57W_ %FAW7.B)6<Y
MYSE$,;)XRJ4U^YOIE%+V'2TO6;_6^MMUR3YSTLWI4M(:LJ\.<12A;UYO9726
M"IU)-_GENC)_G=S?>?G+!"*BT(          .,<V<W:KPIK,F7S,C+V;N,DB
MUW6H9V,OYBXB=$<[T>ZIBZSE1;%ES5:Q/HM1\CF,=T6G--WVH[U6]NN&VC^<
MJ->;!?JR?L8].]X)-J/^8?,3)>7N3N^S!JIF-1-4+=-*=677T\-./LZC6"6Q
M*4W&+HTW?=-DY(VO)[9LMM^0S69LHYR1L5(8(FHD5/'4*[>[V:E2%&QQ,3JO
M1.JJYRJY;+9;EUGE%C"QLX\%M37JM[W*3Z6WM;_ MAG)J+4&;:MSJMG>;S=7
M,+B?0MB6Z,(1Z(Q6$8K?UMMMNV_Q&X#?Q5J\NU;/42+>]MK1+/!*Q/?UW JK
M+%;#*J]7QW;<C6SW$].CVQQ*G6%7.@?7NJ5GEZK&RECEE"3P:W5)[G/R+UL.
MS&7LL%>+D9RREHO)GG6<0PU+?06*:VT*.R4:76IR>$ZN[!J$&L:;;F&1^3R
M                    9#?,KBMW#ODIRII\4#H,1-L4^SZW]!60KKVVM;L&
M.@K*O_&Q8OZ^^DKORR5G)\4,=^=.DWHSF;FV30CPV<KEUZ.S!=S<>_04>M4^
M-TL>N#-W/#_K5:^Y19)GTY*5_&T5O<;<7W]M[Q.4NIU.!5DOQ:D2,)%I,@
M!,#P8YS;P)Y%:?L62M?5M1V=S]&W5SG(R&'!;#/69!DYG.7MCBP6<KU+LKNB
MN]B"1C?5Y,G(?7BY?\R+/,KJ?#D]UC:W/4J59QPF^I4JJIU9/?P0DEO(&\27
M+:7,[E1?Y39PX\]LTKRTP6+=:@I-TUTMUJ,JM&*V+CG"3]::T#78PX
M      (J><7X2^=ON/:_7:)$W/7[(L_^02]*)-GAQ^W+37TE'T)F1HQ^-U
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MG3QR[*\WJU>JHK>DONQKUG_DGT9?X">9-2KAFN<9'1HX[Z4KJM+#W,[:@O\
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MQ<,7U-,OIX<M*O)=&3SVXCPWF:5>-8K!]Q2QA26W\:3J33Z8SB^IDUB.2P@
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MCVFC^C]=Z/U]EBS?1V86U_8X+B=*:<Z;DL5&K3>%2C/#V%6$)+J.<G-G6
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MWM+KZ5TAD&B\L65:?H1HT-\I;ZE27X]2;VREU>QBO-@HQ22]Z>6=,
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M9PS.]:OM2)8JK*/F4G_H(/'!]'>2QF_8\";B2M.&)K
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MC4YN/^3)2],A#./"U9SFYY#FU2G#HA<4E4?\)3E3^"9R2_X"<OUU<M'8./\
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M:F6"$5%H0
M
M
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MDHQ2Z$DDD?L/UG[P
M
M
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MU>J*GHJ%YHRC.*G!IQ:Q36U-/I1G1*,H2<)IJ:>#3V--;TUT-'^S_3\0
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M3"DFXQZ&W*>"X\#OQRQ)P
M
M
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M#^34I+;1IR6#JR36*JU$\(K?"FWCYTVH6 $5EGP
M
M
M
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M]<>P>$14\XOPE\[?<>U^NT2)N>OV19_\@EZ42;/#C]N6FOI*/H3,C1C\;J
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M&M5BU^;6^G!K&H\)OWO!5+2"%"Y8
M
M
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MF-%K&3P=1*/FSL^1$1$1$1$1.B(GHB(GP1$_(B$+EQ4DE@MQ_P!
M
M
M
M                      /\21LE8^*5C)(I&.CDCD:CV2,>BM>Q['(K7,<U
M>BHOHJ'^2C&<7":3BU@T]J:?0S\HRE"2G!M33Q36QIK<T^AHI=\ROED5M@ER
M_)WC?1JX[,RK/D,]Q4QT53%Y29RNFLW-)EE?'7Q5V5RJY<:]S*KU7I7=#T;"
M^DO.GPNTLQG6U1RTIPIWKQG5L-D83>]RMF\%3D]_<MJF_P!S<,%"6A'A_P#&
M)5RN%#1W-NI.KE\<(4<R:<JE-;HPNTDY5(+<JZ3J+]U53%U(T29;$Y3 Y._A
M<WC;V'S&*MST,GBLG4GHY''W:TCHK%2[3LLBL5;,$K5:]CVM<U4Z*A0B[M+J
MPNJEE?4JE&\I3<)TYQ<)PE%X.,HR2<9)[&FDTS2RQOK+,[.EF&75J5Q85X*=
M.I3DITYPDL8RA.+<91:VIIM-;CYY\Y]0             -BG+/X;-S_A5;^P
M&F]6@/G#*/=6_P"")_,MSH^J>I?DUY^64-EMS+              'V,!KV<V
MG+TL#KF*O9K,9&5L-/'X^!]BS,]?BO8Q%2.*-O5SY'*UD;$5SE1J*J?/=7=M
M8T)75W.-.W@L7*3P2_Y>I+:WL6T^_+,KS'.KZGEN4T:EQ?U981A"+E)OR+<E
MO<G@HK%MI)LME\=_#[$<?.H;CR*RGG]VB6.UC\2B,M8+6)D1'12)WM='ELU7
M=]))U3V().BPHYS&SK!6K-?W&:J67Y1Q4LM>R4MTZBZ?<P?5ODO78)N)=SE7
MR(L=+NEGVJU3NM0QPE"ELE1MWT/;LJU8[^/UD)>L3<54<XR-2QH
M
M
M
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M)*/\JDDJE>>$JU3W4L%A'':H048+?ACBWUP\$[D
M
M
M
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M#_0
M
M
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ME"X[JMY?,V=.\C^J*U5:Y%1R*J*BIT5%3T5%1?5%12/&FG@]Y**::Q6X_P"
M   &Q3EG\-FY_P *K?V TWJT!\X91[JW_!$_F6YT?5/4OR:\_+*&RVYE@
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M18/2W*+06DG&ME]C"M?QW5KCWZICUQXEP0?;3A!G>CER2P
M
M
M
M                                       #G.X</<3<A*YV]\9Z#N$K
MD<GUC9-1P.9ML5Z='/AN7Z$]J"3I\',>UR?D4YK.=&Z1U%B\_P KR^]D^FM;
MTJDEVJ4X.2?:FF=9D&O=<:5P6FLXS.P@O8V]U6I1>'0XPFHM=C3781MV+Y=O
MA[LCGRS</T\39?TZ6-=V7<,$V/T8B]E&AGXL5ZMC3^57=TZJJ=%556-,R\.'
M)K,VYSR:%&J^FC6N*6&[="%54^CI@^GI;)<RGQ6\^\H2A3SZI7HKV->WM:V.
M_?.=!U.GHFNA;DD<=RORF/%O(=?JF0Y6P77LZ?LK;<--V]G7NZ?MO5,S_P ;
M_.Z]?^#H<9=^$3E5<_F:F;6^[\W<4W\+0J;^G[V!WUEXX^=%K^?I9)<[_P Y
M;55O_>;FENZ/OXGC[7R?.!7S.=2Y'Y>KUU1O9%:NZ9;F:J-3N5T\6GT6.17>
MJ(D:=$]/7XGBU?!MH!S;H9GG$:?5*5M)_=5O%?>/?H^/7F;&FE<91D,JO2XP
MNXKL\UW4W_E/U"SC9-*H;-H>5T"W;N5\;EM<DUN:[7]GZ]'5EI)26>)98I(/
MK"1IU]6*WK^3H7$R6O+)*]M7MTIRM7#AXMSX,,,<,-^&W# H3JK+J6K<MO\
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M><I>DV=]EN09%DT>')[*TM8_Z&C3I^A%;^D](?&>L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
)        ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6767791984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Aug. 13, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Dare Bioscience, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001401914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,683,411<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6761002704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,630,569<span></span>
</td>
<td class="nump">$ 6,805,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">493,019<span></span>
</td>
<td class="nump">31,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">437,958<span></span>
</td>
<td class="nump">403,097<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,561,546<span></span>
</td>
<td class="nump">7,240,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,081<span></span>
</td>
<td class="nump">9,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">692,305<span></span>
</td>
<td class="nump">577,968<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">7,260,932<span></span>
</td>
<td class="nump">7,827,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable</a></td>
<td class="nump">632,118<span></span>
</td>
<td class="nump">459,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,341,811<span></span>
</td>
<td class="nump">631,351<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,973,929<span></span>
</td>
<td class="nump">1,091,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">203,948<span></span>
</td>
<td class="nump">9,711<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,177,877<span></span>
</td>
<td class="nump">1,100,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 120,000,000 shares authorized; 16,683,411 and 11,422,161 shares issued and outstanding, respectively</a></td>
<td class="nump">1,668<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(97,024)<span></span>
</td>
<td class="num">(96,728)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">41,942,062<span></span>
</td>
<td class="nump">35,791,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(36,763,651)<span></span>
</td>
<td class="num">(28,969,767)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">5,083,055<span></span>
</td>
<td class="nump">6,726,620<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 7,260,932<span></span>
</td>
<td class="nump">$ 7,827,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6767959824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">16,683,411<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">16,683,411<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6768204384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 1,307,379<span></span>
</td>
<td class="nump">$ 1,157,174<span></span>
</td>
<td class="nump">$ 2,584,559<span></span>
</td>
<td class="nump">$ 2,460,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">2,512,572<span></span>
</td>
<td class="nump">2,217,622<span></span>
</td>
<td class="nump">4,205,963<span></span>
</td>
<td class="nump">3,304,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFee', window );">License expenses</a></td>
<td class="nump">162,500<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,187,519<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,982,451<span></span>
</td>
<td class="nump">3,624,796<span></span>
</td>
<td class="nump">7,065,522<span></span>
</td>
<td class="nump">11,302,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,982,451)<span></span>
</td>
<td class="num">(3,624,796)<span></span>
</td>
<td class="num">(7,065,522)<span></span>
</td>
<td class="num">(11,302,157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">30,001<span></span>
</td>
<td class="nump">42,626<span></span>
</td>
<td class="nump">61,232<span></span>
</td>
<td class="nump">54,370<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,952,450)<span></span>
</td>
<td class="num">(3,582,170)<span></span>
</td>
<td class="num">(7,004,290)<span></span>
</td>
<td class="num">(11,247,787)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Deemed dividend from trigger of down round provision feature</a></td>
<td class="num">(789,594)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(789,594)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss to common shareholders</a></td>
<td class="num">(4,742,044)<span></span>
</td>
<td class="num">(3,582,170)<span></span>
</td>
<td class="num">(7,793,884)<span></span>
</td>
<td class="num">(11,247,787)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(7,917)<span></span>
</td>
<td class="num">(27,485)<span></span>
</td>
<td class="num">(296)<span></span>
</td>
<td class="num">(41,231)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (4,749,961)<span></span>
</td>
<td class="num">$ (3,609,655)<span></span>
</td>
<td class="num">$ (7,794,180)<span></span>
</td>
<td class="num">$ (11,289,018)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share - basic and diluted (in usd per share)</a></td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (1.13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in shares)</a></td>
<td class="nump">16,105,252<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
<td class="nump">13,776,643<span></span>
</td>
<td class="nump">10,031,249<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=SL109261905-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12B<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL109261756-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769099216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock [Member]</div></th>
<th class="th"><div>Additional paid-in capital [Member]</div></th>
<th class="th"><div>Accumulated other comprehensive loss [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,047,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 13,292,782<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">$ 25,541,210<span></span>
</td>
<td class="num">$ (18,080)<span></span>
</td>
<td class="num">$ (12,230,953)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 18,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">375,000<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 1,037,764<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">1,037,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Deemed dividend from trigger of down round provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares', window );">Net proceeds from issuance of common stock and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued', window );">Public offering costs</a></td>
<td class="nump">9,157,888<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">9,157,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,247,787)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,247,787)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(41,231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="nump">12,217,963<span></span>
</td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">35,754,872<span></span>
</td>
<td class="num">(59,311)<span></span>
</td>
<td class="num">(23,478,740)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2018</a></td>
<td class="nump">15,820,356<span></span>
</td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">35,747,609<span></span>
</td>
<td class="num">(31,826)<span></span>
</td>
<td class="num">(19,896,570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Public offering costs</a></td>
<td class="num">$ (2,160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Deemed dividend from trigger of down round provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,582,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,582,170)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(27,485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="nump">12,217,963<span></span>
</td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">35,754,872<span></span>
</td>
<td class="num">(59,311)<span></span>
</td>
<td class="num">(23,478,740)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">6,726,620<span></span>
</td>
<td class="nump">$ 1,143<span></span>
</td>
<td class="nump">35,791,972<span></span>
</td>
<td class="num">(96,728)<span></span>
</td>
<td class="num">(28,969,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 209,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,261,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 5,151,702<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">5,151,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Deemed dividend from trigger of down round provision</a></td>
<td class="num">(789,594)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">789,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(789,594)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,004,290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,004,290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,683,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">5,083,055<span></span>
</td>
<td class="nump">$ 1,668<span></span>
</td>
<td class="nump">41,942,062<span></span>
</td>
<td class="num">(97,024)<span></span>
</td>
<td class="num">(36,763,651)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">3,780,369<span></span>
</td>
<td class="nump">$ 1,143<span></span>
</td>
<td class="nump">35,889,940<span></span>
</td>
<td class="num">(89,107)<span></span>
</td>
<td class="num">(32,021,607)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 111,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,261,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 5,151,702<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">5,151,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Deemed dividend from trigger of down round provision</a></td>
<td class="num">(789,594)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">789,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(789,594)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,952,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,952,450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(7,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,683,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">$ 5,083,055<span></span>
</td>
<td class="nump">$ 1,668<span></span>
</td>
<td class="nump">$ 41,942,062<span></span>
</td>
<td class="num">$ (97,024)<span></span>
</td>
<td class="num">$ (36,763,651)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=SL109261905-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12B<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL109261756-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6768679808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (7,004,290)<span></span>
</td>
<td class="num">$ (11,247,787)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Non-cash adjustments reconciling net loss to operating cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2,315<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">209,319<span></span>
</td>
<td class="nump">18,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NonCashLeaseExpense', window );">Non-cash lease expenses</a></td>
<td class="nump">10,549<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">452,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,187,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(461,982)<span></span>
</td>
<td class="nump">259,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(34,861)<span></span>
</td>
<td class="num">(35,838)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">193,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges', window );">Other non-current assets</a></td>
<td class="nump">79,063<span></span>
</td>
<td class="nump">66,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable</a></td>
<td class="nump">172,413<span></span>
</td>
<td class="nump">9,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">710,459<span></span>
</td>
<td class="nump">288,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(9,711)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(6,326,726)<span></span>
</td>
<td class="num">(4,807,544)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Acquisition of Pear Tree and Hydra asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(452,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(460,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds from issuance of common stock and warrants</a></td>
<td class="nump">5,151,702<span></span>
</td>
<td class="nump">10,195,653<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,151,702<span></span>
</td>
<td class="nump">10,195,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(296)<span></span>
</td>
<td class="num">(41,231)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(1,175,320)<span></span>
</td>
<td class="nump">4,886,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">6,805,889<span></span>
</td>
<td class="nump">7,559,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">5,630,569<span></span>
</td>
<td class="nump">12,446,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash operating and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">231,698<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Deemed dividend from trigger of down round provision</a></td>
<td class="nump">$ 789,594<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in other non-current assets and deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NetProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=SL109261905-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12B<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL109261756-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6758993408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of the Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of the Business</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ORGANIZATION AND DESCRIPTION OF THE BUSINESS</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dar&#233; Bioscience, Inc. is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women&#8217;s health. Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries operate in </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;"> segment. In this report, the &#8220;Company&#8221; refers collectively to Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is driven by a mission to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. The Company's business strategy is to license or otherwise acquire the rights to differentiated product candidates in women's health, some of which have existing clinical proof-of-concept data, and to advance those candidates through clinical development and regulatory approval alone or in collaboration with strategic partners.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has assembled a portfolio of clinical-stage and pre-clinical-stage candidates addressing unmet needs in women&#8217;s health. The Company&#8217;s portfolio includes these six clinical-stage candidates:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-BV1, a novel solution-to-gel formulation containing clindamycin phosphate 2% to treat bacterial vaginosis, or BV; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ovaprene, a non-hormonal monthly contraceptive intravaginal ring; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder, or FSAD; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy, or VVA, in patients with hormone-receptor positive breast cancer; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and for fertility support as part of an </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:Arial;font-size:10pt;"> fertilization, or IVF, treatment plan.</font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company's portfolio also includes several pre-clinical stage product candidates:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ORB-204 and ORB-214, 6-month and 12-month formulations of injectable etonogestrel for contraception;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-RH1, a novel approach to non-hormonal contraception for both men and women by targeting the CatSper ion channel; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-OAB1, an intravaginal ring containing oxybutynin for the treatment of overactive bladder. </font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s primary operations have consisted of, and are expected to continue to consist of, product research and development and advancing its portfolio of product candidates through clinical development and regulatory approval. We expect that the bulk of our development expenses over the next two years will support the advancement of our clinical-stage product candidates.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">To date, the Company has not obtained any regulatory approvals for any of its product candidates, commercialized any of its product candidates or generated any product revenue. The Company is subject to several risks common to clinical-stage biopharmaceutical companies, including dependence on key individuals, competition from other companies, the need to develop commercially viable products in a timely and cost-effective manner, and the need to obtain adequate additional capital to fund the development of product candidates. The Company is also subject to several risks common to other companies in the industry, including rapid technology change, regulatory approval of products, uncertainty of market acceptance of products, competition from substitute products, competition from larger companies with recognized brands, greater capital resources and higher levels of dedicated staff, and compliance with government regulations, protection of proprietary technology, dependence on third parties, and product liability.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6632724112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">GOING CONCERN</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, as of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company had an accumulated deficit of approximately </font><font style="font-family:Arial;font-size:10pt;">$36.8 million</font><font style="font-family:Arial;font-size:10pt;"> and had cash and cash equivalents of approximately </font><font style="font-family:Arial;font-size:10pt;">$5.6 million</font><font style="font-family:Arial;font-size:10pt;">. The Company also had negative cash flow from operations of approximately </font><font style="font-family:Arial;font-size:10pt;">$6.3 million</font><font style="font-family:Arial;font-size:10pt;"> during the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"> In March of 2019, the Company announced that it received a second Notice of Award for an additional </font><font style="font-family:Arial;font-size:10pt;">$982,851</font><font style="font-family:Arial;font-size:10pt;"> of the anticipated </font><font style="font-family:Arial;font-size:10pt;">$1.9 million</font><font style="font-family:Arial;font-size:10pt;"> from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or the NIH Grant, which is being applied to the clinical development efforts supporting Ovaprene. As of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company recorded a receivable in the amount of </font><font style="font-family:Arial;font-size:10pt;">$456,484</font><font style="font-family:Arial;font-size:10pt;"> for expenses eligible for reimbursement under the NIH Grant that were incurred through </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">. See Note 9, "Grant Award," herein. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In April of 2019, the Company completed a sale of common stock raising net proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$5.2 million</font><font style="font-family:Arial;font-size:10pt;">. See Note 6, "Stockholders' Equity," herein. The Company needs to raise additional capital to continue to fund its operations and to successfully execute its current operating plan, including the development of its current product candidates. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has a history of losses from operations, expects negative cash flows from its operations will continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops its existing product candidates and seeks to acquire, license or develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is focused primarily on the development and commercialization of innovative products in women&#8217;s health. The Company will continue to incur significant research and development and other expenses related to these activities. If the clinical trials for any of the Company&#8217;s product candidates fail to produce successful results such that those product candidates do not advance in clinical development, then the Company&#8217;s business and prospects may suffer. Even if the product candidates advance in clinical development, they may fail to gain regulatory approval. Even if the product candidates are approved, they may fail to achieve market acceptance, and the Company may never become profitable. Even if the Company becomes profitable, it may not sustain profitability.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company believes that its current available cash resources will be sufficient to fund planned operations into the first quarter of 2020. For the foreseeable future, the Company's ability to continue its operations will depend on its ability to obtain additional capital.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is currently evaluating a variety of capital raising options, including financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements to cover its operating expenses, including the development of its product candidates and any future product candidates it may license or otherwise acquire. The amount and timing of the Company's capital needs have been and will continue to depend highly on many factors, including the product development programs the Company chooses to pursue and the pace and results of its clinical development efforts. If the Company raises capital through collaborations, strategic alliances or other similar types of arrangements, it may have to relinquish, on terms that are not favorable to the Company, rights to some of its technologies or product candidates it would otherwise seek to develop or commercialize. There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. Additionally, equity or debt financings may have a dilutive effect on the holdings of the Company's existing stockholders. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6758986848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s significant accounting policies are described in Note 1 to the interim consolidated financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, filed with the Securities and Exchange Commission, or SEC on April 1, 2019. Since the date of those consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies, except as described below.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#8217;s opinion, the accompanying interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying interim consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use, or ROU, lease assets, current portion of lease obligations, and long-term lease obligations on the Company's balance sheets.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. If the lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease and the related payments are only included in the lease liability when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. (See Note 7, Leased Properties.)</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 2: inputs other than level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents of </font><font style="font-family:Arial;font-size:10pt;">$5.6 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$6.8 million</font><font style="font-family:Arial;font-size:10pt;"> are measured at fair value as of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, respectively, and are classified within Level 1 of the fair value hierarchy. Other receivables are financial assets with carrying values that approximate fair value due to the short-term nature of these assets. Accounts payable and accrued expenses and other liabilities are financial liabilities with carrying values that approximate fair value due to the short-term nature of these liabilities.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Standards</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2014, FASB issued Accounting Standards Update, or ASU, 2014-09, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Arial;font-size:10pt;">, which impacts the way in which some entities recognize revenue for certain types of transactions. The new standard became effective beginning in 2018 for public companies. Because the Company does not currently have any contracts with customers, the Company&#8217;s adoption of this accounting standard did not impact the Company&#8217;s interim consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2016, FASB issued ASU 2016-02, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Arial;font-size:10pt;">, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The new standard is effective for public companies for fiscal years beginning after December&#160;15, 2018, with early adoption permitted. ASU 2016-02 became effective for the Company on January 1, 2019 and was adopted using a modified retrospective approach and the effective date is as of the initial application. Consequently, financial information was not updated, and the disclosures required under ASU 2016-02 are not provided for dates and periods prior to January 1, 2019. ASU 2016-02 provides a number of optional practical expedients and accounting policy elections. The Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases. The Company recorded approximately </font><font style="font-family:Arial;font-size:10pt;">$232,000</font><font style="font-family:Arial;font-size:10pt;"> right-of-use assets and </font><font style="font-family:Arial;font-size:10pt;">$241,000</font><font style="font-family:Arial;font-size:10pt;"> lease liabilities related to its lease of office space as of the adoption date in the consolidated balance sheets. There are no changes to the statement of operations or cash flows as a result of the adoption.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2017, FASB issued ASU 2017-01, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</font><font style="font-family:Arial;font-size:10pt;">, which intended to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The standard became effective for the Company on January 1, 2018. The Company&#8217;s early adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Disclosure Update and Simplification,</font><font style="font-family:Arial;font-size:10pt;"> amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements relating to the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of income is required to be filed. This final rule was effective November 5, 2018. In accordance with the new rule, the Company added a Consolidated Statement of Stockholders' Equity in this report and elected to present a reconciliation in a single statement that shows the changes in stockholders' equity for each interim period, as well as each comparable period.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6607942944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ACQUISITIONS</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Cerulean/Private Dar&#233; Stock Purchase Transaction</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In </font><font style="font-family:Arial;font-size:10pt;">July 2017</font><font style="font-family:Arial;font-size:10pt;">, the Company completed its business combination with Dar&#233; Bioscience Operations, Inc., a privately held Delaware corporation, or Private Dar&#233;, in which Private Dar&#233; stockholders sold their shares to the Company in exchange for newly issued shares of the Company&#8217;s common stock, and as a result, Private Dar&#233; became a wholly owned subsidiary of the Company and the Private Dar&#233; stockholders became majority stockholders of the Company. In connection with the closing of that transaction, the Company changed its name from &#8220;Cerulean Pharma Inc.&#8221; to &#8220;Dar&#233; Bioscience, Inc.&#8221; In this report, that transaction is referred to as the Cerulean/Private Dar&#233; stock purchase transaction and &#8220;Cerulean&#8221; refers to Cerulean Pharma Inc. before that transaction closed.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Cerulean/Private Dar&#233; stock purchase transaction was accounted for as a reverse merger under the acquisition method of accounting whereby Private Dar&#233; was considered to have acquired Cerulean for financial reporting purposes. Pursuant to business combination accounting, the Company applied the acquisition method, which requires the assets acquired and liabilities assumed be recorded at fair value with limited exceptions. The excess of the purchase price over the assets acquired and liabilities assumed represents goodwill. The goodwill was primarily attributable to the cash and cash equivalents at closing of the transaction of approximately </font><font style="font-family:Arial;font-size:10pt;">$9.9 million</font><font style="font-family:Arial;font-size:10pt;"> and the impact of the unamortized fair value of stock options granted by Cerulean that were outstanding immediately before the transaction closed of approximately </font><font style="font-family:Arial;font-size:10pt;">$3.7 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company tests its goodwill for impairment at least annually as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31</font><font style="font-family:Arial;font-size:10pt;"> and between annual tests if it becomes aware of an event or change in circumstance that would indicate the carrying value may be impaired. The Company tests goodwill for impairment at the entity level because it operates on the basis of a single reporting unit. A goodwill impairment is the amount by which a reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. When impaired, the carrying value of goodwill is written down to fair value. Any excess of the reporting unit goodwill carrying value over the fair value is recognized as impairment loss.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company assessed goodwill at March 31, 2018, determined there was an impairment and recognized an impairment charge of approximately </font><font style="font-family:Arial;font-size:10pt;">$5.2 million</font><font style="font-family:Arial;font-size:10pt;"> in the interim consolidated statement of operations and comprehensive loss for the three months ended March 31, 2018. As of March 31, 2018, the goodwill carrying value on the Company&#8217;s consolidated balance sheet was written off in its entirety.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Pear Tree Merger</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On </font><font style="font-family:Arial;font-size:10pt;">April&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company entered into an Agreement and Plan of Merger, the Merger Agreement, with Pear Tree Pharmaceuticals, Inc., or Pear Tree, Dar&#233; Merger Sub, Inc., a wholly-owned subsidiary of the Company, or Merger Sub, and two individuals in their respective capacities as Pear Tree stockholders&#8217; representatives. The transactions contemplated by the Merger Agreement closed on </font><font style="font-family:Arial;font-size:10pt;">May&#160;16, 2018</font><font style="font-family:Arial;font-size:10pt;">, and as a result, Pear Tree became the Company&#8217;s wholly owned subsidiary. The Company acquired Pear Tree to secure the rights to develop DARE-VVA1, a proprietary vaginal formulation of tamoxifen, as a potential treatment for vulvar and vaginal atrophy.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company determined that the acquisition of Pear Tree should be accounted for as an asset acquisition instead of a business combination because substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, and therefore, the asset is not considered a business. Transaction costs of approximately </font><font style="font-family:Arial;font-size:10pt;">$452,000</font><font style="font-family:Arial;font-size:10pt;"> associated with the merger were included in the Company&#8217;s research and development expense.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under the Merger Agreement, certain former and continuing Pear Tree service providers and former holders of Pear Tree&#8217;s capital stock, or the Holders, were eligible to receive a </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;"> payment due on the one-year anniversary of the closing of the merger and are eligible to receive tiered royalties, subject to customary provisions permitting royalty reductions and offset, based on percentages of annual net sales of certain products subject to license agreements the Company assumed and a percentage of sublicense revenue. The Company must also make contingent payments to the Holders based on achieving certain clinical, regulatory and commercial milestones, which may be paid, in the Company&#8217;s sole discretion, in cash or shares of the Company&#8217;s common stock.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In accordance with the terms of the Merger Agreement, because the Negative Consideration Amount (as defined below) exceeded the Positive Consideration Amount (as defined below), at the time of the closing of the merger, the excess amount (approximately </font><font style="font-family:Arial;font-size:10pt;">$132,000</font><font style="font-family:Arial;font-size:10pt;">) offset the </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;"> payment due on the </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;">-year anniversary of the closing of the merger and the balance will offset future payments otherwise due under the Merger Agreement to the Holders. Positive Consideration Amount means the sum of </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;">, and the cash and cash equivalents held by Pear Tree at closing, and Negative Consideration Amount means the sum of (i) certain Pear Tree indebtedness and transaction expenses, (ii) transaction expenses of the stockholders&#8217; representatives, and (iii) amounts payable under Pear Tree&#8217;s management incentive plan.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6758986048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">The 2015 Employee, Director and Consultant Equity Incentive Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to the Cerulean/Private Dar&#233; stock purchase transaction, Private Dar&#233; maintained the 2015 Employee, Director and Consultant Equity Incentive Plan, or the 2015 Private Dar&#233; Plan. Upon closing of the Cerulean/Private Dar&#233; stock purchase transaction, the Company assumed the 2015 Private Dar&#233; Plan and each then outstanding award granted thereunder, which consisted of options and restricted stock. Based on the exchange ratio for the Cerulean/Private Dar&#233; stock purchase transaction and after giving effect to the reverse stock split effected in connection with the closing of that transaction, the outstanding options and restricted stock awards granted under the  2015 Private Dar&#233; Plan were replaced with options to purchase </font><font style="font-family:Arial;font-size:10pt;">10,149</font><font style="font-family:Arial;font-size:10pt;"> shares of the Company&#8217;s common stock with a correspondingly adjusted exercise price, all of which were outstanding as of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">223,295</font><font style="font-family:Arial;font-size:10pt;"> restricted shares of the Company&#8217;s common stock. Those options are fully vested and expire in December 2025.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No further awards may be granted under the 2015 Private Dar&#233; Plan following the closing of the Cerulean/Private Dar&#233; stock purchase transaction.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">2014 Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s 2014 Employee Stock Purchase Plan, or the ESPP, became effective in April 2014, but no offering period has been initiated thereunder since January 2017 and there was </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> stock-based compensation related to the ESPP for the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;"> or </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Amended and Restated 2014 Stock Incentive Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company maintains the Amended and Restated 2014 Plan, or the Amended 2014 Plan. There were </font><font style="font-family:Arial;font-size:10pt;">2,046,885</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock authorized for issuance under the Amended 2014 Plan when it was approved by the Company's stockholders in July 2018. The number of authorized shares increases annually on the first day of each fiscal year until, and including, the fiscal year ending December 31, 2024 by the least of (i) </font><font style="font-family:Arial;font-size:10pt;">2,000,000</font><font style="font-family:Arial;font-size:10pt;">, (ii) </font><font style="font-family:Arial;font-size:10pt;">4%</font><font style="font-family:Arial;font-size:10pt;"> of the number of outstanding shares of common stock on such date, or (iii) an amount determined by the Company&#8217;s board of directors. On January 1, 2019, the number of authorized shares increased by </font><font style="font-family:Arial;font-size:10pt;">456,886</font><font style="font-family:Arial;font-size:10pt;"> to </font><font style="font-family:Arial;font-size:10pt;">2,503,771</font><font style="font-family:Arial;font-size:10pt;">, which increase represented </font><font style="font-family:Arial;font-size:10pt;">4%</font><font style="font-family:Arial;font-size:10pt;"> of the number of outstanding shares of common stock on such date.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Summary of Stock Option Activity</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below summarizes stock option activity under the Amended 2014 Plan, and related information for the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">. The exercise price of all options granted during the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;"> was equal to the market value of the Company&#8217;s common stock on the date of the grant. As of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, unamortized stock-based compensation expense of </font><font style="font-family:Arial;font-size:10pt;">$1,348,159</font><font style="font-family:Arial;font-size:10pt;"> will be amortized over a weighted average period of </font><font style="font-family:Arial;font-size:10pt;">2.9 years</font><font style="font-family:Arial;font-size:10pt;">. At </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">497,032</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock were reserved for future issuance under the Amended 2014 Plan.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Outstanding at December 31, 2018 (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,635,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">698,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.79</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Canceled/forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(316,832</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24.55</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">59.48</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Outstanding at June 30, 2019 (unaudited) (1)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,016,888</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exercisable at June&#160;30, 2019 (unaudited)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">427,702</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">21.83</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:0px;padding-top:8px;text-indent:0px;"><font style="padding-top:8px;font-family:Arial;font-size:10pt;padding-right:48px;">(1)</font><font style="font-family:Arial;font-size:10pt;">Includes </font><font style="font-family:Arial;font-size:10pt;">10,149</font><font style="font-family:Arial;font-size:10pt;"> shares subject to options granted under the 2015 Private Dar&#233; Plan assumed in connection with the Cerulean/Private Dar&#233; stock purchase transaction.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Compensation Expense</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total stock-based compensation expense related to stock options granted to employees and directors recognized in the consolidated statement of operations is as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>June 30,</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Six Months Ended<br clear="none"/>June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26,996</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">51,699</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">84,355</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,423</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">157,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18,547</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">111,351</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,423</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">209,319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18,547</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;padding-bottom:24px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Six Months Ended<br clear="none"/>June 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected life in years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.0</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.09%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.58%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">123%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">121%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Forfeiture rate</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.0%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.0%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.0%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Weighted-average fair value of options granted</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$0.86</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$0.75</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6632444000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">STOCKHOLDERS&#8217; EQUITY</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">ATM Sales Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2018, the Company entered into a common stock sales agreement under which the Company may sell up to an aggregate of </font><font style="font-family:Arial;font-size:10pt;">$10 million</font><font style="font-family:Arial;font-size:10pt;"> in gross proceeds through the sale of shares of common stock from time to time in &#8220;at-the-market&#8221; equity offerings (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended). The Company will pay a commission of up to </font><font style="font-family:Arial;font-size:10pt;">3%</font><font style="font-family:Arial;font-size:10pt;"> of the gross proceeds of any common stock sold under this agreement plus certain legal expenses. This agreement was amended in August 2018 to refer to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-227019) that was filed to replace the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-206396) that expired on August 28, 2018.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company sold </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> shares under this agreement during either the three or six months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;"> or the three months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">. During the six months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company sold an aggregate of </font><font style="font-family:Arial;font-size:10pt;">375,000</font><font style="font-family:Arial;font-size:10pt;"> shares common stock under this agreement for gross proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$1.1 million</font><font style="font-family:Arial;font-size:10pt;"> and incurred issuance costs of </font><font style="font-family:Arial;font-size:10pt;">$237,403</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">February 2018 Underwritten Public Offering</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2018, the Company closed an underwritten public offering of </font><font style="font-family:Arial;font-size:10pt;">5.0 million</font><font style="font-family:Arial;font-size:10pt;"> shares of its common stock and warrants to purchase up to </font><font style="font-family:Arial;font-size:10pt;">3.5 million</font><font style="font-family:Arial;font-size:10pt;"> shares of its common stock. Each share of common stock was sold with a warrant to purchase up to </font><font style="font-family:Arial;font-size:10pt;">0.70</font><font style="font-family:Arial;font-size:10pt;"> of a share of the Company&#8217;s common stock. The Company granted the underwriter a </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;">-day over-allotment option to purchase up to an additional </font><font style="font-family:Arial;font-size:10pt;">750,000</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock and/or warrants to purchase up to </font><font style="font-family:Arial;font-size:10pt;">525,000</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock.&#160; The underwriter exercised the option with respect to warrants to purchase </font><font style="font-family:Arial;font-size:10pt;">220,500</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock. The Company received gross proceeds of </font><font style="font-family:Arial;font-size:10pt;">$10.3 million</font><font style="font-family:Arial;font-size:10pt;">, including the proceeds from the sale of the warrants upon exercise of the underwriter&#8217;s over-allotment option, and net proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$9.4 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Warrants</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The warrants issued in the February 2018 underwritten offering initially had an exercise price of </font><font style="font-family:Arial;font-size:10pt;">$3.00</font><font style="font-family:Arial;font-size:10pt;"> per share and</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font><font style="font-family:Arial;font-size:10pt;">are exercisable through February 2023.</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font><font style="font-family:Arial;font-size:10pt;">The warrants include a price-based anti-dilution provision, which provides that, subject to certain limited exceptions, the exercise price of the warrants will be reduced each time the Company issues or sells securities for a consideration per share less than a price equal to the exercise price of those warrants in effect immediately prior to such issuance or sale. In addition, subject to certain exceptions, if the Company issues, sells or enters into any agreement to issue or sell securities at a price which varies or may vary with the market price of the shares of the Company&#8217;s common stock, the warrant holders have the right to substitute such variable price for the exercise price of the warrant then in effect. These warrants are exercisable only for cash, unless a registration statement covering the shares issued upon exercise of the warrants is not effective, in which case the warrants may be exercised on a cashless basis. A registration statement covering the shares issued upon exercise of the warrants is currently effective. The Company estimated the fair value of the warrants as of February 15, 2018 to be approximately </font><font style="font-family:Arial;font-size:10pt;">$3.0 million</font><font style="font-family:Arial;font-size:10pt;"> which has been recorded in equity as of the grant date. The Company early adopted ASU 2017-11 as of January 1, 2018 and recorded the fair value of the warrants as equity. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On April 11, 2019, in accordance with the anti-dilution provision of these warrants and as a result of the sale of shares in the public offering that closed on that date and which is discussed below, the exercise price of these warrants was automatically reduced to </font><font style="font-family:Arial;font-size:10pt;">$0.98</font><font style="font-family:Arial;font-size:10pt;"> per share. For the three and six months ended June 30, 2019 the Company recorded </font><font style="font-family:Arial;font-size:10pt;">$0.8 million</font><font style="font-family:Arial;font-size:10pt;"> to additional paid in capital as a result of the triggering of the anti-dilution provisions.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to the warrants issued in the February 2018 underwritten offering, as of June 30, 2019, there are outstanding warrants to purchase </font><font style="font-family:Arial;font-size:10pt;">30,333</font><font style="font-family:Arial;font-size:10pt;"> shares of the Company&#8217;s common stock, which are further described in the table below. </font></div><div style="line-height:120%;padding-top:8px;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No</font><font style="font-family:Arial;font-size:10pt;"> warrants were exercised during the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;"> or </font><font style="font-family:Arial;font-size:10pt;">2018</font><font style="font-family:Arial;font-size:10pt;">. As of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company had the following warrants outstanding:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Shares Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Outstanding Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Expiration Date</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,906</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120.40</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;1, 2021</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,737</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120.40</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;6, 2021</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17,190</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">60.50</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">January&#160;8, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,500</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">April&#160;4, 2026</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,720,500</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.98</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">February&#160;15, 2023</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,750,833</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">April 2019 Underwritten Public Offering</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On April 11, 2019, the Company closed an underwritten public offering of </font><font style="font-family:Arial;font-size:10pt;">4,575,000</font><font style="font-family:Arial;font-size:10pt;"> shares of its common stock at a public offering price of </font><font style="font-family:Arial;font-size:10pt;">$1.10</font><font style="font-family:Arial;font-size:10pt;"> per share. The Company granted the underwriters a </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;">-day over-allotment option to purchase up to an additional </font><font style="font-family:Arial;font-size:10pt;">686,250</font><font style="font-family:Arial;font-size:10pt;"> shares which was exercised in full on April 12, 2019. Including the over-allotment shares, the Company issued a total of </font><font style="font-family:Arial;font-size:10pt;">5,261,250</font><font style="font-family:Arial;font-size:10pt;"> shares in the underwritten public offering, and received gross proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$5.8 million</font><font style="font-family:Arial;font-size:10pt;"> and net proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$5.2 million</font><font style="font-family:Arial;font-size:10pt;"> after deducting underwriting discounts and offering expenses.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6758978864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leased Properties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leased Properties</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">LEASED PROPERTIES</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effective January 1, 2019, the Company adopted ASC 842, which requires recognition of a right-of-use asset and lease liability for all leases at the commencement date based on the present value of lease payments over the lease term. Additional qualitative and quantitative disclosures regarding the Company's leasing arrangements are also required. The Company adopted ASC 842 prospectively and elected the package of transition practical expedients that does not require reassessment of: (1) whether any existing or expired contracts are or contain leases, (2) lease classification and (3) initial direct costs. In addition, the Company has elected other available practical expedients to not separate lease and nonlease components, which consist principally of common area maintenance charges, for all classes of underlying assets and to exclude leases with an initial term of 12 months or less.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company's lease for its corporate headquarters (</font><font style="font-family:Arial;font-size:10pt;">3,169</font><font style="font-family:Arial;font-size:10pt;"> square feet of office space) commenced on July 1, 2018, has term of </font><font style="font-family:Arial;font-size:10pt;">37 months</font><font style="font-family:Arial;font-size:10pt;">, and terminates on July 31, 2021. The Company has the option to extend the term of the lease for </font><font style="font-family:Arial;font-size:10pt;">one year</font><font style="font-family:Arial;font-size:10pt;"> at the Company's discretion. The gross monthly base rent is </font><font style="font-family:Arial;font-size:10pt;">$8,873</font><font style="font-family:Arial;font-size:10pt;">, which increases approximately </font><font style="font-family:Arial;font-size:10pt;">4%</font><font style="font-family:Arial;font-size:10pt;"> per year, subject to certain future adjustments. The base rent was abated during the second month of the lease. The Company evaluates renewal options at lease inception and on an ongoing basis, and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The lease does not require material variable lease payments, a residual value guarantee or restrictive covenants. This is the Company&#8217;s only lease.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The lease does not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company used an incremental borrowing rate of </font><font style="font-family:Arial;font-size:10pt;">7%</font><font style="font-family:Arial;font-size:10pt;"> as of January 1, 2019 for the operating lease that commenced prior to that date. The depreciable lives of operating lease assets and leasehold improvements are limited by the expected lease term.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company recorded a right of use asset of </font><font style="font-family:Arial;font-size:10pt;">$193,399</font><font style="font-family:Arial;font-size:10pt;"> in other non-current assets, and </font><font style="font-family:Arial;font-size:10pt;">$87,859</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$116,089</font><font style="font-family:Arial;font-size:10pt;">, respectively, in current and non-current other liabilities on the consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, future minimum lease payments for the Company's corporate headquarters are:</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Years ending December 31:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Remainder of 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">55,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">112,943</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">67,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total future minimum lease payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">236,069</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Less: Difference between future minimum lease payments and discounted operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">42,669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total operating lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">193,400</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Operating lease costs were&#160;</font><font style="font-family:Arial;font-size:10pt;">$27,038</font><font style="font-family:Arial;font-size:10pt;">&#160;and </font><font style="font-family:Arial;font-size:10pt;">$54,076</font><font style="font-family:Arial;font-size:10pt;"> for the three and six months ended&#160;</font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, respectively. Operating lease costs are included in general and administrative expenses in the condensed consolidated statement of operations. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash paid for amounts included in the measurement of operating lease liabilities were&#160;</font><font style="font-family:Arial;font-size:10pt;">$26,620</font><font style="font-family:Arial;font-size:10pt;">&#160;and </font><font style="font-family:Arial;font-size:10pt;">$53,240</font><font style="font-family:Arial;font-size:10pt;"> for the three and six months ended&#160;</font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, respectively, and these amounts are included in operating activities in the condensed consolidated statements of cash flows.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6759011472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">License and Research Agreements</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">ADVA-Tec License Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In March 2017, the Company entered into a license agreement, or the ADVA-Tec License Agreement, with ADVA-Tec, Inc., or ADVA-Tec, under which the Company was granted the exclusive right to develop and commercialize Ovaprene for human contraceptive use worldwide. ADVA-Tec and its affiliates own issued patents or patent applications covering Ovaprene and control proprietary trade secrets covering the manufacture of Ovaprene. As of the date of this report, this patent portfolio includes </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> issued U.S. patents and </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;"> pending U.S. patent application, and </font><font style="font-family:Arial;font-size:10pt;">59</font><font style="font-family:Arial;font-size:10pt;"> granted patents and </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;"> pending patent applications in other major markets, all of which are exclusively licensed to the Company for the human contraceptive use of Ovaprene as a human contraceptive device. Under the terms of the ADVA-Tec Agreement, the Company has a right of first refusal to license these patents and patent applications for additional indications.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of other terms of the ADVA-Tec License Agreement:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Research and Development.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">ADVA-Tec will conduct certain research and development work as necessary to allow the Company to seek a Premarket Approval, or PMA, from the United States Food and Drug Administration, or the FDA, and will supply the Company with its requirements of Ovaprene for clinical and commercial use on commercially reasonable terms. The Company must use commercially reasonable efforts to develop and commercialize Ovaprene, and must meet certain minimum spending amounts per year, such amounts totaling </font><font style="font-family:Arial;font-size:10pt;">$5.0 million</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate over the first </font><font style="font-family:Arial;font-size:10pt;">three years</font><font style="font-family:Arial;font-size:10pt;">, to cover such activities until a final PMA is filed, or until the first commercial sale of Ovaprene, whichever occurs first.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone Payments.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">The Company will pay ADVA-Tec: (1) up to </font><font style="font-family:Arial;font-size:10pt;">$14.6 million</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate based on the achievement of specified development and regulatory milestones; and (2) up to </font><font style="font-family:Arial;font-size:10pt;">$20 million</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate based on the achievement of certain worldwide net sales milestones. The development and regulatory milestones  include: the completion of a successful postcoital clinical study, which is required before the Company can commence a Phase 3 pivotal human clinical trial; approval by the FDA to commence such Phase 3 pivotal human clinical trial; successful completion of such Phase 3 pivotal human clinical trial; the FDA&#8217;s acceptance of a PMA filing for Ovaprene; the FDA&#8217;s approval of the PMA for Ovaprene; obtaining Conformit&#233; Europ&#233;enne Marking of Ovaprene in at least </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;"> designated European countries; obtaining regulatory approval in at least three designated European countries; and obtaining regulatory approval in Japan. Because these milestone payments depend upon the successful progress of the Company&#8217;s product development programs, the Company cannot estimate with certainty when these payments will occur, if ever.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For products currently in development, future potential milestone payments based on product development are approximately </font><font style="font-family:Arial;font-size:10pt;">$14.6 million</font><font style="font-family:Arial;font-size:10pt;"> as of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">. Future potential milestone payments related to commercialization totaled </font><font style="font-family:Arial;font-size:10pt;">$20 million</font><font style="font-family:Arial;font-size:10pt;"> at </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">. The Company is unable to estimate with certainty the timing on when these milestone payments will occur as these payments depend on the Company's product development programs.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Royalty Payments.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">After the commercial launch of Ovaprene, the Company will pay to ADVA-Tec royalties based on aggregate annual net sales of Ovaprene in specified regions, at a royalty rate that will vary between </font><font style="font-family:Arial;font-size:10pt;">1%</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">10%</font><font style="font-family:Arial;font-size:10pt;"> and will increase based on various net sales thresholds. The Company is unable to estimate with certainty the timing on when these royalty payments will occur as these payments depend on the Company's product development programs.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Termination Rights.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">Unless earlier terminated, the license the Company received under the ADVA-Tec License Agreement continues on a country-by-country basis until the later of the life of the licensed patents or the Company's last commercial sale of Ovaprene. In addition to customary termination rights for both parties: (A) the Company may terminate the agreement with or without cause in whole or on a country-by-country basis upon </font><font style="font-family:Arial;font-size:10pt;">60</font><font style="font-family:Arial;font-size:10pt;"> days prior written notice; and (B) ADVA-Tec may terminate the agreement if the Company develops or commercializes any non-hormonal ring-based vaginal contraceptive device competitive to Ovaprene or if the Company fails to: (1) in certain limited circumstances, commercialize Ovaprene in certain designated countries within three years of the first commercial sale of Ovaprene, (2) satisfy the annual spending obligation described above, (3) use commercially reasonable efforts to complete all necessary pre-clinical and clinical studies required to support and submit a PMA, (4) conduct clinical trials as set forth in the development plan that is agreed by the Company and ADVA-Tec, and as may be modified by a joint research committee, unless such failure is caused by events outside of the Company&#8217;s reasonable control, or (5) enroll a patient in the first non-significant risk medical device study or clinical trial as allowed by an institutional review board within </font><font style="font-family:Arial;font-size:10pt;">six months</font><font style="font-family:Arial;font-size:10pt;"> of the production and release of Ovaprene, unless such failure is caused by events outside of its reasonable control.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">SST License and Collaboration Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2018, the Company entered into a license and collaboration agreement, or the SST License Agreement, with Strategic Science &amp;&#160;Technologies-D,&#160;LLC and Strategic Science &amp; Technologies, LLC, referred to collectively as SST. The SST License Agreement provides the Company with an exclusive, royalty-bearing, sublicensable license to develop and commercialize, in all countries and geographic territories of the world, for all indications for women related to female sexual dysfunction and/or female reproductive health, including treatment of female sexual arousal disorder, or the Field of Use, SST&#8217;s topical formulation of Sildenafil Cream, 3.6% as it exists as of the effective date of the SST License Agreement, or any other topically applied pharmaceutical product containing sildenafil or a salt thereof as a pharmaceutically active ingredient, alone or with other active ingredients, but specifically excluding any product containing ibuprofen or any salt derivative of ibuprofen, or the Licensed Products.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of other terms of the SST License Agreement:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Invention </font><font style="font-family:Arial;font-size:10pt;">Ownership</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">The Company retains rights to inventions made by its employees, SST retains rights to inventions made by its employees, and each party shall own a </font><font style="font-family:Arial;font-size:10pt;">50%</font><font style="font-family:Arial;font-size:10pt;"> undivided interest in all joint inventions.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Joint </font><font style="font-family:Arial;font-size:10pt;">Development</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"> Committee</font><font style="font-family:Arial;font-size:10pt;">. The parties will collaborate through a joint development committee that will determine the strategic objectives for, and generally oversee, the development efforts of both parties under the SST License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Development</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">The Company must use commercially reasonable efforts to develop the Licensed Products in the Field of Use in accordance with a development plan in the SST License Agreement, and to commercialize the Licensed Products in the Field of Use. The Company is responsible for all reasonable internal and external costs and expenses incurred by SST in its performance of the development activities it must perform under the SST License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Royalty </font><font style="font-family:Arial;font-size:10pt;">Payments.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">SST will be eligible to receive (1) tiered royalties based on percentages of annual net sales of Licensed Products in the single digits to the mid double digits, subject to customary royalty reductions and offsets, and (2) a percentage of sublicense revenue.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone Payments.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">SST will be eligible to receive payments (1) ranging from </font><font style="font-family:Arial;font-size:10pt;">$0.5 million</font><font style="font-family:Arial;font-size:10pt;"> to </font><font style="font-family:Arial;font-size:10pt;">$18.0 million</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate on achieving certain clinical and regulatory milestones in the U.S. and worldwide, and (2) between </font><font style="font-family:Arial;font-size:10pt;">$10.0 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$100 million</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate upon achieving certain commercial sales milestones. If the Company enters into strategic development or distribution partnerships related to the Licensed Products, additional milestone payments would be due to SST.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">License Term.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s license received under the SST License Agreement continues on a country-by-country basis until the later of </font><font style="font-family:Arial;font-size:10pt;">10 years</font><font style="font-family:Arial;font-size:10pt;"> from the date of the first commercial sale of such Licensed Product or the expiration of the last valid claim of patent rights covering the Licensed Product in the Field of Use. Upon expiration (but not termination) of the SST License Agreement in a particular country, the Company will have a fully paid-up license under the licensed intellectual property to develop and commercialize the applicable Licensed Products in the applicable country on a non-exclusive basis.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Termination.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">In addition to customary termination rights for both parties: (1) prior to receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including New Drug Application Approval, or NDA Approval, the Company may terminate the SST License Agreement without cause upon </font><font style="font-family:Arial;font-size:10pt;">90</font><font style="font-family:Arial;font-size:10pt;"> days prior written notice to SST; (2)&#160;following receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including NDA Approval, the Company may terminate the SST License Agreement without cause upon </font><font style="font-family:Arial;font-size:10pt;">180</font><font style="font-family:Arial;font-size:10pt;">&#160;days prior written notice; and (3) SST may terminate the SST License Agreement with respect to the applicable Licensed Product(s) in the applicable country(ies) upon </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;">&#160;days&#8217; notice to the Company if the Company fails to use commercially reasonable efforts to perform development activities in substantial accordance with the development plan and does not cure such failure within </font><font style="font-family:Arial;font-size:10pt;">60</font><font style="font-family:Arial;font-size:10pt;">&#160;days of receipt of SST&#8217;s notice thereof.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Orbis Development and Option Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In March 2018, the Company entered into an exclusive development and option agreement, or the Orbis Agreement, with Orbis Biosciences, or Orbis, for the development of long-acting injectable etonogestrel contraceptive with 6- and 12-month durations (ORB-204 and ORB-214, respectively). Under the Orbis Agreement, the  Company paid Orbis </font><font style="font-family:Arial;font-size:10pt;">$300,000</font><font style="font-family:Arial;font-size:10pt;"> to conduct the first stage of development work, Stage 1, as follows: </font><font style="font-family:Arial;font-size:10pt;">$150,000</font><font style="font-family:Arial;font-size:10pt;"> upon signing the Orbis Agreement, </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;"> at the </font><font style="font-family:Arial;font-size:10pt;">50%</font><font style="font-family:Arial;font-size:10pt;"> completion point, not later than 6 months following the date the Orbis Agreement was signed (which the Company paid in September 2018), and </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;"> upon delivery by Orbis of the 6-month batch, not later than 11 months following the date the Orbis Agreement was signed (which the Company paid in January 2019). Upon Orbis successfully completing Stage 1 of the development program and achieving the predetermined target milestones for Stage 1, the Company will have </font><font style="font-family:Arial;font-size:10pt;">90</font><font style="font-family:Arial;font-size:10pt;"> days to instruct Orbis whether to commence the second stage of development work, Stage 2. Should the Company execute its option to proceed to Stage 2, it will have to provide additional funding to Orbis for such activities. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pre-clinical studies for the 6- and 12-month formulations have been completed, including establishing pharmacokinetics and pharmacodynamics profiles. The collaboration with Orbis will continue to advance the program through formulation optimization with the goal of achieving sustained release over the target time period.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Orbis Agreement provides the Company with an option to enter into a license agreement for ORB-204 and ORB-214 should development efforts be successful.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Juniper Pharmaceuticals - License Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In April 2018,&#160;the Company entered into an Exclusive License Agreement, or the Juniper License Agreement, with Juniper Pharmaceuticals, Inc., or Juniper, under which Juniper granted the Company (a) an exclusive, royalty-bearing worldwide license under certain patent rights, either owned by or exclusively licensed to Juniper, to make, have made, use, have used, sell, have sold, import and have imported products and processes; and (b) a non-exclusive, royalty-bearing worldwide license to use certain technological information owned by Juniper to make, have made, use, have used, sell, have sold, import and have imported products and processes. The Company is entitled to sublicense the rights granted to it under the Juniper License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-indent:94px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of certain terms of the Juniper License Agreement:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Upfront Fee.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">The Company paid a </font><font style="font-family:Arial;font-size:10pt;">$250,000</font><font style="font-family:Arial;font-size:10pt;"> non-creditable upfront license fee to Juniper in connection with the execution of the Juniper License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Annual Maintenance Fee</font><font style="font-family:Arial;font-size:10pt;">. The Company will pay an annual license maintenance fee to Juniper on each anniversary of the date of the Juniper License Agreement, the amount of which will be </font><font style="font-family:Arial;font-size:10pt;">$50,000</font><font style="font-family:Arial;font-size:10pt;"> for the first two years and </font><font style="font-family:Arial;font-size:10pt;">$100,000</font><font style="font-family:Arial;font-size:10pt;"> thereafter, and which will be creditable against royalties and other payments due to Juniper in the same calendar year but may not be carried forward to any other year.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone </font><font style="font-family:Arial;font-size:10pt;">Payments.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">The Company must make potential future development and sales milestone payments of (1) up to </font><font style="font-family:Arial;font-size:10pt;">$13.5 million</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate upon achieving certain clinical and regulatory milestones, and (2) up to </font><font style="font-family:Arial;font-size:10pt;">$30.3 million</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate upon achieving certain commercial sales milestones for each product or process covered by the licenses granted under the Juniper License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Royalty Payments</font><font style="font-family:Arial;font-size:10pt;">. During the royalty term, the Company will pay Juniper mid-single-digit to low double-digit royalties based on worldwide net sales of products and processes covered by the licenses granted under the Juniper</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">License</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">Agreement. In lieu of such royalty payments, the Company will pay Juniper a low double-digit percentage of all sublicense income the Company receives for the sublicense of rights under the Juniper License Agreement to a third party. The royalty term, which is determined on a country-by-country basis and product-by-product basis (or process-by-process basis), begins with the first commercial sale of a product or process in a country and terminates on the latest of (1) the expiration date of the last valid claim within the licensed patent rights with respect to such product or process in such country, (2) </font><font style="font-family:Arial;font-size:10pt;">10 years</font><font style="font-family:Arial;font-size:10pt;"> following the first commercial sale of such product or process in such country, and (3) when one or more generic products for such product or process are commercially available in such country, except that if there is no such generic product by the 10th year following the first commercial sale in such country, then the royalty term will terminate on the 10-year anniversary of the first commercial sale in such country.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Efforts</font><font style="font-family:Arial;font-size:10pt;">. The Company must use commercially reasonable efforts to develop and make at least one product or process available to the public, which efforts include achieving specific diligence requirements by specific dates specified in the Juniper License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">T</font><font style="font-family:Arial;font-size:10pt;">erm. Unless earlier terminated, the term of the Juniper License Agreement will continue on a country-by-country basis until the later of (1) the expiration date of the last valid claim within such country, or (2) 10 years from the date of first commercial sale of a product or process in such country. Upon expiration (but not early termination) of the Juniper License Agreement, the licenses granted thereunder will convert automatically to fully-paid irrevocable licenses. Juniper may terminate the Juniper License Agreement (1) upon </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;"> days&#8217; notice for the Company&#8217;s uncured breach of any payment obligation under the Juniper License Agreement, (2) if the Company fails to maintain required insurance, (3) immediately upon the Company&#8217;s insolvency or the making of an assignment for the benefit of the Company&#8217;s creditors or if a bankruptcy petition is filed for or against the Company, which petition is not dismissed within </font><font style="font-family:Arial;font-size:10pt;">90 days</font><font style="font-family:Arial;font-size:10pt;">, or (4) upon </font><font style="font-family:Arial;font-size:10pt;">60</font><font style="font-family:Arial;font-size:10pt;"> days&#8217; notice for any uncured material breach by the Company of any of its other obligations under the Juniper License Agreement. The Company may terminate the Juniper License Agreement on a country-by-country basis for any reason by giving </font><font style="font-family:Arial;font-size:10pt;">180</font><font style="font-family:Arial;font-size:10pt;"> days&#8217; notice (or </font><font style="font-family:Arial;font-size:10pt;">90 days</font><font style="font-family:Arial;font-size:10pt;">&#8217; notice if such termination occurs prior to receipt of marketing approval in the United States). If Juniper terminates the Juniper License Agreement for the reason described in clause (4) above or if the Company terminates the Juniper License Agreement, Juniper will have full access including the right to use and reference all product data generated during the term of the Juniper License Agreement that is owned by the Company.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Pear Tree Acquisition</font></div><div style="line-height:120%;padding-top:8px;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company may be required to make certain royalty and milestone payments under the Merger Agreement (see Note 4).</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Hammock/MilanaPharm Assignment and License Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 5, 2018, the Company entered into (a) an Assignment Agreement with Hammock Pharmaceuticals, Inc., or the Assignment Agreement, and (b) a First Amendment to License Agreement with TriLogic Pharma, LLC and MilanaPharm LLC, or the License Amendment. Both agreements relate to the Exclusive License Agreement among Hammock, TriLogic and MilanaPharm dated as of January 9, 2017, or the MilanaPharm License Agreement. Under the Assignment Agreement and the MilanaPharm License Agreement, as amended by the License Amendment, the Company acquired an exclusive, worldwide license under certain intellectual property to, among other things, develop and commercialize products for the diagnosis, treatment and prevention of human diseases or conditions in or through any intravaginal or urological applications. The licensed intellectual property relates to the hydrogel drug delivery platform of TriLogic and MilanaPharm known as TRI-726. In DARE-BV1, this proprietary technology is formulated with clindamycin, an antibiotic used to treat certain bacterial infections, including BV, and has been engineered to produce a dual release pattern after vaginal application, providing maximum duration of exposure to clindamycin at the site of infection.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of other terms of the License Amendment:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">License Fees.</font><font style="font-family:Arial;font-size:10pt;"> The Company paid </font><font style="font-family:Arial;font-size:10pt;">$25,000</font><font style="font-family:Arial;font-size:10pt;"> to MilanaPharm in connection with the execution of the License Amendment and must pay </font><font style="font-family:Arial;font-size:10pt;">$200,000</font><font style="font-family:Arial;font-size:10pt;"> to MilanaPharm (in the Company's discretion, either in cash or with shares of the Company's common stock) within 15 days of the first to occur of December 5, 2019 or the closing of an equity financing in which the Company raises aggregate proceeds of at least </font><font style="font-family:Arial;font-size:10pt;">$10.0 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone Payments.</font><font style="font-family:Arial;font-size:10pt;"> The Company will pay to MilanaPharm (1) up to </font><font style="font-family:Arial;font-size:10pt;">$300,000</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate upon achievement of certain development milestones; and (2) up to </font><font style="font-family:Arial;font-size:10pt;">$1.75 million</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate upon achieving certain commercial sales milestones. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Foreign Sublicense Income.</font><font style="font-family:Arial;font-size:10pt;"> The Company will pay MilanaPharm a low double-digit percentage of all income received by the Company or its affiliates in connection with any sublicense granted to a third party for use outside of the United States, subject to certain exclusions.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Royalty Payments.</font><font style="font-family:Arial;font-size:10pt;"> During the royalty term, the Company will pay MilanaPharm high single-digit to low double-digit royalties based on annual worldwide net sales of licensed products and processes. The royalty term, which is determined on a country-by-country basis and licensed product-by-product basis (or process-by-process basis), begins with the first commercial sale of a licensed product or process in a country and terminates on the latest of (a) the expiration date of the last valid claim of the licensed patent rights that cover the method of use of such product or process in such country, or (b) 10 years following the first commercial sale of such product or process in such country. Royalty payments are subject to reduction in certain circumstances, including as a result of generic competition, patent prosecution expenses incurred by the Company, or payments to third parties for rights or know-how that are required for the Company to exercise the licenses granted to it under the MilanaPharm License Agreement or that are strategically important or could add value to a licensed product or process in a manner expected to materially generate or increase sales.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Efforts</font><font style="font-family:Arial;font-size:10pt;">. The Company must use commercially reasonable efforts and resources to (1) develop and commercialize at least one licensed product or process in the United States and at least one licensed product or process in at least one of Canada, the United Kingdom, France, Germany, Italy or Spain, and (2) continue to commercialize that product or process following the first commercial sale of a licensed product or process in the applicable jurisdiction.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Term</font><font style="font-family:Arial;font-size:10pt;">. Unless earlier terminated, the term of the MilanaPharm License Agreement will continue until (1) on a licensed product-by-product (or process-by-process basis) and country-by-country basis, the date of expiration of the royalty term with respect to such licensed product in such country, and (2) the expiration of all applicable royalty terms under the MilanaPharm License Agreement with respect to all licensed products and processes in all countries. Upon expiration of the term with respect to any licensed product or process in a country (but not upon earlier termination of the MilanaPharm License Agreement), the licenses granted to the Company under the MilanaPharm License Agreement will convert automatically to an exclusive, fully paid-up, royalty-free, perpetual, non-terminable and irrevocable right and license under the licensed intellectual property. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to customary termination rights for all parties, MilanaPharm may terminate the license granted to the Company solely with respect to a licensed product or process in a country if, after having launched such product or process in such country, (1) the Company, or its affiliates or sublicensees, discontinue the sale of such product or process in such country and MilanaPharm notifies the Company of such termination within 60 days of having first been notified by the Company of such discontinuation, or (2) the Company, or its affiliates or sublicensees, (A) discontinues all commercially reasonable marketing efforts to sell, and discontinues all sales of, such product or process in such country for nine months or more, (B) fails to resume such commercially reasonable marketing efforts within 120 days of having been notified of such failure by MilanaPharm, (C) fails to reasonably demonstrate a strategic justification for the discontinuation and failure to resume to MilanaPharm, and (D) MilanaPharm gives 90 days&#8217; notice to the Company.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of other terms of the Assignment Agreement with Hammock:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Assignment; Technology Transfer</font><font style="font-family:Arial;font-size:10pt;">. Hammock assigned and transferred to the Company all of its right, title and interest in and to the MilanaPharm License Agreement and agreed to cooperate to transfer to the Company all of the data, materials and the licensed technology in its possession pursuant to a technology transfer plan to be agreed upon by the parties, with a goal for the Company to independently practice the licensed intellectual property as soon as commercially practical in order to develop and commercialize the licensed products and processes. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Fees</font><font style="font-family:Arial;font-size:10pt;">. The Company paid </font><font style="font-family:Arial;font-size:10pt;">$250,000</font><font style="font-family:Arial;font-size:10pt;"> to Hammock in connection with the execution of the Assignment Agreement and must pay </font><font style="font-family:Arial;font-size:10pt;">$250,000</font><font style="font-family:Arial;font-size:10pt;"> to Hammock (in the Company's discretion either in cash or with shares of the Company's common stock) within 15 days of the first to occur of December 5, 2019 or the closing of an equity financing in which the Company raises aggregate proceeds of at least </font><font style="font-family:Arial;font-size:10pt;">$10.0 million</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone Payments</font><font style="font-family:Arial;font-size:10pt;">. The Company will pay Hammock up to </font><font style="font-family:Arial;font-size:10pt;">$1.1 million</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate upon achievement of certain clinical and regulatory development milestones.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Term</font><font style="font-family:Arial;font-size:10pt;">. The Assignment Agreement will terminate upon the later of (1) completion of the parties&#8217; technology transfer plan, and (2) payment to Hammock of the last of the payments described above, including the milestone payments.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6758950960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Award<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_GrantAwardTextBlock', window );">Grant Award</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">GRANT AWARD</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In April 2018, the Company received a Notice of Award for the first </font><font style="font-family:Arial;font-size:10pt;">$224,665</font><font style="font-family:Arial;font-size:10pt;"> of the anticipated </font><font style="font-family:Arial;font-size:10pt;">$1.9 million</font><font style="font-family:Arial;font-size:10pt;"> in grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, a division of the National Institutes of Health, or the NIH.&#160;The Company must incur and track expenses eligible for reimbursement under the award and submit a detailed accounting of such expenses to receive payment. The Company received all </font><font style="font-family:Arial;font-size:10pt;">$224,665</font><font style="font-family:Arial;font-size:10pt;"> of the award payments under this Notice of Award. Such payments were applied to clinical development efforts supporting Ovaprene and were recognized in the statement of operations as a reduction to research and development activities as the related costs were incurred to meet those obligations over the period. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On March 11, 2019, the Company received a second Notice of Award for an additional </font><font style="font-family:Arial;font-size:10pt;">$982,851</font><font style="font-family:Arial;font-size:10pt;"> of the anticipated </font><font style="font-family:Arial;font-size:10pt;">$1.9 million</font><font style="font-family:Arial;font-size:10pt;"> in grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The second award followed the NIH's review of an interim data analysis and other results of the first phase of the research supporting Ovaprene. Award payments under this second notice of award (</font><font style="font-family:Arial;font-size:10pt;">$161,007</font><font style="font-family:Arial;font-size:10pt;"> received through June 30, 2019) are being applied to clinical development efforts supporting Ovaprene. At June&#160;30, 2019, the Company recorded a receivable of </font><font style="font-family:Arial;font-size:10pt;">$456,484</font><font style="font-family:Arial;font-size:10pt;"> for expenses incurred through such date that are eligible for reimbursement under this second notice of award.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The remaining portion of the award under the grant, </font><font style="font-family:Arial;font-size:10pt;">$730,722</font><font style="font-family:Arial;font-size:10pt;">, is contingent upon, among other matters, assessment that the results of the ongoing Ovaprene study satisfy specified requirements set out in the award notice, and the availability of funds.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_GrantAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Award [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_GrantAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6758981840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NET LOSS PER SHARE</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under outstanding options and warrants to purchase shares of the Company&#8217;s common stock. Common share equivalents are excluded from the diluted net loss per share calculation if their effect is anti-dilutive.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Potentially dilutive securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Six Months Ended<br clear="none"/>June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,190,360</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">547,571</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,190,360</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">547,571</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,750,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,751,002</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,750,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,751,002</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,941,193</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,298,573</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,941,193</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,298,573</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6894766544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#8217;s opinion, the accompanying interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying interim consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use, or ROU, lease assets, current portion of lease obligations, and long-term lease obligations on the Company's balance sheets.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. If the lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease and the related payments are only included in the lease liability when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 2: inputs other than level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents of </font><font style="font-family:Arial;font-size:10pt;">$5.6 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$6.8 million</font><font style="font-family:Arial;font-size:10pt;"> are measured at fair value as of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, respectively, and are classified within Level 1 of the fair value hierarchy. Other receivables are financial assets with carrying values that approximate fair value due to the short-term nature of these assets. Accounts payable and accrued expenses and other liabilities are financial liabilities with carrying values that approximate fair value due to the short-term nature of these liabilities.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Standards</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2014, FASB issued Accounting Standards Update, or ASU, 2014-09, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Arial;font-size:10pt;">, which impacts the way in which some entities recognize revenue for certain types of transactions. The new standard became effective beginning in 2018 for public companies. Because the Company does not currently have any contracts with customers, the Company&#8217;s adoption of this accounting standard did not impact the Company&#8217;s interim consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2016, FASB issued ASU 2016-02, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Arial;font-size:10pt;">, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The new standard is effective for public companies for fiscal years beginning after December&#160;15, 2018, with early adoption permitted. ASU 2016-02 became effective for the Company on January 1, 2019 and was adopted using a modified retrospective approach and the effective date is as of the initial application. Consequently, financial information was not updated, and the disclosures required under ASU 2016-02 are not provided for dates and periods prior to January 1, 2019. ASU 2016-02 provides a number of optional practical expedients and accounting policy elections. The Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases. The Company recorded approximately </font><font style="font-family:Arial;font-size:10pt;">$232,000</font><font style="font-family:Arial;font-size:10pt;"> right-of-use assets and </font><font style="font-family:Arial;font-size:10pt;">$241,000</font><font style="font-family:Arial;font-size:10pt;"> lease liabilities related to its lease of office space as of the adoption date in the consolidated balance sheets. There are no changes to the statement of operations or cash flows as a result of the adoption.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2017, FASB issued ASU 2017-01, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</font><font style="font-family:Arial;font-size:10pt;">, which intended to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The standard became effective for the Company on January 1, 2018. The Company&#8217;s early adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Disclosure Update and Simplification,</font><font style="font-family:Arial;font-size:10pt;"> amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements relating to the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of income is required to be filed. This final rule was effective November 5, 2018. In accordance with the new rule, the Company added a Consolidated Statement of Stockholders' Equity in this report and elected to present a reconciliation in a single statement that shows the changes in stockholders' equity for each interim period, as well as each comparable period.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6899333344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity for Amended 2014 Plan and Related Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below summarizes stock option activity under the Amended 2014 Plan, and related information for the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">. The exercise price of all options granted during the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;"> was equal to the market value of the Company&#8217;s common stock on the date of the grant. As of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, unamortized stock-based compensation expense of </font><font style="font-family:Arial;font-size:10pt;">$1,348,159</font><font style="font-family:Arial;font-size:10pt;"> will be amortized over a weighted average period of </font><font style="font-family:Arial;font-size:10pt;">2.9 years</font><font style="font-family:Arial;font-size:10pt;">. At </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">497,032</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock were reserved for future issuance under the Amended 2014 Plan.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Outstanding at December 31, 2018 (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,635,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">698,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.79</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Canceled/forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(316,832</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24.55</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">59.48</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Outstanding at June 30, 2019 (unaudited) (1)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,016,888</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exercisable at June&#160;30, 2019 (unaudited)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">427,702</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">21.83</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:0px;padding-top:8px;text-indent:0px;"><font style="padding-top:8px;font-family:Arial;font-size:10pt;padding-right:48px;">(1)</font><font style="font-family:Arial;font-size:10pt;">Includes </font><font style="font-family:Arial;font-size:10pt;">10,149</font><font style="font-family:Arial;font-size:10pt;"> shares subject to options granted under the 2015 Private Dar&#233; Plan assumed in connection with the Cerulean/Private Dar&#233; stock purchase transaction.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total stock-based compensation expense related to stock options granted to employees and directors recognized in the consolidated statement of operations is as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>June 30,</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Six Months Ended<br clear="none"/>June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26,996</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">51,699</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">84,355</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,423</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">157,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18,547</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">111,351</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,423</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">209,319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18,547</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;padding-bottom:24px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Six Months Ended<br clear="none"/>June 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected life in years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.0</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.09%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.58%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">123%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">121%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Forfeiture rate</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.0%</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.0%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.0%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Weighted-average fair value of options granted</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$0.86</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$0.75</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6758976656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Common Stock Warrants Outstanding</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company had the following warrants outstanding:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Shares Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Outstanding Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Expiration Date</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,906</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120.40</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;1, 2021</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,737</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120.40</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;6, 2021</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17,190</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">60.50</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">January&#160;8, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,500</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">April&#160;4, 2026</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,720,500</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:60px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.98</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">February&#160;15, 2023</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,750,833</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6653012640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leased Properties (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Lease Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Arial;font-size:10pt;">, future minimum lease payments for the Company's corporate headquarters are:</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Years ending December 31:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Remainder of 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">55,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">112,943</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">67,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total future minimum lease payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">236,069</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Less: Difference between future minimum lease payments and discounted operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">42,669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total operating lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">193,400</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6635357088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Potentially dilutive securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Six Months Ended<br clear="none"/>June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,190,360</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">547,571</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,190,360</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">547,571</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,750,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,751,002</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,750,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,751,002</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,941,193</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,298,573</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,941,193</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,298,573</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6639796416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of the Business - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769996000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 11, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,763,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,969,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,630,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,805,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flow from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,326,726<span></span>
</td>
<td class="nump">$ 4,807,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">456,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ReimbursementOfGrantExpensesReceivable', window );">Reimbursement of grant expenses receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">456,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate net proceeds on sales of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from grant for notice of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant | National Institutes Of Health | Eunice Kennedy Shriver National Institute Of Child Health And Human Development | Second Phase Of Research And Availability Of Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from grant for notice of award</a></td>
<td class="nump">$ 982,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 982,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ReimbursementOfGrantExpensesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of grant expenses receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ReimbursementOfGrantExpensesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_NationalInstitutesOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_NationalInstitutesOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareTrustFundAxis=dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareTrustFundAxis=dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6768721616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use leases</a></td>
<td class="nump">$ 193,399<span></span>
</td>
<td class="nump">$ 232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">193,400<span></span>
</td>
<td class="nump">$ 241,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769984432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 16, 2018</div></th>
<th class="th"><div>Jul. 19, 2017</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerLineItems', window );"><strong>Business Combination Reverse Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions', window );">Unamortized fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,187,519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dare_PearTreePharmaceuticalsIncMember', window );">Pear Tree Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerLineItems', window );"><strong>Business Combination Reverse Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PotentialCashPaymentsToAcquireBusiness', window );">Potential cash payments to acquire business</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration amount</a></td>
<td class="nump">132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense | Pear Tree Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerLineItems', window );"><strong>Business Combination Reverse Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost', window );">Transaction costs</a></td>
<td class="nump">$ 452,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverse merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverses merger stock purchase transaction cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverse merger unamortized fair value of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PotentialCashPaymentsToAcquireBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Cash Payments To Acquire Business</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PotentialCashPaymentsToAcquireBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dare_PearTreePharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dare_PearTreePharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769336464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Jul. 10, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,016,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,016,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,635,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,683,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,683,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Unamortized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,348,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,348,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_WeightedAverageAmortizationPeriod', window );">Amortized weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,351<span></span>
</td>
<td class="nump">$ 9,423<span></span>
</td>
<td class="nump">$ 209,319<span></span>
</td>
<td class="nump">$ 18,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Options to purchase number of outstanding shares of common stock (in shares)</a></td>
<td class="nump">2,503,771<span></span>
</td>
<td class="nump">2,046,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual percentage increase in outstanding number of common stock</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease', window );">Increase in number of shares authorized (in shares)</a></td>
<td class="nump">456,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan | Employee Stock Option | Private Dare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan | Restricted Stock | Private Dare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_WeightedAverageAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Amortization Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_WeightedAverageAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) of non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dare_PrivateDareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dare_PrivateDareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6757553232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding beginning balance (in shares)</a></td>
<td class="nump">1,635,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">698,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled/forfeited (in shares)</a></td>
<td class="num">(316,832)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding ending balance (in shares)</a></td>
<td class="nump">2,016,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">427,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 11.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled/forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">24.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in usd per share) | $ / shares</a></td>
<td class="nump">59.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">5.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">$ 21.83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding ending balance (in shares)</a></td>
<td class="nump">10,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=dare_PrivateDareMember', window );">Private Dare | 2015 Stock Incentive Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding beginning balance (in shares)</a></td>
<td class="nump">10,149<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dare_PrivateDareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dare_PrivateDareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6757751552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details) - Employee Stock Option - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 111,351<span></span>
</td>
<td class="nump">$ 9,423<span></span>
</td>
<td class="nump">$ 209,319<span></span>
</td>
<td class="nump">$ 18,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">26,996<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">51,699<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 84,355<span></span>
</td>
<td class="nump">$ 9,423<span></span>
</td>
<td class="nump">$ 157,620<span></span>
</td>
<td class="nump">$ 18,547<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6897859920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">2.58%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">123.00%<span></span>
</td>
<td class="nump">121.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted (in usd per share)</a></td>
<td class="nump">$ 0.86<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by Share-based payment award fair value assumptions forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769668880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 11, 2019</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Feb. 15, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds on sale of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfAggregateCommission', window );">Aggregate commission rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued and sold (in shares)</a></td>
<td class="nump">5,261,250<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Amount recorded to additional paid in capital as a result of triggered anti-diluted provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 789,594<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 789,594<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NumberOfCommonStockWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwritten Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued and sold (in shares)</a></td>
<td class="nump">686,250<span></span>
</td>
<td class="nump">220,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod', window );">Underwriters overallotment option to purchase additional shares of common stock and warrants period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_UnderwritersOptionToPurchaseAdditionalShares', window );">Underwriters option to purchase additional shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants', window );">Gross proceeds from offering of common stock and warrants</a></td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds received in public offering, net of underwriting discounts and offering expenses</a></td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="nump">$ 9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dare_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued and sold (in shares)</a></td>
<td class="nump">4,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price in the Offering (in usd per share)</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="nump">$ 0.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember', window );">Warrants Expiring on February 15, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201711Member', window );">Accounting Standards Update 2017-11</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_EstimatedFairValueOfWarrantsRecordedInEquity', window );">Estimated fair value of warrants recorded in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_EstimatedFairValueOfWarrantsRecordedInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Fair Value Of Warrants Recorded In Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_EstimatedFairValueOfWarrantsRecordedInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issuance Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Offering Of Common Stock And Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_GrossProceedsFromOfferingOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NumberOfCommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NumberOfCommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PercentageOfAggregateCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate commission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PercentageOfAggregateCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_UnderwritersOptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriters option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_UnderwritersOptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriters option to purchase additional shares of common stock period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=SL109261905-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12B<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL109261756-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dare_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dare_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201711Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201711Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6760942864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Apr. 11, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares Underlying Outstanding Warrants</a></td>
<td class="nump">3,750,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember', window );">Warrants Expiring on December 1, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares Underlying Outstanding Warrants</a></td>
<td class="nump">2,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 120.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Dec.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember', window );">Warrants Expiring on December 6, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares Underlying Outstanding Warrants</a></td>
<td class="nump">3,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 120.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Dec.  06,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember', window );">Warrants Expiring on January 8, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares Underlying Outstanding Warrants</a></td>
<td class="nump">17,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 60.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Jan.  08,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember', window );">Warrants Expiring on April 4, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares Underlying Outstanding Warrants</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Apr.  04,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember', window );">Warrants Expiring on February 15, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares Underlying Outstanding Warrants</a></td>
<td class="nump">3,720,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Feb. 15,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights warrants expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ClassOfWarrantOrRightsWarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6757100512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leased Properties - (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Square footage of office space | ft&#178;</a></td>
<td class="nump">3,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of operating lease</a></td>
<td class="text">37 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term of operating lease</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Gross monthly base rent</a></td>
<td class="nump">$ 8,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfIncreaseInAnnualBaseRent', window );">Percentage of increase in annual base rent, each year</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,399<span></span>
</td>
<td class="nump">$ 193,399<span></span>
</td>
<td class="nump">$ 232,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, short term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,859<span></span>
</td>
<td class="nump">87,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, long term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,089<span></span>
</td>
<td class="nump">116,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Non-cash lease expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,038<span></span>
</td>
<td class="nump">54,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for measurement of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,620<span></span>
</td>
<td class="nump">$ 53,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PercentageOfIncreaseInAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Increase In Annual Base Rent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PercentageOfIncreaseInAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77910348&amp;loc=d3e34039-112682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseMinimumRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6895987504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leased Properties Leased Properties - Future Minimum Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Remainder of 2019</a></td>
<td class="nump">$ 55,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">112,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">67,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">236,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Difference between future minimum lease payments and discounted operating lease liabilities</a></td>
<td class="nump">42,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 193,400<span></span>
</td>
<td class="nump">$ 241,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6775154144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 05, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>country</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>patent </div>
<div>Patent</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>patent </div>
<div>Patent</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFee', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,500<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember', window );">ADVA Tec Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NumberOfPatentsIssued', window );">Number of patents issued | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NumberOfPendingPatents', window );">Number of pending US patent applications | Patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NumberOfPatentsGranted', window );">Number of patents granted | Patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NumberOfPatentApplications', window );">Number of patent applications in other major markets | Patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | ADVA Tec Agreement | Ovaprene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries', window );">Agreement termination period on failing to commercialize in certain designated countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease', window );">Agreement termination on failing to enroll patient within months of production and release</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NoticePeriodForTerminationOfAgreementForBothParties', window );">Prior written notice period for termination of agreement for both parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | ADVA Tec Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NumberOfDesignatedCountries', window );">Number of designated European countries | country</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfRoyaltyRate', window );">Percentage of royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | ADVA Tec Agreement | Minimum | Ovaprene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Minimum spending amounts per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | ADVA Tec Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfRoyaltyRate', window );">Percentage of royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member', window );">Juniper Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne', window );">Potential annual license maintenance fee, payments in year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter', window );">Potential annual license maintenance fee payments, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess', window );">License agreement, period of continuation from date of first commercial sale of product or process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation', window );">License agreement notice period of termination for breach of payment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PeriodOfDismissalOfBankruptcyPetition', window );">Period of dismissal of bankruptcy petition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation', window );">License agreement notice period of termination for breach of other obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementNoticePeriodOfTermination', window );">License agreement, notice period of termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member', window );">Juniper Pharmaceuticals, Inc. | Clinical And Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MaximumPotentialMilestonePayments', window );">Maximum potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member', window );">Juniper Pharmaceuticals, Inc. | Sales Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MaximumPotentialMilestonePayments', window );">Maximum potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsMember', window );">Juniper Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval', window );">License agreement, termination period prior to receipt of approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_UpfrontLicenseFeePaid', window );">Upfront license fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember', window );">SST</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure', window );">License agreement, termination period due to performance failure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement', window );">Percentage of rights to inventions by employees under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementExpirationPeriod', window );">License agreement, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval', window );">License agreement, termination period prior to receipt of approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval', window );">License agreement, termination period after receipt of approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries', window );">License agreement, termination period for applicable license products of applicable countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember', window );">SST | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_SecuredInvestmentRequiredForLicenseAgreement', window );">Secured investment required for license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember', window );">SST | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember', window );">SST | License And Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement', window );">Percentage of rights to inventions by employees under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_OrbisMember', window );">Orbis | Development And Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne', window );">Commencement period for stage two upon achievement of stage one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember', window );">MilanaPharm | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFee', window );">License fee</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFeeToBePaidUponContingency', window );">License fee to be paid upon contingency</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ProceedsRaisedFromEquityFinancing', window );">Proceeds raised from equity financing</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember', window );">MilanaPharm | Assignment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFeeToBePaidUponContingency', window );">License fee to be paid upon contingency</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_HammockPharmaceuticalsInc.Member', window );">Hammock Pharmaceuticals, Inc. | Assignment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFee', window );">License fee</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFeeToBePaidUponContingency', window );">License fee to be paid upon contingency</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ProceedsRaisedFromEquityFinancing', window );">Proceeds raised from equity financing</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember', window );">Upon Achieving Certain Commercial Milestones | SST | License And Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember', window );">Upon Achieving Certain Commercial Milestones | MilanaPharm | Licensing Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=dare_UponSigningOfDevelopmentAndOptionAgreementMember', window );">Upon Signing Of Development And Option Agreement | Orbis | Development And Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember', window );">Upon Completion Of Fifty Percent Development Not Later Than Six Months | Orbis | Development And Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember', window );">Upon Achieving Certain Clinical And Regulatory Development Milestones | Hammock Pharmaceuticals, Inc. | Assignment Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember', window );">Upon Achievement Of Specified Development And Regulatory Milestones | Licensing Agreements | ADVA Tec Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponReachingCertainWorldwideNetSalesMilestonesMember', window );">Upon Reaching Certain Worldwide Net Sales Milestones | Licensing Agreements | ADVA Tec Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember', window );">Future Milestone Payments Based On Product Development [Member] | Licensing Agreements | ADVA Tec Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_FutureMilestonePaymentsBasedOnCommercializationMember', window );">Future Milestone Payments Based On Commercialization [Member] | Licensing Agreements | ADVA Tec Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement termination on failing to enroll patient within months of production and release.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement termination period on failing to commercialize in certain designated countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commencement Period For Stage Two Upon Achievement Of Stage One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_CommencementPeriodForStageTwoUponAchievementOfStageOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementNoticePeriodOfTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Notice Period Of Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementNoticePeriodOfTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Notice Period Of Termination For Breach Of Other Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Notice Period Of Termination For Breach Of Payment Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Period Of Continuation From Date Of First Commercial Sale Of Product Or Process</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement, termination period after receipt of approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement, termination period due to performance failure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement, termination period for applicable license products of applicable countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement, termination period prior to receipt of approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseFeeToBePaidUponContingency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee, To Be Paid Upon Contingency</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseFeeToBePaidUponContingency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MaximumPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Potential Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MaximumPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePaymentsContingentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments, contingent amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePaymentsContingentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NoticePeriodForTerminationOfAgreementForBothParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notice period for termination of agreement for both parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NoticePeriodForTerminationOfAgreementForBothParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NumberOfDesignatedCountries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of designated countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NumberOfDesignatedCountries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NumberOfPatentApplications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patent applications.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NumberOfPatentApplications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NumberOfPatentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Patents Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NumberOfPatentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NumberOfPatentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patents issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NumberOfPatentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NumberOfPendingPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Pending Patents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NumberOfPendingPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of rights to inventions by employees under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PercentageOfRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PercentageOfRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PeriodOfDismissalOfBankruptcyPetition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period Of Dismissal Of Bankruptcy Petition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PeriodOfDismissalOfBankruptcyPetition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Annual License Maintenance Fee, Payments In Year One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Annual License Maintenance Fee Payments, Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ProceedsRaisedFromEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds Raised From Equity Financing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ProceedsRaisedFromEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ResearchAndDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ResearchAndDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_SecuredInvestmentRequiredForLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Secured investment required for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_SecuredInvestmentRequiredForLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_UpfrontLicenseFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront License Fee Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_UpfrontLicenseFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dare_OvapreneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dare_OvapreneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_OrbisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_OrbisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_DevelopmentAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_DevelopmentAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_HammockPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_HammockPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponSigningOfDevelopmentAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponSigningOfDevelopmentAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponReachingCertainWorldwideNetSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponReachingCertainWorldwideNetSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_FutureMilestonePaymentsBasedOnProductDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_FutureMilestonePaymentsBasedOnCommercializationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_FutureMilestonePaymentsBasedOnCommercializationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6758347328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Award - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 11, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 456,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred', window );">Cash received from federal grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from grant for notice of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant | Eunice Kennedy Shriver National Institute Of Child Health And Human Development | Second Phase Of Research And Availability Of Funds | National Institutes Of Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from grant for notice of award</a></td>
<td class="nump">$ 982,851<span></span>
</td>
<td class="nump">$ 982,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,007<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant | Eunice Kennedy Shriver National Institute Of Child Health And Human Development | Remaining Portion Of Research And Availability Of Funds | National Institutes Of Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from grant for notice of award</a></td>
<td class="nump">$ 730,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareTrustFundAxis=dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareTrustFundAxis=dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_NationalInstitutesOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_NationalInstitutesOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6759035040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">5,941,193<span></span>
</td>
<td class="nump">4,298,573<span></span>
</td>
<td class="nump">5,941,193<span></span>
</td>
<td class="nump">4,298,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">2,190,360<span></span>
</td>
<td class="nump">547,571<span></span>
</td>
<td class="nump">2,190,360<span></span>
</td>
<td class="nump">547,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">3,750,833<span></span>
</td>
<td class="nump">3,751,002<span></span>
</td>
<td class="nump">3,750,833<span></span>
</td>
<td class="nump">3,751,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>49
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " #*@ Y/,A_@(_     K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+/3L,P#(=?!>7>NNE@0-3ULHD32$A, G&+$F^+:/XH,6KW]K1A
MZX3@ 3C&_N7S9\F-"D+YB,_1!XQD,%T-MG-)J+!B!Z(@ )(ZH)6I'!-N;.Y\
MM)+&9]Q#D.I#[A'JJEJ"19):DH0)6(29R-I&*Z$B2O+QA-=JQH?/V&685H =
M6G24@)<<6#M-#,>A:^ "F&"$T:;O NJ9F*M_8G,'V"DY)#.G^KXO^T7.C3MP
M>'MZ?,GK%L8EDD[A^"L90<> *W:>_+I8;[8/K*TK?E]4=P6_WO*EJ&Y$??L^
MN?[PNPA;K\W._&/CLV#;P*^[:+\ 4$L#!!0    ( ,J #D^97)PC$ 8  )PG
M   3    >&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&V
MM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X
M>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3
M$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E
M'S/X%<M4C66C 1-702:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(
MX53"Q,!J9S]6:\?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T
M;1K@X_%X.+;+THMP' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?
MZYMHG J-6T_3:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;C
MZWH2%;7E0-,@ %AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6
M-$9RG9 %#@ WQ-%,4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[
MR:0S>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3
M<CH<9T)\S_;VD:4E,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>I
MP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^
M",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\T
MJC4LQ=9XE<#QK9P\'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*
MD8]ILR.G=";-Z#,:P4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\D
MCIJMPA$K0CYB&38:<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1
M#A&27C="/F+.BY 1OQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4
M%TKD#R:G/^DR- >CFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[
M ?_1VC?"J_B"P#E_+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC
M5W+-R,=4KY,IV#F?P.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH
M9%LE"<M4TV4WBA*>0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#
MMW)+ZK:4OK4F.$KTL<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#
M;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'
MB/*B(>ZAAIC/PT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"
M\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*
MWF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15
M.+]%,[82EQB\X^;'<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WM
MU>>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"
M(Y4<!A87,N10[I*0!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.
M7M(E$A2*L P%(1=RX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF
M"X7;XE3-NQJ^)F!+PWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>
M^3+?.7#;.MX#7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@
M#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:
M&C/5BZPYC0IO0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+
MOP%02P,$%     @ RH .3Q4C$,"& @  I0D  !@   !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q]5NV.FS 0?!7$ QS8)H2<"%*2JFJE5HJN:OO;29R #C"U
MG7!]^]J&H]1>^@=_,+/C91EY\YZ+5UDRIH*WIF[E-BR5ZIZC2)Y+UE#YQ#O6
MZC=7+AJJ]%+<(MD)1B^6U-01CN,T:FC5AD5N]XZBR/E=U57+CB*0]Z:AXO>>
MU;S?ABA\WWBI;J4R&U&1=_3&OC'UO3L*O8JF*)>J8:VL>!L(=MV&._1\0)DA
M6,2/BO5R-@],*B?.7\WB\V4;QN9$K&9G94)0/3S8@=6UB:3/\6L,&DZ:ACB?
MOT?_:)/7R9RH9 =>_ZPNJMR&61A<V)7>:_7"^T]L3&@5!F/V7]B#U1IN3J(U
MSKR6]AF<[U+Q9HRBC]+0MV&L6COVPYN$C#28@$<"G@@8_Y= 1@*9""BQR0\G
MLZE^H(H6N>!]((9J==3\%.B9Z(]Y-IOVV]EW.ENI=Q]%G$</$V9$[ <$GB'0
MA(AT[$D 0P)[[-'QOP(''T%@ 0)F0"R=S.@)3$] >F+IR8R^<CZ CTAA@14H
ML/+H:T? 1V2P0 H*I!Y]XPCX"!3#"FM08>WSD2,!0# LD8$2F<\GC@0 6:CT
M!I38^'RWU !DH=8HANT4^Q'<<D.8A8*C!=,B/X);<P"#%XJ.0.?N$/8CN&6'
M, MU1[!]$?$CN)6', NE1[#+D6]B[!8?PBRIP%9'OI-QZJH F"45V._(MS/V
M_C$?L_2+P99'OJ%QYHH F,V""NQZY'N:./?/8<2L+*8=39EF)$'N/13-+KV&
MB9OM#V1PYO?6-B>SW:D'V=E;-OH+'QJ8KU3<JE8&)Z[TU6LOR"OGBND#Q4_Z
M**7NF:9%S:[*3-=Z+H;&85@HWHU-431U9L4?4$L#!!0    ( ,J #D^3L+L-
MEP,  !(/   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL?9==CYLX%(;_
M"N*^Q<>?>)1$VJ2JME(KC;KJ[C63.).H$++ 3-I_OX8P67+.86X"=MYCO\<?
MC_'B4C<_VT,(7?*K*D_M,CUTW?DAR]KM(51%^[$^AU/\9U\W5='%8O.<M><F
M%+LAJ"HS*83-JN)X2E>+H>ZQ62WJEZX\GL)CD[0O554TO]>AK"_+%-*WBN_'
MYT/75V2KQ;EX#G^%[L?YL8FE[-;*[EB%4WNL3TD3]LOT#WC82-T'#(J_C^'2
M3MZ3/I6GNO[9%[[LEJGH'84R;+N^B2(^7L,FE&7?4O3Q[]AH>NNS#YR^O[7^
M>4@^)O-4M&%3E_\<=]UAF>9IL@O[XJ7LOM>7/\.8D$F3,?NOX3644=X[B7UL
MZ[(=?I/M2]O5U=A*M%(5OZ[/XVEX7L;VW\+X #D&R%L Z'<#U!B@4$!V=3:D
M^JGHBM6BJ2])<YVM<]$O"GA0<3"W?>4P=L-_,=LVUKZN%"RRU[Z=4;*^2N1$
M(N\5&ZI0_TNRV/_-A&1-R"%>3>,5'Z_8>#7$ZVF\1DE<)7:0G :)L4H8ZU$J
M5&=S8?+<\WXTZT=3/P;YN4K,I!_ME0!LA\H4".5X,X8U8Z@9B\P8:D8Y;W)D
MAI$))?R,&\NZL=2-0VXLZ<8:"T8CUQNJ<U(+(6>6CF/]..H'I;UVM!^1HTVR
MH2*OO.6=Y*R3G#I!JV&=TY'Q,JYBY(7*C'/>YKP;S[KQQ(T6R(UGQM\*KS =
M&%TNG<IGU@T('E2"0$+#3 LSJ .:D\2L SK$2@+@K<#HM/%N,A7WCGCN@:2.
M%'8D24^@-.2 5R CM J4F1LD'J5 6:HQ2T?-G27OE)>87IQ0>(C8G?'$XQ0H
M3S7F*5!22J&\)A-'==[!W!CQ1 6*5 RG-5!82G N=PX;HD( (9R=VQX\5X&"
M56.P<AHR/N]J[IWP1 5'-^K,Z0D\"8&BT&#X (6<P*F\)[GWP3,0* 0-^3BB
M= -KR:@R*M S!Y7D 2@%=8/Q-6JF_7R(5))H!V]8G75R9J8E#U1)@6HPOB0#
M2O!:"HN/"4:IC/.1+'/?DC,?DQ2J!A-,4E9^4-999?$$;SBIS+WULSM4\F25
ME*P&4TQ28!J1QQ,>'_&,,$Z?M7)FA4N>K)*2U6"2C9KI)S%_SG-"]J#/)I>3
M_K;XK6B>CZ<V>:J[>,\9;B/[NNY";%1\C"D>X@7U5BC#ONM?77QOKK>T:Z&K
MS^,--+M=@U?_ 5!+ P04    " #*@ Y/5>N[SD("  "R!P  &    'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;(V5VX[;(!1%?\7R!PSX[D2.I295U4JM%$W5
M]IDD)+8&&Q=(//W[ O:X-M!D\A!N>Q_6P8A3])2]\ ICX;TVI.4;OQ*B6P/
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M=V]R:W-H965T<R]S:&5E=#0N>&ULC9C;CMLV$(9?1=!]5QR>M; -K ]%"[3
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MWW>'5\Z'B[K:=J_3Y\=W^C?_ 5!+ P04    " #*@ Y/*0?J748$  ! $P
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MC?& 4G8WN$(M/K#%45#[8'Y VTYK-CG>]/,+8LLS+OX 4$L#!!0    ( ,J
M#D\1SFD@L0$  -(#   8    >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL?5/;
M;MLP#/T501]0)8K;#H%MH.E0M, &!!VV/BLV?4$ET97DN/O[2;+C>IVQ%XND
M>0X/*2H=T+S:!L"1=R6US6CC7+=GS!8-*&&OL /M_U1HE'#>-36SG0%11I"2
MC&\V-TR)5M,\C;&CR5/LG6PU' VQO5+"_#Z Q"&C6WH)/+=UXT* Y6DG:O@!
M[F=W--YC,TO9*M"V14T,5!F]V^X/2<B/";]:&.S")J&3$^)K<)[*C&Z"()!0
MN, @_'&&>Y R$'D9;Q,GG4L&X-*^L#_$WGTO)V'A'N5+6[HFHU\H*:$2O73/
M.#S"U,\U)5/SW^ ,TJ<');Y&@=+&+REZZU!-+%Z*$N_CV>IX#A/_!;8.X!.
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M0NO#\0V>[3QFL^'-L/P@MG[CZA=02P,$%     @ RH .3T8B6*RS 0  T@,
M !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL?5/;;M0P$/T5RQ]0;RY
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M9SN/V6QX,RP_B*W?N/H-4$L#!!0    ( ,J #D_$>!MIM@$  -(#   9
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;&U386_;(!#]*X@?4!+';:K(MM1T
MFCIIDZ)6VSX3^VRC N<"CKM_7\"NZW;^ MQQ[]V[X\@&-,^V!7#D54EM<]HZ
MUQT8LV4+BMLK[$#[FQJ-XLZ;IF&V,\"K"%*2)9O-#5-<:%IDT7<R18:]DT+#
MR1#;*\7-OR-(''*ZI>^.1]&T+CA8D76\@2=PO[N3\1:;62JA0%N!FABH<WJW
M/1S3$!\#_@@8[.),0B5GQ.=@_*ARN@F"0$+I @/WVP7N0<I Y&6\3)QT3AF
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M?-G8_\H8#R@EN<(1:O"#S8:$RH?C9SS;<<Q&PYMN^D%L_L;Y7U!+ P04
M" #*@ Y/)(-"8^ !   !!0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6QU5-MNG# 0_17D#XA9KML5(&431:W42JM439^],%P4&U/;+.G?US:$4N*^
M8,_XS#DS@\?9Q,6K; &4]\9H+W/4*C6<,)9E"XS(.SY KT]J+AA1VA0-EH,
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MUM'O_R.0;@JD42#]J\3D38E;F/1-$+;JJ0+3Q&FRI,1!QTE>>9>!?>#Q3?[
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M**3>)FK/^P'3!Y*UP^Q$XP#/_@!02P,$%     @ RH .3T+I+GYR @  ^ @
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MGA+PKP0\?S"E+214D$I!9C-7_LP^OM'''_E $ R,_)&1%]TQ"HQ&@<$H'!1
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M.6L=WIV'!NMC!Y9(?:Y<!\W7,>^4GT)%+QE$2>I=M%"/67<8.,)$\2UD.X>
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M_>#"/9<._)4#QL-B?:T.%)UWUHTVGW, <F^&:H<MAP++86Q  EL)];]0?FP
M%!F _N2@0/UL]<(M1J&6UU#]H+&54--*O,%6P'-/HR^4#D\I-:?4<[5&>:1@
M2EWD",[9HU[SAN)'4N[2HK)>1"V?&MMGNZT0-9>B[HVLX9XGF]-!QK=ULQO)
M_;)[,] =U.*@WGHXIU<OL_]02P,$%     @ RH .3V'WBT#K @  "0T  !D
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ML^@PX0 #9^$M9NG"H%O,RH6);S'K*>9O)*"<]'9"IYW0T*,;.\@M$#D%(B.
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M7N60E[AB.:D,BH]+\Q4LML"6!(7XG>.&#?:&M+(GY%T>OAV6IBTSP@5.N91
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M_?Y0X".7VT#L:3OZV@,G=3?6K?Z_1?(?4$L#!!0    ( ,J #D_85&7:2F4
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M39/83=Q[K<G)..>VDU(U,'#X#!37H#WR!8%K02& LD/K7N[6@<F B/8-VW_
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MC:G#BF8];\RD+,B\M\@J:D-M;4^4N@OO?ZI@KP!N<X%K;.S4+@-[FZT6:9Z
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MF89_M6T(N5$V_1J;F"./NR\CT'+O!@FGI&4Y2G!\-L"IBSL,OD^;=F6:ZFC
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MM:IN/FG!W8>X@EB3)V:>I@-+.?.68CH0+%)8-,M0:"HQ&8;8:,%V#+$F.>\
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M8PE3Q%L(1.IP#'_Q:S#IZ#3>'^,4_&H/2DP1!07.GSA7,'J[ N5Z<#L'7@N
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M&CNY-EY;)8X'E*R@SB:'[<Y4S\[8N$AH>7'N$5V=DJ1$HH1LM[:%%0/X*J.
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M74+MJ7H0U)O#R3OS\^#F_AP:"_#8#&,)=*#J"UYL^1*_JZKZC_\?4$L#!!0
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MM,*CQ3!K-5 D>+0_048;?ND*CJ_.Y7=02P,$%     @ RH .3]4/9YA^ P
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M(?0]JGO-_+OJ=H[UCP"7OP%02P,$%     @ RH .3^R615"- 0  D18  !H
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MD=*AWV+-<'VX.L/4WPAS=0*]_0%02P,$%     @ RH .3UP- YJ< 0  "A<
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS9C?;L(@%(=?Q?1VL0AL[D_4FVVW
MF\GV JP]M<2V$$"G;S]:=<F6+G%1D]]-*1PXYX.2[Z*3]ZTE/]C45>.G21F"
M?6#,9R75RJ?&4A,CA7&U"K'K%LRJ;*D6Q,1H-&:9:0(U81C:',EL\D2%6E5A
M\+@;;U-/$V5MI3,5M&G8NLE_)1WN$Z:.JFZ.+[7U5W%",GC>Q"P^CDV3&/4)
M.Z+"[X5M/ZY[79-S.J=_H9FBT!GE)EO5<4GJK2.5^Y(HU%7J2^4H?PM.-XL]
M[URY\*+JF)AM*O9C0GHYCK"MJ!^@BYRS<HC7@OI*=8'=DY]4\' ;,N-H:%V,
MNJ![MA>1YC'J63OQG%ND]NKDE!]5/*:^W(?]-&[9O?<=^'?0LZXY[=3/QR%
M."0(QS4(QPT(QQB$XQ:$XPZ$XQZ$@X]00%",RE&4RE&<RE&DRE&LRE&TRE&\
MRE'$RE',*E#,*E#,*E#,*E#,*E#,*E#,*E#,*E#,*E#,*E#,*E',*E',*E',
M*E',*E',*E',*B]HUJY-:Z6;OT@^C%D>ZK/N%_CL"U!+ 0(4 Q0    ( ,J
M#D\?(\\#P    !,"   +              "  0    !?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( ,J #D\GZ(<.@@   +$    0              "  >D   !D
M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ RH .3S(?X"/P    *P(  !$
M             ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MRH .3YE<G",0!@  G"<  !,              ( !N (  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " #*@ Y/%2,0P(8"  "E"0  &
M    @ 'Y"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MRH .3Y.PNPV7 P  $@\  !@              ( !M0L  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ,J #D]5Z[O.0@(  +('   8
M          "  8(/  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " #*@ Y/ID[J"@0$  !,$0  &               @ 'Z$0  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ RH .3Y=X>8CV!0  WQ\
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M965T.2YX;6Q02P$"% ,4    " #*@ Y/1B)8K+,!  #2 P  &0
M    @ &3)@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M ,J #D_$>!MIM@$  -(#   9              "  7TH  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ RH .3^:F_RZU 0  T@,  !D
M             ( !:BH  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " #*@ Y/)""F:;,!  #2 P  &0              @ %6+   >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,J #D\MP+!(M $
M -(#   9              "  4 N  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ RH .3\X*GT*U 0  T@,  !D              ( !
M*S   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #*@ Y/
M$JL\#[(!  #2 P  &0              @ $7,@  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( ,J #D\D@T)CX $   $%   9
M      "  0 T  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ RH .3V._DY;- 0  G 0  !D              ( !%S8  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #*@ Y/,+."<K8!  #2 P
M&0              @ $;.   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( ,J #D]G%989M0$  -(#   9              "  0@Z  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ RH .3Z4\87*S
M 0  T@,  !D              ( !]#L  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " #*@ Y/VXL[_K@!  #2 P  &0
M@ '>/0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,J
M#D^$XMS,NP(  #0*   9              "  <T_  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ RH .3VC6*#4& @  S 4  !D
M         ( !OT(  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " #*@ Y/0NDN?G("  #X"   &0              @ '\1   >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,J #D^;Z%5N8 ,  ' /
M   9              "  :5'  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ RH .3Q!@_V'F @  2 L  !D              ( !/$L
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #*@ Y/FF+!
M27D"  !*"   &0              @ %93@  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( ,J #D^(MJ(6,0(  !L'   9
M  "  0E1  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
MRH .3R2M="R9 P  AA$  !D              ( !<5,  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " #*@ Y/8?>+0.L"   )#0  &0
M            @ %!5P  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( ,J #D^+B407D (  %$)   9              "  6-:  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ RH .3Y,9<N80 @
MW 4  !D              ( !*ET  'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " #*@ Y/Q-Y15'L&   E*@  &0              @ %Q
M7P  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ,J #D]:
M24K24@(   ,(   9              "  2-F  !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ RH .3_S@=,5O @  9P@  !D
M     ( !K&@  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
M" #*@ Y/V%1EVDIE  "I?@$ %               @ %2:P  >&PO<VAA<F5D
M4W1R:6YG<RYX;6Q02P$"% ,4    " #*@ Y/C@\833L"  """@  #0
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4!08     +0 M "T,  !QV@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>150</ContextCount>
  <ElementCount>273</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0002000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Statements of Stockholders Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/OrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/GoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Leased Properties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedProperties</Role>
      <ShortName>Leased Properties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Grant Award</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/GrantAward</Role>
      <ShortName>Grant Award</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://darebioscience.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/StockBasedCompensation</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/StockholdersEquity</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Leased Properties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedPropertiesTables</Role>
      <ShortName>Leased Properties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/LeasedProperties</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/NetLossPerShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Organization and Description of the Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Organization and Description of the Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Going Concern - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/GoingConcernAdditionalInformationDetail</Role>
      <ShortName>Going Concern - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Acquisitions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/AcquisitionsAdditionalInformationDetail</Role>
      <ShortName>Acquisitions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Stock Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2406404 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2406405 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Leased Properties - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedPropertiesDetails</Role>
      <ShortName>Leased Properties - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://darebioscience.com/role/LeasedPropertiesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Leased Properties Leased Properties - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leased Properties Leased Properties - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2409401 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2410401 - Disclosure - Grant Award - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/GrantAwardAdditionalInformationDetail</Role>
      <ShortName>Grant Award - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="dare-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail</Role>
      <ShortName>Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>dare-20190630.xml</File>
    <File>dare-20190630.xsd</File>
    <File>dare-20190630_cal.xml</File>
    <File>dare-20190630_def.xml</File>
    <File>dare-20190630_lab.xml</File>
    <File>dare-20190630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>54
<FILENAME>0001401914-19-000081-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001401914-19-000081-xbrl.zip
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M\QIQY@738%&:M'<N,NF4);6]DWROO7N733<&2K7%]&SA6T$ .-C#V ?C."/
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M&.VW(S,:S7I#"W__D#5:BV52;Q5VLD)Y#"P&;$ ?C]XRZVG08"HID;P;R+9
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M^[$S!^PDP=@I88+F-D0C,*5(6T2HMI&(U\4<GGH[MF(.D1GI/8U<4,%URG+
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M80T:#:@%3!J%?0CM"T#?$_UD"^C8 >I8RG!@,64*!)NB+!GR\(?EC"M%.A;
MY7X+*,/4SB^JH6OGH^88ZYWK*+"4[J,4MX%SI)S1H(T[&;F3PF-/ZDH$)K2B
M0NP"V^'6M($320H:'(V@'',>(S413 OB0"L*1LI85XQ(M:;7OBO:4#9J5S4Z
M>;*B-XA'4/-"2HHRCB3-E%K03G5#W7PNP4"]7\<&>!X*>E=D+65$4AJ")8$#
M,:4;%Y!)Q D>J27U<M1,("KHTX#>K5,3!:84"A:,EIA*'VL0IRSZ=-QYJJA0
MUQ*0I%(_&>A=)QFL*">B]19$+HA>@Y'%"&Q#HJ1UJ@8ZV-N,\SU!'X\'7_/A
M\.WU32\OYG6_FGK1J5_Q&K)7\DRT"UPS0W 4((VI,3;$"(:,\R"BJ:IKFF1-
MTVR&8S](.UNS W=,?92 D:@4'YYR%4'5 0TQI0V9KJJF!P6Q8_NY2?+4(!.D
MYE()B\'\#DDOE!:(HE83F6,E>;66W^$ W= 0A.( &B'BQ@,ZHU8"<8RQ!&G#
M@JW3Z:/@LOLH48YI2@5!J6>)3=<'0H3D'F!(J&AK?I;=0"RO*#]D_0RDR.?A
M;AX@BXTFSBB&)+$T(,,%3X5WE%'$>ESOY\4%4U6AL/;QK0%;9!>9FXZLL<AH
MZK.L051Q@ ^L14.%9\PA1H P:[Q3KY_F#N#J\?S;-$G<]1"E$K74R%0/DW&-
MI27:""FL=\)&76]6HR6MG*#]8'R,57:3-S RBATR!NL -@32V/G@.0HR1#B!
M]8V2A%6-AT=:YP/WSD2"C0J46]#ZE F:6>,#04XIJ=QZR'YI$*_D]&T#T\/7
ML*'13' ,[/?4YH1PE/S.(M#4F0+4$"L:$A,Q8GP3!>ZTAGF[Q87?HJ'RP1;[
MH#&,LL0H%;D!=HE]:I4#RI3!TI':&L[ !&15#_\V0#U\$1O\E 1T:8<\!IV$
M1P]\5B&3*L.7P82R2P(<"/SSFS*/?W3Y@".A9 1;R"IJ*.,."3CQH+\H(0,"
M#=?4%/$SN7D;FN ZV'*Z-\4("_H!&-\>$RX]L]0*4,4,)3:QY[I=IV7U6NZP
M"[H74SMOBTQU;9*"E@H#6Y/Z,B-%F UE;RY3/R&$:U[MR;D9I(<N8(.!#8S5
M4Q#OF$DNX(PHC\ NY>G*A-'U; #00@0HHP>$_WV1@78UV-,\-5(2K5(&38KD
M 5D!0L^8D(Z&L U%Z2E75'4!OPK.PT#O1KRE#N,(MBEF0!,TV*B(!QDAI? $
MUZ]\*%.B\P2T@_YS!IPJNS\<Y;Q\4LKYY!)IR*K _^B-<$>8:C2<>4X#\"30
M$,$\37X9K[ 74I,5;C0JH['+T)R*RVP32)O O_/+@YI2.NK]CO>O/%IFO+8!
M!!IW7FK8#A)8"B=UR-49$*$"53.KMP5JGX6\@T5\^IH-OV2_P(JN=BQ8)!41
M%&$94EDT8*4@DXER08>0ZB+4.!+GO.H$W!?&?=;Y>ZJWDR);=TR*9U'RD#PA
M!B1A5)ZDXY_:T4K%3+U$C>15E61GX/9>V=?Q3NLR I1WJ\L<HA2O @:+!?XF
M2'1<2U4O(I3*'M ]%_9UO/6R?AL-%@<S ^;23\63&BJB;:1*3"2(&,-$Y!P'
M+9R4T5*"%%@NKK8X4)VW/FUM &Y:X8=LE'WM#3]EQ76#?4S_,1OB57LR..]=
M)!$4%%A$H)Z'=$L?0C1@D_ST'O_>#7'E@YM@2V/.+Y:WKUN AW0J[<)<5(!4
MKI$!R  \!YJZ LM) 7A4_M(-W^I'5T!LT_0V!-^@5.E*4>] 3G I4F\3QP+8
M.2IE9->W'6/0R$553C0K<IWP=)"A",XIZA(E,E##O(K:>^*$XXPBOWYGF(H3
MRM3?;1=XP& NXW*NQL-!5DSF/0YW0EK"#^PFF._><^-3T?R G(^.14RIKC&X
M6N&[3= \#/(N%N9#3"V16 1ETD1C4[\,RI@F&O3,^FU!K5C>GI#O4TN/,1H2
M6 +AR .(CE3E6J=H&SC=B-5*6V"D,>*B$=:&XG7;0->EGOAH$1"H#$IPK)'V
M.-75 "E.C9"V'N*0W%?52]5NZ-YETW3]];X8?\D'*3/NMTDV>#N*^:@WZJ<(
MD_XT_[*?G9I"S9U B"'/+08JP*FD5.H9AI*%44<KV$Z"5^38]K =:D4;%'4$
MJJ*% YG@YR;5/@@!.P2"VDHO:HY$CCF6U4+<!UW0V]&7;#)]T!9YAA"HAHR#
MUBZ<8X;"H0U!1S #854-P6:IY";:N* &T ZUH.X=<M%(@Y37F"#B4P8$Q_,%
M$4])7>5]K*7<2=/]]R8R;-.!#]QQCB28JP&9D$Z\U5;5!>894S"*L8TK:H#M
M4"O:< %3=DY2@@BBD[JN,74@X^$DI:LC5G._G0E*! B&XUK1ZNU(6@^VCB@X
M,C:E>(@4#6^X=8XTQ)_!DM:N1_9>TCQ*<I][3UP&9S,0>:F>4%#&:>2 .U,O
ME-:T7LJ)\A3WOPKT_>=WAFO']L\?LFDO'X%"OXBMZ:YY[+%'"(X*LIRG>K1,
M8,-!Y? 6.>!N]:#?0RZNB]7&H E5AG.GN&2@FWNED 8*"T)S7NM(FH*165(Y
M#P78HV)=!APD<6"NII"CR!TPV]1M.\*!-[HYU/I J^N^E[98>8 D^4' 3D,L
MM< #1=-9KH((NG9_=)9:23!^ '+0CT_K5##&C,"I-8Y&U*;*2X!U[D*$D^WK
M#/60B^N2P@YL%:I2$:.8$E95E(YB@W 0Z6JKCG2)$CLZ&%R/BG2@G*@D8C0"
M$1DPKK&7U 5-L3 1S.U#+<Y\Z>7#Y#;_-*[D>"QLH#*N<%>^S[!.L;O&.^](
MZMR:NGX!Z7C)J4"R'A78S1HW WCHM77=L0JMP=:DP1";2NT$E/PRL#81+0CI
MG=GK$R]N Q-#%A2,X(/&H-@2&1WW\XW#4=!Z5\"4$Y)*HA[-VKKZ=G"E C:*
M@W;N74HM)'.B%$F8L%K@4,H=H4H=;&T?@!V4T0U%UFMWKK6%I#*B@J/,F*@1
MIPZ$#0\2M#]F.*,K^9#_N9B^^0EXA%X!O/KU%< 6A6ONU,"/V>7UME&S:\F/
M/#6% 8;L)%CA,I6,#2GTU$9%07%=27Z<?P1,\0J0;9!4P;U[N+ARVEDE95@)
M34/4/G >*9Q9EB(V,4,TU?FM43@5<'JK\;TU"'8'KXN[&!61I"B LL\]2%<"
M%EF*?F6@\LMZ=!O&%!%<#0Q_*'S=#(+Y% ;@/*CQ8"A*I@&3L+V&.8F!+]:<
MF50K$ #XH.!U>8(< >4$K#DNX+A+8:A43D@!EE.2/+6;98G *"1D5_#VMXB
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MG#)+!3(*K7@$EV!O +A>W'\78#MQ;*0O<08(9KQL>H*](BK0(#G2MJF&^T&
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MX#5:X/9;!KC*(*M#C'C@M\ZP=;-8_6Y54UF/WRQV+WX@'!2&%0$K'T00].V
MNV&;%OBUACVP1P/319_>&#AC#?ASI Q=4_GAS_\=Y1]GX:V4Y?=1\*<?YO#(
ML[F_"*/[#Y?A(LBDS\&=]"U9^/%'^EL6_B?XH"K+_.,/_WV=?US[>@0J\.R&
M=OI!U90_?,3UG?E1>!U_^-<JR\/Y_<;'X._;EN&EH1^M?XM^O&,ONH+@ESWF
MYV_>YTO)^X?W;81/_ D_)1[_$RQSEQ4O_1F>PUF>+/%5W]NV0+\*XQE8@0^N
M!9_I9$_TK4^QY"W3,))0W\A2?A-(:''\^%Y*^2@\R9<^)SE"^B1SB5A"FB<I
M?70>IEDN-?:^_S)^U#1#MBRS@T?A*G%MP+_A-%QB4J^3%:KGK@2?B<!/Z6*5
M82Q=HXQ)\Q5#")BGR8(6S@;(2GR"K,1'R$IBIJM4#'7%G=(868G-=H4MPS]Q
MDJQ4&>8JP_D! X89?%O0IOFL#/_$'B-+_'0_?_K+^7_[B^7'_U(MY>-EA346
MP)BP@^DJI7?BC-7?I> [0KC DP)@WO J"HA-TB!<7*W2C%P:4%RS@#W<)T;"
M;V>KJT68XRK1IXF0X:93=""0*K"J;#6]*1^>)X(QI25#A#F7+ENY-HJ.E3-I
MZWSU64&3,%N7LW/I O=>?/(N2.';RV44POZ $%/0)N$4CG%6'K<4S('L\.%L
MM5SBH'H@XI=;?YD&<4#DIH< E9+KF ;- "/BHC+A=N+;DR4?AYE)/OP??!P'
M)",#$?G9;%]Z6O7-."SS%ASY@+Z%#TW9=&*P')E8/G%-RM:_"((</I=DL.4K
M8!K^RN26\\B2:KS/F\=X(LKU2RS]0I1251D5K+M1P68T/+E5SX(T^T5\U E'
MNXXF.Z;:Z]K.=2U31?PP?7Z$493<(;\SC?K'#,[]-@0O!YX(WPYQ7%>XD&9^
M[L//?G2?@2+ IR=X%872MHKR3%":6=PE3MD6ORKDL47BSSDCM2D;OLRXX#FV
MX'>='*"ERHIB=W%XA93D-VFRNKZ1_KH"3:8K3*+>2^"M2E<!;OH)FA'HE-.#
M2WLGWM"0V22=D<RRA>%L(21>%U0S3$LV'*,+JJ'F*&QFJ7,Y"<FDSG#H77[C
MYT3"'8SV1IXY/U4%?4GBL_!#S*%(Q!2ED\3$H?182(7(G1RT#<QE:UH'CY*E
MD#5RP0;HK)9)#![?(D'?B13(PL]!PV3P2YIW3R=*I\YU1U6[P+>2FL.0Y2M0
MBXC+E\WAOTN(5^<H8FGP[U68,D1-8 IP&E:Y\"08W1B+R,P_Q-_>@F\G1L?#
MZU 59]L91_S[?W[:%))68W.,9+,O<Z_P';\F43B]9_^[3Q"KV@/%'=J*X]B6
M.32&@Z$UIFM@;S111L;XX$%L32BL=J'H+JJE#W_ ?&LXW1#G$FGQT+ZBK8ES
MLHZ=R+SS(B*/\06I<^1U88"!,3+@E1DY,?,P]N,I/*/TBS/IQK]%4Q/$$@C'
MTD^9\XP/2V?PZ4"Z"]$Q*(,7"*SA(<L(. *$$USJ*+K'OP?+O'2\?XU#_(G2
MOAG%7C][WE<45S!><\SQ2E?W],E)L:B2R?%[,8C'+),&"?R''C#Q+@8R*7*Q
MN7(_80R_7[ 9X4(V0_!R4N;@4X U@4](JG+V=_J$!UIQ"H;!00[X%EQCH0Q^
M^^+L_ZN$AQZ1 584W9/%O)=F"2H!-#[1:A90/,;5S/H:YDF2PT>#3.@5VC*2
M@3:!AQ4%>=!Z*N?@HX&.BWV&&,H6Y&BJ_1$X=@F*'?5A_OA#3X-Y%$QS6KX_
M0P:EW\OTU3 306J,&XK0)P!+2\Y(X[-@1^ E,7@-6>:G]\RYE^9^F"(_%7)5
M<>NJJEFLF,5$F?A*T)'Q?7Y!_-1@3;%C=$>0<P2IX#FP_1GX<SB'!@E2?+(2
M=[!8Z9Y;O3JY4"B*G-4*3O(>/&;FK#^2+;*;9 7!P!6>DT^R#-_YURIF43(I
M F*ZU2S<^ R?>5(!Q<II (+'9:70#=SKK#&U%\<K>,ZW -T5L-B%M/YOL47<
MG13$LVZBL1$< R:/*ZXQ"V>=#AZ^JP>PGY6O^06K#!@_RX"65W *>#ZC,)M&
M2;9*@WW\ F>L3083<^B.;>SM5!U]I \\<Z1-)N@@6*\LN>T-__[KIXM/EY^^
M?+[HQK\_!E=F&*2K*/#CG_A4.&GD<\;6=/VC1-5MTM<5A-,885^"RYGYTQ-V
M=\ X=B"E?UV!"L:^[DXBEFH\+6P[J#S0B%=<5O'70EB9,JT?TR!,LFD8H,_U
MI4A5RN )3,\QW;UD9PMKO@E 28^""&,2Q$9/06G2I\E/:N4!&97OW4T($7([
MCV25"D@)S 3Y4&#$V5T<^D_5#<+#@N_ 31">D7Z.@SLT9X1D(;["37R;MI]2
MZ2I[)PNF>$(6#:"\8857P=1?@/&!;23H<B9WZ$5F!3[GV@L+/W"'_?)'+_Q_
M)2E&<K4_UA]+GAFH53#C=:.(NI>[32P0+:5LC3F(;(PU8GPMY>T$?32ED&;I
M*Q!RX1,#%']6/^)95#Z]B8?DQO<^Q2S=D9*1E1O+E.AO\T DLGFZ^P'E0K22
MED*Y5)^')]"RK^J:Z'W$7FV[AH,![@J:*T5BGZZ3>/DDJMZAK#!/03B(3'AN
M@9+ Q$%Z#:YBY4YJ"M%'1JEV^&-^@X[CO!K0W:&?!J%)^TKP=15/'TZ*(D9Z
M*OZB.#=<2=7M%=E(V,023@MB&K! V0HSUO"05J58+JHN,D4.M'4[,E=L/,QB
M7(MY(?1&Q3*1%Z.0I6K874ZV6@3<UQ79SYP%+K<T\I<D.PH7Y.J"M@L86B!S
ML/'GK- -Q3DM:4A,<=6SZR* 6"SP@9 Z269W812QUXB?Z!3@X0L6-_AYGH97
MJYS2M%PU3_V,Y>_I'T@*V ;SR/.Z<JJS$_+"<IDFW^'A9%TZN8SI]JJC".F!
M'::YV,4*M"?R&-[W5<X-+U=)>A)V8"S%R:+O@EE)H]#575+!LP\7<!HA(T.A
M>H(6S7,8JNGG=H=4.VGMR 4?PDA@X+ B%RP!!'\-4W8]FTMPH!G\@R)(%(ZL
MHYN+MA"Q*VZ^"O([S+FQ58M]SF&KZ(PD&%8Q[X[=IX%NQSOLE#L/%)F'Z72U
M0-:=<@-Y1\$[SRD$7"FD*>4 F&@L?.1K3CZPGU*3UEOHC \,: PUD/PVB,AM
M6H'6@T6SNW7T^EB,?R62J[Z$BB<**@8!Z[S.):]\5>4U(=?>K*H4)):I=G_M
MZW5OLKY)5,W!C'%-J19D2KZ KF1_KE.'OPZ66ZK??]S \0A*R6W4K'P<UWT'
MKF,.WYF!8XHO*M\-FP7ZUDU&?3_E@];?(4Q)1<&1FU94.@"[5^@'VNF!^X?3
M$'QVK0/;*P@##,C*#D2>1L;2FB!=4#*9<DW,-8IK;!O/:L2J_1&$"7REP^AR
M\USK^+*_FB^MI?(V%KF@,U!M^B3N*/)I^4T:@$J M]UD/*]6)S"P+;'K.MGS
MJF.RSJ^;4WRU-5_Y$2FN[ :K9?#<A/@D\SGN%J47E4T:Y/<=W<0>0Z;F*R8Q
M+Y'POY"??J*B^J63! S5:#9J$[I(P-;#![Q18/=:&-7&DG<-!U"H!QP!3VQ.
M!\*^R?Y=?E!FT4!Y>BQ(G0:K' LRBBP-IE_$9^2U0(H_\V)U5>9T6"KC[(%4
M!CVW^G7RA^\2LO6WX0P\B(QKB)!J:W!4'\K[U =_N:A=*U=?S6]49+2,0^A.
M@H<Z%>^7HZLNEJP CM_@K1.K\)$[89)?_/N2152K0Q9IYIT* O&$T"95MB$#
M5?>GBJBO?"RP7X9W:>S)*4HSY3YX/8\T\KZ-SW[[S5-9OB\!^0ARY(=;_SK$
MRBV\810WE<@CX+A\#^=!++.-+),<=28ZE&G@TST=J?O;573KLZI6\20_A\??
M=*1:7]97J+D!W$^M9@GPBK]D_>**JYE#B5G 7OLRWB+C71BYLJU)"^$%(Q_D
M/I$?HY#R8K@>F[*B&S3$Z]D!5O."T[%3GU^E%]YSB$0,YR%%_&R5L&AXSFI)
M 6\(]((M-C^6%<4J*06T<IF8P!>B4US)[I1;/*]>$_!2UX,X2H:IR8JB=!)8
M95DR#8EV15J6I\-$E>Z#%Y$;ZX!YW=FI"LRO13ZP:=NF08I]=Z1=@I3[C9B&
M6Z%C5Y&=(+W%_!:PP&U(N7%6YT#?JJ3+BV^LA6G4_RBR_MP+_0O[FLQ.J*C7
MJQ3$^]T4IYE=<1FO.I5FI;N;P%'3]32$\UAJFU5L^%KJC?,CV9X-&P9[C;*8
M)O=^A+9;1M7R+RS7P!I08)5D@<^G4\C(*B]1_^443;)OW9?%[;SL=CX'B9<E
M&CJ+RX:OH*;QK]E-#<]#Q* 5,C]BOQ-L 2_"9V7598"'B](@^8*+LGK"EB<V
M:9N5=['.AROQ;<Q9QQ@?-]HPP*-)I(7_>U M RSJ?7G*\R_B^D9LRI_>A,$M
M3:;D:Q<ELS*\BVI\DO1>!$8+'/L"FX8##X"H,5*:I1MXG@0"Q9F\35E /!-(
MLS";0I1"]SSX1DR_)NF>MV!/5RM720Z,09KEQ2]GUZO'*-P$'BW(T=1!PHI2
M07EPS8IBAMPR,4/+6XW?56O(0#W?O><Y'9[5^9J@Z=[]V[+(;>7A(M@JM<QV
M\CR.+Y[7N454]:XLXGLN][3NH]>B'3P6A+B#ISQ"E[.<9\19GGP_(OQ\A2WE
MI>:B.JZ[$!@=-[[::)375-SY UR]"/R8:6#0NUT5[G=VV&6]].9+*JIIP$O(
MPMLHKZW8][=KA08%WH7O"RM0/A15WA4XB.3%\RZ_PLL5K04R?!F^W?8G<?0[
M1M!LY? T>!Q3&!GR KGG[/#;?:6R]!.=5O3IL3,0V&OORK*=ZL2JE64(*Q:R
M$L_'590-QMIPJ#JFXKBNZ0T=QQQ;]DC%^:#8UF^_LHJRX9=??OET^<OX\^6%
MY'T>2<,OGR\_??YY_'GX:=Q1B9G2E7UNW\'?A"\'K/I-A#^%)LJZ2[X^:Z;5
M&_WFG5T&4TELK]C1B49PGT3?)9:L;4MP-IWS(MK:3!2>X10?J"0TRU\QC<5<
MY.KK,7TO+MFYAQ2MZ,*!4ES5#%?=]88-EETYF(6YH=Y#U#&I3P47\ ST"N^2
M-)K=@=(_+[> C\); G\^#Z.073[>Q:((#<NGR>"F_)^LB&3JBSSF+0VOKG<1
MTXN3J)9Z@Y7,J/LQQ61-\3VR_WZ\FH/*6[%[VDK;76$GJ!V-_ETKO HSL2K\
MS3R)PJ),.NO"=L=A)XZ0(.:OYQ?G!46IJNM87#6(+5GI1F6)U9.6NUJNZ7:Q
M6B$E'=-RGJR:-TE/(&:;Q( ;)5KO_I7@_Z:_L^PB2W3R>_JT(OT0#G%--%NO
M'Q5WD)ODO2)-++/=]D'0*?#X<ZE,;=5BS$)15'1<=0TW+/=/&@I;]Z@'.0WF
MJPSSYV6* [Z#E5V5$VLC#^60RXYVT=F!!6,G:F\P)\/ZO*DT"HD%KO6"AT.,
M%]H)WC N'TZ/!$TW@Y[SK9H>KO;([RQ^80R$"_-V >SB4E6< KN>3V+,W161
MT,;T-EC8WU'4RDXN="7P]&M"0S=8 7P2NR:9#I \S(#<8HX-KS]_\>02B:#6
M!BA-DH2E!$?IZEKR9HLP#K.\4KI._8 CCREM6C]VM4?W=6\#_90P+]KJ>& ]
MKWL21:_\6K*/M$M<^4V$N5(_ ZFE-"PR=$L^$K^VZ3NB W\G-X?MC9Y)0"'B
M8) 6"XA<,Z&#BW 1Q SS$3+K;Q>_SA/D2OA<-\4JR@&*5?QKD/]K<H"**J:N
MH)58\0K2I1F?/"9!@9EU6B4C<HGY@N7($78TTJTI<#=JPCD"^A#'LC^76ZMP
M&N;1JVS)D\M8IBTET^DJS=AW3M ^;%".OXA$NO25Y[N.1RU>UC0(:):E?U]8
MK _2._6]M%I2:T47&5SCW#JH0!4W'NRN&V\]B@JP$L^@!F-$A7#%%4AYY\'J
M4=]I7>Y?.ZPZV;9[H4^+B+%RIU5NFFGXG>@CB<#L \M@LM8N43F/^@(-YGP%
M')5D^32A.\["^A#4A+A6"JNMX&5Y>=$8Y'.[A$ED'TN,P.CHTC*\15TO7&#Q
MY)P(QB[DP?@6[?0CCRDS_AS29[L]JK*5^B[W> 9?0BV9R; !*#5.)$,EBB$[
M0A:!"A7Z<<.7Q?ZXDTE?KGTKN<HYU,DPH19\41Y,55?C%<3RY<\(B81IE-]Y
M&K_P&;#80I22=V6?NF#^69"!/J>:!MI*0$P"9B<-47;+S5?O-P7-JIMB%O.!
MQ]%5\4./_*L/['HN#<H;.VP[*G1_<=<Q"]"7(? 6GI@O125-0)BSK=>C_-JY
M)J7T/7^1R>N"@W4L\'ZZAF,>(E<$.9:0!W$1Q0G0.;JC02LL8]D]&N43M,/T
MK0FFN,05/4$BQ3EA"U0I)Q<W446)6,N)E=4!+;3W&4Q?UY>='9O*SKH_VG&S
M.GCPN339X2@$R*#0Y3R0\#E>(6C@CE#INK75?B?:\X"TK_J!(;KWHH=ND_;@
ME0%D+^*J+FDYM%*K\.;9K*D.ZQ7R?]RNYTY0)VU*G/"ZI..+#+QYSJ/32O 6
M^:L8G)Y:^):WA1# .47&I:C8JE0D%4YK6X55U?NHPI!=L\Y_!+$K"[H*8#MZ
M]RVF:$0760=44/_0B?AWD\]6E<Y6P[JS.*1_>2Y OC!9997C0/\HPQO]K$LE
M(4ZO5Q$/JXA+JN)F%NX;U<8?CY+X-8[070W\- IYWCLD-YJIA<I=01,(MZSR
MV9PA%P6WK(/2YS[Y_=G5_1G_)V^I+!-.Z!^DPH&.PGE0_IM?NE3N0.O\%/G;
M4U4$<B%N,^I5IWGED'@# X9C5TF.D,XI:K\/TCOO?8T46$]9D(P'\V+C)$GP
M!/POXBWREM*8FBP"_,L#!%EVTV=B=5+6-O/OJ5$?-\0;VAAF)$^S#-Z73+"-
M*F$=RX0+/AUE+:^<$3I8G,1G-Q#YTM532M6@I.A$LT?;O1G%^!#BTZ_@B M;
MA'V_];?/_3#"C#-+DV&-*T^R"'2$:B\R <.U7O!7OE@)0XOHDSB <CU%:K>.
M#[PUMXH)+('H2:1DYK9(IY=0W/CR:1I>87GR57*+W]7?[YK@+U#[\-JSO"N!
M19S5;QRJ":"PB@&(-R@,JK>.$T\7)^^,]^6532VU0AU<5%$(W[P1.;&:08@$
MK@'>U2$G%1U:54B<LIR#]S_Q8N=%,F/N!WS'E_Z5@%TK;XNF5!268U/;BFE"
MR@DA8V D@YTK*+;T9>I5SPA7 =-O6R+\"HEYY07EU-^9[Z4@AI\P[PXZ+&1E
M<!5.0'Y'!H(%3Q%/) VSWR6$;N#@R,C>#.2U>A-$=*3K9 Y>C3ME'3Z(ALTN
M;CF,]17"3@J.[$ Q9.%WWFK;A981L"/,+1!0.Q R!GZV)A>/."YVM[9^-!TV
MX1[(B:#?-.K +BXNI6J%VQ#X"N1>5(^>?E'8)+A*5ZB$FL-.-M6%T>UDE0S-
M2K$JV=:+Q"ZH0>TZG$H7'*^,Q!K_?QFU@XJYB9,HN0;M=S:2RS_\[6]#6L&6
MITC5+\L2?$.N(5/AXEF+*\/[@,4RI[UUU:)?*5N+X COOBQ7D86S?G8%2H_*
MCHM6%1*$PLG;<L]++2 ^7;P+LX:?N0[065_>P&;A1, Q2.A/7([IKH)!V_I1
MK7:$?G>7P"ZJ":%YL$#[EP7?T<3-[K.Y@.B$=_V$,$SL UB,S#0$F/@;/@:%
MW690"5O1(XKE+[5G^FE"93"S,$-HI+2\G0^Q3AL^_VL&>P5RUQ0ZR !IVK4V
MU8LP M[WY^"X#N&="UG2SZT_$'(%]M6%V%OH%]0 :\O;E\OBN8W\6(-'Y:^/
M2L"H9:U-NXBC4*7Q''=6KHV0:V'7.>N6Q+L*:JJM/8.PCFEU\&U@QY"6X4<)
M\YR8-TNK:7P,./D*'%P>Z+-G$?>Q^_[XOFU]X=4*?CM'8 2V55H@' EB=7'@
MV.(SQ3']380 7WEB^ 2CQ,<5(;7RR>NI/_H4H[D.NPEYOMS%09K=A,NG/6O#
M4H\G>+^L1>4H65FE^3X4)$57&#P@\(D(? 0<_>0^0/N#//68[Z'F#_PI"XSO
ML2,0<S]W<3<MK68W2;(5PY!@7@*H/9J!17:(Q0#E-D]0AVQ@S;_2SCJ@7J4"
M\" R) U%X-79Y0=/THCR0.$%$AX0C5$1P5\UMBSBOTH&NH!=X U1PIM+J$D8
MNY_0#Y"Y_R,&!22$4LFSZ6US;$"/5Y-)E>Q9JVH_0:9\%LXY3NW[F%K*5G]&
MY .J_FCKW(IFBH1_<X-#23V!R5H*:^<E-*X.$(P'VQ7%#"+4JY7MDLJ-><X(
MF(W]P- VV*_6AQV!E<&5<X2L99#2T E>6[,N4Y4Z1O"TB?C\&Z]0K#8(@KAX
M[("3C^_N$L^.E/%5.Y0$YFO7X23VPH#8R/4<EV8&[RP!&1;A3)HEJZOB#QN@
M*[:"5(BF6>W]+M 1KX9/C[EX]B$V*RXPD=]2/[XNQA%V4:&BG)M=EJAT5>/K
M'+IH?AN>R99Z53&!"1OBZ 9<5,*6<M5AW<"/JM(M'3HJ(8!U'?9XZ-ZQY8#J
MEU3UHN-/\V9Z-F/9V=)_KAIP\!AFV"*#8-\8]*-3S&/V6HE8JX,B5QO2VJJ5
M!!(:0E' 0S"+^FK4J?!HL*C@>!1IQ3NL)4Y+J]:H&6A/:3^A7*"3^IS.6F_*
M7K%JMG?CA2_=8ZUSNLAZ@K<<IK5Q8U3H< M<@3>R?DC (+Q[DR=R:@W=C0>W
MNOB_+AD@B'C7.\SJ$KIT61OQ?FL^DD'[480[72%N'S^TEAHS-FR!YGO=$R#5
MV6I9L$O))47-!T84=#FR8OEN<*#R^^VM::376"\KVO6-+E_E,X+)B/GP-K9L
M^2>^>SUZI%*4=#QJY(G5.>"DL1(5X<(M\P+;D;>2^+7B_U5^PP;CU.?\-0N3
MJ;]CDQ1!9,["8;KO^-<J#;-9.!7 :>(>!+%?6']HV5Y=;S']//(JO]A>9]0N
M?O5:HZXJB-S#5A!Q$_T1/;CR-K6\'#F^DSS2<U*=+@ZJ/(*':K[T][2]?38M
M0)R%;[=%/;_+WF]6T.] X-]W1CB]>[I5L;-*-J_RRH9:M%VSB"+?M2DM%E=Q
M>UN!"QL)1&J=3P(.GHL%-;7JFNZ*ACHI25SC4YHS6BB*]0M\<03L_OM42WZ^
MI%?@^H[6NCN_+%]+Q4\! [6UW*=2VM+H=&6CD5K*?ACIU@M^V&_+V7)LHC/]
M5BZP7&IQZUR*$B 12AI-H,4<(!--B$&3:PA%(7I=JTNE5UEGM$!5.Z-R.8A-
MQ3B+=U^^#<XTQ6"'B?]6#;F"=A_=OZ]BP31V@K\L2(6>-/](%\D&75&Z L:D
MRP=6 5I&0IG(@*Y#=LB(K0%_4@D!GCD#X.)UDD Q.]L3&2 JV.2!5N-PNEAP
M=^"D?F>(J1U=TE?ZL9=X.<NF&;&0/K\!4;?$()?2'RQBZA:"$V0;'@AHBW=-
M0#>2#K!A%SC3'4=@D;)YWQF85H='1:PU"R*$:KU'?Y?ME$??%M<B5WX^O6D0
M354/0K6_^K&HQW3?\W0!>U+9 1T50V+YN'N4X;8K/-[FPXJUBVPCJ_X-JI,/
M<)117LT#HUXNE$-[7N&X@AZJJ0'#@*J/T>ON)N"%?26@ 5T^!:@B']:*VKET
MP>8]U,SD]V"ZR@.Z0.6&$!W%-&&#P1+Q91DO34MBL<]@J4PUKSI?L2 (.RAH
MS4CV-1"9\R:A3Q;=^VNUTT$T-P@78-UX5^I ,T;$*[QV*,8C5Z-%8%MP$,+L
MA@#H6,UE\CO0 SQ2#KO&?SF[CV&54VJ+0R0>WK!7KVBN^"T""(L2I@1K-;OU
M!2L)^1+5+[72U27V]/VG\D#\QG7"T"A*:<R [#Y)85&"+P"/N%@2M#B$(F%R
MTD-KU_7AUL+J4K3(+]T(3LK@/)J^G1C5TE8D=%5%DSC5,.6OJSA$=*^U65+2
MV6N"K*497RQ6*2/1;4'+N A:VLN]\;N"<IL:%#90M@)JRS]1Q[057ZMBV8IE
MOO/?;^\6J" .U=/SQ1B-ZKV#+ 4AF38V0^J*.I4V(6<6B\W93 R9Z5*L.I4Q
M#\)_QHX>&6QC%/%?X!AW&0<>BF8S^BW[&8OC17Z?E"N:/QRZR)-65^_7,_N[
M[%CD9?B6\Z*-8TK0,52KQ%2KV+:@^7-LK5&=A86M>22:\HK:$CQWGCTO6"%!
M9Z"\;]G(@1VK=R&7QC-6U9>G5ZFKW[CAUU-;_^MRGN)C)D%+6=&F%SQG]20%
M&-V,0]*Z"^Y124RQQ84E>%:<BD*8YFSNG> ?*I&(XV!:=ZJ83UZYN7TN 7M!
M?O-8O=TO""$1Q.213CHL]&Y E?C%N&EQ-HO*J]?.":^X?<*);4Q!J5[4;['$
M="-1#%9F%E84D77!PMUQL A?6*X-!VNR[O,.2Y$ZRPYB9MY'Q!H.DELC:T4,
M_6ML5\DK99^4]R6?H\0;6:W+)D77./IRBG-99C[#GJ6^-;R_P@3*%1N$';+!
MB7?8)TV>F^C"PR^\'B$MRS([.+[CJ^QL%.?3S+42F8RCQJW?'ZR5ME7F&\V[
MAE+5NZW^W+F.[\%"R[*<LKO=ZLJY?F15BZ0=61=;66W%76I6/57B3'"[4KK-
MS^\P'T&G@9#R3BSY:%54IXFJ>?3+-Z"1"2HOPMD9J] _HT)\FF>0W/'B?/Z[
MEHZ -M1<+)EK#:?V/_UC4'L;#H_SY3&LD#F'A7P@%E,4!JNB_'$=4^P!7O";
M)U_OJO )9[^(?L,8M$$KE%69Z*U\' L*6*R\@["3IP ?"=,9:XIEKFJ=LPNP
MY,KUQO8J5\Z6R*/X1Z&HV!_?E?J*_Y%4%_WQ/0Z>O,:^WB(2V5AZZK<IP+"R
M+M8[)BI\,@'CAA=.62XLXUJ=:M67;A2K%H!(#4PO0?+U6B'BC_9ETI^*.E,T
M6UV44G59"%R[@]M> ;S+%D7M%:'Q<7B&!6)N4S-J."VU6G%ET_)81+VME1GY
MMWX8\>:]M3?B9-!ESC&8YLQ79T.VV0?77BSTIJK (9*;O0L)&F_-.=I@38J8
M&BC+S3@OJLK&V98[O>WU&.LQNTGH/-I^[+00\KL+L&[RJ5N8L> ]7B2W)#TL
M5*9X- >LK]Y0<<P1:18"R>D>M38]!3BQ_ @IKQ*.E&N@-^# 77; #=AN(CV
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M%(Q<1@;@,%4#W5> 597;52!548TI@BGF3/)8E$*;YC5!J4Q_"=)K^&?%8\J
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M*:ZL=U>QW0MZ[PCUCE"O(5^1ACQDCJQ7D)M3:YOAAYYM83M#TL Y/C=JRTW
M<'HX"LLJ*\%5!A'PT-G%]":)@HSCM)PMTQ"A1J1%,@LB:9ZDTHXP+O"+$LD%
MWI &V1(AAI*Y=)7X*?![D-Z&4_CT;)7B&W )#;+NO\,L_-[!4V"_U#L=8.]T
M%\MJQ\OL8J5^&G2*=R/TK+%F[7H,G-;L?:$TNX' L;67A1+13^KUC[M2>9:6
MQ]?K-/?T.37^.FIPEW9#V/-FSYLOC8FS%V>^8)'PT81X6^?"@?,/KG04S@,,
M!^Z!YEDO]2=CL94#\5E#YI^<=U'..ROUZ_FJYZO'\%4/#;(1&B3,?C^;HXL8
MXOD$62ZE?KY/&\FIT/"T)/F0A%,Z] B??&]YKKA_. 6B]=SV*KC-=';FMC??
M95C$"+=)Y.=A%.;W1^2HO&J!?&5RIVIZ9TJ^9YTWQCKJ837V$3D-AU/EDR2=
M!V&^2H/>O3\&(7TK#A?$Z+UWWS/;\3';FW?N1^%M"*P[D^[#()H=D?/QJD7Q
M#4M<SSHO3I]399W>K]]$Q7_0E7HP._.!"/YU(,W],)5N_6@5L"%\M:+04W H
M7K4,OQ5/[$?EW#D\['?/;3VW<6ZS=\9SVWLPLOCW__RTRLZN?7_Y811FTRC)
M5FGP95X=(/N-C58=)EF>7> <WP&.8?WJW^.LA>P2*#"(DNGO?_Z__^=_Q*/&
M?AH#5;.O04K?*#Z$DU619M^"^9]^F(RP\.GOVC\O1S](X0Q^X4_SLZ'K6:.Q
M/O$&SL#4+=4UE:%I#733&(R&NF[^\.>U,ZA2\X%R[+8C;!2H'W1X;Z-8[//X
M4OK;EXL+Z>OXFW3Q%^_;>.N1[]SS493$/VO/!_*-']_3C-Y5#D=QY6?A5(J#
M7 +6RJ1ED+)9T-(J"WDSQATW]I(P]O%J<06? T,/CUDDL9@>G:SR+/=CW&.U
MF0.>&2:S<VD41BM\#+XLC.&K0>5U(2T%YTPODWB_UV*7R3+)@6*P\^A>FN%[
MPMM RH(IK"(/X3/OJE^1@G^O0G!64#S>/[3JX88O5K\G2[, =,L"#GQ6(5R>
M!CZ(ZSUOE5D$^4TRDZE1 ^F?AKA?V [?1W[CY]+"OY>ND!S9JABZ75VA<*UP
MTW=^B@Y6ACTVQ<!L<19S-FR;G7<!!6M_S KJX:*V[(]^_D[#RF?2/$T6],!9
MY1#7. 8,P705L;'/(;T>?,)@/L=N'YS%#.=S)LZFFUG>+S#M&DC .FSP,%JY
MKGI:%0Z\"QKT;*5EC5&QSZID1I":&9A;_,I5,/576<"/&>A<HRZG>F<]0,Z:
MK=Y ]QV4><T%>$M=0:K>S61LXV7[<EZX*ZE??;_ZM]00=I ,3KN?^W6[!W5$
MZ<13#YZKG:+/SH]/&;+8.<\== )XSX8]&^[&AOV,] -=$QSE;=2KD=N7 )M^
M@)9[2G(_.[IGM!-EM'U&P?>,=E*,=D)#RGMUUW/ARW/ASKJP+ZC9Y"E?5,'4
MNA+J(Z+<T4G[\Q'N%$ J-5EU%5FWNAN.]*9A*'O![ 6S&\$T#5LV[>X&C?1B
MV8ME+Y:]O>P%LQ?,URB8O;WL4"S?_/W5/WB!99]E>R9U=>B;YI=33+ILFXKL
MZ/W ZG[\<"]3W<F4*BN*ULM4+U.]3/5VJI>I7J:.5*9Z._5< >@1)8L.%YE>
M)KD?'666Z.WJK,<,-WQU^3?9-519=?O1S\?A=?2BW8MV1Z)MR)KKR*;=BW8O
MVKUHORK1[JUV+]J]:+]*T>ZM]HNE+!Z+\[41G*N*X#7QP_0WQ%O\A3"& L3Z
M^@H4G=ZS_]T'T6ND3,:>-C)-R[)-S52<B3=4'=T:>HXVT@WGX(A>55E3$;#G
MH!!?].$/80[/GVYH:D#J2D1>J4+?[74 QPM:]+/G?95FP1Q6E561.OV,@0NE
MX31@Z%-WR2I"<"$I#:9!>(M 10EB"^&L^""7.!I1\#W,6[^U]$,:^)ZG?IS-
M _BF%(7^%8UP$=/EX7OQ-%SZ$3YMD62YY,]N_3CWKX-DE4D+/_V=\,'PK:0P
MHGOV/.!41):Z"O*[((C%!Y<^*BEX'D%RL5<LRB.39GX>R(26Y4=9(@49"F68
MW2!N6)46-V&0^NGTYEZZNPFG-T" ?Z]"ABXF(2X&;  VMO"_APL@+KV&XR\E
M5SC!GI"(PGBYRC,9'H%@3_ZM'T;X^W,)8:-R!#L ^W(;1)6WP0-P 0PU*P^F
M-W'X[Q6\MEPH491OJ;KB,.-G.MMY[/M>>$GK/+M-Z*5-S+H9R8AX?$]$F$/A
MO\ 6][$_#?%>VWW-ES"0=D\07@'=IEE/]Y)@GWL9VF>#7J1O_8U$0_W Q8@
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MP((DX%?^AYE]? ZB[0=PF$6NF$^A2$2RFJVW<#O7UH6WHVM[/Y<^S2N_FB7
MO!BC@B['R8=(P7"Q!,$/<YJ)*U>)@30&.<DQU)TRS0OFX@H#51HXD#96&,9S
M1,DGXA4)Y\V[ \D1 AF*01?;]\B2UVOD9<ET+H](Z_MURBS\&3.0?.1!QC^
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MMYDG*^'\-C?+/DBC<#X/4KR0*;H8MN=?\49C%F94=H"W!/5+T>H=?V^/M[3
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M%W5W&K Z2-PJ1,M9Q@@,9$ ;(J6\^+N#]__HR$X+NLUC#H[I*:J\97:P;,"
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M 9_[FB8Q_)-5)V>/G2VK3G1#'RK6R-!-T]0U;SQ1+-/ (0^..1Z[;V^RP[<
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MM-Z*:'WQ!COX^<GW^ZM5?A^'<0G149;'S*E:V>>-Y1&6EJ8/0,&\'F^W7NQ
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M.A*A-S1;MI7.$MB/I_!!J'5T&J'/%)R4EW/\S'H,_D]'5<3'JR0U]=QY443
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M%GHATJEAIQBG=+3T3_)&"R);!OL@U;R;D5*)7.DXZ9_DC9/8.,=1DC#?'26
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M;"C]F5[!W#=84 YE_BEDKR.78%8<J'WG07UWC&QTSDRWN9IS)KW,"EDSLVO
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MT>&O4GFZ0*TO??E4E83-O!N;8@8>='GO21CYD-IT54R[OG-LA$ZL,!Y%#")
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M<44PUALI16<IG!_W#@R^F32K2EL^Y_<RILL3R2>F3.T*#+8<*>8.M$< $-K
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M(;75+M?-W6_ ^%F>I;;SG:;-:-B?WFQ$W@90+3W@ZB.!9_^/7_X74$L#!!0
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MAR<:K=NP3RKQT]YVO+U:IY?$::JIY1@BCZ V7$B)*]J4PGYXMFE+O'K=5NT
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M<9?-YOHQFDX'PQQ:Z#\6-Y*!'1I9PKCUA@)4;9 & -]<MSQ^?1F @^L<F%Z
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MU3I:?<E(+" <B_>&'S&(]7,Z*0O6+8+5-GL,E!S*D:_5/LP/X)42S"I+' -
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M9KW72A M'=O@JDWS6IG#*PH[S&7W=*9<BK"[KP_YK&S3A["_\K;$:D:)\0(
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M#7J:1R*\TJG-E#.*--<V.ZH+U8F2T18\O8G TRAC*8VKFX]!RN?IJ'09'ZR
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MSZFM:;TZR?;GI&F(K5<+GTW#?;-I5?&P_) O<I4<Z\+.&10H"1.49202  C
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MSEV%\_@VG8N3LJX\8I;QC^L,NWCR^$QM [<]=?#AU"\UY,,;CJ.=M36CU.P
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MP72,L,>Z*:L44IK"(@$LBG,BYI@$';<-J=[;B^JMYC+#D4 N0G8,&4RS(L<
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M"V]E M+M;5O=EOM*MEGO=G+8<,33&"0QPW$14X"S,!SW=W 6I^I;+I8-^4X
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ME4&.:)0F*:$,DCQ#C YW_#(6AQI/V?G',D6(.YH@AW5G1-!;\6R0"SN"SI!
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MW!NBY8;H9=QRM;2A<=GU],3II!7YX);H32>=Z;0O]1(9QGE*A$2& $1Y!#.
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M^W%;/U3M^;0%BA!F!>5YD18)Q7F4@B%M(0\A5K\C8-V2YS#0X[-.%+-G5"$
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MHPZ0G.H^BAE *3'-N?!\08_R:M.4UF4,+T>V7%Q7VC%D-K#&=Q3[&Q\KDB$
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MA#-/@%&8E;13F!1U!WN4(:'-4[AI(9P,P!<E2[8L6*C[J%'NPMC!CAF C$"
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M5>[JBO&"L=>,:-J"XC^*8O1U/)F\NW\8C&=QQ@<,WM<[9!"HL(FB>.'EC/&
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M:BP6KN2+HC+E-#X?;TX=QV_3K&\U_FC^(1_F84??'R7[O&EFJ6,$!N782N0
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M@)J;SJJ%7_@"ZI%,SW(=E1O'OQ=!5BL3MLV5]/K7,VE@V*Q X#[1E&@A' <
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M ML_\FD^&TS"Q-7H?CP=1S=#S$A=%6Z5^F?2.N"-(5*%)0RDU-:6ZH1PFJ4
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M92TR,#$Y,#8S,"YX<V102P$"% ,4    " #*@ Y/DG@I3D\2  "AL   %0
M            @ '][@  9&%R92TR,#$Y,#8S,%]C86PN>&UL4$L! A0#%
M  @ RH .3S944::E.0  ::D" !4              ( !?P$! &1A<F4M,C Q
M.3 V,S!?9&5F+GAM;%!+ 0(4 Q0    ( ,J #D^PQEV>]Y<  -RS!P 5
M          "  5<[ 0!D87)E+3(P,3DP-C,P7VQA8BYX;6Q02P$"% ,4
M" #*@ Y/WE]8 :Y7  !1-P0 %0              @ &!TP$ 9&%R92TR,#$Y
B,#8S,%]P<F4N>&UL4$L%!@     &  8 B@$  &(K @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
